row no,publication number,kind code,title,priority document,priority country,earliest priority date,earliest priority year,application date,publication date,publication year,applicant,inventors,ipc classes,family members,family size,family size,wo in family,grant or application type families,granted patent
1,AU2007202956,B2,Polymorph of a pharmaceutical,AU19990050037,Australia,1999-07-19T00:00:00Z,1999,2007-06-27T00:00:00Z,2007-07-19T00:00:00Z,2007,ABBOTT LAB,SALEKI-GERHARDT AZITA      | ALLEN KIMBERLY A      | NARAYANAN BIKSHANDARKOIL A      | SPIWEK HARRY O      | BAUER JOHN F      | CHEMBURKAR SANJAY R      | PATEL KETAN      | BAUER PHILIP E,C07D41700,AU2003254711A1 | AU2007202943A1 | AU2003254711B2,3,1,No,Grant,Yes
2,CA2425495,A1,ANTI-RETROVIRAL ANALYSIS BY MASS SPECTROMETRY,CA2425495,Canada,2003-04-14T00:00:00Z,2003,2003-04-14T00:00:00Z,2004-10-14T00:00:00Z,2004,STEVEN J SOLDIN,SOLDIN STEVEN J    US,H01J04900 | G01N03072,None,1,1,No,Application,No
3,CN101440091,A,"Ritonavir water-soluble derivatives, synthesizing method and use thereof",CN20081072486,China,2008-12-26T00:00:00Z,2008,2008-12-26T00:00:00Z,2009-05-27T00:00:00Z,2009,XIAMEN UNIVERSITY,JIANFENG ZHENG    CN  | GUOZONG SHI    CN,C07D41714 | A61P03118 | A61K031426,None,1,1,No,Application,No
4,CN101613325,A,Process for producing 5-hydroxymethylthiazole,CN20081031608,China,2008-06-27T00:00:00Z,2008,2008-06-27T00:00:00Z,2009-12-30T00:00:00Z,2009,CUICENG YE,CUICENG YE      | HONGBO XIAO      | CHUNTAO KUANG      | ZUOHU YIN      | HANZHOU SUN,C07D27724,None,1,1,No,Application,No
5,CN1247554,C,Process for synthesizing ritonavir,CN20031121091,China,2003-12-24T00:00:00Z,2003,2003-12-24T00:00:00Z,2006-03-29T00:00:00Z,2006,XIAMEN UNIVERSITY,JIN LIREN XU    CN,C07D27728 | A61P03118,CN1554647A ,1,1,No,Grant,Yes
6,DE10131036,A1,"Medicinal composition, useful for treating infection with human immunodeficiency virus, comprises condurango bark, guaiacum wood, dandelion leaves and roots, peppermint leaves and arnica",DE20011031036,Germany,2001-06-29T00:00:00Z,2001,2001-06-29T00:00:00Z,2003-06-05T00:00:00Z,2003,JOHANN TEUBNER,TEUBNER JOHANN    DE,A61K03627 | A61K036185 | A61K03600 | A61K03628 | A61K036288 | A61K036534,None,1,1,No,Application,No
7,DE10145361,A1,Sterile liquid composition for pulmonary administration in aerosol form comprises a sparingly water-soluble drug in the form of suspended particles of defined size,DE20011045361,Germany,2001-09-14T00:00:00Z,2001,2001-09-14T00:00:00Z,2003-04-03T00:00:00Z,2003,PARI GMBH,KELLER MANFRED    DE  | LINTZ FRANK    DE,A61K031568 | A61K031282 | A61K0317072 | A61K031496 | A61K03146 | A61K04506 | A61K031522 | A61K0314174 | A61K0314196 | A61K031426 | A61K031445 | A61K03152 | A61K0314709 | A61K00912 | A61K0317048 | A61K031436 | A61K03158 | A61K03157 | A61K00900 | A61K031573 | A61K031427 | A61K03119 | A61K031137 | A61K031415 | A61K031337 | A61K031167 | A61K03117 | A61K00910,None,1,1,No,Application,No
8,DE102005012681,A1,"New 1,5-dihydro-pyrrol-2-one compounds are HDM2 inhibitors, useful for treating e.g. stroke, heart infarct, ischemia, multiple sclerosis, Alzheimer's disease, degenerative disease, viral infection and cancer",DE200510012681,Germany,2005-03-18T00:00:00Z,2005,2005-03-18T00:00:00Z,2006-09-21T00:00:00Z,2006,LUTZ WEBER,WEBER LUTZ    DE,C07D20736 | A61P02528 | A61P00900 | A61K0314015 | A61P03112 | A61P03500,None,1,1,No,Application,No
9,DE102007030695,A1,"Co-crystal, useful e.g. to prepare a pharmaceutical formulation for the treatment of psychosis, neurological disorder and struma lymphomatosa, comprises an amino compound and urea as further component",DE200710063623,Germany,2007-07-01T00:00:00Z,2007,2007-07-01T00:00:00Z,2009-01-08T00:00:00Z,2009,SCICONCEPT GMBH,BENDELE TANJA    DE  | FELDERHOFF MICHAEL    DE,C07C27502 | A61K03117 | A61K03116 | A01N03718 | C07C23300 | A61P00310,None,1,1,No,Application,No
10,EP0490667,B1,HIV protease inhibitors.,JP19900409673,Japan,1990-12-11T00:00:00Z,1990,1991-12-11T00:00:00Z,1992-06-17T00:00:00Z,1992,JAPAN ENERGY CORPORATION,MIMOTO TSUTOMU  JP  | HATTORI NAOKO  JP  | NAGANO YUUICHI  JP  | SHINTANI MAKOTO  JP  | KISO YOSHIAKI  JP,C07K00502 | C07K00702 | A61K03702,ES2134764T3 | DK0490667T3 | AT181080T  | ZA9109721A  | DE69131317D1 | AU8890091A  | CA2056911C  | US6329502B1 | NO920023A  | EP490667B1 | CA2056911A1 | NO305085B1 | EP490667A3 | FI108113B1 | GR3031004T3 | JP2700511B2 | AU653972B2 | FI915819A  | NO920023D0 | US6313094B1 | DE69131317T2 | FI915819D0 | JP5170722A ,14,13,No,Grant,Yes
11,EP0728481,A2,Use of quinoxaline and protease inhibitors in a composition for the treatment of AIDS and/or HIV infections,DE19951006742,Germany,1995-02-27T00:00:00Z,1995,1996-02-14T00:00:00Z,1996-08-28T00:00:00Z,1996,BAYER AG,PAESSENS ARNOLD DR    DE  | BLUNCK MARTIN DR    DE  | RIESS GUENTHER DR    DE  | KLEIM JOERG-PETER DR    DE  | ROESNER MANFRED DR    DE,C12N00999 | A61P03112 | A61P03118 | A61P03704 | A61K031425 | A61K031365 | A61K03134 | C07D24144 | A61K03155 | A61K03144 | A61K04500 | A61K03147 | A61K031495 | A61K03855 | A61K04506,PL312908A1 | NO960775A  | ZA9601516A  | HU9600455A3 | HU9600455A2 | SK25196A3 | IL117247A  | AU710158B2 | BR9600809A  | AU4561596A  | DE19506742A1 | FI960850A  | HU9600455D0 | NZ286058A  | CN1141196A  | NO960775D0 | CZ9600578A3 | IL117247D0 | JP8245392A  | FI960850D0 | HR960070A2 | EP728481A3 | CA2170222A1,18,17,No,Grant,Yes
12,EP1112741,A1,Use of protease inhibitors for the treatment of necrotizing infections,US19970069389P,United States,1997-12-11T00:00:00Z,1997,1999-12-29T00:00:00Z,2001-07-04T00:00:00Z,2001,BIOVAIL TECHNOLOGIES LTD,FUISZ RICHARD C   US,A61K03100 | A61P03100,US6143742A  | CA2293913A1 | JP2001187746A ,4,4,No,Grant,Yes
13,EP1125936,A2,Aryl substituted azabenzimidazoles and their use in the treatment of HIV and AIDS related diseases,US20000177920P,United States,2000-01-25T00:00:00Z,2000,2001-01-24T00:00:00Z,2001-08-22T00:00:00Z,2001,PFIZER,SHERER BRIAN ALAN  US  | GOLDSTEIN STEVEN WAYNE  US  | STIRTAN WILLIAM GEORGE  US,C07D47104 | A61K031437 | A61P03118 | C07D47104 | 7C 07D 235:00 J | 7C 07D 221:00 J,CA2332087C  | JP2001226374A  | EP1125936A3 | CA2332087A1 | BR200100155A  | JP3489821B2 | JP2004002483A  | US6242461B1,6,5,No,Grant,Yes
14,EP1166782,A3,ANTI-RETROVIRAL Pharmaceutical compositions,JP20000188524,Japan,2000-06-22T00:00:00Z,2000,2000-06-29T00:00:00Z,2002-01-09T00:00:00Z,2002,TSAI HSIU HSIEN | TSAI SHIOU REN | YANG CHI CHIANG,YANG CHI-CHIANG   TW,A61K031216 | A61P03114 | A61P03118,EP1166782A2 | JP2002020283A  | CA2312644A1 | BR200005954A ,4,4,No,Application,No
15,EP1207394,A2,Immunoassay for HIV protease inhibitors,US20000712525,United States,2000-11-14T00:00:00Z,2000,2001-11-10T00:00:00Z,2002-05-22T00:00:00Z,2002,F. HOFFMANN-LA ROCHE AG,SALAMONE SALVATORE J    US,G01N03353 | C12Q00128 | G01N03368 | G01N033569,US2007148684A1 | JP2002207039A  | JP2004294443A  | EP1207394B1 | JP2000151613A  | US6348874B1 | US2006127938A1 | US2006040257A9 | DE60140929D1 | EP1207394A3 | US2003124518A1,6,3,No,Grant,Yes
16,EP1281755,A2,Variants of the human cyp2d6 gene,US20010309111P,United States,2001-07-31T00:00:00Z,2001,2002-07-16T00:00:00Z,2003-02-05T00:00:00Z,2003,PFIZER,MILOS PATRICE M    US  | WEBB SUZIN M    US,C12N001509 | C07K001480 | C07K001618 | C12N000902 | C12N001553 | C12Q000168,CA2391621A1 | EP1281755A3 | JP2003111597A | US20030083485A1,4,4,No,Application,No
17,EP1382692,A2,Enzymatic assay of HIV protease inhibitors,US20020200096,United States,2002-07-18T00:00:00Z,2002,2003-07-15T00:00:00Z,2004-01-21T00:00:00Z,2004,F. HOFFMANN-LA ROCHE AG,ARABSHAHI LILI   US  | LI HAIJUAN   US,C12Q00137,CA2432925A1 | US2004014030A1 | EP1382692A3 | JP2004049239A ,4,4,No,Application,No
18,EP1418432,B1,"Method, assay, and kit for quantifying hiv protease inhibitors",US20020284040 ,United States,2002-10-29T00:00:00Z,2002,2003-10-23T00:00:00Z,2004-05-12T00:00:00Z,2004,F. HOFFMANN-LA ROCHE AG,VON DER ELTZ HERBERT  DE  | ARABSHAHI LILI  US  | LI HAIJUAN  US  | HUBER ERASMUS  DE,G01N003353 | G01N0033573 | C12N001102 | C12Q000137 | G01N002178 | G01N0033543 | G01N0033566 | G01N0033569,AT347105T | CA2447172A1 | DE60310012D1 | DE60310012T2 | EP1418432A1 | ES2277018T3 | JP2004147655A | US20040081957A1 | US6821744B2,7,7,No,Grant,Yes
19,EP1542012,B1,Antibodies for detecting efavirenz,US20030732767,United States,2003-12-10T00:00:00Z,2003,2004-12-07T00:00:00Z,2009-08-15T00:00:00Z,2009,F. HOFFMANN-LA ROCHE AG,GHOSHAL MITALI  US  | SIGLER GERALD  US  | OUYANG ANLONG  US  | ROOT RICHARD  US,G01N003353 | A61K0039385 | C07D026518 | C07K001644 | C12N000510 | C12P002108 | G01N0033531 | G01N0033577,AT439589T | CA2489266A1 | DE602004022504D1 | EP1542012A1 | EP1542012B8 | ES2330104T3 | JP2005225864A | US20050131216A1 | US20080227959A1 | US7420043B2,7,6,No,Grant,Yes
20,EP1820493,A2,Aerosols for sinunasal drug delivery,EP20060002735,European Patent Office,2006-02-10T00:00:00Z,2006,2007-02-09T00:00:00Z,2007-08-22T00:00:00Z,2007,PARI GMBH,SCHUSCHNIG UWE    DE,A61K000900,EP1820493A3 | US20070202051A1,2,2,No,Application,No
21,EP1894559,A1,Means to solubilise steroids for inhalation,EP20060018356,European Patent Office,2006-09-01T00:00:00Z,2006,2006-09-01T00:00:00Z,2008-03-05T00:00:00Z,2008,PARI GMBH,KELLER MANFRED    DE,A61K00910 | A61K03157 | A61K00912 | A61K03158 | A61K04748,None,1,1,No,Application,No
22,FR2773994,B1,"New human immunodeficiency virus protease inhibitor prodrugs for inhibiting viral proliferation in central nervous system - comprising protease inhibitor coupled to substance that improves bioavailability, targeting and/ or delivery to CNS",FR19980000728,France,1998-01-23T00:00:00Z,1998,1998-01-23T00:00:00Z,1999-07-30T00:00:00Z,1999,UNIVERSITE DE NICE SOPHIA ANTIPOLIS,VIERLING PIERRE    | GUEDJ ROGER    | FARESE DI GIORGIO ANDREY    | GREINER JACQUES    | ROUQUAYROL MARIELLE,A61K03855,FR2773994B1,1,1,No,Grant,Yes
23,IN00496MUM2008,A,NOVEL PROCESS FOR MANUFACTURE OF LOPINAVIR AND RITONAVIR TABLETS,,,2008-03-11T00:00:00Z,2008,2008-03-11T00:00:00Z,2009-10-16T00:00:00Z,2009,MACLEODS PHARMACEUTICALS LTD ;,AGARWAL RAJENDRA ;       BHIRUD SHEKHAR BHASKAR ;       S B LADE ;       ASHISH GOGIA ;       VIJENDER GUPTA ;       PUSHPALATHA RATHINASABAPATHY ;,A61K31/427 | A61K9/20 | A61K31/513 ,None,1,1,No,Application,No
24,IN01730CH2007,A,[EN]PHARMACEUTICAL FORMULATION CONTAINING RITONAVIR,,,2007-08-06T00:00:00Z,2007,2007-08-06T00:00:00Z,2009-09-11T00:00:00Z,2009,MATRIX LABORATORIES LTD ;,VERMA SANJAY DESHRAJ ;       VELAVENI KIRAN KUMAR NARSAIAH ;       DIXIT AKHILESH ;       DESHMUKH ABHIJIT MUKUND ;,C12N15/09 | A61K35/76 ,None,1,1,No,Application,No
25,IT1313575,B1,SOLID DRUGGIST PREPARATIONS OF RITONAVIR FOR ORAL USE,IT1999MI01661,Italy,1999-07-27T00:00:00Z,1999,1999-07-27T00:00:00Z,2001-01-29T00:00:00Z,2001,RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A,RONCHI MASSIMO    | SANTUS GIANCARLO,A61K000,IT1313575B1 | ITMI991661D0,1,1,No,Grant,Yes
26,US20010041706,A1,Blockade of taxane metabolism,US20000191828P,United States,2000-03-24T00:00:00Z,2000,2001-03-22T00:00:00Z,2001-11-15T00:00:00Z,2001,CITY OF HOPE,DOROSHOW JAMES H  US  | SYNOLD TIMOTHY W  US,A61K03578 | A61K0317048 | A61K031496 | A61K031337,None,1,1,No,Application,No
27,US20020192273,A1,Therapeutic patch useful for the treatment of hemorrhoids,US20010298718P,United States,2001-06-15T00:00:00Z,2001,2002-04-10T00:00:00Z,2002-12-19T00:00:00Z,2002,LEC TEC CORPORATION,BUSEMAN TERI  US  | ROLF DAVID  US,A61K031137 | A61K00970,None,1,1,No,Application,No
28,US20030082594,A1,System and method for analyzing resistance of a pathogen to one or more treatments,US20010311068P,United States,2001-08-08T00:00:00Z,2001,2002-08-07T00:00:00Z,2003-05-01T00:00:00Z,2003,BAYER AG,GABE CHRISTOPHER J    CA  | LLOYD ROBERT M    US  | DYER KELLY N    CA,G01N03350 | G01N03348 | C12Q00168 | G06F01900,None,1,1,No,Application,No
29,US20030138483,A1,Soft elastic capsules and compositions thereof,US20010293623P,United States,2001-05-25T00:00:00Z,2001,2002-05-17T00:00:00Z,2003-07-24T00:00:00Z,2003,ABBOTT LAB,PETRICONI SERGIO  IT  | BARBATO ALESSANDRO  IT  | SCUPPA ROBERTA  IT  | SALEKI-GERHARDT AZITA  US  | URCH MARTIN  US,A61K00964,None,1,1,No,Application,No
30,US20040019027,A1,Method of treating cerebrotendinous xanthomatosis,US20020371701P,United States,2002-04-12T00:00:00Z,2002,2003-04-11T00:00:00Z,2004-01-29T00:00:00Z,2004,CITY OF HOPE,DUSSAULT ISABELLE  US  | FORMAN BARRY  US,A61K031573,None,1,1,No,Application,No
31,US20040073259,A1,Treatment of patients infected by disease causing organisms or biological warfare agents using hyperthermia,US20020406478P,United States,2002-08-28T00:00:00Z,2002,2003-08-26T00:00:00Z,2004-04-15T00:00:00Z,2004,CYGENE INC.,MUNZER MARTIN  US,A61N00100,None,1,1,No,Application,No
32,US20040197321,A1,Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients,US20020100716,United States,2002-03-19T00:00:00Z,2002,2004-04-08T00:00:00Z,2004-10-07T00:00:00Z,2004,DIGESTIE CARE INC.,SIPOS TIBOR  US  | DAS SIMANTINI  US  | WIGNOT TERESE MARIE  US,A61K03854 | A61K031695 | A61K0317076 | A61K0317072 | A61K031522,CA2503754A1 | US2003180279A1,3,2,No,Application,No
33,US20050020580,A1,Materials and methods for the prevention or treatment of apoptosis and apoptosis-related diseases and conditions,US20020436114P,United States,2002-12-23T00:00:00Z,2002,2003-12-19T00:00:00Z,2005-01-27T00:00:00Z,2005,MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH,BADLEY ANDREW D  US  | LYNCH DAVID H  US,A61K031551 | A61K031522,None,1,1,No,Application,No
34,US20050026902,A1,Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents,US20030443910P,United States,2003-01-31T00:00:00Z,2003,2004-01-30T00:00:00Z,2005-02-03T00:00:00Z,2005,PHARMACIA CORPORATION,MAZIASZ TIMOTHY  US,A61K03155 | A61K03154,None,1,1,No,Application,No
35,US20050031713,A1,Methods for administering active agents to CYP3A4 sensitive patients,US20030635234,United States,2003-08-06T00:00:00Z,2003,2003-08-06T00:00:00Z,2005-02-10T00:00:00Z,2005,ALKERMES CONTROLLED THERAPEUTICS,EHRICH ELLIOT  US  | MUNDEL TREVOR  US,A61K03578 | A61K031554 | A61K031704 | A61K0317048,US2009022823A1,2,1,No,Application,No
36,US20050182105,A1,Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function,US20040541780P,United States,2004-02-04T00:00:00Z,2004,2005-02-01T00:00:00Z,2005-08-18T00:00:00Z,2005,BRISTOL MYERS SQUIBB PHARMA CO,NIRSCHL ALEXANDRA A    US  | HAMANN LAWRENCE G    US,A61K04506 | A61K0314439 | A61K03144,None,1,1,No,Application,No
37,US20060172945,A1,Human neutrophil alpha-defensin 4 inhibition of HIV-1,US20050649873P,United States,2005-02-03T00:00:00Z,2005,2006-02-03T00:00:00Z,2006-08-03T00:00:00Z,2006,UNIVERSITY OF MARLYAND BIOTECHNOLOGY INSTITUTE,LU WUYUAN    US  | COCCHI FIORENZA    US  | WU ZHIBIN    US,A61K03816 | A61K031551 | A61K031522 | A61K031513 | A61K0317076,None,1,1,No,Application,No
38,US20070098802,A1,Organic nanoparticles and associated methods,US20050263725,United States,2005-10-31T00:00:00Z,2005,2005-10-31T00:00:00Z,2007-05-03T00:00:00Z,2007,HEWLETT-PACKARD COMPANY,FARR ISAAC    US  | CARTAGENA JULIO    US,A61K00914 | A61K0317048 | A61K031401 | A61K031337 | A61K0317034 | A61K03143 | A61K03813 | A61K03156 | A61K031573,None,1,1,No,Application,No
39,US20080026040,A1,Active agent-releasing dosage forms,US20060496770,United States,2006-07-31T00:00:00Z,2006,2006-07-31T00:00:00Z,2008-01-31T00:00:00Z,2008,HEWLETT-PACKARD COMPANY,FARR ISAAC    US  | RIVERA GUZMAN LESLIE    US  | DIAZ-FELIPE RICARDO G    US  | VALENTIN-SIVICO JAVIER    US  | TIRADO SAUL    US  | FIGUEROA IDDYS D    US  | KANE KEVIN MICHAEL    US  | APONTE MIRAYDA    US,A61K00970 | A61P04300 | A61K03118,None,1,1,No,Application,No
40,US20080026062,A1,Pharmaceutical compositions including nano-sized active agent,US20060496873,United States,2006-07-31T00:00:00Z,2006,2006-07-31T00:00:00Z,2008-01-31T00:00:00Z,2008,HEWLETT-PACKARD COMPANY,FARR ISAAC    US  | RIVERA LESLIE    US  | DIAZ-FELIPE RICARDO G    US  | VALENTIN-SIVICO JAVIER    US  | TIRADO SAUL    US  | FIGUEROA IDDYS D    US  | KANE KEVIN MICHAEL    US  | APONTE MIRAYDA    US,A61K00914,None,1,1,No,Application,No
41,US20080039428,A1,Antiretroviral combination therapy,US20060817067P,United States,2006-06-29T00:00:00Z,2006,2007-06-29T00:00:00Z,2008-02-14T00:00:00Z,2008,"MYRIAD PHARMACEUTICALS, INC",ALLAWAY GRAHAM    US  | KILGORE NICOLE    US  | WILD CARL T    US,A61K031661 | A61K03144 | A61K03134 | A61K031145 | A61K03152 | A61K03147 | A61P03112 | A61K031505 | A61K031519,None,1,1,No,Application,No
42,US20080045495,A1,Treatment of Patients with Cystic Disease by Alteration of Fibrocystin Proteolysis,US20060820573P,United States,2006-07-27T00:00:00Z,2006,2007-07-27T00:00:00Z,2008-02-21T00:00:00Z,2008,"BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM",HIESBERGER THOMAS R    US  | IGARASHI PETER    US,A61K031415 | A61K031437 | A61K031335 | A61K03127 | A61K031195 | A61K031343 | A61P01312 | A61K031397 | A61K031403,None,1,1,No,Application,No
43,US20080124407,A1,INHIBITING CYP3A4 INDUCTION,US20060828893P,United States,2006-10-10T00:00:00Z,2006,2007-10-04T00:00:00Z,2008-05-29T00:00:00Z,2008,THE UNIVERSITY OF WASHINGTON,EATON DAVID L    US  | THUMMEL KENNETH    US  | ZHOU CHANGCHENG    US  | BAMMLER THEO    US,A61K03638 | A61K0315517 | A61K031497 | A61K03126 | A61P00912,None,1,1,No,Application,No
44,US20080260837,A1,Physically stable aqueous suspensions of active pharmaceuticals,US20070788466,United States,2007-04-20T00:00:00Z,2007,2007-04-20T00:00:00Z,2008-10-23T00:00:00Z,2008,"TRIAD GROUP, INC",NAMBURI RANGA R    US  | VATTIKUTI BALA MURALI K    US  | MULAMALLA RATNA PRABHA    US  | PALKHIWALA BURGISE F    US,A61K00914 | A61K03155 | A61K031225 | A61K031135 | A61K031522 | A61K031473 | A61K0317056 | A61K03156 | A61K031496 | A61K031519,None,1,1,No,Application,No
45,US20080286343,A1,Solid form,US20070803996,United States,2007-05-16T00:00:00Z,2007,2007-05-16T00:00:00Z,2008-11-20T00:00:00Z,2008,FMC CORP,CENGIC DZENANA    BE  | DARMUZEY OLIVIA    BE  | MACLEOD GRAEME    BE,A61K00970 | A61P02900 | A61P00100 | A61K00914 | A61P02500 | A61P00300 | A61P03306 | A61P03100 | A61P00900 | A61P01100,None,1,1,No,Application,No
46,US20080286344,A1,Solid form,US20070804005,United States,2007-05-16T00:00:00Z,2007,2007-05-16T00:00:00Z,2008-11-20T00:00:00Z,2008,FMC CORP,DARMUZEY OLIVIA    BE  | MACLEOD GRAEME    BE  | CENGIC DZENANA    BE  | STOKES KEVIN M    US,A61K00970 | A61P01100 | A61P03100 | A61P03300 | A61K00924 | A61K00922 | A61K00914 | A61P00900 | A61P02900 | A61P02500 | A61P00100 | A61P00300,None,1,1,No,Application,No
47,US20080311162,A1,Solid form,US20070803825,United States,2007-05-16T00:00:00Z,2007,2007-05-16T00:00:00Z,2008-12-18T00:00:00Z,2008,FMC CORP,DARMUZEY OLIVIA    BE  | MACLEOD GRAEME    BE  | CENGIC DZENANA    BE,A61K00802 | A61K031522 | A61K00914 | C11D01706,None,1,1,No,Application,No
48,US20090105791,A1,"LIGHT EMITTING MEDICAL GARMENT DEVICE, KIT AND METHOD OF USING",US20070876921,United States,2007-10-23T00:00:00Z,2007,2007-10-23T00:00:00Z,2009-04-23T00:00:00Z,2009,NEUROPHYSIOLOGICAL CONCEPTS LLC,MCGINNIS WILLIAM J    US  | METRICK SCOTT A    US,A61B01818,None,1,1,No,Application,No
49,US20090123425,A1,"MACROCYCLIC, PYRIDAZINONE-CONTAINING HEPATITIS C SERINE PROTEASE INHIBITORS",US20070982924P,United States,2007-10-26T00:00:00Z,2007,2008-10-24T00:00:00Z,2009-05-14T00:00:00Z,2009,ENANTA PHARM INC,MOORE JOEL D    US  | OR YAT SUN    US  | WANG ZHE    US,A61K0315025 | A61P03114 | A61K03821 | C07D49816,None,1,1,No,Application,No
50,US20090149491,A1,CARBOCYCLIC OXIME HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS,US20070987627P,United States,2007-11-13T00:00:00Z,2007,2008-11-13T00:00:00Z,2009-06-11T00:00:00Z,2009,ENANTA PHARM INC,LIU DONG    US  | OR YAT SUN    US  | WANG ZHE    US,A61K0314709 | C07D21500 | A61K0314375 | C07D24502 | C07D47112,None,1,1,No,Application,No
51,US20090318519,A2,PROCESS FOR RELEASE OF BIOLOGICALLY ACTIVE SPECIES,US20080024324P,United States,2008-01-29T00:00:00Z,2008,2009-01-28T00:00:00Z,2009-12-24T00:00:00Z,2009,KATHOLIEKE UNIVERSITEIT LEUVEN,AUGUSTIJNS PATRICK    BE  | MARTENS JOHAN ADRIAAN    BE  | MELLAERTS RANDY    BE  | VAN DEN MOOTER GUY    BE,A61K0314196 | A61K04702 | A61K03141,US2009192205A1 | US2011060020A9,1,1,No,Application,No
52,US20100021427,A1,Use of Antiviral Peptides For Treatment of Infections Caused by Drug-Resistant HIV,US20080057102P,United States,2008-05-29T00:00:00Z,2008,2009-05-29T00:00:00Z,2010-01-28T00:00:00Z,2010,"TIANJIN FUSOGEN PHARMACEUTICALS, INC",CHEN XIN    CN  | ZHANG LINQI    US  | JIANG SHIBO    US,A61K03816 | A61P03118 | A61K03821,None,1,1,No,Application,No
53,US20100041014,A1,Biological targeting compositions and methods of using the same,US20080228892,United States,2008-08-13T00:00:00Z,2008,2008-08-13T00:00:00Z,2010-02-18T00:00:00Z,2010,SEARETE LLC,HYDE RODERICK A    US  | ISHIKAWA MURIEL Y    US  | JUNG EDWARD K Y    US  | GATES WILLIAM    US  | LANGER ALOIS A    US  | LEUTHARDT ERIC C    US  | LEVIEN ROYCE A    US  | TEGREENE CLARENCE T    US  | WEAVER THOMAS A    US  | WHITMER CHARLES    US  | WOOD JR LOWELL L    US  | WOOD VICTORIA Y H    US,C12Q00170 | G01N03353 | C12Q00168,US2011070154A1 | US2010040546A1 | US2010041133A1 | US2011070153A1 | US2010042072A1,7,1,No,Application,No
54,US20100056622,A1,Methods of Using Ramelteon to Treat Patients Suffering from a Variety of Neurodegenerative Diseases,US20080092129P,United States,2008-08-27T00:00:00Z,2008,2009-08-27T00:00:00Z,2010-03-04T00:00:00Z,2010,LAUTERBACH EDWARD C,LAUTERBACH EDWARD C    US,A61K031343 | A61P02500,None,1,1,No,Application,No
55,US20100068786,A1,METHODS AND COMPOSITIONS FOR REVERSING P-GLYCOPROTEIN MEDICATED DRUG RESISTANCE,US20080097308P,United States,2008-09-16T00:00:00Z,2008,2009-09-16T00:00:00Z,2010-03-18T00:00:00Z,2010,PURDUE RESEARCH FOUNDATION,CHMIELEWSKI JEAN A    US  | HRYCYNA CHRISTINE A    US  | PIRES MARCOS M    US,C12N00916 | C07D23302 | C07D22128 | C07D21542 | C07H01906,None,1,1,No,Application,No
56,US20100135960,A1,ANTIVIRAL ACYLSULFONAMIDE DERIVATIVES,US20080115749P,United States,2008-11-18T00:00:00Z,2008,2009-11-17T00:00:00Z,2010-06-03T00:00:00Z,2010,ENANTA PHARM INC,OR YAT SUN    US  | YING LU    US  | WANG CE    US  | PENG XIAOWEN    US  | QIU YAO-LING    US,A61K03821 | C07D40102 | A61K0314439 | A61K031427 | A61K031422 | A61P03114 | A61K03819 | C07D41702 | C07D41302 | A61K03900,None,1,1,No,Application,No
57,US20100160262,A1,COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY,US20080343177,United States,2008-12-23T00:00:00Z,2008,2008-12-23T00:00:00Z,2010-06-24T00:00:00Z,2010,THE J. DAVID GLADSTONE INSTITUTES,OTT MELANIE    US  | VERDIN ERIC M    US  | JUNG MANFRED    DE,A61K031655 | G01N033573 | A61K031506 | A61K031497 | A61K0314725 | A61K03152 | A61K031538 | A61K031551,None,1,1,No,Application,No
58,US20100261731,A1,"Method for Treating a Disease, Disorder or Adverse Effect Caused by an Elevated Serum Concentration of an UGT1A1 Substrate",US20090422434,United States,2009-04-13T00:00:00Z,2009,2009-04-13T00:00:00Z,2010-10-14T00:00:00Z,2010,ABBOTT LAB,KEMPF DALE J    US  | BERTZ RICHARD J    US  | WARING JEFFREY F    US,A61K031496 | A61K0314402 | A61P03118 | A61K031426,None,1,1,No,Application,No
59,US20100273733,A1,HIV Treatment,US20090173302P,United States,2009-04-28T00:00:00Z,2009,2010-04-07T00:00:00Z,2010-10-28T00:00:00Z,2010,FABUNAN RUBEN G,FABUNAN RUBEN G    US,A61K0317072 | A61P03118 | A61K031573,None,1,1,No,Application,No
60,US5874430,A,"4,4-disubstitued-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same",US19960027137P,United States,1996-10-02T00:00:00Z,1996,1997-10-01T00:00:00Z,1999-02-23T00:00:00Z,1999,BRISTOL MYERS SQUIBB PHARMA CO,CHRIST DAVID DONALD    US  | COCUZZA ANTHONY JOSEPH    US  | KO SOO SUNG    US  | MARKWALDER JAY ANDREW    US  | MUTLIB ABDUL EZAZ    US  | PARSONS JR RODNEY LAWRENCE    US  | PATEL MONA    US  | SEITZ STEVEN PAUL    US,C07D26518,US6303780B1 | US6492515B2 | US6140499A  | US2002040138A1,4,1,No,Grant,Yes
61,US5905068,A,Retroviral protease inhibiting compounds,US19960718882,United States,1996-09-24T00:00:00Z,1996,1996-09-24T00:00:00Z,1999-05-18T00:00:00Z,1999,ABBOTT LAB,CHEN XIAOQI    US  | GREEN BRIAN E    US  | KEMPF DALE J    US  | LI LIN    US  | NORBECK DANIEL W    US  | SHAM HING L    US,C07D33502 | C07D33348 | C07D33332 | C07D49304 | C07D51900,ZA9708552A ,2,2,No,Grant,Yes
62,US6040434,A,Aldehyde oxidase inhibitors for treatment of aids,US19970984478,United States,1997-12-01T00:00:00Z,1997,1997-12-01T00:00:00Z,2000-03-21T00:00:00Z,2000,INABA TADANOBU | FAYZ SHIRIN | STEWART DAVID JOHN,FAYZ SHIRIN   CA  | INABA TADANOBU   CA  | STEWART DAVID JOHN   CA,A61K03170 | A61K00900 | A61K00922,CA2255325A1,2,2,No,Grant,Yes
63,US6232333,B1,Pharmaceutical composition,US19960031463P,United States,1996-11-21T00:00:00Z,1996,1997-11-07T00:00:00Z,2001-05-15T00:00:00Z,2001,ABBOTT LAB,AL-RAZZAK LAMAN A  US  | LINDENHURST GHOSH  US  | LIPARI JOHN  US,A61K031425 | A61K03142 | A01N04378 | A01N04376,US6458818B1 | US6521651B1 | US2003032619A1,4,1,No,Grant,Yes
64,US6251906,B1,Retroviral protease inhibiting compounds,US19980085709P,United States,1998-05-15T00:00:00Z,1998,1999-05-10T00:00:00Z,2001-06-26T00:00:00Z,2001,ABBOTT LAB,CHEN XIAOQI    US  | KEMPF DALE J    US  | NORBECK DANIEL W    US,C07D41714 | C07D41712 | C07D27724,US2001008892A1,2,1,No,Grant,Yes
65,US6391919,B1,Bis-amino acid sulfonamides containing substituted benzyl amines HIV protease inhibitors,US20000482146,United States,2000-01-12T00:00:00Z,2000,2000-01-12T00:00:00Z,2002-05-21T00:00:00Z,2002,BRISTOL MYERS SQUIBB PHARMA CO,KALTENBACH ROBERT F  US  | TRAINOR GEORGE L  US,A61K03118 | A61K03136 | A61K03134,None,1,1,No,Grant,Yes
66,US6440946,B1,"Multiple-agents-binding compound, production and use thereof",JP19990047557,Japan,1999-02-25T00:00:00Z,1999,1999-08-09T00:00:00Z,2002-08-27T00:00:00Z,2002,TAKEDA PHARMACEUTICAL COMPANY,KISO YOSHIAKI  JP  | FUJINO MASAHIKO  JP,A61K03170,CA2281133A1 | JP2000309598A  | CA2281133C ,3,3,No,Grant,Yes
67,US6558923,B2,Rapid single-cycle assay for human immunodeficiency virus type 1 drug resistance,US19980087335P,United States,1998-05-29T00:00:00Z,1998,2001-11-16T00:00:00Z,2003-05-06T00:00:00Z,2003,PASTEUR INSTITUT,DAM ELISABETH  FR  | RACE ESTHER  FR  | CHARNEAU PIERRE  FR  | CLAVEL FRANCOIS  FR  | OBRY VERONIQUE  FR  | PAULOUS SYLVIE  FR  | ZENNOU VERONIQUE  FR,C12P02106,US6103462A  | US2002119444A1,2,1,No,Grant,Yes
68,US6602885,B2,Piperidine derivatives useful as CCR5 antagonists,US19990132510P,United States,1999-05-04T00:00:00Z,1999,2001-11-08T00:00:00Z,2003-01-02T00:00:00Z,2003,SCHERING CORP,BAROUDY BAHIGE M    US  | CLADER JOHN W    US  | JOSIEN HUBERT B    US  | MCCOMBIE STUART W    US  | MCKITTRICK BRIAN A    US  | MILLER MICHAEL W    US  | NEUSTADT BERNARD R    US  | PALANI ANANDAN    US  | STEENSMA RUO    US  | TAGAT JAYARAM R    US  | VICE SUSAN F    US  | LAUGHLIN MARK A    US,C07D41714 | A61P03118 | A61P02528 | A61P01902 | C07D41314 | A61P03706 | C07D21158 | C07D40114,US6602885B2 | US20030004185A1 | US6387930B1,2,1,No,Grant,Yes
69,US6623761,B2,Method of making nanoparticles of substantially water insoluble materials,US20000748803,United States,2000-12-22T00:00:00Z,2000,2000-12-22T00:00:00Z,2002-08-29T00:00:00Z,2002,HASSAN EMADELDIN M,HASSAN EMADELDIN M    US,A61K000914 | A61K0031192 | A61K0031519 | A61K003157,US20020119916A1 | US20050129777A1,2,1,No,Grant,Yes
70,US6911214,B2,Flavoring systems for pharmaceutical compositions and methods of making such compositions,US20000230095P,United States,2000-09-05T00:00:00Z,2000,2001-09-04T00:00:00Z,2005-06-28T00:00:00Z,2005,ABBOTT LAB,ALANI LAMAN  US  | GAUWITZ DONALD P  US  | KAUL DILIP  US  | LIPARI JOHN M  US  | GHOSH SOUMOJEET  US  | MARSH KENNAN C  US  | WHELAN RICHARD H  US  | PETROSSIAN VANIK D  US,A61K00900,US2005191324A1 | US2002090445A1,3,1,No,Grant,Yes
71,US7141593,B1,Pharmaceutical formulations,US19990137634P,United States,1999-06-04T00:00:00Z,1999,2000-05-22T00:00:00Z,2006-11-28T00:00:00Z,2006,ABBOTT LAB,ALANI LAMAN    US  | GHOSH SOUMOJEET    US,A61K031425,US2007032436A1 | US7432294B2 | US2009053305A1 | US2007032435A1,4,1,No,Grant,Yes
72,US7148359,B2,Polymorph of a pharmaceutical,US19980093432P ,United States,1998-07-20T00:00:00Z,1998,2005-05-04T00:00:00Z,2006-12-12T00:00:00Z,2006,ABBOTT LAB,CHEMBURKAR SANJAY R    US  | PATEL KETAN    US,C07D27730 | A61K03804 | A61K031427 | C07D41702 | C07D41712,US2010144804A1 | US2007015804A1 | US2005203152A1 | US6894171B1 | US7183416B2 | US2005009756A1 | US7659405B2,5,1,No,Grant,Yes
73,US7205413,B2,Solvates and polymorphs of ritonavir and methods of making and using the same,US20020377211P,United States,2002-05-03T00:00:00Z,2002,2003-05-01T00:00:00Z,2007-04-17T00:00:00Z,2007,CENTOCOR ORTHO BIOTECH INC.,MORISSETTE SHERRY L    US  | ALMARSSON ORN    US  | SOUKASENE STEPHEN    US,C07D27730 | C07D41700 | A61K04506 | A61K031427 | C07D27728 | A01N04378 | B65D06900,US2004024031A1,1,1,No,Grant,Yes
74,US7364752,B1,Solid dispersion pharamaceutical formulations,US19990165018P,United States,1999-11-12T00:00:00Z,1999,2000-11-10T00:00:00Z,2008-04-29T00:00:00Z,2008,ABBOTT LAB,FORT JAMES J    US  | KRILL STEVEN L    US  | LAW DEVALINA    US  | QIU YIHONG    US  | PORTER WILLIAM R    US  | SCHMITT ERIC A    US,A61K00872 | A61K00948 | A61K00920 | A61K031425 | A61K031505,None,1,1,No,Grant,Yes
75,US7445897,B2,"Novel sequence variants of multi-drug resistance genes, MDR1 and MRP1, and recombinant cells expressing MRP1 and MDR1 for assessment of drug penetration and disposition",US20040539362P,United States,2004-01-26T00:00:00Z,2004,2005-01-26T00:00:00Z,2008-11-04T00:00:00Z,2008,THE UNIVERSITY OF WASHINGTON,HO RODNEY J  US  | YANG ZIPING  US  | SHEN DANNY D  US  | WU DANIEL  US,C12Q00168,US2009130701A1 | US2006024685A1,2,1,No,Grant,Yes
76,US7468274,B2,Single cell analysis of HIV replication capacity and drug resistance,US20040540716P,United States,2004-01-30T00:00:00Z,2004,2005-01-25T00:00:00Z,2008-12-23T00:00:00Z,2008,THE JOHNS HOPKINS UNIVERSITY,SILICIANO ROBERT    US  | ZHANG HAILI    US  | ZHOU YAN    US,G01N03348 | C12Q00170 | C12N015867 | G01N03350 | G06F01900,US2005244818A1,1,1,No,Grant,Yes
77,US7666419,B2,Anti-CCR5 antibody,US20020358886P,United States,2002-02-22T00:00:00Z,2002,2006-10-16T00:00:00Z,2010-02-23T00:00:00Z,2010,ABBOTT LAB,OLSON WILLIAM C    US  | MADDON PAUL J    US  | TSURUSHITA NAOYA    US  | HINTON PAUL R    US  | VASQUEZ MAXIMILLANO    US,A61K039395 | C12N01513 | C07K01628,US7851600B2 | US7122185B2 | US2003228306A1 | US2007031408A1 | US2008107595A1,3,1,No,Grant,Yes
78,US7785879,B1,"Pregnane X receptor compositions, crystals and uses thereof",US20050718516P,United States,2005-09-19T00:00:00Z,2005,2006-09-18T00:00:00Z,2010-08-31T00:00:00Z,2010,SCHERING CORP,WANG WENYAN    US  | TAREMI SHAHRIAR SHANE    US  | PROSISE WINIFRED W    US  | REICHERT PAUL    US  | LESBURG CHARLES A    US  | MADISON VINCENT S    US  | CHENG KUO-CHI    US,C12N00500 | C12N00100 | C07K01400 | C07H02104 | C12N00120 | C12P02106,None,2,1,No,Grant,Yes
79,US7812034,B2,Method of using protease inhibitors for the treatment of liposarcomas,US20030517612P,United States,2003-11-04T00:00:00Z,2003,2004-11-02T00:00:00Z,2010-10-12T00:00:00Z,2010,CITY OF HOPE,CHOW WARREN  US  | SHIH CHU-CHIH  US,A61N00500 | A61K0317056 | A61K031551,US2005176658A1,1,1,No,Grant,Yes
80,US7902203,B2,Anti-infective agents,US20020423209P,United States,2002-11-01T00:00:00Z,2002,2003-10-31T00:00:00Z,2011-03-08T00:00:00Z,2011,ABBOTT LAB,PRATT JOHN K    US  | BETEBENNER DAVID A    US  | DONNER PAMELA L    US  | GREEN BRIAN E    US  | KEMPF DALE J    US  | MCDANIEL KEITH F    US  | MARING CLARENCE J    US  | STOLL VINCENT S    US  | ZHANG RONG    US,C07D47104 | C07D41714 | C07D41704 | C07D49504 | C07D51304 | C07D51900,US2004167123A1,1,1,No,Grant,Yes
81,US7906519,B2,Methods for Concomitant Administration of Colchicine and a Second Active Agent,US20090138141P,United States,2009-01-14T00:00:00Z,2009,2010-08-18T00:00:00Z,2011-03-15T00:00:00Z,2011,MUTUAL PHARMACEUTICAL COMPANY,DAVIS MATTHEW W    US,A61K031427 | A61P02900,US2011039940A1 | US2010179169A1 | US2010305171A1 | US2010305172A1 | US7915269B2 | US7820681B1,5,1,No,Grant,Yes
82,WO1989010752,A1,RETROVIRAL PROTEASE INHIBITORS,US19880194678,United States,1988-05-13T00:00:00Z,1988,1989-05-12T00:00:00Z,1989-11-16T00:00:00Z,1989,ABBOTT LAB,KEMPF DALE J    US  | PLATTNER JACOB J    US  | NORBECK DANIEL W    US  | BOYD STEVEN A    US  | BAKER WILLIAM R    US  | ERICKSON JOHN W    US  | FUNG ANTHONY K L    US  | CROWLEY STEVEN R    US,A61K03116 | C07C23722 | C07D30728 | A61K03154 | C07D40704 | A61K03138 | C07C23336 | A61K031535 | C07D41304 | A61K031428 | C07C23347 | C07D27764 | A61K0315377 | A61K031405 | C07C23712 | A61K03142 | C07C23512 | C07D23112 | C07D27766 | C07D23336 | A61K031421 | A61K031426 | C07D27728 | C07D30904 | C07D25704 | A61K0315375 | C07D30714 | C07D27110 | C07D30920 | C07D31734 | A61K03144 | A61K031335 | A61K031275 | C07C23710 | A61P04300 | C07C23510 | A61K031425 | C07D29520 | A61P03112 | C07D26510 | C07D23364 | A61K03855 | A61K0314245 | A61K031365 | C07D20712 | A61K03134 | A61K03140 | C07D26316 | C07D21381 | A61K031381 | A61K031341 | C07D207337 | C07D23904 | A61K031357 | C07C27122 | C07D23910 | C07D27300 | C07K00506 | C07D295215 | C07C32360 | C07K00702 | C07D26320 | C07K005107 | C07D30768 | C07D26324 | C07D30758 | C07D26506 | C07D295205 | C07D41306 | C07K005103 | C07D33338 | C07K005065 | C07D23332 | C07D31736 | C07D26322 | C07D26306 | C07D26326 | C07C31744 | A61K03800,EP415981A4 | EP415981A1 | JP3504247T  | AU3566089A  | EP342541A3 | IL90218D0 | EP342541A2,5,4,Yes,Application,No
83,WO1992008701,A1,RETROVIRAL PROTEASE INHIBITORS,US19900615210,United States,1990-11-19T00:00:00Z,1990,1991-11-18T00:00:00Z,1992-05-29T00:00:00Z,1992,MONSANTO CO | SEARLE & CO,CLARE MICHAEL    US  | DECRESCENZO GARY ANTHONY    US  | FRESKOS JOHN NICHOLAS    US  | GETMAN DANIEL PAUL    US  | HEINTZ ROBERT MARTIN    US  | LIN KO-CHUNG    US  | MUELLER RICHARD AUGUST    US  | REED KATHRYN LEA    US  | TALLEY JOHN JEFFREY    US  | VAZQUEZ MICHAEL LAWRENCE    US  | SUN ERIC TAK ON    US,C07C069593 | C07D21340 | A61K031472 | A61K031343 | A61K0315375 | A61K031454 | C07D23926 | A61K0314427 | C12N00999 | C07D20716 | A61K0314184 | A61P04300 | A61K03144 | C07D30779 | C07C31131 | A61P03112 | A61K0314402 | A61K0314418 | C07C31740 | C07C32340 | C07C27526 | C07D21116 | C07C31748 | C07D23508 | A61K031445 | A61K031185 | A61P03704 | A61K0315355 | C07D29512 | C07C27504 | A61K0314409 | C07C31145 | A61K031535 | A61K031505 | A61K0314406 | A61K03134 | C07C31728 | A61K031415 | C07C27540 | A61K03140 | C07C21300 | C07D23524 | C07D40112 | C07C27524 | C07C31750 | C07D24144 | A61K0315377 | C07C32360 | A61K0314709 | C07C21308 | C07D29515 | C07D21548 | C07C31147 | C07C27122 | C07D21381 | C07C32906 | C07C27514 | C07K00502 | C07C33512 | C07D23938 | C07D21550 | C07D29513 | A61K03147 | C07D21554 | C07D21726 | A61K031195 | C07K00506 | C07K005078 | C07D23506 | C07C33508 | C07C31744 | C07D30785 | C07C27518 | A61K031496 | C07C27528 | A61K03117 | A61K031197 | C07C27120 | A61K031216 | C07C21302 | C07C27522 | A61K03127 | A61K03800 | C07C21528 | C07C27116,CA2096409A1 | DE69129235T2 | US5708004A  | GR3035176T3 | PT99554A  | EP855388B1 | AT147378T  | EP558630B1 | US2002161234A1 | US5872298A  | JP2003192648A  | ES2243958T3 | EP731088A2 | EP558673B1 | EP855388A2 | EP730570A1 | CA2096408C  | EP813868A3 | EP730570B1 | DE69304051T2 | US5872299A  | AU1083395A  | HU9301447D0 | EP735019A2 | DE69126987T2 | EP641333A1 | EP815856B1 | DK0558673T3 | US5475013A  | DE69130070D1 | AT164839T  | GR3020814T3 | WO9208699A1 | ES2059293T1 | CA2096409C  | US5510349A  | DE69118907T2 | US7189864B2 | US6974876B2 | EP813867A3 | DK0855388T3 | DE69132439T2 | CA2096525C  | MX9102139A  | AT170169T  | DE69130070T2 | US5620977A  | IE914018A1 | AU9085191A  | EP813867B1 | DE69124110D1 | JP7508041T  | PT730570E  | ES2059289T1 | CA2131182C  | GR3023051T3 | JP6503092T  | PT99553A  | AU4253193A  | DE69424065D1 | DK0813868T3 | DE69129235D1 | ZA9109164A  | ES2151618T3 | DE69133466T2 | US2005171366A1 | AT214046T  | ZA9109160A  | EP558657B1 | DE69133463D1 | IL100085D0 | IL100083D0 | EP815856A3 | AT136888T  | AU9125191A  | AU9053191A  | CA2096528A1 | ZA9109161A  | US5583238A  | JP6502860T  | DE69133464D1 | ES2145252T3 | ES2059289T3 | GR3020451T3 | EP813867A2 | AU4253093A  | ZA9109163A  | ES2059294T1 | MX9102136A  | WO9208698A1 | AU676479B2 | DK0558657T3 | AT296626T  | DE69132423D1 | DK0554400T3 | AT141265T  | EP641333B1 | ES2091000T3 | IL100087D0 | DK730570T3 | EP855388A3 | EP735019A3 | US6022996A  | AT296624T  | CA2096408A1 | DE69132439D1 | PT99552A  | DE69126987D1 | US5610190A  | MX9102138A  | EP731088A3 | EP731088B1 | AU662114B2 | IE914019A1 | DK0813867T3 | US5510378A  | DK0815856T3 | DE69133466D1 | DE69430077T2 | ES2059296T1 | PT855388E  | MX9102137A  | EP813868B1 | DE69304051D1 | EP558630A1 | EP558603B1 | JP2003160545A  | MX9102151A  | DK0731088T3 | CA2096407C  | AT296625T  | DE69118907D1 | DE69132423T2 | ZA9109162A  | EP813868A2 | JP3492362B2 | US6570027B2 | ES2243959T3 | HU9301446D0 | AU9133291A  | DE69133463T2 | WO9514653A1 | EP554400A1 | IE914022A1 | EP558603A1 | HU9301445D0 | IE914021A1 | US5510487A  | US5622949A  | CA2131182A1 | ES2059294T3 | AU9092591A  | AT196759T  | DK0558630T3 | ES2059295T1 | DK0558603T3 | EP558673A1 | US5698569A  | DE69424065T2 | CA2096528C  | US2003225285A1 | ES2173520T3 | DE69124110T2 | JP6502866T  | EP554400B1 | ES2059293T3 | IE914020A1 | WO9208688A1 | JP6505963T  | US5703076A  | AU662309B2 | US5482947A  | GR3024586T3 | WO9208700A1 | US5602175A  | PT99551A  | ES2059295T3 | AT155779T  | AU661667B2 | GR3034894T3 | CA2096525A1 | IL100086D0 | AT191907T  | WO9323368A1 | US5614522A  | EP735019B1 | EP558657A1 | US5648511A  | DK641333T3 | ES2059296T3 | DE69133464T2 | JP6502859T  | IL100084D0 | PT99555A  | WO9323388A1 | US5475027A  | ES2243960T3 | US6388094B1 | AT196466T  | EP815856A2 | DK0735019T3 | ES2151975T3 | GR3033429T3 | DE69430077D1 | CA2096407A1,148,14,Yes,Grant,Yes
84,WO1993009096,A1,HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS,US19910789508,United States,1991-11-08T00:00:00Z,1991,1992-11-03T00:00:00Z,1993-05-13T00:00:00Z,1993,MERCK & CO INC,VACCA JOSEPH P    US  | DORSEY BRUCE D    US  | GUARE JAMES P    US  | HOLLOWAY M KATHARINE    US  | HUNGATE RANDALL W    US,A61K03147 | C07F00909 | C07F00718 | A61K031495 | C07D33506 | A61K031535 | A61P03112 | A61P03118 | C07D21708 | A61K03140 | A61K031195 | C07C23712 | A61K03116 | A61P04300 | A61K031472 | A61K0314025 | A61K031497 | A61K031496 | A61K031415 | C12N00999 | C07D40106 | C07D40512 | C07D21726 | C07D21160 | C07D40906 | C07D41712 | C07D41306 | C07D20716 | C07D24104 | C07D41706 | C07D40506 | C07D40912 | C07D40312 | C07D40112 | C07D40306,CN1176250A  | CY2326B1 | JP8508496T  | ZA9402255A  | CA2195027A1 | BR9406503A  | IL109166D0 | IL103613A  | BR9406576A  | HU220866B1 | AU5921394A  | BG61725B1 | CZ9502528A3 | AT163926T  | SK52394A3 | KR273623B1 | JP2004101C  | DE69224703D1 | CZ9401110A3 | SG52731A1 | IL109166A  | AT230610T  | BG62083B1 | HK1006060A1 | FI954580D0 | FI981591A  | FI942112A  | RU2139052C1 | HU9503170D0 | BG100114A  | RU2131416C1 | NO941696D0 | CZ286412B6 | KR100273623B1 | JP7033373B  | WO9426717A1 | MX9403380A  | AU676563B2 | CY2090A  | SI9420017A  | DK617968T3 | RO118000B1 | DE69431972T2 | SK279471B6 | PT617968E  | NZ265164A  | CN1126469A  | EP617968B1 | WO9422480A1 | HU9401424D0 | DE69224703T2 | BG98745A  | BG100016A  | PL310895A1 | NO941696A  | LV12208A  | HR940209B1 | FI106025B1 | FI955315D0 | LV12208B  | RO115726B1 | CA2195027C  | GB9508300D0 | FI955315A  | ES2188604T3 | CY2090B1 | GR3026334T3 | NO303383B1 | FI954580A  | US5527799A  | ZA9208563A  | US5413999A  | SG64366A1 | FI942112D0 | SK136395A3 | JP5279337A  | SK122595A3 | HU73135A2 | ZA9403104A  | SI9420017B  | NO953876D0 | NZ244986A  | HR940286A2 | IL103613D0 | AU659234B2 | RU2171254C2 | CA2081970C  | CA2161334A1 | AU2819992A  | DZ1766A1 | ES2112880T3 | US5717097A  | FI981591D0 | CN1090187C  | CZ287610B6 | EP617968A1 | HU74006A2 | AU6669294A  | EP541168B1 | SK281864B6 | IL109503D0 | CZ9502900A3 | HK1009248A1 | NO953876A  | NO954427A  | PL171340B1 | CA2081970A1 | NO954427D0 | LV13141B  | EP696277A1 | HU9502860D0 | JP8509980T  | EP541168A1 | DE69431972D1 | AU685772B2 | PL311635A1 | HR940209A2 | CN1120316A  | CA2120192A1 | HU70519A2 | US5668132A  | GB2288801A  | DK0541168T3,87,36,Yes,Grant,Yes
85,WO1994014436,A1,RETROVIRAL PROTEASE INHIBITING COMPOUNDS,US19800518730,United States,1980-05-09T00:00:00Z,1980,1993-12-16T00:00:00Z,1994-07-07T00:00:00Z,1994,ABBOTT LAB,KEMPF DALE J    US  | NORBECK DANIEL W    US  | SHAM HING LEUNG    US  | ZHAO CHEN    US  | SOWIN THOMAS J    US  | RENO DANIEL S    US  | HAIGHT ANTHONY R    US  | COOPER ARTHUR J    US,C07D27502 | C07D26324 | C07D26108 | A61K031426 | A61P03704 | A61P03500 | A61K0315375 | A61K0315377 | A61K03154 | C07D41714 | A61P04300 | A61P03502 | A61P03112 | A61K03142 | A61K031535 | A61K031421 | C07D26530 | A61K031422 | C07C21518 | C07C23722 | C07D27734 | C07C27120 | C07C053134 | C07D26106 | C07D26332 | C07D30336 | C07C27134 | C07D41314 | C07D27722 | C07D27728 | A61P03118 | C07D27736 | C07F00504 | A61K0314164 | A61K031415 | C07C27524 | C07C23710 | C07C27122 | C07D27724 | C07D41312 | C07C23340 | C07F00502 | C07D27730 | C07C21520 | C07D27742 | A61K031395 | C07C21528 | A61K04506 | A61K031425 | C07D26348 | C07D41712 | C07D27756 | A61K031427 | C07D26330 | C07D27732,US5597927A  | JP10087639A  | HK1012337A1 | DK0674513T3 | JP2001354663A  | AT143262T  | DK0402646T3 | DE69332616T2 | HU9500480A3 | IL117425D0 | EP727419A3 | DE69632949D1 | US5616714A  | JP3128335A  | JP2010215650A  | EP727419B1 | US5597926A  | DE69632949T2 | EP674513A4 | GR95300059T1 | IL112962A  | GR3021170T3 | US5659045A  | ES2088839T3 | MX9706827A  | EP486948A2 | CA2214629C  | US5837873A  | US5648497A  | US5565418A  | US5354866A  | DE69133610D1 | CA2055670C  | US5580984A  | HK1039612A1 | EP1302468A1 | DE69305093T2 | NZ233717A  | US6150530A  | DK1302468T3 | DE69332616D1 | ES2225874T3 | EP402646B1 | CA2135890A1 | US5955420A  | EP815224A1 | CA2585898A1 | CA2170020A1 | AU650491B2 | IL108126A  | WO9217176A1 | DE10199053I1 | KR187613B1 | DK0727419T3 | WO9323361A1 | CH689001A5 | AU5571190A  | KR100187613B1 | JP3569240B2 | ES2088839T1 | US5635523A  | AT230402T  | EP997459B1 | JP8505844T  | AT415394T  | CA2017252A1 | DE69034202T2 | DE69032493D1 | DE69034202D1 | US6211142B1 | EP839798A2 | JP2006232845A  | AU645493B2 | GR3035148T3 | JP2761374B2 | IL94444A  | US5256677A  | EP839798A3 | US5886036A  | CA2605872A1 | CA2393271C  | JP3342873B2 | JP2963910B2 | AT271606T  | DE69132435D1 | NL300060I2 | EP486948B1 | IL136396D0 | DK0997459T3 | HK1021530A1 | EP997459A1 | ES2119737T3 | JP10505507T  | JP4308574A  | AT417836T  | US5659044A  | EP815224B1 | US5674882A  | KR255897B1 | HU211606B3 | EP317847A1 | JP3812969B2 | US5541334A  | EP1090914A3 | EP674513A1 | US5362912A  | PT1302468E  | US5608072A  | MX9203679A  | IL133409D0 | KR0184866B1 | DE69334250D1 | KR100255897B1 | ZA9601946A  | KR184866B1 | WO9628548A1 | US6531610B1 | US5892052A  | JP9118679A  | US5539122A  | AT302180T  | PT727419E  | AU697681B2 | ES2070660B1 | AU5183696A  | HK130697A  | MX9302878A  | DE69331643T2 | ES2070660A1 | JP64160532A  | IL108126D0 | US5625072A  | MX9204259A  | AT196761T  | CA2585898C  | IT1273979B  | EP674513B1 | EP1090914A2 | US5846987A  | JP2637847B2 | AU1492795A  | CA2502856A1 | IE20010533A1 | CA2393271A1 | ITMI913081A1 | CA2214629A1 | DK1090914T3 | EP727419A2 | AU2856097A  | PT100304A  | AT168677T  | IL136396A  | IL148516A  | IL94444D0 | HK1057038A1 | US5597928A  | JP3207901B2 | AT213733T  | DK0839798T3 | MX9203693A  | ES2317977T3 | US5583233A  | EP402646A1 | EP486948A3 | EP1302468B1 | IL133409A  | US5696270A  | PT99545B  | JP3914065B2 | US6255068B1 | AU712585B2 | ES2189721T3 | IL148516D0 | PT99545A  | ITMI913081D0 | IL99952A  | US5670675A  | US5545750A  | US5554783A  | US5541206A  | LU90839A9 | KR187990B1 | ES2174992T3 | US5679797A  | CA2017252C  | CA1324067C  | AU5954694A  | US6667404B2 | BR1100661A  | AU659575B2 | CA2055670A1 | CA2135890C  | CA2502856C  | US5142056A  | IL99952D0 | IL112962D0 | US5583232A  | US5552558A  | KR100187990B1 | JP2002322159A  | NL300060I1 | AU677500B2 | DE69331643D1 | US5616720A  | US5151438A  | EP839798B1 | EP1090914B1 | IE920714A1 | US2003195362A1 | IE913840A1 | DE69032493T2 | US5591860A  | AU8771591A  | US6169070B1 | DE69132435T2 | DE69305093D1 | DK0486948T3 | CH688551A5 | CA2170020C  | US6017928A  | DE674513T1 | CH684696A5,142,24,Yes,Grant,Yes
86,WO1995006061,A1,RETROVIRAL PROTEASE INHIBITORS AND COMBINATIONS THEREOF,US19930109787,United States,1993-08-20T00:00:00Z,1993,1994-08-09T00:00:00Z,1995-03-02T00:00:00Z,1995,MONSANTO CO | SEARLE & CO,CHANG MIN S   US  | STOLZENBACH JAMES C   US  | TALLEY JOHN J   US  | VAZQUEZ MICHAEL L   US  | GETMAN DANIEL P   US  | MUELLER RICHARD A   US  | OTTINGER JAMES C   US  | DECRESCENZO GARY A   US,C07K00503 | A61K03806,US5750648A  | IL110724D0 | ZA9406325A  | AU7518694A  | IL110724A ,5,5,Yes,Grant,Yes
87,WO1995007696,A1,PHARMACEUTICAL COMPOSITION OF HIV-PROTEASE INHIBITORS,US19930120886,United States,1993-09-13T00:00:00Z,1993,1994-08-30T00:00:00Z,1995-03-23T00:00:00Z,1995,ABBOTT LAB,AL-RAZZAK LAMAN A      | MARSH KENNAN C      | MANNING LOURDES P      | KAUL DILIP,A61K031425 | A61K03855 | A61K00948 | A61K04702 | A61K04712 | A61K04710,JP9502715T  | IL110752A  | AU7717694A  | US5948436A  | AU695516B2 | US5876749A  | IL110752D0 | EP719142A1 | CA2167412A1 | US5725878A ,10,7,Yes,Grant,Yes
88,WO1995009614,A1,PHARMACEUTICAL COMPOSITION,US19930130409,United States,1993-10-01T00:00:00Z,1993,1994-09-09T00:00:00Z,1995-04-13T00:00:00Z,1995,ABBOTT LAB,AL-RAZZAK LAMAN A      | MARSH KENNAN C      | PYTER RICHARD A,A61K00914 | A61K00916 | A61K00948,US5610193A  | EP721330B1 | DE69426984D1 | EP721330A1 | JP9503501T  | AU685509B2 | CA2167413A1 | PT721330E  | DE69426984T2 | ES2156904T3 | IL110915D0 | AT200023T  | IL110915A  | AU7722994A  | DK721330T3 | GR3036091T3 | US5559158A ,15,13,Yes,Grant,Yes
89,WO1995011224,A1,"PROCESS FOR THE PREPARATION OF A SUBSTITUTED 2,5-DIAMINO-3-HYDROXYHEXANE",US19930141795,United States,1993-10-22T00:00:00Z,1993,1994-09-26T00:00:00Z,1995-04-27T00:00:00Z,1995,ABBOTT LAB,STUK TIMOTHY L    US  | KERDESKY FRANCIS A J    US  | LIJEWSKI LINDA M    US  | NORBECK DANIEL W    US  | SCARPETTI DAVID    US  | TIEN JIEN-HEH J    US  | ALLEN MICHAEL S    US  | LANGRIDGE DENTON C    US  | MELCHER LAURA    US  | RENO DANIEL S    US  | SHAM HING LEUNG    US  | ZHAO CHEN    US  | HAIGHT ANTHONY R    US  | LEANNA M ROBERT    US  | MORTON HOWARD E    US  | ROBBINS TIMOTHY A    US  | SOWIN THOMAS J    US,C07C23335 | C07C22718 | C07C25527 | C07C22936 | C07C23112 | C07C25140 | C07C26906 | C07C27120 | C07D20944 | C07C22516 | C07C21528 | C07C21300 | C07D22114 | C07C25542,CA2174000A1 | US5491253A  | DE69420421T2 | JP2006206597A  | ES2138667T3 | EP724563B1 | US5616776A  | US5786500A  | EP916646A2 | AT238983T  | US5543549A  | JP3822233B2 | US5543552A  | ES2198094T3 | DE69432611D1 | US5543551A  | JP4172717B2 | US5625092A  | US5654466A  | AT183993T  | GR3031939T3 | JP9504024T  | US5541328A  | US5508409A  | EP916646B1 | DK916646T3 | EP724563A1 | CA2174000C  | EP916646A3 | US5569777A  | PT916646E  | DK724563T3 | DE69420421D1 | DE69432611T2 | HK1011677A1 | US5565604A ,29,12,Yes,Grant,Yes
90,WO1995020384,A1,PHARMACEUTICAL COMPOSITIONS CONTAINING HIV PROTEASE INHIBITORS,US19940189021,United States,1994-01-28T00:00:00Z,1994,1995-01-03T00:00:00Z,1995-08-03T00:00:00Z,1995,ABBOTT LAB,AL-RAZZAK LAMAN      | MARSH KENNAN C      | MANNING LOURDES P      | KAUL DILIP,A61K00908 | A61K04712 | A61K04500 | C07D27728 | A61K00948 | A61K00900 | A61K04710 | A61K031425 | A61K04744 | A61K04714 | A61K04708,EP732923B1 | HK1011609A1 | AT210441T  | PT732923E  | CA2178632C  | CA2178632A1 | MX9602984A  | DK0732923T3 | DE69524567T2 | CA2540258A1 | AU1524895A  | IL111991D0 | DE69524567D1 | EP732923A1 | ES2169121T3 | AU700942B2 | IL111991A  | JP4353542B2 | US5484801A ,16,14,Yes,Grant,Yes
91,WO1995023793,A1,2-ISOXAZOLINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME  AND PROCESS FOR PRODUCING RELATED DERIVATIVES FROM THE SAME ,JP19940056639,Japan,1994-03-02T00:00:00Z,1994,1995-03-02T00:00:00Z,1995-09-08T00:00:00Z,1995,DAICEL CHEMICAL INDUSTRIES,ONOMURA OSAMU    JP  | NISHIKAWA MASAHIRO    JP  | TAKASE ICHIRO    JP  | UEDA YOICHIRO    JP | MURAI YOSHIYUKI    JP,C07C21300 | C07C21310 | C07C21528 | C07C26906 | C07C273/18 | C07D261/04 ,DE69524737D1 | DE69524737T2 | EP0748801A1 | EP0748801A4 | EP0748801B1 | US5750717A | US5962692A | US5994558A | US6018069A,7,4,Yes,Grant,Yes
92,WO1995033464,A2,RETROVIRAL PROTEASE INHIBITOR COMBINATIONS,US19940253638,United States,1994-06-03T00:00:00Z,1994,1995-06-02T00:00:00Z,1995-12-14T00:00:00Z,1995,SEARLE & CO,BRYANT MARTIN L  US  | POTTS KAREN E  US  | SMIDT MARY  US  | TUCKER SIMON P  US,A61K031425 | A61K031495 | A61K03116 | A61K03144 | A61K03118 | A61K031395,FI118986B1 | US2006240410A1 | NO965136D0 | US2003207813A1 | PL180070B1 | NO965136A  | FI964835A  | CZ9603525A3 | DE69534549D1 | NZ287702A  | NO322963B1 | CZ296149B6 | DK0762880T3 | FI20085256A  | EP762880A1 | EP762880B1 | HU76979A2 | EP1649871A1 | HU9603328D0 | ES2252742T3 | BR9507912A  | JP2007020576A  | JP10505324T  | AU2651095A  | AU696299B2 | JP3896159B2 | MX9700237A  | CN1290500C  | PL317425A1 | CN1166786A  | CA2191948A1 | FI964835D0 | US6100277A  | DE69534549T2 | AT307581T  | WO9533464A3 | RU2166317C2,26,20,Yes,Grant,Yes
93,WO1996004232,A1,PROCESS FOR THE PREPARATION OF A SUBSTITUTED 2.5-DIAMINO-3-HYDROXYHEXANE,US19940283109,United States,1994-07-29T00:00:00Z,1994,1995-07-17T00:00:00Z,1996-02-15T00:00:00Z,1996,ABBOTT LAB,HAIGHT ANTHONY R      | GOODMONSON OWEN J      | PAREKH SHYAMAL I      | ROBBINS TIMOTHY A      | SEIF LOUIS S,C07C21308 | C07C21528,JP10503772T  | MX9700720A  | GR3032553T3 | DK773921T3 | EP773921A1 | PT773921E  | DE69513667T2 | EP773921B1 | AT187160T  | US5672706A  | CA2192836A1 | DE69513667D1 | ES2143058T3,12,12,Yes,Grant,Yes
94,WO1996004913,A1,HIV PROTEASE INHIBITOR COMBINATION,US19940289474,United States,1994-08-11T00:00:00Z,1994,1995-08-07T00:00:00Z,1996-02-22T00:00:00Z,1996,MERCK & CO INC,DEUTSCH PAUL J      | EMINI EMILIO A      | VACCA JOSEPH P,A61K031425 | A61P03704 | A61K031495 | A61K031435 | A61P03118 | A61P03112 | A61K031496 | A61K031427 | A61K031426 | A61K03144 | A61K03147 | C07D21726 | C07D27722 | C07D40106,NO970632D0 | ES2190456T3 | SI774969T1 | IL114808D0 | MX9701121A  | CY2360B1 | CZ9700389A3 | IL114808A  | EP774969B8 | CZ292577B6 | HU76540A2 | EP774969A1 | FI970565A  | PL181578B1 | AU3361195A  | CN1160350A  | CA2197207A1 | CA2197207C  | CN1101190C  | NO970632A  | PL318506A1 | DE69529678T2 | NO314168B1 | SK18197A3 | AU698664B2 | ZA9506662A  | DK774969T3 | EP774969B1 | RU2194506C2 | FI970565D0 | AT232727T  | DE69529678D1 | JP10504036T ,22,22,Yes,Grant,Yes
95,WO1996026734,A1,ANTIVIRAL COMBINATIONS OF BCH-189 AND RITONAVIR,GB19950003850,United Kingdom,1995-02-25T00:00:00Z,1995,1996-02-22T00:00:00Z,1996-09-06T00:00:00Z,1996,GSK LLC,MCDADE HUGH BROWNLIE  GB,A61K03806,GB9503850D0 | EP810873A1 | AU4879496A  | CA2213621A1 | JP11501303T ,5,5,Yes,Application,No
96,WO1996026934,A1,SYNTHESIS OF OPTICALLY ACTIVE CALANOLIDES A AND B AND ENANTIOMERS AND RELATED COMPOUNDS,US19950395035,United States,1995-02-27T00:00:00Z,1995,1996-02-27T00:00:00Z,1996-09-06T00:00:00Z,1996,UNIVERSITY OF TENNESSEE RESEARCH CORPORATION,BAKER DAVID C      | DESHPANDE PRASHANT P      | YAN SHIJIA      | TAGLIAFERRI FRANK      | VICTORY SAMUEL F,C07D49314 | C07D49304 | C07D31116,US5608085A  | US5843990A ,3,2,Yes,Grant,Yes
97,WO1996039398,A1,PROCESS FOR THE PREPARATION OF AN HIV PROTEASE INHIBITING COMPOUND,US19950469965,United States,1995-06-06T00:00:00Z,1995,1996-05-13T00:00:00Z,1996-12-12T00:00:00Z,1996,ABBOTT LAB,TIEN JIEN-HEH      | MENZIA JEROME A      | COOPER ARTHUR J,C07D27728,DE69620882D1 | PT830353E  | JP11507029T  | EP830353B1 | DK830353T3 | DE69620882T2 | ES2176456T3 | US5567823A  | AT216696T  | JP2010270123A  | CA2219983A1 | CA2219983C  | EP830353A1 | MX9709454A  | JP4580044B2,12,11,Yes,Grant,Yes
98,WO1997001349,A1,USE OF RITONAVIR (ABT-538) FOR IMPROVING THE PHARMACOKINETICS OF DRUGS METABOLIZED BY CYTOCHROME P450 IN A METHOD OF TREATING AIDS,US19950000654P,United States,1995-06-29T00:00:00Z,1995,1996-06-28T00:00:00Z,1997-01-16T00:00:00Z,1997,ABBOTT LAB,NORBECK DANIEL W      | KEMPF DALE J      | LEONARD JOHN M      | BERTZ RICHARD J,C07D24304 | C07D41712 | C07D27724 | A61K0315375 | C07D29508 | A61K031445 | C07D40114 | C07D30346 | A61K03147 | A61K031535 | A61K03155 | A61K031336 | C07D30720 | C07D29518 | C07D21722 | A61P03112 | A61K031335 | A61K031472 | A61K031425 | A61K03134 | A61K0314427 | C08F00234 | A61K03855 | A61K031426 | A61K0317048 | A61K03806 | A61K031453 | A61K03805 | A61K031337 | A61K031498 | A61P03118 | A61K03144 | A61K031341 | A61K031395,PT1284140E  | DE69624136T2 | EP1284140A2 | DK1293207T3 | EP1293207A1 | IL122546D0 | PT1293207E  | ES2186787T3 | EP1273298A2 | EP1210941A2 | CA2224738C  | DE69637511D1 | EP1210941A3 | AT225186T  | DK0871465T3 | US6037157A  | EP871465B1 | PT871465E  | KR20070120619A  | EP1293207B1 | EP871465A1 | MX9710403A  | US2002039998A1 | CA2224738A1 | DE69637511T2 | DE69637976D1 | DK1284140T3 | JP2007291131A  | AU6342096A  | AU722812B2 | ES2304416T3 | DE69624136D1 | US6703403B2 | JP11508884T  | HK1053782A1 | EP1284140B1 | EP1273298A3 | EP2130534A1 | HK1053783A1 | EP1284140A3 | ES2328559T3 | JP4023823B2 | AT392895T  | EP2295052A1 | HK1016088A1,32,14,Yes,Grant,Yes
99,WO1997021685,A1,RETROVIRAL PROTEASE INHIBITING COMPOUNDS,US19950572226,United States,1995-12-13T00:00:00Z,1995,1996-12-06T00:00:00Z,1997-06-19T00:00:00Z,1997,ABBOTT LAB,SHAM HING LEUNG      | NORBECK DANIEL W      | CHEN XIAOQI      | BETEBENNER DAVID A      | KEMPF DALE J      | HERRIN THOMAS R      | KUMAR GONDI N      | CONDON STEPHEN L      | COOPER ARTHUR J      | DICKMAN DANIEL A      | HANNICK STEVEN M      | KOLACZKOWSKI LAWRENCE      | OLIVER PATRICIA A      | PLATA DANIEL J      | STENGEL PETER J      | STONER ERIC J      | TIEN JIEH-HEH J      | LIU JIH-HUA      | PATEL KETAN M,C07D25300 | A61K031513 | A61K0314184 | A61P03118 | A61K031496 | A61P04300 | A61K031505 | A61K031425 | C07C27516 | A61K031427 | A61K0314427 | A61K0314439 | C07D23330 | A61K0314965 | C07D26320 | A61K031495 | A61K0314015 | A61K03140 | C07C27318 | A61K04500 | A61K0314433 | A61K03153 | A61K03100 | A61K031443 | A61K0314166 | A61K031421 | C07D23336 | A61K03142 | A61K031415 | A61K0314164 | C07D20722 | C07D26322 | C07D40112 | C07D40312 | A61K03147 | C07D23328 | C07D24106 | C07D40514 | C07D24118 | C07D26316 | C07D207273 | C07D41712 | C07D23340 | C07D41312 | C07D26504 | C07C23520 | C07D23366 | C07D207408 | C07D26334 | C07D24304 | C07D21172 | C07D23910 | C07D25306 | C07D24108 | C07D40512 | C07D26704 | C07D40914 | C07D23922 | C07D27712 | C07D28102 | C07D27732 | C07C23112 | C07D40912 | C07D207416 | C07D27906 | C07D23342 | A61K03805 | C07D23920 | C07D21184 | C07D23332 | A61K03155 | C07D20734 | A61K03141 | C07D23906 | C07D207404 | C07D20727 | C07D22306 | C07D20726 | C07D20740,DE69619140T2 | CN1208405A  | US6313296B1 | AT212986T  | EP882024A1 | JP2008115189A  | CZ296915B6 | HK1016585A1 | US7279582B2 | DE69619140D1 | CA2285119A1 | AU725369B2 | IL124607D0 | NZ510329A  | CN1207288C  | ZA9610475A  | US2002004503A1 | US5914332A  | HU223782B1 | ES2173341T3 | US6472529B2 | CA2238977A1 | EP882024B1 | IL156237A  | DK0882024T3 | NZ338003A  | EP1295874A2 | CO5070655A1 | HU222731B1 | AU1342297A  | NZ510328A  | JP2001058979A  | CZ294246B6 | TW494097B  | EP1170289A2 | JP4181291B2 | HU9901079A2 | CA2238978A1 | JP3170292B2 | IL156237D0 | HU9901079A3 | JP2000502085T  | EP1170289A3 | CZ293650B6 | IL156236D0 | CZ9801762A3 | US6284767B1 | US2008139811A1 | NZ326132A  | CA2285119C  | BR1100397A  | US2003100755A1 | TWI259178B  | JP2000502997T  | EP876353A1 | HU200003305A3 | IL173966D0 | EP1295874A3 | MX9804734A  | WO9721683A1 | CA2238978C  | AU725369C  | IL136661D0 | PT882024E  | CZ300131B6 | IL156236A  | CA2509505A1 | CZ300127B6,48,21,Yes,Grant,Yes
100,WO1997027180,A1,ASPARTYL PROTEASE INHIBITORS,US19960724563,United States,1996-01-26T00:00:00Z,1996,1997-01-22T00:00:00Z,1997-07-31T00:00:00Z,1997,VERTEX PHARMA,TUNG ROGER DENNIS    US  | SALITURO FRANCESCO GERALD    US  | DEININGER DAVID D    US  | BHISETTI GOVINDA RAO    US  | BAKER CHRISTOPHER TODD    US  | SPALTENSTEIN ANDREW    US  | KAZMIERSKI WIESLAW M    US  | ANDREWS CLARENCE WEBSTER III    US,C07D23332 | C07D20726 | A61P04300 | C07D49804 | A61K031495 | A61K03141 | A61K0315365 | A61K03147 | A61K0314353 | C07D27502 | A61K0315375 | A61K0314725 | A61K0314166 | A61P03118 | C07D20736 | A61K0314192 | A61K031538 | C07D24106 | C07D51304 | C07D41712 | C07D26528 | A61K031425 | A61K031435 | C07D47104 | A61K031472 | C07D491107 | A61K031401 | A61K031437 | A61K03140 | A61P03100 | A61K031535 | A61K0315377 | C07D24136 | A61K031433 | C07D41714 | C07D40304 | A61K031506 | A61K031496 | A61K03100 | A61K031427 | A61K031505 | A61K031407 | A61K0314015 | C07D20954 | A61K0314164 | C07D40504 | C07D40112 | A61K031415 | A61K0314025 | A61K031403 | C07D41306 | C07D41706 | C07D49110 | C07D40114 | C07D40306 | C07D40506 | C07D41314 | C07D28510 | C07D40514 | C07D40512 | C07D26532 | C07D40106 | C07D23336 | C07D20727 | C07D26534,BR9707086A  | HU9901024A2 | US5883252A  | JP2000501111T  | NO983435A  | AU1758097A  | IL125479D0 | AP844A  | AU709239B2 | EP882022A1 | NO983435D0 | PL328223A1 | AP9700961D0 | US5945413A  | CZ9802344A3 | CA2243121A1 | ZA9700613A ,15,13,Yes,Grant,Yes
101,WO1997027480,A1,METHOD OF MANAGING THE CHEMOTHERAPY OF PATIENTS WHO ARE HIV POSITIVE BASED ON THE PHENOTYPIC DRUG SENSITIVITY OF HUMAN HIV STRAINS,EP19960200175,European Patent Office,1996-01-26T00:00:00Z,1996,1997-01-24T00:00:00Z,1997-07-31T00:00:00Z,1997,VIRCO NV,BETHUNE MARIE-PIERRE DE    BE  | HERTOGS KURT    BE  | PAUWELS RUDI    BE,G01N03350 | C12N01586,SK283878B6 | DE69712731D1 | US2002042679A1 | CA2244735A1 | US6528251B2 | IL125442D0 | AU717755B2 | BG102710A  | DE69712731T2 | SK100298A3 | BR9707204A  | AU1316897A  | ES2177922T3 | NO321329B1 | HU9902618A3 | AT217971T  | CA2244735C  | PL186473B1 | CZ9802335A3 | ZA9700669A  | US2003152917A1 | IL125442A  | IS4799A  | HU9902618A2 | NZ325912A  | NO983300D0 | CZ292899B6 | PL328069A1 | TR9801443T2 | EP877937B1 | EP877937A1 | CN1209875A  | CN1991365A  | US6221578B1 | HU226203B1 | NO983300A ,25,21,Yes,Grant,Yes
102,WO1997027856,A1,REMEDIES OR PREVENTIVES FOR AIDS,JP19960014825,Japan,1996-01-31T00:00:00Z,1996,1997-01-30T00:00:00Z,1997-08-07T00:00:00Z,1997,"SANKYO COMPANY LIMITED, | UBE INDUSTRIES LTD",KOMAI TOMOAKI    JP  | OHMINE TOSHINORI    JP  | NISHIGAKI TAKASHI    JP  | KIMURA TOMIO    JP  | KATSUBE TETSUSHI    JP,C07D21556 | A61K03855,NO983512D0 | AU1556497A  | CZ9802386A3 | CN1214632A  | AU713704B2 | HU9901642A2 | NO983512A  | CA2245179A1 | HU9901642A3 | EP878194A1 | JP9323932A ,10,9,Yes,Grant,Yes
103,WO1997035587,A1,COMPOSITIONS COMPRISING AN HIV PROTEASE INHIBITOR SUCH AS VX 478 AND A WATER SOLUBLE VITAMIN E COMPOUND SUCH AS VITAMIN E-TPGS,US19960013893P,United States,1996-03-22T00:00:00Z,1996,1997-03-21T00:00:00Z,1997-10-02T00:00:00Z,1997,GSK LLC,ROY ARUP K    US  | TILLMAN LLOYD GARY    US,A61K00908 | A61K04500 | A61K03100 | A61K04732 | A61P03100 | A61P03118 | A61K04710 | A61K00948 | A61K031635 | A61K031425 | A61K04722 | A61K031495 | A61K031535,EP906107A1 | CZ9803035A3 | CO4790151A1 | JP2000500504T  | SI906107T1 | ES2190528T3 | RO119923B1 | CA2249336C  | KR2000004919A  | IL126185A  | AP1150A  | TR9801881T2 | HK1016896A1 | CZ289958B6 | ZA9702387A  | UY25926A1 | ID16781A  | IL126185D0 | BG102838A  | DE69718315D1 | GB9606372D0 | SK126998A3 | OA10880A  | NO317639B1 | IS4840A  | UA67723C2 | CN1225587A  | DK906107T3 | CY2444B1 | EE04093B1 | PL328916A1 | TW455491B  | BG64457B1 | AU2159197A  | EA001484B1 | IS2066B  | CA2249336A1 | US6730679B1 | NO984386D0 | JP3117726B2 | AT230602T  | DE69718315T2 | NZ331645A  | SK284244B6 | EP906107B1 | PL187919B1 | BR9708238A  | AP9801343D0 | EE9800323A  | KR20000004919A  | AU724239B2 | NO984386A ,38,36,Yes,Grant,Yes
104,WO1997037657,A1,ANTI-HIV COMPOSITION CONTAINING IMIDAZOLE DERIVATIVE,JP19960082563,Japan,1996-04-04T00:00:00Z,1996,1997-03-14T00:00:00Z,1997-10-16T00:00:00Z,1997,"SHIONOGI & CO., LTD",FUJIWARA TAMIO    JP,A61K031425 | A61K03144 | A61K031505 | A61K0314439 | C07D40106 | A61K03147 | A61K03166,AU712071B2 | MXPA98008158A  | CN1111406C  | CN1220604A  | US6083958A  | AU1940797A  | PL329174A1 | CA2250844C  | KR20000005115A  | RU2188638C2 | JP3272369B2 | HU9902175A2 | PL187925B1 | TW477701B  | EP906756A4 | EP906756A1 | NO984616D0 | KR2000005115A  | HU9902175A3 | CA2250844A1 | NO984616A  | BR9708592A ,16,15,Yes,Grant,Yes
105,WO1997042962,A1,FORMULATION FOR USE IN THE PREVENTION OF PATHOGEN INDUCED DISEASES INCLUDING HIV AND HSV,US19960017106P,United States,1996-05-09T00:00:00Z,1996,1997-05-09T00:00:00Z,1997-11-20T00:00:00Z,1997,"INFECTIO RECHERCHE, INC.",BERGERON MICHEL G  CA  | DESORMEAUX ANDRE  CA  | TREMBLAY MICHEL  CA,A61K009127 | A61K03166 | A61P03104 | A61P02900 | A61K04500 | A61P01700 | A61P03500 | A61P03100 | A61K03100 | A61K04732 | A61K031522 | A61K03109 | A61K03170 | A61K031662 | A61K03114 | A61K03152 | A61K031765 | A61K04506 | A61K00900 | A61K04710,OA11096A  | NO985148A  | EP930886A1 | CA2258811A1 | CA2258811C  | KR20000010834A  | AU2629997A  | NO985148D0 | KR2000010834A  | DE69729646D1 | JP2000510836T  | DE69729646T2 | US6068851A  | AU723081B2 | IL126804D0 | NZ332578A  | CN1218403A  | HK1019560A1 | AP1406A  | EP930886B1 | BR9709228A  | AT269711T  | CN1177594C  | AP9801382D0,17,16,Yes,Grant,Yes
106,WO1997046222,A1,PEDIATRIC FORMULATION FOR HIV PROTEASE INHIBITORS,US19960019097P,United States,1996-06-03T00:00:00Z,1996,1997-05-30T00:00:00Z,1997-12-11T00:00:00Z,1997,MERCK & CO INC,OSTOVIC DRAZEN    US  | THOMPSON KAREN C    US,A61K03147 | A61K031427 | A61K00900 | A61K0314725 | A61K031496 | A61K04710,ZA9704829A  | AU3146997A  | GB9613109D0,3,3,Yes,Application,No
107,WO1998000393,A1,PROCESS FOR THE PREPARATION OF AN ACTIVATED AMINO ACID,US19960671893,United States,1996-06-28T00:00:00Z,1996,1997-06-04T00:00:00Z,1998-01-08T00:00:00Z,1998,ABBOTT LAB,OLIVER PATRICIA A      | COOPER ARTHUR J      | PATERSON JOSEPH B JR      | LANGRIDGE DENTON C      | TIEN JIEH-HEH J,C07D27728 | C07C27154 | C07C26904,MX9801637A  | CA2229790A1 | ES2166545T3 | US6022989A  | EP854862A1 | JP4090506B2 | DK854862T3 | JP11513039T  | PT854862E  | AT207461T  | DE69707639T2 | EP854862B1 | DE69707639D1,12,11,Yes,Grant,Yes
108,WO1998000410,A1,PROCESS FOR THE PREPARATION OF A DISUBSTITUTED THIAZOLE,US19960673445,United States,1996-06-28T00:00:00Z,1996,1997-05-19T00:00:00Z,1998-01-08T00:00:00Z,1998,ABBOTT LAB,OLIVER PATRICIA A      | COOPER ARTHUR J      | LALLAMAN JOHN E      | LANDGRIDGE DENTON C      | TIEN JIEH-HEH J,C07D27730 | C07D27728,PT854872E  | JP2009035560A  | EP854872A1 | DE69711590D1 | DK854872T3 | CA2229788A1 | JP11512114T  | US6160122A  | MX9801636A  | ES2177980T3 | EP854872B1 | AT215535T  | DE69711590T2,12,11,Yes,Grant,Yes
109,WO1998003476,A1,ANILINOPEPTIDE DERIVATIVES,CH19960001788,Switzerland,1996-07-17T00:00:00Z,1996,1997-07-16T00:00:00Z,1998-01-29T00:00:00Z,1998,NOVARTIS AG,FAESSLER ALEXANDER    GB  | BOLD GUIDO    CH  | CAPRARO HANS-GEORG    CH  | LANG MARC    FR,C07D29512 | A61K0314196 | A61K03140 | A61K03127 | A61K031495 | A61P03118 | C07D24908 | C07D52100 | C07D295135 | C07C27122,US6451973B1 | AU3767797A  | DE69710731T2 | SI915841T1 | JP4100710B2 | ES2173466T3 | EP915841B1 | JP2000515147T  | PT915841E  | DE69710731D1 | DK915841T3 | AT213725T  | EP915841A1,11,11,Yes,Grant,Yes
110,WO1998004290,A2,"COMPOSITIONS COMPRISING AN INDUCING AGENT AND AN ANTI-VIRAL AGENT FOR THE TREATMENT OF BLOOD, VIRAL AND CELLULAR DISORDERS",US19960687670 | US19960687671,United States,1996-07-26T00:00:00Z,1996,1997-07-28T00:00:00Z,1998-02-05T00:00:00Z,1998,BOSTON UNIVERSITY TRUSTEES,PERRINE SUSAN P    US  | FALLER DOUGLAS V    US  | WHITE BRIAN F    US,A61P03500 | A61K03122 | A61K031195 | A61P03112 | A61K03821 | A61K03855 | A61K03119 | A61K04506,EP1611885A8 | EP969869A2 | WO9804290A3 | US2001009922A1 | JP2001527517T  | AU3889197A  | EP1886677A1 | CA2263675C  | US6677302B2 | US5939456A  | EP1611885A1 | EP2298350A2 | US6403647B1 | US6197743B1 | CA2263675A1,12,6,Yes,Grant,Yes
111,WO1998014436,A1,"4,4-DISUBSTITUTED-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS AND INTERMEDIATES AND PROCESSES FOR MAKING THE SAME",US19960725294,United States,1996-10-02T00:00:00Z,1996,1997-10-01T00:00:00Z,1998-04-09T00:00:00Z,1998,BRISTOL MYERS SQUIBB PHARMA CO,CHRIST DAVID DONALD      | MARKWALDER JAY ANDREW      | FORTUNAK JOSEPH MARIAN      | KO SOO SUNG      | MUTLIB ABDUL EZAZ      | PARSONS RODNEY LAWRENCE JR      | PATEL MONA      | SEITZ STEVEN PAUL,A61K0315365 | A61K031536 | C07D41314 | A61K031535 | A61P03118 | A61P03704 | A61P04300 | C07C21300 | C07D49804 | C07D26524 | C07D33908 | C07D41306 | C07B05900 | C07D26518 | C07D41304 | C07D41706 | C07D21375,JP2001505873T  | CA2268953A1 | DE69724630D1 | AU4802797A  | ZA9708759A  | AT248826T  | JP4212650B2 | DE69724630T2 | ES2203790T3 | EP929533B1 | EP929533A1 | EP1359147A1,10,9,Yes,Grant,Yes
112,WO1998017282,A1,METHODS OF USING SUCROSE OCTASULFATE TO TREAT OR PREVENT ENVELOPED VIRUS INFECTION,US19960735460,United States,1996-10-23T00:00:00Z,1996,1997-10-23T00:00:00Z,1998-04-30T00:00:00Z,1998,VERTEX PHARMA,NAVIA MANUEL A,A61K03170,AU4995597A ,2,2,Yes,Application,No
113,WO1998020009,A1,"(4R,5S,6S,7R)-HEXAHYDRO-1- [5-(3-AMINOINAZOLE)METHYL] -3-BUTYL-5,6-DIHYDROXY-4,7-BIS [PHAENYLMETHYL] -2H-1,3-DIAZEPIN-2-ONE, ITS PREPARATION AND ITS USE AS HIV PROTEASE INHIBITOR",US19960747104 | US19960029746P,United States,1996-11-08T00:00:00Z,1996,1997-11-04T00:00:00Z,1998-05-14T00:00:00Z,1998,BRISTOL MYERS SQUIBB PHARMA CO,RODGERS JAMES DAVID      | LAM PATRICK YUK-SUN,A61P03118 | A61K031551 | A61K03155 | C07D40306,EE9900188A  | DE69723456D1 | CA2270966A1 | KR20000053122A  | NZ335919A  | CZ9901575A3 | IL129726D0 | HR970586A2 | CN1235602A  | LT99044A  | NO992229D0 | LV12375B  | LT99045A  | AU5103398A  | HR970595A2 | WO9820008A1 | JP2001503428T  | CN1235601A  | LT4676B  | US2001011088A1 | LV12375A  | SI9720071A  | NO992228A  | BR9712755A  | LV12374B  | SI20074A  | NO992229A  | KR2000053123A  | US5932570A  | EA001154B1 | KR2000053122A  | EP937067B1 | HU9904143A2 | US6218386B1 | SK59599A3 | LT4619B  | EP937067A1 | CZ9901574A3 | SK59699A3 | AT244714T  | ZA9709867A  | PL333421A1 | ES2202645T3 | AU722489B2 | KR20000053123A  | BR9712910A  | JP2001503429T  | HU9904143A3 | PL333412A1 | ZA9709868A  | IL129727D0 | US6451999B2 | DE69723456T2 | EP937066A1 | LV12374A  | EE9900187A  | AU5165198A  | CA2270963A1 | TW383304B  | NO992228D0 | HU9904676A2,48,26,Yes,Grant,Yes
114,WO1998020888,A1,AIDS REMEDY,JP19960312772,Japan,1996-11-08T00:00:00Z,1996,1997-11-07T00:00:00Z,1998-05-22T00:00:00Z,1998,JAPAN ENERGY CORPORATION,SATO HIDEHARU  JP  | SHINTANI MAKOTO  JP  | FUKAZAWA TOMINAGA  JP  | MUTO AKIHIRO  JP  | TERAJIMA KEISUKE  JP,A61K03806 | A61K03855,NZ335639A  | NO992244A  | EP955054A4 | CA2270546A1 | ZA9710056A  | NO992244D0 | US2002068749A1 | AU716760B2 | EP955054A1 | AU4885397A ,9,8,Yes,Application,No
115,WO1998022106,A1,PHARMACEUTICAL COMPOSITION,US19960754390,United States,1996-11-21T00:00:00Z,1996,1997-11-12T00:00:00Z,1998-05-28T00:00:00Z,1998,ABBOTT LAB,LIPARI JOHN      | AL-RAZZAK LAMAN A      | GHOSH SOUMOJEET      | GAO RONG      | KAUL DILIP,A61K031425 | A61K04508 | A61K0314545 | A61K04744 | A61K03117 | A61K031635 | A61P03118 | A61K04742 | A61P04300 | A61K0314709 | A61K031472 | A61K04710 | A61K04712 | A61K03145 | A61K031535 | A61K031551 | A61K031341 | A61K0315375 | A61K03855 | A61K031513 | A61K00948 | A61K031496 | A61K0314704 | A61K0314725 | A61K03147 | A61K031426 | A61K03805 | A61K0314433 | A61K04726,SK285022B6 | JP2000515555T  | JP3592337B2 | AU5257398A  | KR20000057169A  | HU200002932A2 | SK65599A3 | BG64411B1 | JP2004346077A  | EP942721B1 | DE69718668D1 | TR9901129T2 | HK1022441A1 | AU200039414A  | NZ335002A  | CN1250219C  | PL190185B1 | IL129300D0 | EP942721A1 | CZ9901602A3 | CN1248914A  | KR100478075B1 | IL129300A  | AU717546B2 | JP4523799B2 | ES2191862T3 | EP1283041A1 | TW475895B  | DK942721T3 | AT231393T  | NO992427D0 | HU224319B1 | CN1989963A  | CN101103984A  | CA2271196A1 | KR2000057169A  | NO992427A  | NO326927B1 | CZ299728B6 | BG103425A  | CA2505430A1 | DE69718668T2 | PT942721E  | HU200002932A3 | AU757970B2 | PL336980A1 | BR9714310A  | ZA9710071A  | CA2271196C  | AR048891A2,35,26,Yes,Grant,Yes
116,WO1998028330,A1,"NOVEL CYCLOSPORIN DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",FR19960015955,France,1996-12-24T00:00:00Z,1996,1997-12-23T00:00:00Z,1998-07-02T00:00:00Z,1998,AVENTIS PHARMA S.A,BARRIERE JEAN-CLAUDE    FR  | BASHIARDES GEORGES    FR  | CARRY JEAN-CHRISTOPHE    FR  | EVERS MICHEL    FR  | FILOCHE BRUNO    FR  | MIGNANI SERGE    FR,A61K04500 | A61P03114 | A61K03800 | A61P03702 | A61P04300 | C07K00764,PT951474E  | US5994299A  | DE69713152D1 | JP4146518B2 | EP951474A1 | JP2001507347T  | ZA9711607A  | ES2178038T3 | MA26458A1 | AU5669398A  | EP951474B1 | FR2757521A1 | FR2757521B1 | AT218582T  | DK951474T3,12,12,Yes,Grant,Yes
117,WO1998032442,A1,QUINOXALINE IN TRIPLE COMBINATION WITH PROTEASE INHIBITORS AND REVERSE TRANSCRIPTASE INHIBITORS AS MEDICINES FOR TREATING AIDS,DE19971003131,Germany,1997-01-29T00:00:00Z,1997,1998-01-15T00:00:00Z,1998-07-30T00:00:00Z,1998,BAYER AG,PAESSENS ARNOLD  DE  | BLUNCK MARTIN  DE  | RIESS GUENTER  DE  | KLEIM JOERG-PETER  DE  | ROESNER MANFRED  DE,A61K031495 | A61K03170 | A61K04506 | A61K03170 | 6A 61K 31:495 J,ZA9800679A  | JP2001511124T  | CN1251525A  | IL130877D0 | SK99899A3 | PL334770A1 | AU6094098A  | NO993670D0 | ID22414A  | NO993670A  | EP977570A1 | DE19703131A1 | CA2278773A1 | BR9807523A ,13,13,Yes,Application,No
118,WO1998033067,A1,TRANSCRIPTION FACTORS THAT REPRESS HIV TRANSCRIPTION AND METHODS BASED THEREON,US19970036242P,United States,1997-01-23T00:00:00Z,1997,1998-01-13T00:00:00Z,1998-07-30T00:00:00Z,1998,UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE,MARGOLIS DAVID    US  | ROMERIO FABIO    US  | DEVICO ANTHONY    US,A61K03855 | A61K03819 | A61K03817 | A61K04800,AU6240098A  | US2009081183A1,3,3,Yes,Application,No
119,WO1998035666,A1,FORMULATIONS OF NANOPARTICLE NAPROXEN TABLETS,US19970800006,United States,1997-02-13T00:00:00Z,1997,1998-02-11T00:00:00Z,1998-08-20T00:00:00Z,1998,NANOSYSTEMS LLC,LIVERSIDGE GARY GEORGE      | EICKHOFF WILLIAM MARK      | RUDDY STEPHEN BERNARD      | MUELLER KARL RAYMOND      | ROBERTS MARY ELLEN      | ENGERS DAVID ALAN,A61K0314725 | A61K00951 | A61K00920 | A61K03855 | A61K00914 | A61K031472 | A61K031192 | A61K031635 | A61K031551 | A61K031366 | A61K031427,CA2295588A1 | AU8183198A  | CA2295588C  | US6221400B1 | US6045829A  | EP1002065A1 | JP2001509518T  | DE69831677T2 | US6068858A  | AT305033T  | JP2010047579A  | WO9902665A1 | EP1002065B1,12,8,Yes,Grant,Yes
120,WO1998038193,A1,METHOD FOR THE PREPARATION OF (+)-CALANOLIDE A AND ANALOGUES THEREOF,US19940285655,United States,1994-08-03T00:00:00Z,1994,1997-02-27T00:00:00Z,1998-09-03T00:00:00Z,1998,SARAWAK MEDICHEM PHARMACEUTICALS,FLAVIN MICHAEL T    US  | XU ZE-QI    US  | KHILEVICH ALBERT    US  | ZEMBOWER DAVID    US  | RIZZO JOHN D    US  | LIAO SHUYUAN    US  | MAR AYE    US  | LIN LIN    US  | VILAYCHAK VILAYPHONE    US  | BRANKOVIC DARKO    US  | DZEKHSTER SERGEY    US  | LIU JINJUN    US,C07D49314 | C07D49304,WO9604263A1 | EP1054007A3 | CA2196656A1 | US5977385A  | EP775130B1 | US2002013478A1 | US6277879B1 | MX9700782A  | CA2196656C  | AT239008T  | US5874591A  | US5869324A  | JP3043813B2 | EP1054007A2 | US5981770A  | US5847164A  | EP1308448A1 | US5872264A  | JP9512829T  | AU704247B2 | DE69530592D1 | US5892060A  | US5859050A  | DE69530592T2 | EP775130A1 | US6043271A  | AU3274695A  | US5489697A  | US5840921A ,26,9,Yes,Grant,Yes
121,WO1998043969,A1,INDAZOLES OF CYCLIC UREAS USEFUL AS HIV PROTEASE INHIBITORS,US19970042219P,United States,1997-03-31T00:00:00Z,1997,1998-03-26T00:00:00Z,1998-10-08T00:00:00Z,1998,BRISTOL MYERS SQUIBB PHARMA CO,RODGERS JAMES DAVID      | JOHNSON BARRY LAINE      | WANG HAISHENG,A61P03704 | A61P03118 | C07D41314 | C07D52100 | A61K031551 | C07D40514 | C07D40114 | C07D49104 | C07D41714 | C07D40306 | C07D40314,CA2282593A1 | JP2001518094T  | EP973767A1 | US5985867A  | AU6870098A ,6,6,Yes,Grant,Yes
122,WO1998045276,A2,"4,4-DISUBSTITUTED-3,4-DIHYDRO-2(1H)-QUINAZOLINONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS",US19970838540,United States,1997-04-09T00:00:00Z,1997,1998-04-07T00:00:00Z,1998-10-15T00:00:00Z,1998,BRISTOL MYERS SQUIBB PHARMA CO,CORBETT JEFFREY W      | KO SOO SUNG,C07D40506 | A61P03118 | A61K031519 | C07D41706 | C07D491056 | A61K031517 | C07D40306 | A61P04300 | C07D41306 | C07D40906 | C07D23980 | C07D40106,AU6796098A  | US2003092722A1 | SK137899A3 | PL336305A1 | EE9900452A  | JP2002504095T  | HU200001446A3 | CA2284996A1 | BR9808513A  | EP973753A2 | CN1252063A  | US6124302A  | US6423718B1 | HU200001446A2 | NZ500592A  | AU734928B2 | NO314936B1 | ZA9802339A  | HR980143A2 | NO994904A  | NO994904D0 | WO9845276A3 | IL132188D0 | EA001991B1 | TW587078B ,21,18,Yes,Grant,Yes
123,WO1998046241,A1,A COMBINATION THERAPY FOR HIV INFECTIONS,US19970839649,United States,1997-04-15T00:00:00Z,1997,1998-04-15T00:00:00Z,1998-10-22T00:00:00Z,1998,"TRIAD BIOTHERAPEUTICS, INC.",HIRSCHMAN SHALOM Z,A61K03520 | A61K03516 | A61K03534 | A61K031675 | A61K031535 | A61K031425,CN1103221C  | AT383161T  | EP1690545A3 | CN1251996A  | US2001005712A1 | US6696422B2 | EP988042A1 | AU6971298A  | BR9808564A  | CA2501751A1 | JP2001520657T  | AU748594B2 | CA2285463A1 | DE69838980D1 | EP988042B1 | EP1690545A2 | EP988042A4 | CA2285463C ,12,9,Yes,Grant,Yes
124,WO1998047492,A1,NANOSIZED ASPARTYL PROTEASE INHIBITORS,US19970844015,United States,1997-04-18T00:00:00Z,1997,1998-04-14T00:00:00Z,1998-10-29T00:00:00Z,1998,VERTEX PHARMA,CHATURVEDI PRAVIN RAMSEWAK   US  | TUNG ROGER DENNIS   US  | BOGER JOSHUA S   US,A61K00951 | A61K03100 | A61K00914 | A61K031635,AU7133898A ,2,2,Yes,Application,No
125,WO1998048021,A1,KAPOSI'S SARCOMA HERPESVIRUS (HHV8) PROTEASE AND ASSEMBLY PROTEIN,US19970044152P,United States,1997-04-22T00:00:00Z,1997,1998-04-22T00:00:00Z,1998-10-29T00:00:00Z,1998,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA,CRAIK CHARLES S    | UENAL AYCE    | GANEM DONALD E,C12N01555 | C12N01538 | C12N00950 | C07K01403 | A61K03843,US6033894A  | AU7254498A ,3,3,Yes,Grant,Yes
126,WO1998052571,A1,ANTIVIRAL COMBINATIONS CONTAINING THE CARBOCYCLIC NUCLEOSIDE 1592U89,GB19970009945,United Kingdom,1997-05-17T00:00:00Z,1997,1998-05-14T00:00:00Z,1998-11-26T00:00:00Z,1998,GSK LLC,ST CLAIR MARTHA HEIDER  US  | BARRY DAVID WALTER  US,A61K03152,NZ510622A  | IL132793D0 | CN1515572A  | HK1024236A1 | CO4940435A1 | IL132793A  | PL189527B1 | IS5246A  | PT983271E  | CN100408580C  | SK285159B6 | GB200010222D0 | GB2340491A  | AU739953B2 | AU7765598A  | AU8017298A  | ID24910A  | NO995620A  | HU200002754A3 | PL336888A1 | JP3150711B2 | EE03924B1 | NZ500868A  | EG23836A  | RS49655B  | BR9809126A  | AR059120A2 | NO995622D0 | NO995621A  | NO995622A  | EA001809B1 | GB9719883D0 | GB2340491B  | AT259811T  | AP2009A  | CN1150194C  | CN1263529A  | WO9852570A1 | WO9852949A1 | EP983271B1 | GB2348202B  | SI983271T1 | HR980265A2 | TW480259B  | DE69821758D1 | HR980265B1 | EP1019056A1 | US6294540B1 | AP9901688D0 | GB9926839D0 | BG103959A  | JP2001525840T  | EE9900537A  | ZA9804085A  | BG64390B1 | AU7912398A  | DK983271T3 | HU226563B1 | PA8451301A1 | CA2289654A1 | EP979082A1 | ZA9804083A  | MA26496A1 | JP2000327679A  | MA26498A1 | CA2289753C  | UY25004A1 | HU200002754A2 | JP2000514096T  | BR9809124A  | NO324731B1 | GB9709945D0 | BR9809127A  | DE69821758T2 | CA2289753A1 | IS2207B  | SV1998000057A  | NO995621D0 | ES2214712T3 | GB9719866D0 | OA11304A  | NZ500865A  | SK156199A3 | GB2348202A  | HR980264A2 | NO995620D0 | EP983271A1 | DZ2493A1 | CA2289655A1 | JP2001525839T  | TR9902810T2 | CO4950569A1,67,42,Yes,Grant,Yes
127,WO1998057648,A1,METHODS OF INCREASING THE BIOAVAILABILITY OF STABLE CRYSTAL POLYMORPHS OF A COMPOUND,US19970876558,United States,1997-06-16T00:00:00Z,1997,1998-06-16T00:00:00Z,1998-12-23T00:00:00Z,1998,VERTEX PHARMA,CHATURVEDI PRAVIN RAMSEWAK      | BOGER JOSHUA S      | TUNG ROGER DENNIS,A61K031513 | A61K031352 | A61K031216 | A61K00914 | A61K031496 | A61K031427 | A61K031635 | A61K031551 | A61K0314709 | A61K0314725,AU8145198A ,2,2,Yes,Application,No
128,WO1999008676,A1,COMPOSITIONS CONTAINING BERGAMOTTIN FOR INCREASING THE ORAL BIOAVAILABILITY OF PHARMACEUTICAL AGENTS,US19970056129P,United States,1997-08-19T00:00:00Z,1997,1998-08-11T00:00:00Z,1999-02-25T00:00:00Z,1999,WARNER LAMBERT CO | HE KAN | HOLLENBERG PAUL | WOOLF THOMAS F,HE KAN  US  | HOLLENBERG PAUL  US  | WOOLF THOMAS F  US,A61K03137 | A61K04506,EP1007034B1 | ZA9807436A  | DE69819519D1 | CA2291233C  | AU8777098A  | AT253357T  | PT1007034E  | DE69819519T2 | AU747051B2 | JP2001515035T  | CA2291233A1 | US6509371B1 | ES2209184T3 | BR9812131A  | DK1007034T3 | EP1007034A1 | NZ502668A ,15,14,Yes,Grant,Yes
129,WO1999009005,A1,HIV MATRIX PROTEIN TYROSINE POSITION 29 POCKET BINDERS,US19970911883,United States,1997-08-15T00:00:00Z,1997,1998-08-14T00:00:00Z,1999-02-25T00:00:00Z,1999,CYTOKINE PHARMASCIENCES INC,PAN SENLIANG      | BUKRINSKY MICHAEL      | HAFFAR OMAR K,C07C32100 | C07C32300 | C07C06976 | A61K031235,US5849793A  | EP1015422A1 | JP2001515063T  | AU759210B2 | AU9020198A  | CA2300876A1 | EP1015422A4 | CA2300876C ,7,6,Yes,Grant,Yes
130,WO1999011635,A1,"5,5-DISUBSTITUTED-1,5-DIHYDRO-4,1-BENZOXAZEPIN-2(3H)-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS",US19970057431P,United States,1997-09-02T00:00:00Z,1997,1998-08-19T00:00:00Z,1999-03-11T00:00:00Z,1999,BRISTOL MYERS SQUIBB PHARMA CO,COCUZZA ANTHONY JOSEPH      | RODGERS JAMES DAVID,A61P03118 | A61K031553 | C07D26714 | C07D41306 | C07D49804,US6489320B1 | CN1268944A  | AU9023998A  | CA2303295A1 | BR9814933A  | TW564248B  | US6140320A  | EP1009742A1 | JP2001514256T  | ZA9807539A  | HR980482A2,12,11,Yes,Grant,Yes
131,WO1999012569,A1,METHODS FOR INCREASING CD4,US19970928279,United States,1997-09-12T00:00:00Z,1997,1998-09-14T00:00:00Z,1999-03-18T00:00:00Z,1999,ALCAFLEU MANAGEMENT GMBH & CO,MONGILLO ANNE R    | STEIN DANIEL S,A61K04505 | A61K03170 | A01N04304,US6800280B2 | US2003100498A1 | US2002004200A1 | CA2302423A1 | US6576231B2 | AU9392198A ,5,4,Yes,Grant,Yes
132,WO1999013914,A1,PHARMACEUTICAL COMPOSITIONS CONTAINING PLASMA PROTEIN,HU19970001554,Hungary,1997-09-18T00:00:00Z,1997,1998-09-17T00:00:00Z,1999-03-25T00:00:00Z,1999,SICOR INC.,HEGEDUES LAJOS    HU  | KREMPELS KRISZTINA    HU  | PAAL KRISZTINA    HU  | PETHO GABOR    HU,A61K031137 | A61K03105 | A61K00908 | A61K031192 | A61K03120 | A61P03700 | A61P03500 | A61K04742,US7119124B2 | IL135055D0 | HU9802107A3 | EA004700B1 | US6743826B1 | SI20189A  | NO20001371D0 | TWI222365B  | LV12493B  | BG64749B1 | ZA9808585A  | US2004014655A1 | AT230611T  | AU9362398A  | PT981375E  | LT4736B  | JP2001508806T  | EP981375B1 | LT2000018A  | US7501455B2 | SK3292000A3 | NO325294B1 | PL193067B1 | US2010076008A1 | NZ503302A  | CN1270529A  | EP981375A1 | PL339369A1 | SI20189B  | TR200001545T2 | SK284683B6 | RS50102B  | ES2187062T3 | US2007232536A1 | HR980499A2 | RO118695B1 | CA2269923A1 | BR9812469A  | US2005064028A1 | SK200000329A3 | DE69810612T2 | HU9701554D0 | HU9802107A2 | HU9802107D0 | CA2269923C  | DK981375T3 | DE69810612D1 | HU223974B1 | CN1189216C  | AU734695B2 | BG104245A  | LV12493A  | NO20001371A ,36,30,Yes,Grant,Yes
133,WO1999025352,A1,COMBINATION THERAPY FOR THE TREATMENT OF AIDS,US19970065421P,United States,1997-11-13T00:00:00Z,1997,1998-11-12T00:00:00Z,1999-05-27T00:00:00Z,1999,MERCK & CO INC,VACCA JOSEPH P    US  | LIN JIUNN H    US  | YEH KUANG C    US  | CHODAKEWITZ JEFFREY A    US  | DEUTSCH PAUL J    US  | JU WILLIAM D    US,A61K031496 | A61K031472 | A61K031426 | A61K031341 | A61P03704 | A61K0317072 | A61P03118 | A61K031536 | A61K031513 | A61K031535 | A61K03806 | A61K04506 | A61K03152 | A61K031495,EP1044000B1 | EP1044000A1 | HU200100365A3 | NO20002481D0 | US6180634B1 | TR200001938T2 | NO20002481A  | ID24922A  | PL340430A1 | IS5481A  | GB9819590D0 | SK200000684A3 | BG104507A  | SK6842000A3 | IL135994D0 | JP2001522889T  | CN1285747A  | ZA9810306A  | AT218866T  | CO4970782A1 | AU749795B2 | DE69806062T2 | BR9814146A  | AU1522599A  | ES2177103T3 | CA2309164A1 | DE69806062D1 | GB9807938D0 | HU200100365A2,22,21,Yes,Grant,Yes
134,WO1999029297,A1,OSMOTIC DOSAGE FORM COMPRISING FIRST AND SECOND COATS,US19970067669P,United States,1997-12-05T00:00:00Z,1997,1998-11-23T00:00:00Z,1999-06-17T00:00:00Z,1999,ALZA CORP,EDGREN DAVID E      | SKLUZACEK ROBERT R,A61K00900 | A61K00928,DK1035834T3 | PT1035834E  | HK1031197A1 | DE69805001D1 | EP1035834A1 | EP1035834B1 | DE69805001T2 | ES2172944T3 | AU1534699A  | AT216220T  | US6210712B1,10,10,Yes,Grant,Yes
135,WO1999033815,A1,SULPHONAMIDE DERIVATIVES AS PRODRUGS OF ASPARTYL PROTEASE INHIBITORS,US19970998050,United States,1997-12-24T00:00:00Z,1997,1998-03-09T00:00:00Z,1999-07-08T00:00:00Z,1999,VERTEX PHARMA,TUNG ROGER D    US  | HALE MICHAEL R    US  | BAKER CHRISTOPHER T    US  | FURFINE ERIC STEVEN    US  | KALDOR ISTVAN    US  | KAZMIERSKI WIESLAW WIECZYSLAW    US  | SPALTENSTEIN ANDREW    US,A61K031496 | A61K031265 | A61K031215 | C07C31137 | C07C31115 | A61P03118 | A61K031664 | A61K0317048 | C07D40712 | A61K03118 | C07D41712 | A61P03112 | A61K0314025 | A61K03127 | A61K031661 | A61K04500 | A61P04300 | A61K03166 | A61K03134 | A61K031341 | C07D40512 | C07H01504 | C07C31118 | C07H01526 | C07F0096584 | C07D30720 | C07F009655 | C07D27730,HK1021737A1 | DE122008000021I1 | OA11468A  | JP3736964B2 | SK9662000A3 | EP1944300A3 | BG104631A  | HU200101831A2 | DE69838903T2 | BG64869B1 | JP11209337A  | AU755087B2 | US7592368B2 | PT933372E  | EE04466B1 | US6838474B2 | SK287123B6 | EP933372B1 | EE200000385A  | US2010124543A1 | CZ20002363A3 | ID24962A  | LU91426A9 | TR200002615T2 | PL342113A1 | AP1172A  | CO4990992A1 | US2003207871A1 | DE69838903D1 | NO2009008I2 | CN1284071A  | ZA9811830A  | JP2005350478A  | AU6546698A  | EA003509B1 | TW486474B  | CZ301653B6 | NO20003304A  | NO2009008I1 | PL202845B1 | JP4282639B2 | DE122008000021I2 | CA2231700A1 | IL136941D0 | EP1944300A2 | BR9814480A  | US2005148548A1 | ES2299193T3 | CN101565412A  | CA2231700C  | US6436989B1 | HU200101831A3 | UA72733C2 | NZ505776A  | EP933372A1 | CN100503589C  | NL300339I1 | IL136941A  | DK0933372T3 | AT204200038T  | JP2009102400A  | AP200001850D0 | SI0933372T1 | NO20003304D0 | IS5546A  | NO326265B1 | SK200000966A3 | US6559137B1 | NL300339I2,48,36,Yes,Grant,Yes
136,WO1999036406,A1,ANTIVIRALS,SE19980000116 | SE19980000113,Sweden,1998-01-16T00:00:00Z,1998,1999-01-15T00:00:00Z,1999-07-22T00:00:00Z,1999,MEDIVIR AB,SAHLBERG CHRISTER    SE  | NOREEN ROLF    SE  | HOEGBERG MARITA    SE  | ENGELHARDT PER    SE,A61P03704 | A61P03118 | A61K03144 | C07D21361 | C07D21375 | C07D21385,JP2002509137T  | US2003119881A1 | JP4488621B2 | CN1292781A  | IL137196D0 | SK285779B6 | HU200100432A3 | EA003327B1 | AU2445099A  | AU739766B2 | DE69916425T2 | TR200002058T2 | NZ505543A  | HU200100432A2 | SE9800113D0 | US7148243B2 | PT1054867E  | DK1054867T3 | CN1522698A  | EP1054867A1 | CZ299387B6 | AT264305T  | BR9906933A  | EP1054867B1 | HK1036280A1 | ZA9900292A  | CA2318694A1 | SE9800116D0 | CA2318694C  | CZ20002604A3 | SK200001033A3 | CN1158261C  | US6486183B1 | TW470645B  | DE69916425D1 | ES2220039T3 | SI1054867T1 | PL191832B1 | SK10332000A3 | PL341819A1,27,24,Yes,Grant,Yes
137,WO1999045025,A1,"ACYLATED BETULIN AND DIHYDROBETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF",US19980076449P,United States,1998-03-02T00:00:00Z,1998,1999-03-02T00:00:00Z,1999-09-10T00:00:00Z,1999,"MYRIAD PHARMACEUTICALS, INC",LEE KUO-HSIUNG      | SUN I-CHEN      | WANG HUI-KANG      | COSENTINO LOUIS MARK,A61K03153 | C07J05300 | A61P03118 | C07J06300 | A61K031575 | A61K031225 | A61P03112 | C07C069013,DE69934486T2 | PT1068219E  | EP1068219B1 | CA2322868C  | AT348839T  | NZ506623A  | ES2281960T3 | AU20047624B2 | DK1068219T3 | JP2002505337T  | EP1068219A4 | CA2322868A1 | US6172110B1 | EP1068219A1 | DE69934486D1 | AU2889499A ,13,12,Yes,Grant,Yes
138,WO1999047146,A1,"ANTI-HIV COMBINATION COMPRISING HYDROXYUREA, DDI, AND A PROTEASE INHIBITOR",WO1998US05092,WIPO,1998-03-17T00:00:00Z,1998,1998-03-17T00:00:00Z,1999-09-23T00:00:00Z,1999,RESEARCH INSTITUTE FOR GENETIC AND HUMAN THERAPY,LISZIWIEWICZ JULIANNA    US  | LORI FRANCO    US,A61K04506 | A61K03855 | A61K03820,AU6761198A ,2,2,Yes,Application,No
139,WO1999048504,A1,COMPOSITIONS FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS USING HYDROXYUREA AND A REVERSE TRANSCRIPTASE INHIBITOR,US19980048886,United States,1998-03-26T00:00:00Z,1998,1999-02-18T00:00:00Z,1999-09-30T00:00:00Z,1999,RESEARCH INSTITUTE FOR GENETIC AND HUMAN THERAPY,LISZIEWICZ JULIANNA    US  | LORI FRANCO    US,A61K04506,US6251874B1 | AU3299199A ,3,3,Yes,Grant,Yes
140,WO1999048526,A1,METHOD OF RENDERING A HUMAN IMMUNODEFICIENCY VIRUS POPULATION REPLICATION INCOMPETENT IN VIVO,US19980048576,United States,1998-03-26T00:00:00Z,1998,1999-02-18T00:00:00Z,1999-09-30T00:00:00Z,1999,RESEARCH INSTITUTE FOR GENETIC AND HUMAN THERAPY,LORI FRANCO    US  | LISZIEWICZ JULIANNA    US,A61K039395 | A61K03912 | A61K03855 | A61K03820 | A61K03929 | A61K03913 | A61P03118 | A61K039145 | A61K03921,AU2685399A ,2,2,Yes,Application,No
141,WO1999050253,A1,"4,4-DISUBSTITUTED-3,4-DIHYDRO-2(1H)-QUINAZOLINTHIONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS HIV REVERSE TRANSCRIPTASE INHIBITORS",US19980079653P,United States,1998-03-27T00:00:00Z,1998,1999-03-23T00:00:00Z,1999-10-07T00:00:00Z,1999,BRISTOL MYERS SQUIBB PHARMA CO,CORBETT JEFFREY W,C07D40506 | A61P03704 | A61P03118 | C07D41706 | C07D491056 | A61K031517 | C07D40306 | A61P04300 | C07D41306 | C07D40906 | C07D40106 | C07D23978,CA2322203A1 | US6127375A  | AU3199099A  | JP2002509922T  | EP1068189A1,6,6,Yes,Grant,Yes
142,WO1999051203,A1,MAXIMIZING EFFECTIVENESS OF SUBSTANCES USED TO IMPROVE HEALTH AND WELL BEING,US19980053487,United States,1998-04-02T00:00:00Z,1998,1999-03-30T00:00:00Z,1999-10-14T00:00:00Z,1999,DRUGTECH CORPORATION,HERMELIN VICTOR M,A61K00902 | A61P02500 | A61K031714 | A61K009107 | A61K00908 | A61P00104 | A61P00912 | A61K031541 | A61K031445 | A61P02522 | A61K00928 | A61K00914 | A61K00954 | A61P00902 | A61K00924 | A61K00952 | A61K0315513 | A61K0314164 | A61K031517 | A61K031277 | A61K0314458 | A61K031549 | A61K00922,JP2002510612T  | US5945123A  | CA2327068A1 | US2004062802A1 | EP1067906A1 | US6214379B1 | ZA200005271A  | AU3546899A  | EP1067906A4 | BR9909903A ,10,8,Yes,Grant,Yes
143,WO1999055370,A1,METHODS FOR REDUCING HIV VIRAL LOAD BY ADMINISTERING GM-CSF AND ANTIRETROVIRAL AGENTS,US19980067926,United States,1998-04-28T00:00:00Z,1998,1999-04-23T00:00:00Z,1999-11-04T00:00:00Z,1999,ALCAFLEU MANAGEMENT GMBH & CO,WHITMORE JAMES B    US  | AGOSTI JAN M    US,A61P03118 | A61K03819,US6309632B1 | CA2329920A1 | AU4069399A ,4,4,Yes,Grant,Yes
144,WO1999055843,A2,EFFICIENT EX VIVO EXPANSION OF CD4<+> AND CD8<+> T-CELLS FROM HIV INFECTED SUBJECTS,US19980082861P,United States,1998-04-24T00:00:00Z,1998,1999-04-23T00:00:00Z,1999-11-04T00:00:00Z,1999,HEMOSOL INC,BELL DAVID      | ROSENTHAL KENNETH,C12N00500 | C12N0050783 | A61K03800 | A61K03512,EP1073720A2 | AU769538B2 | CA2326378A1 | AU3591199A  | ZA200006837A  | NZ508242A  | US6610542B1 | WO9955843A3,8,7,Yes,Grant,Yes
145,WO1999059585,A1,COMPOSITIONS FOR THE TREATMENT OF HIV AND OTHER VIRAL INFECTIONS,US19950420914,United States,1995-04-12T00:00:00Z,1995,1999-05-19T00:00:00Z,1999-11-25T00:00:00Z,1999,"ARISYN THERAPEUTICS, INC",CAMDEN JAMES BERGER  US,A61K031425,US2003187046A1 | US5767138A  | CA2223435A1 | US2001027205A1 | CN1301158A  | AU5802096A  | BR9608730A  | IL118424D0 | EP1079831A1 | AU5389796A  | EP821586B1 | PL322733A1 | TW427887B  | NO974695A  | WO9640122A1 | US6479526B1 | SK168697A3 | NO20005839A  | ZA9602879A  | US6653335B2 | BR9911043A  | US6245789B1 | PL344223A1 | JP11506732T  | CO5050303A1 | DE69628645D1 | TR9801562T2 | TR9701536T1 | HU9801532A3 | SK200001744A3 | CA2217952A1 | AU714078B2 | NO975660D0 | HU9801532A2 | BR9604974A  | NZ305784A  | CN1181010A  | JP11503459T  | IL139002D0 | AT242634T  | IL117875D0 | CA2217952C  | JP2007284446A  | NO974695D0 | US6362207B1 | ZA9604373A  | PL324026A1 | HU9802634A3 | EP821586A1 | ID27457A  | CZ9703234A3 | WO9632107A1 | MX9707809A  | CN1186433A  | DE69628645T2 | US6552059B2 | TR200003383T2 | AU717382B2 | HU9802634A2 | NO975660A  | SK17442000A3 | TR9701147T1 | SK138497A3 | RU2197964C2 | AU4004299A  | HU200103319A2 | US6262093B1 | CA2329877A1 | JP2002515432T  | EP831816A1 | US5929099A  | CZ9703911A3 | NO20005839D0 | US2002198247A1 | US6265427B1 | US5880144A ,62,23,Yes,Grant,Yes
146,WO1999063998,A1,NOVEL USE OF HIV PROTEASE INHIBITING COMPOUNDS,FR19980007373,France,1998-06-11T00:00:00Z,1998,1999-06-11T00:00:00Z,1999-12-16T00:00:00Z,1999,INSTITUT NATIONAL DE SANTE ET DE LA RECHERCHE MEDI | BIOMERIEUX,ANDRE PATRICE  FR  | LOTTEAU VINCENT  FR  | ZINKERNAGEL ROLF  CH  | KLENERMAN PAUL  GB  | GROETTRUP MARCUS  CH,A61K031425 | A61K03147,EP1083898A1 | FR2779653B1 | EP1083898B1 | FR2779653A1 | CA2334990A1 | AT314847T  | AU4049399A  | DE69929330T2 | US2003082207A1 | US6506555B1 | DE69929330D1 | EP1637139A3 | ES2258842T3 | EP1637139A2 | JP2002517441T ,12,10,Yes,Grant,Yes
147,WO1999064001,A2,METHODS AND COMPOSITIONS FOR INCREASING PENETRATION OF HIV PROTEASE INHIBITORS,GB19980012189,United Kingdom,1998-06-05T00:00:00Z,1998,1999-06-03T00:00:00Z,1999-12-16T00:00:00Z,1999,GSK LLC,BROUWER KENNETH RUSSELL  US  | POLLI JOSEPH WILLIAM  US,A61K03147 | A61K03134 | A61K031495 | A61K031425,EP1094814A2 | AU4505199A  | GB9812189D0 | JP2002517443T  | WO9964001A3,4,4,Yes,Application,No
148,WO1999065870,A2,SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE,US19980090094P,United States,1998-06-19T00:00:00Z,1998,1999-06-17T00:00:00Z,1999-12-23T00:00:00Z,1999,VERTEX PHARMA,SHERRILL RONALD GEORGE    US  | HALE MICHAEL R    US  | SPALTENSTEIN ANDREW    US  | FURFINE ERIC STEVEN    US  | ANDREWS CLARENCE WEBSTER III    US  | LOWEN GREGORY THOMAS    US,C07D24142 | C07D41306 | C07D21330 | C07C31149 | C07D41712 | C07D40712 | C07F0096561 | C07D31906 | C07D27730 | C07D30720 | C07C31148 | C07D30912 | C07D23532 | C07D23506 | C07D26502 | C07D30906 | C07D40512 | C07D24304 | C07D23526 | C07D49304 | C07D23530,ES2235492T3 | US2006172936A1 | AP200002023D0 | PT1086076E  | US2004097594A1 | AU2004200636A1 | EP1086076A1 | AU767728B2 | WO9965870A3 | AT285396T  | US6613743B2 | CA2335477A1 | OA11573A  | NO20006405A  | DE69922807D1 | NZ508855A  | EP1086076B1 | US2002049201A1 | NO20006405D0 | CA2335477C  | HK1037605A1 | BR9912169A  | AP1717A  | DK1086076T3 | US7419967B2 | NZ528074A  | AU4576099A  | DE69922807T2,21,16,Yes,Grant,Yes
149,WO1999066936,A1,"USE OF 3'-AZIDO-2',3'-DIDEOXYURIDINE IN COMBINATION WITH FURTHER ANTI-HIV DRUGS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HIV",US19980090552P,United States,1998-06-24T00:00:00Z,1998,1999-06-24T00:00:00Z,1999-12-29T00:00:00Z,1999,NOVIRIO PHARMACEUTICALS LIMITED,BRYANT MARTIN L  US  | MYERS MAUREEN W  US  | SCHINAZI RAYMOND  US,A61K03170,WO9966936A9 | US6194391B1 | JP2002518452T  | MXPA00012842A  | US2001009906A1 | US6602664B2 | JP2010280724A  | AU4716299A  | BR9911457A  | CA2335617A1 | EP1089741A1 | CA2335617C ,10,8,Yes,Grant,Yes
150,WO1999067417,A2,FITNESS ASSAY AND ASSOCIATED METHODS,US19980090393,United States,1998-06-23T00:00:00Z,1998,1999-06-23T00:00:00Z,1999-12-29T00:00:00Z,1999,"THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH",ERICKSON JOHN W    US  | GULNIK SERGEI V    US,G01N03315 | A61P03118 | A61P03704 | A61P04300 | C07D49304 | C12Q00137 | A61K0314525 | A61K03134 | C12Q00102,US2008085918A1 | US7470506B1 | JP2010088437A  | AT500823T  | WO9967254A2 | AU771780B2 | WO9967254A3 | EP1088098A2 | JP2002518063T  | US2005158713A1 | DE69943266D1 | AU4828099A  | CA2336160A1 | EP1088098B1 | WO9967417A3 | AU4828199A ,17,10,Yes,Grant,Yes
151,WO2000000475,A1,SUBSTITUTED QUINOLIN-2(1H)-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS,US19980091253P,United States,1998-06-30T00:00:00Z,1998,1999-06-25T00:00:00Z,2000-01-06T00:00:00Z,2000,BRISTOL MYERS SQUIBB PHARMA CO,PATEL MONA      | RODGERS JAMES D,C07D21554 | C07D215227 | C07D21522,US6265406B1 | CA2333643A1 | AU4719799A  | EP969185A1 | US6090821A  | JP2000034915A  | EP1091939A1,8,6,Yes,Grant,Yes
152,WO2000000478,A1,SUBSTITUTED QUINOXALIN-2(1H)-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS,US19980090893P,United States,1998-06-26T00:00:00Z,1998,1999-06-25T00:00:00Z,2000-01-06T00:00:00Z,2000,BRISTOL MYERS SQUIBB PHARMA CO,PATEL MONA      | MCHUGH ROBERT JOSEPH,C07D40506 | C07D40106 | C07D24144,AU4719699A  | EP1089979A1 | CA2334332A1,4,4,Yes,Application,No
153,WO2000000479,A1,"1,3-BENZODIAZEPIN-2-ONES AND 1,3-BENZOXAZEPIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS",US19980091252P,United States,1998-06-30T00:00:00Z,1998,1999-06-18T00:00:00Z,2000-01-06T00:00:00Z,2000,BRISTOL MYERS SQUIBB PHARMA CO,RODGERS JAMES D      | COCUZZA ANTHONY J,C07D40112 | C07D24304,CA2330110A1 | JP2003534230T  | EP1091944A1 | US6204262B1 | AU4698399A ,6,6,Yes,Grant,Yes
154,WO2000003998,A1,"SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",IT1998CA00015,Italy,1998-07-17T00:00:00Z,1998,1999-07-19T00:00:00Z,2000-01-27T00:00:00Z,2000,NOVIRIO PHARMACEUTICALS LIMITED,LA COLLA PAOLO    IT  | ARTICO MARINO    IT,C07D23952 | C07D23946 | C07D23936 | C07D23956,CN1309647A  | US6635636B1 | US2004092539A1 | IT1305313B1 | CA2338014A1 | AU5284899A  | BR9912142A  | AU2004200446A1 | ITCA980015A1 | AU20097712B2 | EP1098887A1,11,8,Yes,Grant,Yes
155,WO2000004016,A2,POLYMORPH OF A PHARMACEUTICAL,US19980119345,United States,1998-07-20T00:00:00Z,1998,1999-07-19T00:00:00Z,2000-01-27T00:00:00Z,2000,ABBOTT LAB,BAUER JOHN F      | SALEKI-GERHARDT AZITA      | NARAYANAN BIKSHANDARKOIL A      | CHEMBURKAR SANJAY R      | PATEL KETAN      | SPIWEK HARRY O      | BAUER PHILIP E      | ALLEN KIMBERLY A,A61P03118 | A61K031426 | A61P03704 | C07D27736 | C07D41712 | A61K031427 | C07D27730 | C07D27742 | C07D27740 | C07D27724 | C07D27728,PL194710B1 | EP1418174A2 | KR100853371B1 | EP2017269A9 | DK1097148T3 | CA2510949C  | IL140492D0 | AU5003799A  | JP2002520410T  | DE69915628D1 | IL187181D0 | SK922001A3 | CA2510949A1 | CA2337846C  | PL348033A1 | IL140492A  | PT1418174E  | EP1418174A3 | NZ522690A  | EP1418174B1 | AR044029A2 | AT261947T  | IL187181A  | BG65150B1 | EP1097148B1 | DE69915628T2 | ID27996A  | HU200103823A2 | CN101966180A  | HK1037918A1 | CZ298188B6 | SI1418174T1 | IL191582D0 | AR059764A2 | PT1097148E  | AU20077682B2 | SK200100092A3 | HU200103823A3 | ES2214038T3 | CN1502613A  | TR200100171T2 | DE69940616D1 | NZ509125A  | BR9912010A  | CN1310715A  | NO20042393A  | EP2017269A8 | AR059763A2 | EP1097148A2 | NO20010298A  | KR20060118022A  | TWI227713B  | BG105197A  | SK287586B6 | TWI271400B  | SK287381B6 | EP2298751A2 | ES2322759T3 | CA2337846A1 | EP2017269A2 | DK1418174T3 | CN101259128A  | CZ20010203A3 | SK286388B6 | AR049658A2 | NO20010298D0 | JP2010270135A  | SI1097148T1 | AT425974T  | CO5090830A1 | EP2017269A3 | NO318385B1 | BG109682A  | BG110080A  | NO327320B1 | CA2674800A1 | WO200004016A3 | CN1310715B ,54,28,Yes,Grant,Yes
156,WO2000004033,A1,"CALCIUM (3S) TETRAHYDRO-3-FURANYL(1S,2R)-3-[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO] -1-BENZYL-2- (PHOSPHONOOXY) PROPYLCARBAMATE",GB19980015567,United Kingdom,1998-07-18T00:00:00Z,1998,1999-07-15T00:00:00Z,2000-01-27T00:00:00Z,2000,GSK LLC,ARMITAGE IAN GORDON    GB  | SEARLE ANDREW DAVID    GB  | SINGH HARDEV    GB,A61P03114 | A61P03118 | A61P03704 | A61P03112 | A61K03855 | A61K031665 | C07F009655,OA11706A  | IS5808A  | TR200100111T2 | NO329676B1 | HU200103432A2 | NO20010282D0 | EP1098898A1 | SK285311B6 | EP1098898B1 | TWI245770B  | SK762001A3 | DE69904600D1 | US2003096795A1 | AP200102039D0 | CA2337857A1 | IL140824D0 | JP2003521447T  | CZ300447B6 | PT1098898E  | SK200100076A3 | AU5037999A  | EP1240903A2 | HU200103432A3 | PL345620A1 | EA003191B1 | HR20010046A2 | SI1098898T1 | CA2337857C  | PL195736B1 | DE69904600T2 | SV1999000096A  | PA8477801A1 | NZ509291A  | DZ2845A1 | MA26660A1 | US2003100537A1 | ES2189450T3 | ZA200100417A  | CN1324363A  | NO20010282A  | GC0000105A  | DK1098898T3 | CN1188422C  | US6514953B1 | CZ20010219A3 | AT229964T  | HK1034261A1 | EP1240903A3 | EE200100038A  | AU766056B2 | JP3437553B2 | ID28070A  | GB9815567D0 | CO5090836A1 | BG105253A  | BR9912156A ,41,36,Yes,Grant,Yes
157,WO2000006143,A1,CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA,US19980094286P,United States,1998-07-27T00:00:00Z,1998,1999-07-27T00:00:00Z,2000-02-10T00:00:00Z,2000,"ST. JUDE PHARMACEUTICALS, INC.",BACHYNSKY NICHOLAS    US  | ROY WOODIE    US,A61K04100 | A61K03106 | A61K03100,CA2337690A1 | US2010056643A1 | AU750313B2 | EP1098641A4 | US7635722B1 | EP1098641A1 | AU5131899A ,7,5,Yes,Grant,Yes
158,WO2000009150,A2,"CYTOKINE AND CYTOKINE RECEPTOR, AGONIST, ANTAGONIST AND/OR ANTIBODY COMBINATION FOR THERAPEUTIC USE",US19980096735P,United States,1998-08-17T00:00:00Z,1998,1999-08-17T00:00:00Z,2000-02-24T00:00:00Z,2000,PRENDERGAST PATRICK T,PRENDERGAST PATRICK T  IE,A61K03819 | A61K03820 | A61K039395 | A61K03855 | A61P03702 | A61P03300 | A61P03100 | A61P03500 | A61K03820 | 7A 61K 38:17 J | 7A 61K 31:495 J | A61K03819 | 7A 61K 38:17 K | 7A 61K 31:495 K | A61K039395 | 7A 61K 38:20 L | 7A 61K 31:495 L,WO200009150A3 | AU5297299A ,2,2,Yes,Application,No
159,WO2000010965,A2,QUATERNARY AMMONIUM SALTS AND THEIR USE,JP19970351480 ,Japan,1997-12-19T00:00:00Z,1997,1999-08-19T00:00:00Z,2000-03-02T00:00:00Z,2000,TAKEDA PHARMACEUTICAL COMPANY,SHIRAISHI MITSURU      | BABA MASANORI      | ARAMAKI YOSHIO      | NISHIMURA OSAMU      | KANZAKI NAOYUKI,C07C23362 | A61K031452 | A61K031351 | C07D33708 | C07D40712 | A61K031335 | A61K03167 | A61K0314523 | C07D31308 | C07D30914 | A61K0315377 | A61K031665,BR9813691A  | WO9932100A2 | AU1683199A  | WO200010965A3 | JP2000128782A  | JP2000055008A  | CA2337307A1 | AU5301599A  | CA2304959A1 | ID29994A  | JP3698552B2 | JP2000069084A  | US6172061B1 | JP3278616B2 | US6096780A  | AU748064B2 | NO20003179D0 | WO9932100A3 | US6376536B1 | ZA9811574A  | NO20003179A  | EP1104416A2 | EP1039899A2 | JP2000128842A  | US6268354B1 | HU200100199A2 | CN1282243A ,23,12,Yes,Grant,Yes
160,WO2000021514,A2,METHOD AND COMPOSITION FOR TREATING AND PREVENTING TUBERCULOSIS,US19980104409P,United States,1998-10-15T00:00:00Z,1998,1999-10-14T00:00:00Z,2000-04-20T00:00:00Z,2000,SARAWAK MEDICHEM PHARMACEUTICALS,XU ZE-QI  US  | LIN YUH-MEEI  US  | FLAVIN MICHAEL  US,A61K03100,US6268393B1 | AT233089T  | EP1143952A2 | DE69905616D1 | EP1143952B1 | ID29547A  | OA11666A  | EP1143952A3 | AP200102115D0 | US2001027209A1 | CN1334727A  | DE69905616T2 | WO200021514A3 | AU200017054A  | CA2346813A1,11,10,Yes,Grant,Yes
161,WO2000025784,A1,METHOD FOR IMPROVING THE PHARMACOKINETICS OF TIPRANAVIR,US19980106963P,United States,1998-11-04T00:00:00Z,1998,1999-10-29T00:00:00Z,2000-05-11T00:00:00Z,2000,UPJOHN CO.,FERRY JAMES J    US  | BALDWIN JOHN R    US  | BORIN MARIE T    US,A61K0314433 | A61K031427 | A61K03144 | A61P03118,CN1324237A  | CA2346131A1 | CN1154491C  | EP1126847A1 | AU762349B2 | JP2002528502T  | EP1712231A3 | EP1712231A2 | AU200014404A  | US6147095A  | TW580387B  | CO5160321A1 | HK1040625A1 | BR9914940A ,13,11,Yes,Grant,Yes
162,WO2000025799,A1,beta -L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION,US19980107178P,United States,1998-11-05T00:00:00Z,1998,1999-11-05T00:00:00Z,2000-05-11T00:00:00Z,2000,L'UNIVERSITE MONTPELLIER II | EMORY UNIVERSITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE,GOSSELIN GILLES    FR  | IMBACH JEAN-LOUIS    FR  | SOMMADOSSI JEAN-PIERRE    US  | SCHINAZI RAYMOND F    US,C07H01906 | A61K0317052 | A61K0317042 | A61K0317064 | A61K0317068 | A61K0317072 | A61K03170 | A61P03118,AU2003261475A1 | AU200014691A  | US6896900B2 | JP2002528510T  | DE69930678D1 | BR9915037A  | IL142982A  | EP1124565A1 | MXPA01004505A  | ES2262366T3 | US2003036528A1 | IL142982D0 | EP1124565B1 | US6407077B1 | AU2003261475B2 | DE69930678T2 | AT321561T  | AU768059B2 | CA2348948C  | CA2348948A1,15,12,Yes,Grant,Yes
163,WO2000027196,A1,USE OF GM-CSF TO INHIBIT DEVELOPMENT OF DRUG RESISTANCE IN HIV<+> PATIENTS,US19980187784,United States,1998-11-06T00:00:00Z,1998,1999-10-22T00:00:00Z,2000-05-18T00:00:00Z,2000,SCHERING CORP,GILBERT MARK J  US,A01N03718 | A01N03816 | A01N04304 | A01N04390,AU763289B2 | EP1124418A1 | WO200027196A8 | EP1124418A4 | CA2349592A1 | NZ512040A  | WO200027196B1 | AU200012252A  | AU763289C  | JP2002529377T ,7,6,Yes,Application,No
164,WO2000033654,A1,"USE OF PROTEASE INHIBITORS TO MODULATE CELLULAR PATHWAYS, IMMUNITY AND THERAPIES ASSOCIATED THEREWITH",US19980110893P,United States,1998-12-04T00:00:00Z,1998,1999-12-03T00:00:00Z,2000-06-15T00:00:00Z,2000,UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE,WEICHOLD FRANK F    | BRYANT JOSEPH L    | GALLO ROBERT C,A01N03718 | A01N04304 | A61K03170 | A61K03800 | A61K03848,AU200019309A ,2,2,Yes,Application,No
165,WO2000035419,A2,CONVERSION OF LIQUID FILLED GELATIN CAPSULES INTO CONTROLLED RELEASE SYSTEMS BY MULTIPLE COATINGS,US19980112634P,United States,1998-12-17T00:00:00Z,1998,1999-12-10T00:00:00Z,2000-06-22T00:00:00Z,2000,"ENCINAL PHARMACEUTICAL INVESTMENTS, LLC",DONG LIANG C      | WAN JASON      | WONG PATRICK S-L,A61K00900,US2002155154A1 | AU20097659C  | CA2354472C  | JP2002532406T  | EP1140012A2 | AU20097659B2 | HU200104721A2 | CO5271648A1 | US6419952B2 | AT260642T  | IL143691D0 | PT1140012E  | IL143691A  | DE69915346T2 | NO20012959D0 | ES2213404T3 | MXPA01006108A  | NZ512410A  | US6929803B2 | US2001036472A1 | DK1140012T3 | CN1161101C  | CA2354472A1 | EP1140012B1 | DE69915346D1 | HK1040632A1 | ZA200104928A  | NO20012959A  | HU200104721A3 | AU200021994A  | CN1331580A  | WO200035419A3,22,20,Yes,Grant,Yes
166,WO2000035472,A2,CYTOKINE COMBINATION THERAPY,US19980109923P,United States,1998-11-24T00:00:00Z,1998,1999-12-15T00:00:00Z,2000-06-22T00:00:00Z,2000,HOLLIS EDEN PHARMACEUTICALS,PRENDERGAST PATRICK T   IE,A61K03817 | A61K039395 | A61P03704 | A61K03817 | 7A 61K 31:56 J | A61K039395 | 7A 61K 31:56 K,CN1328463A  | EP1163256A1 | AU775614B2 | ES2215631T3 | US2005282732A1 | EP1163256B1 | DE60008353T2 | AU2004237812B2 | AU2004237812A1 | AU2005211675B2 | RU2001128881A  | NZ511721A  | EP2135611A1 | WO200032177A2 | US2006079492A1 | AP200102285D0 | US7524835B2 | WO200130802A3 | DK1163256T3 | AU782736B2 | AU200017453A  | RU2295534C2 | NO20014588D0 | HK1046002A1 | EP1133287A2 | JP2004537506T  | AU2008255138A1 | AU776853B2 | AU2005237117B2 | EP1223941A2 | US2011009372A1 | US2010222313A1 | CA2352387A1 | WO200056757A1 | US2007275936A1 | CA2365081A1 | AU200015797A  | AU200039190A  | US2008176824A1 | US2005159366A1 | TWI262924B  | WO200032177A3 | OA11715A  | CA2388939C  | US2003083231A1 | DE60008353D1 | EP1135138A2 | AP200102182D0 | OA11850A  | IL142941D0 | IL142942A  | EP1372664A1 | US2008045490A1 | ID29864A  | US7723532B2 | CN1837231A  | WO200032201A3 | NZ513803A  | WO200032176A2 | JP2002531407T  | US7396827B2 | AU2008201188B2 | WO200032201A2 | AU200079880A  | ZA200103852A  | ZA200306638A  | WO200032176A3 | CZ20013420A3 | ZA200106980A  | US2004097406A1 | CA2388939A1 | CA2356539A1 | AU2005237117A1 | JP2002531397T  | AU2008255138A2 | EP1422234A3 | NO320801B1 | AP1584A  | NZ511720A  | BR9915623A  | AU2008255138B2 | CN1243767C  | KR20070007394A  | BR200009476A  | WO2002069977A1 | PT1163256E  | AU200019235A  | CA2352205A1 | EP1223941B1 | US2004116359A1 | JP2002540119T  | CN1348373A  | US2006063749A1 | BR9915644A  | US2008015174A1 | US2003060425A1 | IL142942D0 | NO20014588A  | US2010222425A1 | US2009215737A1 | HU200203429A2 | AU200031052A  | AP200102167D0 | ZA200103845A  | US2007129282A1 | CN1355809A  | JP2003512474T  | AU2008201188A1 | AT413179T  | EP1422234A2 | WO200035472A3 | US2004220161A1 | WO200130802A2 | US2004043973A1 | US6667299B1 | IL144916D0 | CA2439687A1 | HU200203429A3 | US2005075321A1 | US2004220114A1 | OA11716A  | AU781997B2 | AU2005211675A1 | US2005256095A1 | KR20070004149A  | DE60040753D1 | NO20056167A  | AT259825T  | AU2002244247B2,99,25,Yes,Grant,Yes
167,WO2000037455,A1,"BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5",JP19980363404,Japan,1998-12-21T00:00:00Z,1998,1999-12-20T00:00:00Z,2000-06-29T00:00:00Z,2000,TAKEDA PHARMACEUTICAL COMPANY,SHIRAISHI MITSURU    JP  | BABA MASANORI    JP  | SETO MASAKI    JP  | KANZAKI NAOYUKI    JP  | NISHIMURA OSAMU    JP,C07D33506 | A61K031535 | A61K03152 | C07D40914 | C07F0096553 | A61K031495 | A61P03500 | A61K03155 | C07D40912 | C07D33708 | A61K03855 | A61K04506,AU200016901A  | US6235771B1 | CA2353635A1 | JP2001058988A  | EP1140896A1,6,6,Yes,Grant,Yes
168,WO2000038650,A1,GASTRIC RETENTION DOSAGE FORM HAVING MULTIPLE LAYERS,US19980113560P,United States,1998-12-23T00:00:00Z,1998,1999-12-16T00:00:00Z,2000-07-06T00:00:00Z,2000,"ENCINAL PHARMACEUTICAL INVESTMENTS, LLC",EDGREN DAVID E    | JAO FRANCISCO    | WONG PATRICK S-L,A61K00900,AU200021995A  | US2005019409A1 | US6797283B1,4,3,Yes,Grant,Yes
169,WO2000038679,A1,TREATMENT OF RETROVIRAL INFECTIONS WITH OXYPHENBUTAZONE,GB19980028548,United Kingdom,1998-12-23T00:00:00Z,1998,1999-12-23T00:00:00Z,2000-07-06T00:00:00Z,2000,VIRAL AS,TJOETTA ENOK  NO  | KLAVENESS JO  NO,A61K031415 | A61K031495 | A61P03118 | A61K031415 | 7A 61K 31:495 J,ZA200104402A  | JP2002533392T  | GB9828548D0 | AU200018793A  | CA2352423A1 | EP1140075A1,6,6,Yes,Application,No
170,WO2000038680,A1,AZABICYCLOALKANES AS CCR5 MODULATORS,GB19980028420,United Kingdom,1998-12-23T00:00:00Z,1998,1999-12-23T00:00:00Z,2000-07-06T00:00:00Z,2000,PFIZER,ARMOUR DUNCAN ROBERT    GB  | PRICE DAVID ANTHONY    GB  | STAMMEN BLANDA LUZIA CHRISTA    GB  | WOOD ANTHONY    GB  | PERROS MANOUSSOS    GB  | EDWARDS MARTIN PAUL    GB,G01N03350 | G01N03315 | A61K031496 | A61P04300 | A61P01100 | A61K031547 | G01N033566 | A61K031551 | A61K0317064 | A61K031439 | A61K031426 | C07D48722 | A61K04500 | A61K0314184 | A61K03821 | A61K0314709 | A61K0315386 | A61K03152 | A61K03147 | C07D51308 | C07D40104 | C07D41304 | C07D41314 | C07D21158 | C07D49808 | C07D45104 | A61K04506 | C07D20714 | A61P03118 | C07D40514 | C07D45102 | C07D40512 | C07D40112 | C07D40304 | A61K031445 | A61K03146,EP1140085A1 | IL143510D0 | CA2292984C  | AU769449B2 | JP2002533393T  | PL349091A1 | IS5941A  | TW577888B  | NO20013183A  | US7041667B1 | AU200012904A  | CZ20012298A3 | GC0000117A  | CN1331691A  | JP3602795B2 | EE200100344A  | HU200104910A2 | EG24400A  | OA11735A  | DZ2978A1 | BG105709A  | AP1697A  | UA72750C2 | TR200101867T2 | MA26715A1 | JP3779111B2 | HU200104795A3 | NO20013149D0 | PL201875B1 | BR9905977A  | AU763644B2 | ZA200104211A  | NO20013183D0 | EP1140085B1 | ID29031A  | CN1150192C  | EA004988B1 | ID28965A  | UY25869A1 | TR200101793T2 | CZ300926B6 | TR200200938T2 | OA11732A  | HR20010468A2 | CA2350073C  | EP1013276A1 | DZ2979A1 | BR9916585A  | CA2292984A1 | GB9922702D0 | HK1039942A1 | JP2000212159A  | AP200102186D0 | CZ20012297A3 | GB9922009D0 | HU200104795A2 | NZ511796A  | BG105721A  | WO200039125A1 | NO20013149A  | EE05170B1 | ZA200104254A  | CA2350573C  | PL349495A1 | PA8488101A1 | IL143512D0 | GB9828420D0 | IS5944A  | AT505190T  | CA2350573A1 | EE200100345A  | BR9917007A  | JP3522691B2 | JP2002533461T  | PA8487201A1 | CN1331591A  | HR20010478A2 | SK287020B6 | AU200016751A  | HU200104910A3 | CU23344A3 | NZ511794A  | EP1140920A1 | GB9921375D0 | AP200102187D0 | CA2350073A1 | US6586430B1 | SK200100876A3 | BG65448B1 | JP2004099618A  | MA26714A1 | SK200100875A3 | CO5300387A1 | US7217714B1,75,38,Yes,Grant,Yes
171,WO2000039143,A2,ANTIVIRAL NUCLEOSIDE ANALOGUES,US19980113797P,United States,1998-12-23T00:00:00Z,1998,1999-12-22T00:00:00Z,2000-07-06T00:00:00Z,2000,BIOCHEM PHARMA INC,NGUYEN-BA NGHE    CA,C07D47316 | A61K0317068 | A61K03152 | A61K031506 | A61K04500 | A61P03112 | A61P03118 | C07D47300 | C07H01916 | C07B06100,DK1140937T3 | NO20013163D0 | NZ513094A  | PT1140937E  | IL143867D0 | UY25878A1 | US2001049372A1 | AU760875B2 | TR200102501T2 | WO200039143A3 | EP1140937B1 | NO20013163A  | BR9916849A  | OA11741A  | CN1334814A  | AP200102207D0 | MXPA01006425A  | CA2355712C  | ZA200105702A  | US6545001B2 | CN1117751C  | DE69912842T2 | EA004767B1 | AU200017657A  | DE69912842D1 | US6358963B1 | CA2355712A1 | EP1140937A2 | AR029153A1 | US2004058893A1 | ID30477A  | HU200104827A2 | JP2002533470T  | CZ20012352A3 | ES2209532T3 | AT254126T  | HU200104827A3,28,24,Yes,Grant,Yes
172,WO2000040269,A2,PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF DISEASED TISSUES,US19990114906P,United States,1999-01-05T00:00:00Z,1999,2000-01-05T00:00:00Z,2000-07-13T00:00:00Z,2000,LEE CLARENCE C | LEE FENG MIN,LEE CLARENCE C  US  | LEE FENG-MIN  US,A61K04506 | A61K03568 | A61K031665 | A61K00900 | A61K03820 | A61K03804 | A61K04710 | A61K03814 | A61K03818,AU200034694A  | WO200040269A3,2,2,Yes,Application,No
173,WO2000042060,A1,BIS-AMINO ACID SULFONAMIDES CONTAINING N-TERMINALLY A SUBSTITUTED BENZYL GROUP AS HIV PROTEASE INHIBITORS,US19990115746P,United States,1999-01-13T00:00:00Z,1999,2000-01-13T00:00:00Z,2000-07-20T00:00:00Z,2000,BRISTOL MYERS SQUIBB PHARMA CO,KALTENBACH ROBERT F      | TRAINOR GEORGE L,C07K005062 | A61K03805 | A61P03118,CN1336934A  | JP2002536298T  | IL143763D0 | CZ20012435A3 | PL349774A1 | SK9522001A3 | HU200105235A3 | HU200105235A2 | NO20013338D0 | EP1140983A1 | NO20013338A  | TR200102033T2 | SK200100952A3 | AU200027257A  | CA2353088A1 | BR200007854A ,13,13,Yes,Application,No
174,WO2000043017,A1,COMPOSITION OF ANTI-HIV DRUGS AND ANTI-CORTISOL COMPOUNDS AND METHOD FOR DECREASING THE SIDE EFFECTS OF ANTI-HIV DRUGS IN A HUMAN,US19990234532,United States,1999-01-21T00:00:00Z,1999,2000-01-20T00:00:00Z,2000-07-27T00:00:00Z,2000,SAMARITAN PHARMACEUTICALS INC.,SAPSE ALFRED T,A61K03170,US2005085464A1 | AU200026206A  | US7354906B2,3,3,Yes,Grant,Yes
175,WO2000047561,A1,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS,SE19960004165 | SE19960004154,Sweden,1999-02-12T00:00:00Z,1999,1999-08-18T00:00:00Z,2000-08-17T00:00:00Z,2000,MEDIVIR AB,ZHOU XIAO-XIONG    SE  | JOHANSSON NILS-GUNNAR    SE  | WAEHLING HORST    SE  | SUND CHRISTIAN    SE  | SALVADOR LOURDES    SE  | LINDSTROEM STEFAN    SE  | WALLBERG HANS    SE  | SAHLBERG CHRISTER    SE,C12N00999 | A61P04300 | A61P03118 | A61K03144 | C07D21375 | C07F009572 | C07D21385 | C07F00940,CA2325523A1 | DE69800753T4 | CZ20000449A3 | SE9800469D0 | EP1123935B1 | CA2318978A1 | EP1058687B1 | EP942916A2 | WO9951613A1 | AU728892B2 | TR200002318T2 | SE9803438D0 | IL144349D0 | SE9604154D0 | AU3856799A  | IL138627D0 | AU754733B2 | TW580500B  | PL190284B1 | CA2271135A1 | PL342404A1 | CZ300757B6 | NZ506033A  | SE9702957D0 | PL338643A1 | US6458772B1 | SE9604165D0 | DE69829784D1 | US7825238B2 | AT256140T  | ZA9901148A  | EP1054891A1 | CN1500800A  | JP2002510698T  | EP1123935A3 | TR200002273T2 | JP4413427B2 | EP1058687A1 | CN1872869A  | AU20017708B2 | AU5665899A  | JP2002503670T  | CN1255422C  | WO9821223A1 | SE9800452D0 | PL192112B1 | PT1058687E  | HU200100879A2 | EP1123935A2 | WO9941268A1 | JP3844654B2 | ES2239637T3 | SI988304T1 | CA2362135A1 | US2003186924A1 | JP2002503673T  | AT200900T  | NZ502837A  | SE9801216D0 | IL134503D0 | US7071173B2 | TR200000398T2 | TWI198092B  | SE9704147D0 | ES2211116T3 | AU3282099A  | HU200100087A3 | JP2002536435T  | DE69800753D1 | EP988304A1 | HU200100879A3 | IL137605D0 | DK988304T3 | AU8754898A  | HK1035907A1 | CA2298704A1 | DE69829784T2 | WO9941275A1 | AU735438B2 | NZ508502A  | HU200100087A2 | AU20077504B2 | CA2318975A1 | DE69800753T2 | HK1097550A1 | KR2000053226A  | CN1286845C  | WO9909031A1 | SI1058687T1 | CN1275983A  | DK1058687T3 | ZA9807267A  | US2006058259A1 | DE69913499T2 | CN1290268A  | CN1130362C  | US2002128301A1 | AU5075998A  | EA002647B1 | ES2158689T3 | PT988304E  | GR3036004T3 | EP1121366A1 | CA2298704C  | HK1032968A1 | IL134503A  | JP2001515079T  | AT293112T  | AU20087324B2 | US6974802B2 | JP2001503767T  | IL137605A  | IL137468D0 | EP988304B1 | EP1150956A1 | DE69913499D1 | CN100460417C  | AU3281999A  | KR20000053226A  | SG96604A1 | US2006122383A1,85,26,Yes,Grant,Yes
176,WO2000050043,A1,METHODS OF TREATMENT OF MITOCHONDRIAL DISORDERS,US19990121588P ,United States,1999-02-23T00:00:00Z,1999,2000-02-23T00:00:00Z,2000-08-31T00:00:00Z,2000,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA,NAVIAUX ROBERT K    US,A61K03100 | A61K04506,HU200400914A2 | EP1171137A1 | EP1808177A3 | AU2004235661A1 | US2004224920A1 | RU2005121711A  | AU776437B2 | MXPA01008549A  | AT381935T  | CN1626107A  | RU2001125913A  | DE60037578D1 | US2010098678A1 | IL180528D0 | CN100379426C  | PT1171137E  | EP1808177A2 | RU2394580C2 | ZA200107727A  | HU200400914A3 | DE60037578T2 | IL144964D0 | CA2362925A1 | DK1171137T3 | JP2002537340T  | ES2298130T3 | EP1171137B1 | KR100879559B1 | CN1191835C  | RU2268732C2 | US7638501B1 | EP1171137A4 | KR20070085864A  | BR200008447A  | NZ513926A  | AU200032434A  | CN1341024A ,25,19,Yes,Grant,Yes
177,WO2000051641,A1,PHARMACEUTICAL COMBINATION OF ANTIVIRAL AGENTS,US19990122480P,United States,1999-03-01T00:00:00Z,1999,2000-03-01T00:00:00Z,2000-09-08T00:00:00Z,2000,BIOCHEM PHARMA INC,RANDO ROBERT  CA  | GU ZHENGXIAN  CA,A61K04506 | A61P03112 | A61P03118,AU771196B2 | AT253938T  | CA2363982A1 | EP1159005A1 | US6887879B2 | US2003045534A1 | AU200028990A  | ES2208281T3 | JP2002538171T  | DE60006495D1 | DE60006495T2 | US6511983B1 | EP1159005B1,11,9,Yes,Grant,Yes
178,WO2000052034,A2,"INHIBITORS OF SERINE PROTEASE ACTIVITY, METHODS AND COMPOSITIONS FOR TREATMENT OF VIRAL INFECTIONS",US19980081936P,United States,1998-04-16T00:00:00Z,1998,2000-03-03T00:00:00Z,2000-09-08T00:00:00Z,2000,"BIO HOLDING, INC",SHAPIRO LELAND,C07K00700,AU200037314A  | WO200051625A1 | WO9953073A2 | EP1071785A2 | AU200038640A  | WO200051624A2 | WO200051623A3 | WO9953073A9 | AU200035115A  | US2006040867A1 | IL139062D0 | WO200051624A3 | BR9910125A  | WO200052034A3 | US6849605B1 | US6489308B1 | US2008261868A1 | AU3862099A  | US2010144630A1 | US2009298747A1 | WO200051623A2 | US7704958B1 | AU200037191A  | US2008051330A1 | WO2011041325A2 | WO9953073A3 | US2010210528A1 | CA2326687A1 | US7807781B2,25,6,Yes,Grant,Yes
179,WO2000056303,A2,TREATMENT OF IMMUNE DISEASES,US19990125674P,United States,1999-03-22T00:00:00Z,1999,2000-03-22T00:00:00Z,2000-09-28T00:00:00Z,2000,IMMUGEN PHARMACEUTICALS INC,TRAVIS CRAIG R    US,A61K031661 | A61P03500 | A61K031085 | A61P03118 | A61P03704 | A61P03112 | C07C03919 | C07C03924 | C07C04323 | A61K03109 | A61K03105 | C07F00912 | A61K031352 | C07C03910,US2002037923A1 | CN1377261A  | WO200056303A3 | HU200203437A3 | IL145470D0 | US2007179135A1 | IL145470A  | EP1189603A2 | US2008108647A1 | CN1939917A  | HU200203437A2 | BR200009200A  | CA2367262A1 | US2003158191A1 | CN1561990A  | US7105685B2 | ZA200107773A  | JP2002539246T  | US6274635B1 | US6566560B2 | AU200039107A ,17,11,Yes,Grant,Yes
180,WO2000056729,A1,CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS,US19990125823P,United States,1999-03-24T00:00:00Z,1999,2000-03-24T00:00:00Z,2000-09-28T00:00:00Z,2000,GENZYME CORPORATION,BRIDGER GARY      | SKERLJ RENATO      | KALLER AL      | HARWIG CURTIS      | BOGUCKI DAVID      | WILSON TREVOR R      | CRAWFORD JASON      | MCEACHERN ERNEST J      | ATSMA BEM      | NAN SIQIAO      | ZHOU YUANXI      | SCHOLS DOMINIQUE,A61P02900 | A61K0315377 | A61P03708 | A61P01902 | A61P01706 | A61P04300 | A61P02104 | A61P00310 | A61P00514 | A61P01100 | A61P01700 | A61P02100 | A61P01712 | A61K031444 | A61K0314439 | A61P03706 | C07D21336 | A61P01312 | A61P03702 | A61P03118 | A61K0314402 | A61P03500 | A61P01106 | A61K0314985 | A61K03146 | A61P00104 | A61K0314709 | A61K0314725 | C07D40114 | C07D40112 | C07D23942 | C07D40914 | C07D21338 | C07D47104 | C07D21540 | C07D48704 | C07D41314 | C07D45104 | A61K04506 | C07D40514 | C07D41714,JP2003524620T  | US2004235823A1 | US7629337B2 | ES2265923T3 | CN1219780C  | MXPA01009674A  | EP1163238B1 | DE60028354T2 | US6750348B1 | HU200200761A2 | DE60028354D1 | TR200102799T2 | AU775123B2 | US2006264434A1 | NO323703B1 | NO20014593A  | CA2368047A1 | PL350998A1 | US7183273B2 | NZ514709A  | NO20014593D0 | AP1654A  | US2010105915A1 | EP1163238A1 | CN1351601A  | BR200010655A  | IL145401A  | AP200102269D0 | AT327988T  | HK1043985A1 | HU200200761A3 | IL145401D0 | CZ20013421A3 | AU200035460A ,25,21,Yes,Grant,Yes
181,WO2000059475,A1,COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF IONIZABLE HYDROPHOBIC THERAPEUTIC AGENTS,US19990287043,United States,1999-04-06T00:00:00Z,1999,2000-03-16T00:00:00Z,2000-10-12T00:00:00Z,2000,LIPOCINE INC,CHEN FENG-JING      | PATEL MANESH V,A61K00964 | A61K009107 | A61K00966 | A61K04702 | A61K00948,EP1165048A4 | EP1165048A1 | AU200037637A  | CA2366702C  | US6383471B1 | CA2366702A1,5,5,Yes,Grant,Yes
182,WO2000059486,A2,USE OF CYP2D6 INHIBITORS IN COMBINATION THERAPIES,US19990128136P,United States,1999-04-07T00:00:00Z,1999,2000-03-20T00:00:00Z,2000-10-12T00:00:00Z,2000,PFIZER,OBACH RONALD SCOTT    US,A61K04500 | A61P04300 | A61K0314375 | A61K031435 | A61K031445 | A61K03618 | A61K03100 | A61K04506,BG106075A  | DZ3032A1 | AU200031850A  | CZ20013599A3 | BR200009564A  | JP2003523936T  | CN1479628A  | NO20014858D0 | WO200059486A8 | TR200102876T2 | US2003144220A1 | SK200101383A3 | AU774923B2 | PL359022A1 | EP1242058A1 | US2004018253A1 | CA2367052A1 | HR20010722A2 | US2004028755A1 | UY26092A1 | EA005158B1 | MA26728A1 | AP200102290D0 | NO20014858A  | NZ514466A  | SV2002000049A  | ZA200108158A  | IL145451D0 | EE200100524A  | IS6083A  | JP3704290B2 | PA8493401A1 | HU200300535A2 | ID30355A  | OA11858A ,31,28,Yes,Grant,Yes
183,WO2000066173,A2,METHODS AND FORMULATIONS FOR TARGETING INFECTIOUS AGENTS BEARING HOST CELL PROTEINS,CA19992270600,Canada,1999-05-03T00:00:00Z,1999,2000-05-03T00:00:00Z,2000-11-09T00:00:00Z,2000,INFECTIO RECHERCHE INC.,BERGERON MICHEL G  CA  | TREMBLAY MICHEL J  CA  | DESORMEAUX ANDRE  CA,A61K04748,JP2002543162T  | EP1173220A2 | CA2369550A1 | WO200066173A3 | US7357930B1 | CA2270600A1 | AU768685B2 | AU200042804A ,8,6,Yes,Grant,Yes
184,WO2000066551,A1,"CYCLIC AMIDE COMPOUNDS, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF",JP19990122549,Japan,1999-04-28T00:00:00Z,1999,2000-04-27T00:00:00Z,2000-11-09T00:00:00Z,2000,TAKEDA PHARMACEUTICAL COMPANY,ISHIHARA YUJI    JP  | IMAMURA SHINICHI    JP  | HASHIGUCHI SHOHEI    JP  | NISHIMURA OSAMU    JP  | KANZAKI NAOYUKI    JP  | BABA MASANORI    JP,C07D21152 | C07D41314 | A61P04300 | C07D40514 | C07D40506 | C07D40106 | C07D40112 | A61P03118 | C07D40312 | C07D21132 | C07D207277 | C07D26530 | C07D40114 | C07D40512 | C07D21178 | C07D21118 | C07D21126 | C07D20726,EP1180513A4 | AU200041433A  | CA2371618A1 | EP1180513A1 | JP2001011073A ,5,5,Yes,Application,No
185,WO2000066559,A1,PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS,US19990305187,United States,1999-05-04T00:00:00Z,1999,2000-05-01T00:00:00Z,2000-11-09T00:00:00Z,2000,SCHERING CORP,BAROUDY BAHIGE M    US  | CLADER JOHN W    US  | JOSIEN HUBERT B    US  | MCCOMBIE STUART W    US  | MCKITTRICK BRIAN A    US  | MILLER MICHAEL W    US  | NEUSTADT BERNARD R    US  | PALANI ANANDAN    US  | STEENSMA RUO    US  | TAGAT JAYARAM R    US  | VICE SUSAN F    US  | LAUGHLIN MARK A    US,A61P01700 | C07D40514 | A61P01902 | A61P02900 | A61P03708 | A61K031454 | A61K0314523 | A61P03700 | A61K0314468 | A61P03118 | A61P01106 | A61K031497 | A61P01706 | A61K031506 | A61P00100 | C07D21158 | C07D41714 | A61P03112 | C07D41314 | C07D40114 | A61P01900,HU200203528A2 | IL145742D0 | TWI283666B  | ES2246233T3 | NZ514675A  | NO322044B1 | JP2006225407A  | DK1175402T3 | EP1659111A2 | TR200402496T2 | NO20015365D0 | CZ20013941A3 | CN1151131C  | TR200103213T2 | HU200203528A3 | SK15672001A3 | BR200010607A  | RU2005120376A  | EP1175402A1 | AU2005202358B2 | DE60021371D1 | AT299866T  | CO5170522A1 | CZ301161B6 | PL203117B1 | CN1524527A  | SK200101567A3 | SI1175402T1 | AU780983B2 | CA2371587A1 | EP1175402B1 | NO20015365A  | HK1039330A1 | DE60021371T2 | CA2371587C  | AU2005202358A1 | JP2002543186T  | RU2266281C2 | PT1175402E  | EP1659111A3 | PL351412A1 | AU200045010A  | SK286968B6 | ZA200108867A  | EG24533A  | CN1349504A  | JP3894729B2,34,27,Yes,Grant,Yes
186,WO2000067801,A2,"PERMEABLE, WATER SOLUBLE, NON-IRRITATING PRODRUGS OF CHEMOTHERAPEUTIC AGENTS WITH OXAALKANOIC ACIDS",US19990132803P,United States,1999-05-06T00:00:00Z,1999,2000-05-05T00:00:00Z,2000-11-16T00:00:00Z,2000,UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION,CROOKS PETER ANTHONY      | CYNKOWSKI TADEUSZ      | CYNKOWSKA GRAZYNA      | GUO HONG      | ASHTON PAUL,C07D239553 | A61K031522 | C07D47318 | C07C069017 | A61P03702 | C07D49122 | C07D21381 | A61P00912 | C07K00500 | A61P01106 | A61P03500 | C07C069708 | A61P03708 | A61K0314409 | A61K031426 | C07D47302 | C07J07100 | A61P03106 | C07D40504 | C07D27728 | A61K03127 | C07D40112 | A61P03104 | A61K031513 | A61K0314725 | A61K031573 | A61K0315377 | A61K0314745 | A61K031505 | A61K04748,JP2003513884T  | US6765019B1 | CA2368831A1 | US2004214784A1 | AU200047037A  | EP1233789A2 | WO200067801A3 | US7214710B2,7,6,Yes,Grant,Yes
187,WO2000068203,A1,CYCLIC COMPOUNDS AND USES THEREOF,JP19990127724,Japan,1999-05-07T00:00:00Z,1999,2000-04-28T00:00:00Z,2000-11-16T00:00:00Z,2000,TAKEDA PHARMACEUTICAL COMPANY,SHIRAISHI MITSURU    JP  | BABA MASANORI    JP  | SETO MASAKI    JP  | KANZAKI NAOYUKI    JP  | NISHIMURA OSAMU    JP,A61K031661 | C07F009655 | A61K031381 | A61K031352 | C07D40914 | C07D40712 | C07D30908 | C07D31308 | A61K031351 | C07D40514 | A61K0314725 | A61K0314025 | C07D21706 | C07D40512 | C07D40912 | A61P03118 | A61K03144 | A61K0314709,CA2373073A1 | US6627651B1 | JP2001026586A  | AU200041452A  | EP1182195A4 | EP1182195A1,6,5,Yes,Grant,Yes
188,WO2000069255,A1,ANTI-INFLAMMATORY THERAPY FOR INFLAMMATORY MEDIATED INFECTION,US19990134091P,United States,1999-05-14T00:00:00Z,1999,2000-05-12T00:00:00Z,2000-11-23T00:00:00Z,2000,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA,ANTON PETER A    US  | POLES MICHAEL A    US  | GIORGI JANIS V    US  | ELLIOTT JULIE E    US,A61K00902 | A61P03104 | A61P01502 | A61K031708 | A61K031603 | A61K031573 | A61K039395 | A61K0317072 | A61K031472 | A61P01102 | A61P03118 | A61K0314725 | A61K04800 | A61K031496 | A61K0315513 | A61K03160 | A61F00614 | A61F00606 | A61P00104 | A61K031536 | A61K03800 | A61K0317088 | A61F00604 | A61K03618 | A61K031513 | A61K00912 | A61P04300 | A61K031192 | A61K00906 | A61P03112 | A61K009107 | A61K03100 | A61K03820 | A61K031606 | A61K03817 | A61K04506 | A61K031454,TR200103271T2 | US2003138399A1 | MXPA01011606A  | CN1353573A  | IS6130A  | EP1202620A1 | CA2368593A1 | PL351710A1 | AU200050108A  | JP2002544210T  | IL146130D0 | WO200069255A8 | BR200010546A ,12,12,Yes,Application,No
189,WO2000072827,A2,POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF,US19990136323P,United States,1999-05-27T00:00:00Z,1999,2000-05-25T00:00:00Z,2000-12-07T00:00:00Z,2000,"ACUSPHERE, INC",STRAUB JULIE      | BERNSTEIN HOWARD      | CHICKERING DONALD E III      | KHATAK SARWAT      | RANDALL GREG,A61K00914 | A61K04702 | A61K04734 | A61K00910 | A61K00908 | A61K00902 | A61K00948 | A61K04726 | A61K04712 | A61K00920 | A61K00916,ES2250141T3 | DK1180020T3 | US2002041896A1 | KR100883477B1 | AU768022B2 | CN1240373C  | WO200072827A9 | US6610317B2 | NZ516083A  | HK1094775A1 | US6645528B1 | NO20015753D0 | EP1180020B1 | JP2003500438T  | US2005058710A1 | AT312601T  | DE60024811D1 | AU200054459A  | MXPA01012106A  | HK1048956A1 | ES2250141T5 | CA2371836C  | US2005048116A1 | NO323761B1 | IL146659D0 | NO20015753A  | ZA200110347A  | DE60024811T3 | TWI274589B  | CN100376291C  | US7919119B2 | BR200010984A  | EP1180020B2 | US40493E1 | IL146659A  | US6395300B1 | DK1180020T4 | DE60024811T2 | US6932983B1 | CA2371836A1 | EP1180020A2 | EP1642572A1 | CN1823737A  | US2002142050A1 | KR20070069219A  | CN1365274A  | WO200072827A3,32,20,Yes,Grant,Yes
190,WO2000073284,A2,"1,4-BENZODIAZEPIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS",US19990135966P,United States,1999-05-26T00:00:00Z,1999,2000-05-19T00:00:00Z,2000-12-07T00:00:00Z,2000,BRISTOL MYERS SQUIBB PHARMA CO,RODGERS JAMES D      | JOHNSON BARRY L      | WANG HAISHENG,C07D40106 | C07D24314 | A61P03118 | C07D40506 | C07D40906 | C07D41706,AU200055884A  | US6462037B1 | CA2370141A1 | EP1183242A2 | WO200073284A3,5,5,Yes,Grant,Yes
191,WO2000074677,A2,IMPROVED PHARMACEUTICAL FORMULATIONS,US19990325826,United States,1999-06-04T00:00:00Z,1999,2000-05-25T00:00:00Z,2000-12-14T00:00:00Z,2000,ABBOTT LAB,ALANI LAMAN A      | GHOSH SOUMOJEET,A61K04730 | A61K04712 | A61P04300 | A61K04742 | A61K031426 | A61K04710 | A61K04500 | A61K031513 | A61K0314725 | A61P03118 | A61K0315375 | A61K031551 | A61K03163 | A61K03117 | A61K00948 | A61K031472 | A61K031427 | A61K031496 | A61K0314433 | A61K0314709,EP1733725A1 | CZ301308B6 | CA2371109A1 | ZA200108641A  | AR032586A1 | SI1183026T1 | DE60029219D1 | ES2324549T3 | BR200007294A  | NO20015670A  | CO5160323A1 | AT429224T  | PL197671B1 | DK1183026T3 | TR200103488T2 | WO200074677A3 | BG106239A  | IL146025D0 | AU778198B2 | EP1733725B1 | SI1733725T1 | AT332132T  | DE60029219T2 | JP2003501386T  | DE60042092D1 | HK1045804A1 | PL351943A1 | CN101361723A  | EP1183026A2 | ES2265946T3 | MXPA01012478A  | PT1733725E  | CN100418527C  | SK17202001A3 | NO20015670D0 | PT1183026E  | NZ515016A  | SK200101720A3 | CN1353607A  | HU200201591A2 | SK287185B6 | HU200201591A3 | BG65445B1 | DK1733725T3 | SK286305B6 | AU200052877A  | NO328968B1 | TWI244390B  | CZ20014293A3 | AR064309A2 | EP1183026B1,37,27,Yes,Grant,Yes
192,WO2000076961,A1,INHIBITORS OF ASPARTYL PROTEASE,US19990139070P,United States,1999-06-11T00:00:00Z,1999,2000-06-08T00:00:00Z,2000-12-21T00:00:00Z,2000,ERTEX PHARMACEUTICALS INCORPORATED,HALE MICHAEL ROBIN    US  | TUNG ROGER    US  | PRICE STEPHEN    GB  | WILKES ROBIN DAVID    GB  | SCHAIRER WAYNE CARL    US  | JARVIS ASHLEY NICHOLAS    GB  | SPALTENSTEIN ANDREW    US  | FURFINE ERIC STEVEN    US  | SAMANO VICENTE    US  | KALDOR ISTVAN    US  | MILLER JOHN FRANKLIN    US  | BRIEGER MICHAEL STEPHEN    US,C07D31762 | A61K031343 | A61K03134 | A61P03112 | C07C31118 | C07D40712 | A61P04300 | A61K0315377 | A61P03118 | A61K031352 | C07D31746 | C07D49304 | A61K03136 | A61K04506,BR200011741A  | ZA200110177A  | EP1194404B1 | DE60016404D1 | CA2380858A1 | JP4503896B2 | TW593248B  | JP2003502337T  | DE60016404T2 | AT283860T  | TR200200407T2 | NO323951B1 | AU200056006A  | AU779994B2 | JP2009046493A  | AR031520A1 | AU774538B2 | US6878728B1 | HK1046899A1 | ES2263478T3 | US2004122000A1 | SI1194404T1 | BR200011745A  | CO5160337A1 | CZ20014431A3 | EP1194404A1 | TR200202528T2 | NO20016034D0 | TR200603871T2 | PT1194404E  | NO20016034A  | EP1185539B1 | AU200056040A  | EP1686113A1 | IL202633D0 | CN1361765A  | WO200077011A1 | CN100516034C  | DE60027722T2 | JP2003502309T  | HU200300385A3 | IL146918D0 | US6452032B1 | PL352830A1 | NZ516003A  | MXPA01012808A  | HU200300385A2 | DE60027722D1 | DK1194404T3 | EP1185539A1 | CN1368975A  | CA2375797A1 | AT325091T  | CN101245058A  | IL146918A  | US2009274650A1,35,27,Yes,Grant,Yes
193,WO2000076993,A1,"BENZAZEPINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF",JP19990170345,Japan,1999-06-16T00:00:00Z,1999,2000-06-15T00:00:00Z,2000-12-21T00:00:00Z,2000,TAKEDA PHARMACEUTICAL COMPANY,SHIRAISHI MITSURU    JP  | BABA MASANORI    JP  | ARAMAKI YOSHIO    JP  | KANZAKI NAOYUKI    JP  | NISHIMURA OSAMU    JP,C07D22316 | A61P04300 | A61P03118 | C07D40512,EP1186604A4 | US6936602B1 | AU200054265A  | JP2001058992A  | CA2380860A1 | EP1186604A1,6,6,Yes,Grant,Yes
194,WO2001010387,A2,ANTIVIRAL THERAPY USE OF P-GLYCOPROTEIN MODULATORS,US19990370266,United States,1999-08-09T00:00:00Z,1999,2000-08-07T00:00:00Z,2001-02-15T00:00:00Z,2001,VANDERBILT UNIVERSITY,WOOD ALASTAIR J J    US  | KIM RICHARD B    US  | WILKINSON GRANT R    US,A61K04500 | A61K031427 | A61K031341 | A61K0314725 | A61P04300 | A61K031496 | A61K031472 | A61K031495 | A61P03118 | A61K03134 | A61K031445 | A61K03855 | A61K03147,CA2378984A1 | WO200110387A3 | AU200077574A  | JP2003523944T  | EP1202737A4 | EP1202737A2,5,5,Yes,Application,No
195,WO2001010454,A2,COMPOSITION AND METHODS FOR TREATMENT OF HIV INFECTION,US19980074066P,United States,1998-02-09T00:00:00Z,1998,2000-08-07T00:00:00Z,2001-02-15T00:00:00Z,2001,"DEFIANTE FARMACEUTICA, S.A",AVRAMIS VASSILIOS L  US  | COHEN LEWIS  US,A61K03800,ZA9901029A  | DE69909747T2 | AU200068944A  | DK1053012T3 | JP2003506409T  | US2004228839A1 | WO200110454B1 | JP2002502826T  | EP1143990A2 | EP1053012B1 | DE69909747D1 | EP1143990A3 | WO200110454A3 | US6689762B1 | WO200110454A9 | EP1053012A1 | ES2203072T3 | ZA200102506A  | CA2346063A1 | AU2658499A  | AT245444T  | WO9939732A1 | CA2319356A1 | AU752434B2,15,11,Yes,Grant,Yes
196,WO2001012168,A2,"PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF VIRAL INFECTIONS, IN PARTICULAR OF THE HUMAN IMMUNODEFICIENCY VIRUS (HIV)",NL19991012825,Netherlands,1999-08-13T00:00:00Z,1999,2000-08-09T00:00:00Z,2001-02-22T00:00:00Z,2001,FACULTEIT GENEESKUNDE UNIVERSITEIT UTRECHT,VAN ASBECK BERNT SWEDER  NL  | MARX JOHANNES JOSEPHUS MARIA  NL,A61K03100,WO200112168A3 | AT282430T  | DE60016044D1 | AU200064831A  | NL1012825C2 | NL1012825A1 | EP1257261A2 | EP1257261B1,6,5,Yes,Grant,Yes
197,WO2001021603,A1,A PROCESS FOR THE SYNTHESIS OF RITONAVIR,IT1999MI01950,Italy,1999-09-21T00:00:00Z,1999,2000-09-18T00:00:00Z,2001-03-29T00:00:00Z,2001,ARCHIMICA S.R.L.,BELLANI PIETRO    IT  | FRIGERIO MARCO    IT  | CASTOLDI PATRIZIA    IT,C07B06100 | C07D27722 | C07C23710 | C07D27728,AU200075546A  | DE60032453T2 | DE60032453D1 | JP2003509504T  | ITMI991950A1 | EP1133485A1 | HU200104259A3 | ES2278631T3 | IT1313624B1 | HU200104259A2 | US6407252B1 | AT348819T  | ITMI991950D0 | EP1133485B1,10,10,Yes,Grant,Yes
198,WO2001025199,A1,"UREA COMPOUNDS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF",JP19990284495,Japan,1999-10-05T00:00:00Z,1999,2000-10-04T00:00:00Z,2001-04-12T00:00:00Z,2001,TAKEDA PHARMACEUTICAL COMPANY,KURASAWA OSAMU    JP  | IMAMURA SHINICHI    JP  | HASHIGUCHI SHOHEI    JP  | NISHIMURA OSAMU    JP  | KANZAKI NAOYUKI    JP  | BABA MASANORI    JP,C07D21114 | A61P04300 | A61P03118,US6787650B1 | DE60027908D1 | AU200075560A  | EP1219605B1 | DE60027908T2 | JP2001172260A  | CA2386387A1 | EP1219605A1 | EP1219605A4 | AT325790T ,8,8,Yes,Grant,Yes
199,WO2001025200,A1,CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS,JP19990282088,Japan,1999-10-01T00:00:00Z,1999,2000-09-29T00:00:00Z,2001-04-12T00:00:00Z,2001,TAKEDA PHARMACEUTICAL COMPANY,IMAMURA SHINICHI    JP  | HASHIGUCHI SHOHEI    JP  | HATTORI TAEKO    JP  | NISHIMURA OSAMU    JP  | KANZAKI NAOYUKI    JP  | BABA MASANORI    JP  | SUGIHARA YOSHIHIRO    JP,C07D21162 | C07D40514 | C07D40512 | A61K031708 | A61K031454 | A61K031513 | A61K031437 | A61K0314355 | A61K0315377 | C07D40112 | A61K031506 | C07D21170 | C07D21158 | C07D21174 | C07D47114 | A61K0317072 | A61K031498 | A61P04300 | A61K031472 | C07D40114 | C07D41312 | A61K0314725 | C07D48704 | A61K04500 | A61K031427 | A61P03118 | A61K031497 | C07D21196 | A61K031445 | C07D47104 | C07D41314 | A61K0314427 | A61K0314709 | C07D47116 | A61K031496 | A61K0315025 | C07D41714 | A61K0314545 | A61K031443 | C07D40914 | C07D41704 | A61K0315513 | A61K0314433 | C07D48714,CO5380013A1 | CA2608807A1 | DK1220842T3 | EP1220842A1 | EP1886994A1 | US2003114443A1 | PT1220842E  | AT400555T  | ZA200202593A  | US7348324B2 | EP1220842B1 | HU200300138A2 | ES2310173T3 | JP2001302633A  | NO20021450D0 | JP3814136B2 | BR200014428A  | CA2385938C  | PL203984B1 | HU200300138A3 | CN1390201A  | DE60039446D1 | HK1046905A1 | JP2003048880A  | AU200074487A  | US6562978B1 | NO20021450A  | CA2385938A1 | PL356034A1,22,18,Yes,Grant,Yes
200,WO2001025240,A1,"HEXAHYDROFURO'2,3-B!FURAN-3-YL-N- {3'(1,3-BENZODIOXOL -5- YLSULFONYL) (ISOBUTYL) AMINO! -1-BENZYL-2-HYDROXYPROPYL} CARBAMATE AS RETROVIRAL PROTEASE INHIBITOR",US19990157850P,United States,1999-10-06T00:00:00Z,1999,2000-10-06T00:00:00Z,2001-04-12T00:00:00Z,2001,TIBOTEC PHARM LTD,WIGERINCK PIET TOM BERT PAUL    BE  | WANG GUANGYANG    US  | EISSENSTAT MICHAEL    US  | ERICKSON JOHN W    US,A61K03136 | A61K03134 | A61P03114 | A61P03118 | A61P04300 | A61P03112 | C07D49304,US6649651B1 | HK1054746A1 | AT398623T  | AP200202472D0 | IL149005A  | SK287153B6 | AU781656B2 | CA2386850C  | EP1222192A1 | CA2386850A1 | NO327996B1 | NO20021598A  | PL204924B1 | CZ20021419A3 | ZA200202655A  | HU200203130A2 | NO20021598D0 | JP2003511383T  | US7157495B2 | CN1191256C  | ES2307533T3 | IL149005D0 | BR200014602A  | EP1222192B1 | RU2247123C2 | EP1222192B8 | CN1407987A  | OA12053A  | DK1222192T3 | SK200200570A3 | AP1459A  | HU200203130A3 | AU200076638A  | US2005261364A1 | NZ518580A  | CZ300031B6 | DE60039244D1 | MXPA02003607A  | PL354351A1 | SK5702002A3,26,24,Yes,Grant,Yes
201,WO2001026467,A1,METHODS OF ENHANCING CHEMOTHERAPY,US19990158322P,United States,1999-10-08T00:00:00Z,1999,2000-10-06T00:00:00Z,2001-04-19T00:00:00Z,2001,ONTOGEN CORP | NEWMAN MICHAEL JAMES | DIXON WILLIAM ROSS,NEWMAN MICHAEL JAMES    US  | DIXON WILLIAM ROSS    US,A61K04500 | A61K031407 | A61P04300 | A61K031337 | A61K03800 | A61K0314164 | A61P03500 | A61K031475 | A61K031704 | A61K031415 | C07D23354 | C07D23358 | C07D23356 | A61K04506,US2007203215A1 | EP2064951A1 | DE60041880D1 | EP1221847A4 | AU200078661A  | US2002147197A1 | JP2003511396T  | AT426335T  | CA2382727A1 | EP1221847A1 | AU20017824B2 | EP1221847B1,10,7,Yes,Grant,Yes
202,WO2001028532,A2,"METHODS AND COMPOSITIONS FOR PREDICTING, DIAGNOSING AND TREATING LIPODYSTROPHY",US19990160346P,United States,1999-10-19T00:00:00Z,1999,2000-10-18T00:00:00Z,2001-04-26T00:00:00Z,2001,KAIN KEVIN C | SERGHIDES LENA,KAIN KEVIN C    CA  | SERGHIDES LENA    CA,A61K031427 | A61K031192 | A61K03107 | G01N033569 | A61K03819 | A61K031496 | A61K031513 | A61K03100 | A61K03817 | A61K031405 | A61K031196 | A61K031472 | A61K031557 | A61K03820 | A61K0314439 | A61K031201 | A61K031203,EP1223983A2 | AU200078949A  | CA2387919A1 | CA2289365A1 | WO200128532A3,5,5,Yes,Application,No
203,WO2001028555,A1,EMULSION COMPOSITIONS FOR POLYFUNCTIONAL ACTIVE INGREDIENTS,US19990420159,United States,1999-10-18T00:00:00Z,1999,2000-10-18T00:00:00Z,2001-04-26T00:00:00Z,2001,LIPOCINE INC,CHEN FENG-JING    | PATEL MAHESH V,A61K031355 | A61K03120,AU200112139A  | US2002107265A1 | US6720001B2,3,3,Yes,Grant,Yes
204,WO2001029037,A2,TRICYCLIC COMPOUNDS USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS,US19990160329P,United States,1999-10-19T00:00:00Z,1999,2000-10-19T00:00:00Z,2001-04-26T00:00:00Z,2001,BRISTOL MYERS SQUIBB PHARMA CO,JOHNSON BARRY L      | PATEL MONA      | RODGERS JAMES D      | WANG HAISHENG,A61P03118 | A61K031496 | C07D47114 | A61K0314375 | A61P04300 | A61K031519 | A61K0317072 | A61K03144 | A61K04506 | A61K031505 | C07D47104,IL149219D0 | EE200200202A  | SK200200534A3 | PL355727A1 | CA2387896A1 | JP2003512375T  | NO20021835D0 | HU200300190A2 | BR200015056A  | CZ20021353A3 | EP1222186A2 | AU20097733B2 | CN1409711A  | WO200129037A3 | US2004002498A1 | ZA200203131A  | AU200112137A  | MXPA02003958A  | NO20021835A  | US6593337B1 | AR026175A1,19,17,Yes,Grant,Yes
205,WO2001034118,A2,SOLID DISPERSION PHARMACEUTICAL FORMULATIONS,US19990439514,United States,1999-11-12T00:00:00Z,1999,2000-11-10T00:00:00Z,2001-05-17T00:00:00Z,2001,ABBOTT LAB,FORT JAMES J      | KRILL STEVEN L      | LAW DEVALINA      | QIU YIHONG      | SCHMITT ERIC A      | PORTER WILLIAM R,A61K00914 | A61K03855,EP1227797A2 | ES2235991T3 | AT286720T  | DK1227797T3 | CA2390092C  | JP2003530310T  | CA2390092A1 | WO200134118A3 | DE60017444T2 | EP1227797B1 | PT1227797E  | DE60017444D1 | MXPA02004739A ,10,10,Yes,Grant,Yes
206,WO2001034119,A2,INHIBITORS OF CRYSTALLIZATION IN A SOLID DISPERSION,US19990438994,United States,1999-11-12T00:00:00Z,1999,2000-11-10T00:00:00Z,2001-05-17T00:00:00Z,2001,ABBOTT LAB,KRILL STEVEN K      | FORT JAMES J      | LAW DEVALINA      | SCHMITT ERIC A      | QIU YIHONG,A61K00914,DE60028754D1 | WO200134119A3 | DE60028754T2 | EP1175205A2 | AT329579T  | CA2359945A1 | WO200134119A9 | JP2003513904T  | EP1175205B1 | US2007249692A1,7,7,Yes,Grant,Yes
207,WO2001038332,A1,GAMMA-HYDROXY-2-(FLUOROALKYLAMINOCARBONYL)-1-PIPERAZINEPENTANAMIDES AS HIV PROTEASE INHIBITORS,US19990167478P,United States,1999-11-24T00:00:00Z,1999,2000-11-21T00:00:00Z,2001-05-31T00:00:00Z,2001,MERCK & CO INC,TATA JAMES R    US  | CHAPMAN KEVIN T    US  | DUFFY JOSEPH LESLIE    US  | KEVIN NANCY J    US  | CHENG YUAN    US  | RANO THOMAS A    US  | ZHANG FENGQI    US  | HUENING TRACY    US  | KIRK BRIAN ANTHONY    US  | LU ZHIJIAN    US  | RAGHAVAN SUBHAREKHA    US  | FLEITZ FRED J    US  | PETRILLO DANIEL E    US  | ARMSTRONG JOSEPH D III    US  | VARSOLONA RICHARD J    US  | ASKIN DAVID    US  | HOERRNER R SCOTT    US  | PURICK ROBERT    US,C12N00999 | A61K04500 | A61K031496 | A61K031427 | A61P03702 | C07B06100 | A61K031519 | A61K031497 | A61P03100 | A61P04300 | A61K031501 | A61K031506 | C07D491048 | C07D40914 | C07D41314 | C07D40514 | C07D49104 | C07D40106 | A61P03118 | C07D49504 | A61K03100 | C07D40506 | A61K04506 | C07D41714,AT377011T  | EP1242426B1 | US6642237B1 | CO5261497A1 | AU777824B2 | CA2391643C  | ECSP003786A  | AU200117909A  | DE60036961D1 | EP1242426A1 | CA2391643A1 | ES2295068T3 | DE60036961T2 | JP2003514910T ,12,11,Yes,Grant,Yes
208,WO2001041742,A2,ANTIVIRAL MEDICATION,US19990169883P,United States,1999-12-09T00:00:00Z,1999,2000-12-08T00:00:00Z,2001-06-14T00:00:00Z,2001,ALZA CORP,DONG LIANG C      | ESPINAL STEVEN D      | WONG PATRICK S-L      | MAGRUDER PAUL R,A61K00922 | A61P03118,EP1239840A2 | CA2393601A1 | WO200141742A3 | EP1239840B1 | JP2003516345T  | US2002071863A1 | DE60019334T2 | ES2236012T3 | DE60019334D1 | AT292453T  | AU200120848A ,9,9,Yes,Grant,Yes
209,WO2001044508,A2,METHOD TO EVALUATE THE HIV DRUG SENSITIVITY,EP19990830776,European Patent Office,1999-12-15T00:00:00Z,1999,2000-12-14T00:00:00Z,2001-06-21T00:00:00Z,2001,BIOSTRANDS S.R.L.,MENZO STEFANO    IT  | CLEMENTI MASSIMO    IT,G01N03350 | C12Q00170 | C12N00950 | G01N033569,RU2002118706A  | EP1242818B1 | EP1109019A1 | AU200123951A  | AT265043T  | US2003175690A1 | WO200144508A3 | DE60010127D1 | BR200016409A  | CA2393620A1 | EP1242818A2,9,8,Yes,Grant,Yes
210,WO2001047511,A2,TREATMENT OF DRUG-RESISTANT HUMAN IMMUNODEFICIENCY VIRUS INFECTION,US19990173610P,United States,1999-12-29T00:00:00Z,1999,2000-12-22T00:00:00Z,2001-07-05T00:00:00Z,2001,UNIVERSITY OF PITTSBURGH | REGENTS OF THE UNIVERSITY OF CALIFORNIA,HOSTETLER KARL Y    US  | MELLORS JOHN W    US,A61P03118 | A61K031662 | A61K031661 | A61K03166 | A61K0317072 | A61K04506,BR200016844A  | WO200147511A3 | JP2003518495T  | US2003207843A1 | CA2395430A1 | AU200124539A  | RU2265439C2 | ZA200205020A  | MXPA02006491A  | CN1414857A  | EP1244459A2,11,11,Yes,Grant,Yes
211,WO2001049700,A1,IMIDAZOPYRIMIDINE NUCLEOSIDE ANALOGUES WITH ANTI-HIV ACTIVITY,US19990173871P,United States,1999-12-30T00:00:00Z,1999,2000-12-28T00:00:00Z,2001-07-12T00:00:00Z,2001,BIOCHEM PHARMA INC,SIDDIQUI ARSHAD    CA  | CIMPOIA ALEX    CA  | PREVILLE PATRICE    CA,C07H01904 | C07D47104 | A61K031519,US2002061896A1 | AU200123381A ,3,3,Yes,Application,No
212,WO2001050987,A2,TREATMENT OF HEPATITIS C USING HYPERTHERMIA,US20000484360,United States,2000-01-14T00:00:00Z,2000,2000-12-20T00:00:00Z,2001-07-19T00:00:00Z,2001,"FIRST CIRCLE MEDICAL, INC",GROTH KARL      | KELLY THEODORE      | WESTERBECK TODD      | BLICK GARY,A61M00136 | A61P03100 | A61K031513 | A61P03114 | A61P03118 | A61F00700 | A61K0317052 | A61P03112 | A61P03120 | A61P03104 | A61K03821 | A61K04500 | A61F00712,JP2003526414T  | US6347633B1 | DE60028960D1 | DE60028960T2 | US2002033181A1 | ES2262558T3 | AU200124506A  | EP1176932B1 | AT330568T  | EP1676551A2 | US2005125039A1 | CN1350445A  | US6951219B2 | US6644320B2 | BR200009267A  | AU783813B2 | US2004055609A1 | CA2366599A1 | EP1176932A1,16,11,Yes,Grant,Yes
213,WO2001052821,A1,IMPROVED PHARMACEUTICAL FORMULATIONS,US20000487739,United States,2000-01-19T00:00:00Z,2000,2000-12-01T00:00:00Z,2001-07-26T00:00:00Z,2001,ABBOTT LAB,ALANI LAMAN      | GHOSH SOUMOJEET,A61K031426 | A61P04300 | A61K04734 | A61P03118 | A61K04710 | A61K00948 | A61K04712,NZ519724A  | IL150265D0 | SI1248600T1 | DE60038899D1 | CZ20022663A3 | CA2395987A1 | BG106976A  | CN1424907A  | EP1917958A3 | EP1248600B1 | CN100536833C  | SK11102002A3 | EP2269591A2 | AU2006235895B2 | HU200302070A3 | AT395049T  | ES2304990T3 | SK200201110A3 | CA2395987C  | AU2006235895A1 | DK1248600T3 | NO20023455A  | EP1248600A1 | MXPA02007097A  | JP2003533435T  | NO20023455D0 | EP1917958A2 | AU200119405A  | PL361396A1 | SK287143B6 | BR200011864A  | PT1248600E  | ZA200205109A  | HU200302070A2,24,21,Yes,Grant,Yes
214,WO2001054652,A2,A METHOD OF INDUCING AUTOVACCINATION AGAINST HIV INFECTION USING STRUCTURED TREATMENT INTERRUPTIONS,US20000493769,United States,2000-01-28T00:00:00Z,2000,2001-01-26T00:00:00Z,2001-08-02T00:00:00Z,2001,RESEARCH INSTITUTE FOR GENETIC AND HUMAN THERAPY,LISZIEWICZ JULIANNA      | LORI FRANCO      | XU JIANQUING      | VARGA GEORG STEPHEN,A61K04506 | A61K03921,AU200132970A  | WO200045844A1 | EP1146904A1 | EP1146904A4 | WO200154652A3 | AU200027537A  | US2003095988A1 | WO200154652A8,6,4,Yes,Application,No
215,WO2001054729,A1,TREATMENT OF NEUROPSYCHIATRIC DISEASE WITH PROTEASE AND NEURAMINIDASE INHIBITORS,US20000177971P,United States,2000-01-25T00:00:00Z,2000,2001-01-25T00:00:00Z,2001-08-02T00:00:00Z,2001,"THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH",VAWTER MARQUIS P    US  | FREED WILLIAM J    US,A61K031352 | A61K031351 | A61K031245 | A61K03855 | A61K04506 | C07K014705,US2003211545A1 | US2006205650A1 | AU200131137A ,4,3,Yes,Application,No
216,WO2001066123,A2,HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPHY,US20000522055,United States,2000-03-09T00:00:00Z,2000,2001-03-08T00:00:00Z,2001-09-13T00:00:00Z,2001,YALE UNIVERSITY,CHENG YUNG-CHI    US  | LIU SHWU-HUEY    US,A61K00902 | A61K0314725 | A61P03118 | A61K03648 | A61K00914 | A61K00908 | A61K03653 | A61P04300 | A61K03618 | A61P03120 | A61P03114 | A61P03122 | A61K0317068 | A61K031513 | A61K04500 | A61P00116 | A61K0317048 | A61K031472 | A61K00920 | A61K031496 | A61K031522 | A61K0317072 | A61K0314745 | A61K00948 | A61K031427 | A61K036725 | A61K03665 | A61P03112 | A61K031505 | A61P03500 | A61K036539,CN1612743A  | CN101730535A  | DE60143857D1 | US7534455B2 | US2005196473A1 | WO2006053049A3 | US2003211180A1 | WO2008101079A1 | US2010255129A9 | EP1812028A4 | US7025993B2 | CA2583761A1 | AT494899T  | AU200145508A  | EP1401458B1 | CA2402466A1 | US2010166892A1 | CN100490845C  | JP2004500390T  | AU2005304493A1 | CN101098705A  | EP1812028A2 | WO200166123A3 | JP2008519767T  | WO2006053049A2 | EP1401458A2,20,10,Yes,Grant,Yes
217,WO2001068086,A1,ANTIVIRAL THERAPY,EP19990202156,European Patent Office,1999-07-02T00:00:00Z,1999,2001-03-19T00:00:00Z,2001-09-20T00:00:00Z,2001,UNIVERSITAIR MEDISCH CENTRUM UTRECHT,NOTTET JOHANNES SERVATIUS LEON    NL,A61P03118 | A61P03112 | A61K03122,US2005059745A1 | EP1263429A1 | CA2373879A1 | AU200144851A  | AU200058561A  | DE60022047D1 | AT301997T  | EP1263429B1 | JP2003503455T  | AT270886T  | WO200101985A1 | DE60022047T2 | US6387959B1 | DE60104288D1 | ZA200200143A  | CA2403358A1 | EP1064940A1 | EP1194141B1 | EP1194141A1 | DE60104288T2 | US2003171441A1 | US6787573B2,18,9,Yes,Grant,Yes
218,WO2001074787,A2,CRYSTALLINE PHARMACEUTICAL,GB20000073718,United Kingdom,2000-03-28T00:00:00Z,2000,2001-03-21T00:00:00Z,2001-10-11T00:00:00Z,2001,ABBOTT LAB,DICKMAN DANIEL A      | CHEMBURKAR SANJAY      | FORT JAMES J      | HENRY RODGER F      | LECHUGA-BALLESTEROS DAVID      | NIU YUPING      | PORTER WILLIAM,A61P04300 | A61K031513 | A61P03118 | C07D23910,AR033360A1 | AR028304A1 | MXPA02009559A  | BR200109433A  | US2007027172A1 | AU2001250920B2 | BG107165A  | AR049560A2 | AU200150920A  | HU200302675A3 | NO20024679A  | PL359727A1 | ZA200206962A  | US6608198B2 | AU2006222711A1 | SK200201483A3 | CN1422259A  | CZ20023529A3 | CN101066952A  | WO200174787A3 | NO325005B1 | CA2403635A1 | US2001051721A1 | EP1268442A2 | NZ521183A  | CN1330639C  | US6864369B2 | IL151551D0 | HU200302675A2 | NO20024679D0 | US2003191313A1 | JP2003529592T  | US2005124810A1 | TWI284640B ,27,19,Yes,Grant,Yes
219,WO2001078681,A1,DRUG DELIVERY SYSTEM FOR AVOIDING PHARMACOKINETIC INTERACTION BETWEEN DRUGS AND METHOD THEREOF,US20000197574P,United States,2000-04-17T00:00:00Z,2000,2001-04-16T00:00:00Z,2001-10-25T00:00:00Z,2001,ASTELLAS PHARMA INC.,SAWADA TOYOHIRO    JP  | SAKO KAZUHIRO    JP  | YOSHIOKA TATSUNOBU    JP  | WATANABE SHUNSUKE    JP,A61K031554 | A61K00900 | A61K0315517 | A61K00928 | A61K00950 | A61K031341 | A61K00920 | A61K00916,US2002022054A1 | EP1275373A1 | US6761895B2 | AU200150646A  | US2005163840A1 | EP1275373A4,5,4,Yes,Grant,Yes
220,WO2001079246,A2,3'-OR 2'-HYDROXYMETHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR TREATMENT OF HEPATITIS VIRUS INFECTIONS,US20000197068P,United States,2000-04-13T00:00:00Z,2000,2001-04-13T00:00:00Z,2001-10-25T00:00:00Z,2001,"PHARMASSET, INC.",WATANABE KYOICHI A    US  | PAI BALAKRISHNA S    US,A61P03502 | A61K03152 | A61K031513 | C07D40504 | C07D49304 | A61P03118 | A61K03821 | A61P00116 | A61K03113 | A61P03114 | A61K0315383 | A61K03800 | A61P03120 | A61K031712 | A61K031662 | C07D41304 | C07H01906 | A61K0317076 | A61P03500 | C07H01920 | C07H01910 | C07H01916 | A61K0317072 | A61P03112 | A61K0317068,WO200179246A3 | EP1284741B1 | DE60136620D1 | CN100457118C  | AT414520T  | US2002055483A1 | KR20100003313A  | JP2003532643T  | EP1284741A2 | EP1964569A2 | AU200159068A  | CN1436082A  | BR200110023A  | US7094770B2 | CA2404639A1 | CN101502531A  | EP1964569A3 | ES2319732T3,13,10,Yes,Grant,Yes
221,WO2001080896,A2,FLAVOPIRIDOL DRUG COMBINATIONS AND METHODS WITH REDUCED SIDE EFFECTS,US20000553829,United States,2000-04-21T00:00:00Z,2000,2001-04-12T00:00:00Z,2001-11-01T00:00:00Z,2001,ARCH DEVELOPMENT CORPORATION,RATAIN MARK J   US  | INNOCENTI FEDERICO   US  | IYER LALITHA   US,A61K04506 | A61K031445,WO200180896A3 | AU200153618A  | US2002016293A1,3,3,Yes,Application,No
222,WO2001082919,A2,METHODS OF AND COMPOUNDS FOR INHIBITING CALPAINS,US20000202378P,United States,2000-05-04T00:00:00Z,2000,2001-05-02T00:00:00Z,2001-11-08T00:00:00Z,2001,"THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH",DE PETRILLO PAOLO B    US  | WAN WENSHUAI    US,A61P01902 | A61K031472 | A61K031427 | A61K03127 | A61P00702 | A61K0314725 | A61P02528 | A61P02500 | A61K031496 | A61K04506,WO200182919A3 | AU200159817A  | US6448245B1 | WO200182919B1 | US2002115665A1,3,3,Yes,Grant,Yes
223,WO2001092288,A2,COBALAMIN COMPOUNDS USEFUL AS ANTIBIOTIC AGENTS AND AS IMAGING AGENTS,US20000208148P,United States,2000-05-31T00:00:00Z,2000,2001-05-31T00:00:00Z,2001-12-06T00:00:00Z,2001,MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | REGENTS OF THE UNIVERSITY OF MINNESOTA,COLLINS DOUGLAS A    US  | HOGENKAMP HENRICUS P C    US,A61P03100 | A61K05104 | A61K04748 | C07H02300,WO200192288A3 | AU200172935A  | US2002042394A1,3,3,Yes,Application,No
224,WO2001094645,A1,TWO-HYBRID ASSAY THAT DETECTS HIV-1 REVERSE TRANSCRIPTASE DIMERIZATION,US20000588939,United States,2000-06-06T00:00:00Z,2000,2001-06-06T00:00:00Z,2001-12-13T00:00:00Z,2001,THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK,GOFF STEPHEN P  US  | TACHEDJIAN GILDA  US,C12Q00170 | C12P02106 | C12P02104 | C12N01500 | A61K03900,US6812025B2 | JP2004509614T  | AU200165383A  | EP1290231A4 | EP1290231A1 | US2003007983A1 | US2002197598A1 | CA2412386A1,7,6,Yes,Grant,Yes
225,WO2001096329,A1,MEDICINAL COMPOSITIONS CONTAINING PROPENONE DERIVATIVES,JP20000176844,Japan,2000-06-13T00:00:00Z,2000,2001-06-11T00:00:00Z,2001-12-20T00:00:00Z,2001,"SHIONOGI & CO., LTD",SATO AKIHIKO    JP,C07D40306 | C07D40506 | A61K0314725 | A61K0317072 | A61K03141 | A61K031341 | A61K04506 | A61K031675 | A61K031551 | A61K031499 | A61K031506 | A61K031165 | A61K031522 | A61K0314439 | A61K0314155 | A61K031498 | A61K031513 | A61K0315517 | A61K031496 | A61K0314196 | A61P03118 | A61K031443,CN1446213A  | AU200162733A  | US2003171406A1 | NO20026013A  | RU2002135640A  | HU200301713A2 | HU200301713A3 | CA2410763A1 | BR200111678A  | PL359364A1 | AP200302716D0 | NO20026013D0 | EP1295879A1 | CZ20023940A3 | EP1295879A4 | IL153363D0 | MXPA02012160A  | ZA200209673A ,14,14,Yes,Application,No
226,WO2001097749,A2,"THE USE OF SYNTHETIC, NON-HORMONAL 21-AMINOSTEROIDS, DERIVATIVES, METABOLITES AND PRECURSORS THEREOF IN THE TREATMENT OF VIRAL INFECTIONS",IE20000000511,Ireland,2000-06-23T00:00:00Z,2000,2001-06-22T00:00:00Z,2001-12-27T00:00:00Z,2001,KOTZE GAVIN SALOMON | PRENDERGAST PATRICK THOMAS,PRENDERGAST PATRICK THOMAS    IE,A61K04726 | A61K00950 | A61K009127 | A61K00900 | A61K04710 | A61K03158 | A61P03112 | A61K04506 | A61K04702,AU200174383A  | WO200197749A3,2,2,Yes,Application,No
227,WO200156547,A2,PREPARATION OF AQUEOUS CLEAR SOLUTION DOSAGE FORMS WITH BILE ACIDS,US19980094069P,United States,1998-07-24T00:00:00Z,1998,2001-02-05T00:00:00Z,2001-08-09T00:00:00Z,2006,YOO SEO HONG   US,YOO SEO HONG   US,A61K000906 | A61K000800 | A61K000863 | A61K000872 | A61K000873 | A61K000900 | A61K000908 | A61K000910 | A61K0031575 | A61K003324 | A61K004506 | A61K004704 | A61K004712 | A61K004714 | A61K004718 | A61K004728 | A61K004732 | A61K004736 | A61K004738 | A61P000102 | A61P000104 | A61P000116 | A61P000306 | A61P003500 | A61Q001100,AT292956T | AT506955T | AU5081999A | AU2001236685B2 | AU3668501A | AU2005295541A1 | AU758679B2 | BR9912395A | BRPI0108080A | BRPI0518191A | CA2338457A1 | CA2338457C | CA2406930A1 | CA2406930C | CA2584184A1 | CN100558407C | CN101039699A | CN101039699B | CN101378769A | CN1205922C | CN1348360A | CN1450914A | DE602005027727D1 | DE69924740D1 | DE69924740T2 | DK1113785T3 | EP1113785A2 | EP1113785B1 | EP1255566A2 | EP1809330A2 | EP1809330B1 | EP1940428A1 | ES2238843T3 | ID29632A | IL140986A | IL140986D0 | IL150952A | IL150952D0 | JP2002522357T | JP2004500378T | JP2008516977T | JP2009511577T | JP2011021031A | KR1020070084211A | KR1020080063401A | PT1113785E | RU2002123352A | RU2224523C2 | RU2277913C2 | US20020031558A1 | US20030186933A1 | US20050158408A1 | US20060089331A1 | US20060188530A1 | US20070072828A1 | US20080057133A1 | US6251428B1 | US7166299B2 | US7303768B2 | US7772220B2 | US7932243B2 | WO2000004875A2 | WO2000004875A3 | WO2001056547A3 | WO0156547B1 | WO2006044771A2 | WO2006044771A3 | WO2007044062A1 | WO2007044062A1,49,17,Yes,Grant,Yes
228,WO2002000168,A2,COMBINATION HIV THERAPY INCLUDING CAMPTOTHECIN,US20000606967,United States,2000-06-28T00:00:00Z,2000,2001-06-20T00:00:00Z,2002-01-03T00:00:00Z,2002,SUPERGEN INC.,SCHOCHETMAN GERALD  US  | CHANG LUCY  US  | RUBINFELD JOSEPH  US,A61K000,US2004116411A1 | AU200168653A  | WO200200168A3 | EP1311266A2,4,4,Yes,Application,No
229,WO2002003879,A1,TREATMENT OF HIV USING HYPERTHERMIA,US20000611878,United States,2000-07-07T00:00:00Z,2000,2001-05-29T00:00:00Z,2002-01-17T00:00:00Z,2002,"FIRST CIRCLE MEDICAL, INC",GROTH KARL      | KELLY THEODORE      | WESTERBECK TODD      | BLICK GARY,A61B01900,AU200165253A ,2,2,Yes,Application,No
230,WO2002003886,A1,TREATMENT OF HUMAN HERPESVIRUSES USING HYPERTHERMIA,US20000611434,United States,2000-07-07T00:00:00Z,2000,2001-05-29T00:00:00Z,2002-01-17T00:00:00Z,2002,"FIRST CIRCLE MEDICAL, INC",GROTH KARL      | KELLY THEODORE      | WESTERBECK TODD      | BLICK GARY,A61F00200 | A61M03700,JP2004502491T  | AU200180440A  | US6415797B1 | EP1317226A4 | EP1317226A1 | CN1383375A ,6,6,Yes,Grant,Yes
231,WO2002006190,A2,CRYSTALLINE AND SALT FORMS OF AN HIV PROTEASE INHIBITOR,US20000219390P,United States,2000-07-19T00:00:00Z,2000,2001-07-19T00:00:00Z,2002-01-24T00:00:00Z,2002,BRISTOL MYERS SQUIBB PHARMA CO,HARRIS THOMAS D    | ANDERSON STEPHEN R    | DESIKAN SRIDHAR    | MEENAN PAUL A    | STONE BENJAMIN R    | TOMA PASCAL H    | DESHMUKH SUBODH SHRINIVAS,C07C000,US2002022659A1 | AU200180636A  | WO200206190A3,3,3,Yes,Application,No
232,WO2002006292,A1,PHOSPHATE ESTERS OF BIS-AMINO ACID SULFONAMIDES CONTAINING SUBSTITUTED BENZYL AMINES,US20000219399P,United States,2000-07-19T00:00:00Z,2000,2001-07-19T00:00:00Z,2002-01-24T00:00:00Z,2002,BRISTOL MYERS SQUIBB PHARMA CO,KALTENBACH ROBERT F III    | TRAINOR GEORGE L,C07F00912 | C07F009655 | A61K03166 | A61K031665,US2002028791A1 | AU200180633A  | US6617310B2,3,3,Yes,Grant,Yes
233,WO2002010124,A2,SALT FORMS OF AN HIV PROTEASE INHIBITOR,US20000219794P,United States,2000-07-19T00:00:00Z,2000,2001-07-19T00:00:00Z,2002-02-07T00:00:00Z,2002,BRISTOL MYERS SQUIBB PHARMA CO,MEENAN PAUL A    | TOMA PASCAL H    | DESIKAN SRIDHAR    | ANDERSON STEPHEN R    | HARRIS GREGORY D    | STONE BENJAMIN R,C07C31100,US2002022742A1 | AR029855A1 | AU200180634A  | WO200210124A3,4,4,Yes,Application,No
234,WO2002020057,A2,FLAVORING SYSTEMS FOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SUCH COMPOSITIONS,US20000655192,United States,2000-09-05T00:00:00Z,2000,2001-09-04T00:00:00Z,2002-03-14T00:00:00Z,2002,ABBOTT LAB,ALANI LAMAN      | GAUWITZ DONALD P      | KAUL DILIP      | LIPARI JOHN M      | GHOSH SOUMOJEET      | MARSH KENNAN C      | WHELAN RICHARD H      | PETROSSIAN VANIK D,A61K00908 | A61K04702 | A61K04726 | A61K04732 | A61K04744 | A61K031425 | C11B00900 | A61P03118 | A61K04712 | A61K04710 | A61K031505 | A61K00900 | A61K03855 | A61K031426 | A61K031513,EP1315487A2 | CA2417258A1 | AU200188695A  | WO200220057A3 | UY26925A1 | MXPA03001952A  | JP2004522698T  | AR030715A1 | BR200108433A ,9,9,Yes,Application,No
235,WO2002033402,A2,ESTABLISHMENT OF BIOLOGICAL CUT-OFF VALUES FOR PREDICTING RESISTANCE TO THERAPY,US20000241836P,United States,2000-10-20T00:00:00Z,2000,2001-10-22T00:00:00Z,2002-04-25T00:00:00Z,2002,VIRCO BVBA,HERTOGS KURT    BE  | LARDER BRENDAN    GB  | HARRIGAN RICHARD P    CA,G01N03315 | C12Q00168 | G01N03350,AT204900042T  | ES2321809T3 | US2004033489A1 | EP1340075B1 | US7292944B2 | JP4264256B2 | JP2004511800T  | AU200212344A  | DE60137580D1 | EP1340075A2 | AU2002212344B2 | CA2425772A1 | WO200233402A3,9,8,Yes,Grant,Yes
236,WO2002033638,A2,NEW MUTATIONAL PROFILES IN HIV-1 REVERSE TRANSCRIPTASE CORRELATED WITH PHENOTYPIC DRUG RESISTANCE,US20000589167,United States,2000-06-08T00:00:00Z,2000,2001-10-22T00:00:00Z,2002-04-25T00:00:00Z,2002,VIRCO BVBA,DEHERTOGH PASCALE ALFONS ROSA    BE  | HERTOGS KURT    BE  | LARDER BRENDAN    GB  | WANG DECHAO    GB,G01N03350 | G01N03315 | C12Q00168 | C12Q00137 | G06F01900,JP2004512032T  | EP1352356B1 | WO200195230A2 | WO200233638A3 | US2003190603A1 | CN1864163A  | EP1356082A2 | BR200115132A  | MXPA03003476A  | CA2425807A1 | EP1352356A2 | ZA200303007A  | US7058616B1 | AU200167520A  | US2008286754A1 | CN100592309C  | US2004073378A1 | AU785353B2 | JP2004523725T  | WO200195230A3 | CA2415832A1 | RU2318213C2 | AU200226316A  | AU2002226316B2 | AT445883T  | ES2334011T3 | DE60140211D1,23,13,Yes,Grant,Yes
237,WO2002034284,A2,METHODS OF THERAPY FOR HIV INFECTION,US20000242090P,United States,2000-10-20T00:00:00Z,2000,2001-10-11T00:00:00Z,2002-05-02T00:00:00Z,2002,CHIRON CORPORATION,SAHNER DAVID    US,C12N01509 | A61K031551 | A61P04300 | A61K03800 | A61K04500 | A61P03704 | A61K0314725 | A61K031472 | A61K031427 | A61K031522 | A61K031496 | A61K031513 | A61K03152 | A61K03820 | A61P03118 | A61K04506 | A61K0317072 | A61K0317068,JP2004528271T  | EP1372701A2 | US6579521B2 | US2003202961A1 | AU2002211676B2 | CA2425596A1 | WO200234284A3 | AU200211676A  | US7048924B2 | US2002048748A1,8,6,Yes,Grant,Yes
238,WO2002053138,A2,TREATMENT FOR INHIBITING NEOPLASTIC LESIONS,IE20010000002,Ireland,2001-01-02T00:00:00Z,2001,2002-01-02T00:00:00Z,2002-07-11T00:00:00Z,2002,SHANAHAN-PRENDERGAST ELISABETH,SHANAHAN-PRENDERGAST ELISABETH    IE,A61P03500 | A61K031343 | A61K031015 | A61K03100 | A61P03300 | A61K04506 | A61P03700 | A61P03104 | A61P03112,AU2002219472A1 | US2004092583A1 | EP1351678A2 | WO2002053138A3,4,4,Yes,Application,No
239,WO2002056861,A2,SYNTACTIC DEFORMABLE FOAM COMPOSITIONS AND METHODS FOR MAKING,US20010765783,United States,2001-01-19T00:00:00Z,2001,2002-01-17T00:00:00Z,2002-07-25T00:00:00Z,2002,INTELLIPHARMACEUTICS INC.,ODIDI ISA  CA  | ODIDI AMINA  CA,A61K00900,CA2435276A1 | CA2435276C  | AU2002226223A1 | US6800668B1 | WO2002056861A3,4,4,Yes,Grant,Yes
240,WO2002056902,A2,COMBINATION METHOD FOR TREATING VIRAL INFECTIONS,US20000256657P,United States,2000-12-19T00:00:00Z,2000,2001-12-17T00:00:00Z,2002-07-25T00:00:00Z,2002,SCHERING CORP,BAROUDY BAHIGE M    US,A61J00300 | A61K0314545 | C07K014155 | A61K04500 | A61K031506 | A61P04300 | A61K03800 | A61K04506 | A61K03100 | A61P03118 | A61K03816,MXPA03005526A  | AR031931A1 | US2005065319A1 | HU200302241A3 | CN1481251A  | JP2005500981T  | BR200116253A  | NO20032769D0 | ZA200304560A  | CA2431919A1 | WO2002056902A3 | EP1385534A2 | NO20032769A  | HU200302241A2,12,12,Yes,Application,No
241,WO2002061798,A1,CHARGED PARTICLE TRAPPING IN NEAR SURFACE POTENTIAL WELLS,US20000219532P,United States,2000-07-20T00:00:00Z,2000,2002-01-28T00:00:00Z,2002-08-08T00:00:00Z,2002,ANALYTICA OF BRANDFORD INC,WHITEHOUSE CRAIG M    US  | WELKIE DAVID G    US,H01J04942 | H01J04940,CA2442248A1 | US6683301B2 | AU200180641A  | PL365958A1 | US2004023955A1 | LT2003003A  | AR031861A1 | IS6690A  | EP1303515A2 | ZA200300255A  | WO200208226A3 | SI21139A  | EE200300027A  | CA2418194A1 | JP2004532793T  | US6872941B1 | BG107439A  | US6596729B2 | WO200208226A2 | BR200112606A  | LV13024B  | SK200300039A3 | NO20030248D0 | NO20030248A  | HU200302862A2 | CN1464878A  | US2002107261A1 | EP1364386A1 | IL153683D0 | US2002100870A1 | EP1364386A4 | CA2442248C  | MXPA03000434A  | US6969721B2,27,21,Yes,Grant,Yes
242,WO2002062123,A2,NOVEL COMPOUNDS AND METHODS FOR INHIBITING/TREATING HIV INFECTIONS AND AIDS RELATED SYMPTOMS,US20010266751P,United States,2001-02-06T00:00:00Z,2001,2002-02-05T00:00:00Z,2002-08-15T00:00:00Z,2002,"YALE UNIVERSITY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC",ANDERSON KAREN S    US  | CHU CHUNG K    US  | RAY ADRIAN STAFFIN    US  | ZHENJUN YANG    US,C07H01916,WO2002062123A3 | US2003018015A1 | US6900315B2 | AU2002242096A1,3,3,Yes,Grant,Yes
243,WO2002070070,A2,COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY,GB20010005131,United Kingdom,2001-03-01T00:00:00Z,2001,2002-02-20T00:00:00Z,2002-09-12T00:00:00Z,2002,PFIZER,HUMPHREY MICHAEL JOHN  GB,A61P02506 | A61K031404 | A61K031404 | 7A 61K 31:275 J,GB200105131D0 | MXPA03007836A  | JP2004529893T  | BR200207751A  | US2002165120A1 | US6579898B2 | EP1372785A2 | WO2002070070A3 | AU2002232061A1 | CA2439917A1,8,8,Yes,Grant,Yes
244,WO2002070470,A2,BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE,US20010272953,United States,2001-03-02T00:00:00Z,2001,2002-02-28T00:00:00Z,2002-09-12T00:00:00Z,2002,GSK LLC,CHAN JOSEPH HOWING    US,C07D29514 | A61K00948 | A61K00920 | A61K00908 | C07C30340 | A61K03163 | A61P03112 | C07C31146 | C07D20716 | C07C31153 | C07D29515 | C07C31151 | A61P03118,NZ527864A  | MXPA03007883A  | NO20033857A  | HU200303326A2 | NO20033857D0 | US2004122064A1 | JP2004525914T  | CA2439820A1 | IL157348D0 | AR043367A2 | BR200207752A  | US6995283B2 | AU2002254056C1 | CN1494528A  | PL364658A1 | AU2002254056B2 | WO2002070470A3 | US2006009651A1 | CZ20032366A3 | ZA200306549A  | AR035436A1 | EP1363877A2,18,16,Yes,Grant,Yes
245,WO2002072109,A1,"SUBSTITUTED 3',4'-DI-O-CAMPHANOYL-(+)-CIS-KHELLACTONE ANALOGS,   COMPOSITIONS THEREOF, AND METHODS FOR USING THEREOF",US20010275043P,United States,2001-03-13T00:00:00Z,2001,2002-03-13T00:00:00Z,2002-09-19T00:00:00Z,2002,PANACOS PHARMACEUTICALS INC | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL,LEE KUO-HSIUNG      | XIE LAN      | ALLAWAY GRAHAM P      | WILD CARL T,C07D49504 | C07D49304 | C07D47104 | C07F0096561,US6768007B2 | US2003008891A1,2,2,Yes,Grant,Yes
246,WO2002074777,A2,PYRANOCOUMARIN COMPOUNDS AS A NOVEL PHARMACOPHORE WITH ANTI-TB ACTIVITY,US20010276531P,United States,2001-03-16T00:00:00Z,2001,2002-03-15T00:00:00Z,2002-09-26T00:00:00Z,2002,SARAWAK MEDICHEM PHARMACEUTICALS,XU ZE-QI    US  | PUPEK KRZYSZTOF    US  | ENACHE LIVIA    US  | FLAVIN MICHAEL T    US,C07D31118 | A61K0314965 | A61K031427 | A61K0314188 | A61P03704 | A61P03104 | A61K031352 | A61P03118 | A61K031496 | A61K0314409 | A61K03800 | A61P03112 | A61P03706 | A61K0317072 | A61K031472 | A61K0314725 | C07D40304 | C07D31116 | C07D49314 | A61P03106 | C07D49304,AU2002254206A1 | JP2005508283T  | EP1379529A2 | US6670383B2 | US2003083369A1 | WO2002074777A3,5,5,Yes,Grant,Yes
247,WO2002077290,A1,METHODS FOR MODIFYING PHARMACOKINETICS AND BIOAVAILABILITY OF EXOGENOUS COMPOUNDS,US20000191767P,United States,2000-03-24T00:00:00Z,2000,2002-03-25T00:00:00Z,2002-10-03T00:00:00Z,2002,CITY OF HOPE,FORMAN BARRY      | DUSSAULT ISABELLE      | SYNOLD TIMOTHY W,A61K031337 | C12Q00170 | G01N03350 | C12Q00168 | A61K03800,WO2002077290A9 | EP1268547A2 | AU200152944A  | CA2402439A1 | US2002022599A1 | WO200172837A3 | JP2003528889T  | US2002061836A1 | US2005037404A1 | WO200172837A2,9,6,Yes,Application,No
248,WO2002078628,A2,"CYANAMIDE, ALKOXYAMINO, AND UREA DERIVATIVES OF 1,3-BENZODIAZAPINES AS HIV REVERSE TRANSCRIPTASE INHIBITORS",US20010279217P,United States,2001-03-28T00:00:00Z,2001,2002-03-27T00:00:00Z,2002-10-10T00:00:00Z,2002,BRISTOL MYERS SQUIBB PHARMA CO,BILDER DONNA M,C07D40106 | C07D24310 | A61P03118 | C07D40506 | C07D40906 | C07D49104,US2003220327A1 | US7015214B2 | AU2002258633A1 | WO2002078628A3,3,3,Yes,Grant,Yes
249,WO2002079157,A1,ARYL OXIME-PIPERAZINES USEFUL AS CCR5 ANTAGONISTS,US20010279950P,United States,2001-03-29T00:00:00Z,2001,2002-03-27T00:00:00Z,2002-10-10T00:00:00Z,2002,SCHERING CORP,CLADER JOHN W      | LIN SUE-ING Y      | MCCOMBIE STUART W      | PUSHPAVANAM PRADEEP B      | VICE SUSAN,A61P02500 | A61P00104 | A61K04500 | A61P03706 | A61P03708 | A61K031506 | C07D40114 | A61P01902 | A61P01106 | A61P02900 | A61P01700 | A61P01706 | A61P03118 | C07D40106,ZA200307171A  | US6689783B2 | HK1057211A1 | MXPA03008801A  | IL157713D0 | AR033622A1 | HU200400389A2 | HU200400389A3 | US2003087912A1 | ES2318009T3 | DE60230491D1 | CN1253435C  | CN1500078A  | JP2004524360T  | AT418542T  | NZ528011A  | EP1373206B1 | CA2442210C  | CA2442210A1 | AU2002303168B2 | JP4303969B2 | EP1373206A1,15,15,Yes,Grant,Yes
250,WO2002079194,A1,CCR5 ANTAGONISTS USEFUL FOR TREATING AIDS,US20010279938P,United States,2001-03-29T00:00:00Z,2001,2002-03-27T00:00:00Z,2002-10-10T00:00:00Z,2002,SCHERING CORP,MILLER MICHAEL W,A61P02528 | A61P00104 | A61P03702 | A61P04300 | A61P01902 | A61P01106 | A61P03112 | A61P03708 | A61P02900 | A61P01700 | A61P01706 | C07D41714 | A61K031506 | C07D40914 | C07D40114 | A61P03118 | A61K03118 | C07D40306,US2005143390A1 | MXPA03008853A  | US2006063771A1 | DE60236218D1 | NO326349B1 | AT466009T  | EP1373256A1 | DE60204951D1 | EP1373256B1 | US2004157854A1 | CA2442227A1 | NO20034311A  | JP2004525157T  | EP1591444B1 | DK1373256T3 | US2005059666A1 | SK287521B6 | HU200400349A2 | US7098213B2 | EP1591444A1 | ES2342942T3 | CN100519554C  | NZ527768A  | BR200208398A  | NO20034311D0 | US6900211B2 | CN1547580A  | US7060701B2 | HU200400349A3 | SI1373256T1 | HK1083505A1 | TWI237638B  | IL157551D0 | RU2003131879A  | SK200301196A3 | AR033452A1 | US6720325B2 | AU2002255947B2 | AT299139T  | AU2002255947B8 | JP4248251B2 | US2003008877A1 | ZA200307474A  | PT1373256E  | CA2442227C  | HK1057363A1 | RU2316553C2 | ES2242856T3 | US7008946B2 | DE60204951T2 | JP2008074862A  | CZ20032636A3 | PL364560A1,35,26,Yes,Grant,Yes
251,WO2002081456,A1,"CYANAMIDE, ALKOXYAMINO, AND UREA DERIVATIVES OF 4, 4-DISUBSTITUTED-3, 4-DIHYDRO-2 (1H)- QUINAZOLINONES AS HIV REVERSE TRANSCRIPTASE INHIBITORS",US20010279214P,United States,2001-03-28T00:00:00Z,2001,2002-03-27T00:00:00Z,2002-10-17T00:00:00Z,2002,BRISTOL MYERS SQUIBB PHARMA CO,CORBETT JEFFREY W      | RODGERS JAMES D,C07D23984 | A61P03118 | A61K031517,US2003018039A1 | US6946469B2,2,2,Yes,Grant,Yes
252,WO2002085860,A1,PYRAZOLE DERIVATIVES FOR TREATING HIV,GB20010008999,United Kingdom,2001-04-10T00:00:00Z,2001,2002-04-04T00:00:00Z,2002-10-31T00:00:00Z,2002,PFIZER,JONES LYN HOWARD    GB  | MOWBRAY CHARLES ERIC    GB  | PRICE DAVIS ANTHONY    GB  | SELBY MATTHEW DUNCAN    GB  | STUPPLE PAUL ANTHONY    GB,C07D41312 | A61K031454 | A61K0314178 | A61K0314155 | A61P03702 | C07D40514 | A61K031683 | A61K0315377 | A61K0314985 | C07D40912 | C07D48704 | A61K031501 | C07D23128 | A61K031415 | C07D23138 | A61K031513 | A61K0314439 | A61K0314196 | A61K031496 | A61K031506 | A61K031675 | C07F0096503 | A61K031455 | A61K031424 | A61P04300 | A61K0314245 | C07D41306 | C07D23120 | C07D40304 | A61P03118 | C07D40306 | C07D40112 | C07D40312 | C07D23118 | C07D40106 | C07D40512 | C07D49804 | C07D47104 | C07D52100,EE200300497A  | NO326518B1 | CZ20032676A3 | IL157875A  | RS51166B  | EP1762567A1 | US2003100554A1 | ECSP034800A  | NO20034523D0 | BR200208811A  | DE60219292T2 | ZA200307095A  | PA8543601A1 | US7435728B2 | MA27009A1 | IS6939A  | UA75124C2 | YUP77503A  | AT358669T  | JP3806090B2 | EP1377556B1 | NO20034523A  | AP200202469D0 | NZ529403A  | EP1377556A1 | US2009215712A1 | IL157875D0 | CA2443449A1 | US2006020012A1 | SK200301244A3 | HK1063781A1 | AR037319A1 | MXPA03009380A  | BG108244A  | DK1377556T3 | GB200127426D0 | JP2004531535T  | SV2003000979A  | CA2443449C  | HU200303735A3 | PL365026A1 | HR20030783A2 | CN100408564C  | AP1846A  | OA12501A  | AU2002242926B2 | PT1377556E  | DE60219292D1 | GB200108999D0 | US7109228B2 | HU200303735A2 | ES2283532T3 | CN1514828A ,40,36,Yes,Grant,Yes
253,WO2002087583,A2,"USE OF INHIBITORS OF THE PROTEASE OF THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) TO BLOCK CELL MIGRATION AND/OR INVASION, TISSUE INFILTRATION AND OEDEMA FOR THE THERAPY OF DISEASES ASSOCIATED THEREWITH",IT2001RM00210,Italy,2001-04-18T00:00:00Z,2001,2002-04-18T00:00:00Z,2002-11-07T00:00:00Z,2002,ISTITUTO SUPERIORE DI SANITA,ENSOLI BARBARA    IT,A61P00100 | A61K031472 | A61K031426 | A61P03500 | A61P03706 | A61K031341 | A61K04506 | A61K0314725 | A61P01706 | A61P03708 | A61P00910 | A61K031496 | A61K031513,ITRM20010210D0 | EE200300507A  | CN1700916A  | HU200401199A2 | BG108368A  | ITRM20010210A1 | AP200302901D0 | WO2002087583A3 | WO2002087583B1 | SK200301421A3 | MXPA03010380A  | CZ20033113A3 | WO2002087583A1 | US2006088545A1 | CA2447748A1 | EP1401447A2,12,12,Yes,Application,No
254,WO2002087585,A1,COMPOSITIONS COMPRISING LOPINAVIR AND METHODS FOR ENHANCING THE BIOAVAILABILITY OF PHARMACEUTICAL AGENTS,US20010367353P,United States,2001-05-01T00:00:00Z,2001,2002-04-29T00:00:00Z,2002-11-07T00:00:00Z,2002,ABBOTT LAB,EVERITT ELIZABETH A      | HAN EDWARD K      | CHERIAN SAJEEV P      | KEMPF DALE J      | SHAM HING L      | NG SHI-CHUNG,A61K04500 | A61K031505 | A61P03500 | A61P04300 | A61K031337 | A61P03112 | A61K0317048 | A61K031426 | A61K03855 | A61K031513 | A61P03118 | A61K0317056,JP2005511481T  | MXPA03010054A  | EP1387684A1 | CA2445967A1 | UY27275A1 | US2002198160A1 | AR033293A1 | TWI231211B ,9,9,Yes,Grant,Yes
255,WO2002094203,A2,INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME,US20010293642P,United States,2001-05-24T00:00:00Z,2001,2002-05-24T00:00:00Z,2002-11-28T00:00:00Z,2002,AVANIR PHARMACEUTICALS,GAETA FEDERICO C A    US  | BAIRD ANDREW    US  | ANCHIN JERRY    US  | YING WENBIN    US  | FLORKIEWICZ ROBERT    US  | SIRCAR JAGADISH    US  | KUMAR K C SUNIL    US,C12Q00102 | A61P00546 | C07D41712 | A61P04300 | A61K031497 | A61K031496 | A61P03706 | C07D41312 | C07D40914 | A61P01106 | A61P01312 | A61K03147 | A61P02528 | A61P00508 | A61K04500 | A61P01100 | A61P01902 | A61P00900 | A61P00104 | C07D21546 | A61P00310 | C07D40112 | C07D21542 | C07D21554 | A61P02900 | C07D40512 | C07D40912 | A61P03500,US2006194792A1 | US2005287617A1 | HU200500101A3 | AU2007201494B2 | JP2005500266T  | US2006194818A1 | US2006199827A1 | US2006235023A1 | US7514225B2 | IL158550D0 | US7230106B2 | US2007021440A1 | US2003195194A1 | US2006094727A1 | US7129236B2 | US7732146B2 | US7157469B2 | UY27304A1 | AU2007201493A1 | ES2342877T3 | US7432374B2 | PL367127A1 | EP1389110A2 | US2007232613A1 | US2006199825A1 | US7238809B2 | US2005282236A1 | JP4346312B2 | PT1389110E  | US7192961B2 | US7235565B2 | AT461920T  | EP1389110A4 | EP1389110B1 | MXJL03000038A  | US7202248B2 | RU2327695C2 | ZA200309738A  | AU2002303906B2 | US7435737B2 | AU2007201494A1 | AR036032A1 | NZ529244A  | US2006194793A1 | US2006205734A1 | CZ20033503A3 | HU200500101A2 | RU2003132534A  | US7192955B2 | DE60235750D1 | CN1523989A  | BR200209948A  | US2007197547A1 | WO2002094203A3 | CA2447103A1 | US7084141B2 | US7105519B2,36,21,Yes,Grant,Yes
256,WO2002095005,A2,THERAPEUTIC DNA VACCINATION,US19970058933P,United States,1997-09-15T00:00:00Z,1997,2002-05-22T00:00:00Z,2002-11-28T00:00:00Z,2002,"GENETIC IMMUNITY, LLC",LISZIEWICZ JULIANNA  US  | LORI FRANCO  IT,A61K04506 | A61K0314353 | A61K031428 | A61K03117 | A61K03921 | A61K03147 | A61K031496 | A61K03900,NZ503334A  | DE69836643D1 | IL134842D0 | EP1024836A1 | DE69836643T2 | CA2302316A1 | AU754425B2 | NO20001244A  | AU9398098A  | WO2002095005A3 | AP200001762D0 | CN1278739A  | US2002193333A1 | IL134842A  | AU2002322013A1 | EA003832B1 | NO327491B1 | JP2001516729T  | AP1427A  | EP1024836A4 | OA11612A  | NO20001244D0 | CN100391542C  | WO9913915A1 | US2002022034A1 | US7910562B2 | BR9813202A  | US6420176B1 | ES2279580T3 | AT347911T  | EP1024836B1,22,17,Yes,Grant,Yes
257,WO2002096395,A1,SOFT ELASTIC CAPSULES COMPRISING RITONAVIR AND/OR LOPINAVIR,US20010866285,United States,2001-05-25T00:00:00Z,2001,2002-05-21T00:00:00Z,2002-12-05T00:00:00Z,2002,ABBOTT LAB,SALEKI-GERHARDT AZITA      | URCH MARTIN      | SCUPPA ROBERTA      | BARBATO ALESSANDRO      | PETRICONI SERGIO,A61K00948 | A61K031513 | A61K031427 | A61P03118,JP2005508294T  | PE00982003A1 | MXPA03010771A  | CA2448438A1 | EP1395249A1 | AR034995A1 | UY27306A1,8,8,Yes,Application,No
258,WO2002097114,A2,"NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATED TO LEVELS OF RAS, HER2 AND HIV",US19920882689,United States,1992-05-11T00:00:00Z,1992,2002-05-29T00:00:00Z,2002-12-05T00:00:00Z,2002,"RIBOZYME PHARMACEUTICALS, INC",MCSWIGGEN JAMES    US,A61K04748 | A61K04506 | C07H02102 | C12N015113 | A61K03800,WO2005007859A2 | GB2397818A  | WO2005045038A8 | WO2006128141A2 | US2007270579A1 | EP1499628A2 | WO2003070911A2 | US2005171040A1 | CA2543029A1 | AU734526B2 | AU2003260890A1 | US2006294362A1 | CA2476394A1 | US2005143333A1 | WO2002081628A3 | US5672511A  | US2005164224A1 | US2009264504A1 | WO9833893A3 | JP2009000106A  | CA2140343A1 | WO2005045037A3 | EP716693A1 | US2005137153A1 | US2005164968A1 | WO2008147438A2 | US2005124568A1 | US2004209832A1 | US2010063308A1 | US2003203870A1 | US2009143325A1 | GB2396155B  | US2010317716A1 | US6849726B2 | US6528639B2 | WO2003070742A1 | WO2005045036A3 | US2009093436A1 | AU2006336384A1 | AU2009200497A1 | WO2005045039A2 | US7514099B2 | EP1664299B1 | WO2005040379A3 | US2002177568A1 | WO2005045032A3 | US7833992B2 | US6022962A  | US2009023676A1 | US6818759B2 | US2007004664A1 | AU2003216315A1 | AU2003211082A1 | US2009099116A1 | US2009099117A1 | US2003105308A1 | CN1685688A  | EP1951873A2 | JP2005517437T  | US7659390B2 | WO2005045038A2 | EP1767632A3 | US2008039412A1 | US7691405B2 | DE69432189T2 | EP1423406A2 | US2007042029A1 | DK1423406T3 | US2010105933A1 | US2004198682A1 | MX9302823A  | ZA200804152A  | AU2003219781A1 | AU1566595A  | JP9502092T  | AU4756799A  | US2010093835A1 | US2003175950A1 | US6117657A  | US2006160757A1 | EP1644500A2 | DE602004021119D1 | WO9641017A2 | US2010331535A1 | EP1442143A4 | US2003105051A1 | US7659389B2 | CA2475132A1 | AU20067305B2 | US2005159380A1 | EP1502950A2 | WO2005045034A3 | US2007042983A1 | US5631359A  | EP1675948A2 | US2005119868A1 | AU2003221258B2 | US5496698A  | US7910724B2 | US6469158B1 | US2006148743A1 | JP2003525037T  | JP2007522794T  | EP1432725A1 | AU2003220136A1 | WO2006060598A3 | US2004249178A1 | US2005196781A1 | AU9825398A  | US2005054598A1 | WO2003070966A2 | US2005233998A1 | AT321129T  | AU2003217675A1 | WO2003070968A3 | US2006247194A1 | WO9504818A1 | WO2003072705A2 | US6362323B1 | ZA200801099A  | AU2003216311A1 | AU8185698A  | US2010173976A1 | US2003025128A1 | US5627053A  | US5405941A  | US6258585B1 | US2006142225A1 | US2003166896A1 | WO2003070912A2 | US6194150B1 | EP1442143A2 | JP3940407B2 | JP2007525206T  | EP1288296A3 | AU1821495A  | AU2003247204A8 | AU2003213163A8 | AU4412096A  | WO9323569A1 | AU2003219833A1 | JP3980635B2 | AU2003213054A8 | WO2003070895A2 | KR20080079329A  | US2003104985A1 | WO2005045039A9 | US2009192104A1 | NO20083208A  | EP746614A1 | EP737247A1 | AU2003211058A8 | WO2003070914A3 | US2004110296A1 | AU2003216315A8 | CA2169645A1 | WO2003070917A2 | EP1675950A2 | AU2003217550A1 | AU2003213119A1 | CA2222305A1 | WO2005105995A2 | US2005153915A1 | US7339521B2 | JP9508423T  | MX9304329A  | AT439438T  | GB200505638D0 | WO2007092059A3 | EP1448580A4 | US2007026394A1 | US2005136436A1 | US6436644B1 | WO2006078798A3 | AU2004266311B2 | EP747489A3 | US2006287267A1 | US2006223990A1 | US5747252A  | EP1465910A2 | JP2002512794T  | CA2463595A1 | AU706417B2 | US2006270623A1 | US5612215A  | EP1423406A4 | NO954094A  | CA2456444A1 | WO9618736A3 | DE602005018324D1 | WO2008011467A3 | US6534872B1 | EP1891217A2 | US6132966A  | WO2003070972A3 | ES2281077T3 | AU2006203725B2 | US2006211642A1 | AU2003213163A1 | US2009093439A1 | JP2006271387A  | JP2005517438T  | GB2406568B  | US2007179104A1 | WO2002097114A3 | US7683166B2 | WO2005045041A3 | US2009306182A1 | DE69434650D1 | EP1644498A2 | US2005148530A1 | AU9820098A  | US7176304B2 | US2010144851A1 | EP786522A2 | US2003166917A1 | ES2186690T3 | CA2447161A1 | US6509460B1 | WO2003070744A1 | WO2007022369A2 | GB2396864B  | WO2008030239A1 | CA2326695A1 | AU2003213090A1 | CA2477014A1 | WO2005028650A3 | US2005054596A1 | US2007160980A1 | MX9704440A  | EP642589A1 | WO2003070970A3 | EP1408111B1 | EP1478730A2 | AU7666296A  | US7897752B2 | RU2008129711A  | WO2003070197A2 | DE60321368D1 | US5631360A  | AU2005212433B2 | US2005048529A1 | MX9406022A  | ES2188648T3 | AT227342T  | US2006293272A1 | US2005159376A1 | US2005187174A1 | WO2003070910A3 | WO9402595A1 | US2005287128A1 | US7893302B2 | CA2398282A1 | EP1817415A2 | US2003130186A1 | US2006217335A1 | US5854043A  | CA2135646A1 | JP2005524393T  | WO9513378A1 | CA2207593A1 | EP1465910A4 | AU2003221258A1 | JP11507239T  | US2005106726A1 | EP2042510A3 | US2003206887A1 | EP1844147A2 | ID28053A  | US2003186909A1 | JP2000504925T  | US2010184824A1 | JP2005517432T  | EP1741781A2 | GB200519282D0 | JP2007525205T  | MX9803354A  | US5869253A  | EP1521768A4 | AU2003213203A8 | ID23491A  | US6074861A  | AU2003213090B2 | US2005233997A1 | US7667029B2 | US2006142557A1 | WO2005019453A3 | JP8500481T  | EP1423406B1 | AU707691B2 | WO200116312A2 | WO2003070885A3 | US2004019001A1 | US2004127446A1 | AU2003216323B2 | WO9424159A1 | EP694044B1 | GB200404912D0 | WO2002081494A1 | GB200404461D0 | WO2003070910A2 | US2005277133A1 | WO2008011431A3 | AU2003219751A1 | GB2406569A  | US2005239731A1 | EP859837A2 | US2005176024A1 | WO2003070887A2 | US5714383A  | EP1260586A2 | WO2002094185A3 | WO2005007854A2 | US2005222064A1 | US2003073207A1 | US2009149407A1 | AU2006330660A1 | JP2009509566T  | US2005164966A1 | EP1472265A4 | US2005209182A1 | CN1097603C  | JP2005517430T  | JP2000342286A  | US20030148507A1 | WO2003070888A2 | EP1710307A3 | US2004220128A1 | JP2000342285A  | JP2005517433T  | CZ9602192A3 | EP1549660A2 | AU1056895A  | AU2003219818A1 | US2011065778A1 | EP1627061A2 | WO9519429A2 | WO2005078097A2 | CA2541643A1 | US2005209180A1 | AU4876099A  | US6093555A  | ES2127948T3 | US2005227937A1 | EP1522583A3 | CA2442092A1 | DE69638198D1 | EP1478730A4 | EP728204A1 | HU218160B  | WO9715662A3 | AU2004288143A1 | US6346398B1 | CA2174339A1 | US5747584A  | WO2005035759A3 | EP1735443A2 | KR20050087783A  | US2006154271A1 | JP2008506351T  | WO2005045034A2 | US2005182008A1 | US2009192105A1 | WO2003072704A3 | WO200159103A3 | US2008249294A1 | AU687736B2 | WO2007022369A8 | GB2397818B  | US6451540B2 | US6159692A  | NO954094D0 | AU2003219751A8 | WO2005045037B1 | WO2005041859A3 | AU2003245512A1 | US2003124513A1 | US6057156A  | NZ266067A  | US2006217331A1 | US2009093438A1 | EP1493818A2 | WO2003071569A3 | US6365374B1 | EP1521768A2 | US6440719B1 | US2003170891A1 | AU2006203725A1 | US2006025361A1 | CA2186526A1 | WO2006128141A3 | US2003207837A1 | US6239272B1 | EP1390472A4 | US5972699A  | MX9603638A  | CA2537085A1 | AU730347B2 | WO2002096927A2 | WO2003074654A2 | AU2006261653A1 | WO2006060598A2 | DE69636917T2 | EP1622572A4 | WO2007092059A2 | CA2624418A1 | TW383316B  | AU757034B2 | US7855284B2 | WO2003070897A3 | NO963104A  | CA2543030A1 | AU2003247204A1 | US2010240730A1 | WO2005007855A3 | NZ276325A  | CA2235368A1 | EP1253199A1 | GB200404907D0 | US7700760B2 | WO2007067981A3 | WO9618736A2 | SG49114A1 | WO2003070896A3 | JP2009060893A  | US2009239931A1 | EP1251170A2 | US2009253774A1 | EP755406B1 | WO2005105995A3 | US2004102413A1 | US7041817B2 | DE602004022535D1 | WO2003009368A3 | WO200159103A9 | US2009099118A1 | CN1312856A  | US2009099121A1 | WO9506731A2 | CA2542527A1 | US2009137511A1 | US2006247429A1 | US6437117B1 | GB200405023D0 | US2009093431A1 | EP1476574A4 | EP1499631A4 | EP654077A1 | WO9955857A3 | US7034009B2 | AU7375594A  | WO2003070886A2 | EP1472267A2 | ES2306917T3 | WO9850530A3 | US7691999B2 | WO2005014811A3 | US5985621A  | WO2005035759A8 | AU2003220136A8 | AU2002316135B2 | CA2542835A1 | AU200074733A  | EP1265995A2 | DE69431669T2 | WO2003070969A3 | US2002082225A1 | EP1474433A2 | US2003198984A1 | WO9955847A3 | AU1457195A  | US5602227A  | JP2005517452T  | US2005014172A1 | AU2005201389A1 | AU2004274951A1 | EP1499628A4 | AU2003219781A8 | WO2005045040A3 | US2006276422A1 | US2006217337A1 | US7923547B2 | WO2005045038A3 | EP1390385A4 | US5891684A  | US7923549B2 | RU2137784C1 | WO2007086881A3 | EP1931781A2 | US2007173467A1 | AU4769893A  | US2006216747A1 | US2005075304A1 | US2009093435A1 | WO200166721A3 | US6623962B1 | US2005182007A1 | US2009281164A1 | AT319821T  | AU4756499A  | EP1549660A4 | US2009143324A1 | EP1476459A4 | US2005227935A1 | US5716824A  | US2006019913A1 | EP1463842A4 | EP980424A2 | JP2010503382T  | US2003216335A1 | US5780368A  | AU2003213054A1 | DE60333979D1 | GB200518779D0 | AU6174496A  | EP1602725A2 | WO2003070881A3 | AU2002344237B2 | GB200507019D0 | WO9513380A2 | US2005196765A1 | AU6666394A  | WO2003072590A1 | CA2528963A1 | EP1476459A2 | US2008039414A1 | EP1472265A2 | US2006019917A1 | EP1448580A2 | US2008201790A1 | US5731295A  | MX9602770A  | WO9511910A1 | US2005176663A1 | GB200406022D0 | US2005080031A1 | US2004006035A1 | US2004138163A1 | US6353098B1 | JP2007522793T  | US2005159378A1 | WO2003070888B1 | EP642589A4 | WO2007086883A2 | EP1713915B1 | US2005170371A1 | EP2052079A2 | US2010184825A1 | US2005070497A1 | US5686599A  | WO2003070884A2 | JP7509133T  | US2005233996A1 | EP1472267A4 | US2004209831A1 | US5753446A  | EP1499631A2 | US2008188675A1 | EP1430157A2 | DE69434650T2 | US5972704A  | AU3872499A  | WO2003070983A1 | WO9833893A2 | JP4464918B2 | PL315691A1 | US2003004122A1 | US2007185043A1 | US2005159382A1 | US2003190635A1 | WO2003070903A2 | US2005256068A1 | US2009306184A1 | DE69636917D1 | EP1664299A1 | WO9523225A3 | US2003068301A1 | US36548E  | EP1073732A2 | US2005196767A1 | US7683165B2 | EP1430157A4 | ES2350763T3 | GB200404898D0 | AU2002316135B9 | WO2005045041A2 | DE69431669D1 | AU2002305729A1 | GB2396155A  | US6379954B1 | JP4126341B2 | US5891683A  | WO2007076328A3 | US7858625B2 | US2005260620A1 | AT479774T  | EP1470256A4 | WO9641017A3 | WO200022894A1 | US5658780A  | AU2003215345A1 | EP1550285A1 | WO2008011467A2 | WO2003106476A8 | CA2288640A1 | US7491805B2 | US2006275903A1 | AU2003216265A1 | AU2003215203A1 | PL311142A1 | US7109165B2 | EP1922300A2 | RU2008110075A  | EP2287306A1 | US7858771B2 | AU2003219817A1 | WO2007147143A2 | CA2658183A1 | EP1408111A3 | BRPI0614407A2 | US5811300A  | US20030143732A1 | WO2004030312A1 | US2007270360A1 | US7678897B2 | CA2471421A1 | US7795422B2 | EP1675953A2 | US7667030B2 | US2007004663A1 | US2010227911A1 | WO2003070886A3 | EP739368B1 | GB2396616A  | JP2005517450T  | JP2007300926A  | JP4293635B2 | CA2181791C  | EP1501853A4 | US2005171039A1 | US2009137500A1 | WO2007120527A2 | EP739368A1 | US2005137155A1 | AU2003210895A8 | EP1627061B1 | US5525468A  | AU1090495A  | HU9602048D0 | EP654077A4 | WO2003070914A2 | CN1142839A  | DE69434670T2 | US2004102389A1 | DK748382T3 | WO2003070743A1 | WO2003070750A3 | EP1476458A4 | US2006127891A1 | JP2007527709T  | WO2003070911A3 | WO2003106476A1 | EP1550285B1 | US5260086A  | US2005096284A1 | US2006217336A1 | AU737017B2 | WO2005007855A2 | EP1436314A2 | EP1622572A2 | JP2008530215T  | JP2008289488A  | US5489470A  | US2005191638A1 | US2005164967A1 | US2008161256A1 | JP2006501790T  | US2007173473A1 | JP2002512791T  | US2003140362A1 | WO2005045039A3 | WO2005045037A2 | JP2004512810T  | WO2003070193A3 | WO2003009396A3 | JP2009149652A  | US2006142226A1 | US2006281175A1 | JP2004147666A  | JP9509323T  | WO2005003350A8 | CA2455506A1 | DE69434670D1 | JP2007505606T  | CA2619876A1 | GB200427814D0 | US5804683A  | US2009221807A1 | EP1432724A4 | JP2007525192T  | AU2006336384B2 | EP1501853A2 | US2009048197A1 | JP2009520039T  | US2010305191A1 | US2009099119A1 | AU6804198A  | WO9520614A1 | US5693535A  | JP2005517423T  | AU2003219712A1 | US2007093437A1 | US2009253773A1 | US2006287266A1 | EP786522A3 | US2009105178A1 | WO2005007854A3 | US5783425A  | JP2006051026A  | US2003191077A1 | AU2003213203A1 | EP1448590A4 | EP2042510A2 | WO2003070750A2 | WO2008011431A2 | US5622854A  | US2005032733A1 | EP1572128A2 | US5693532A  | US2009137508A1 | WO2005028649A1 | EP1390385A2 | CA2459532A1 | EP1495041A1 | ZA9500627A  | EP1472269A1 | US2010130592A1 | AU2003213057A1 | US2005176664A1 | EP694044A1 | US2005266422A1 | US2009176725A1 | WO2005007859A3 | WO9850530A9 | US2004142895A1 | US2003171311A1 | JP9511906T  | WO2004092383A2 | US5981265A  | WO2003102131A2 | EP747489B1 | EP1573770A2 | WO2003070912A3 | WO2007022369A3 | US5767263A  | EP1474433A4 | GB2415961A  | WO9322941A1 | US2003153521A1 | JP2004532022T  | US2001006801A1 | WO2003070197A3 | JP2007523649T  | CA2168566A1 | JP2005505504T  | AU2004274951B2 | AU749561B2 | AU2003207708A1 | MX9302808A  | US2002197684A1 | US7641915B2 | WO2008147438A3 | FI954894A  | US2005124567A1 | US7910725B2 | CA2176035A1 | US5639647A  | EP1463842A1 | WO2004111237A1 | JP2001526521T  | AU200138111A  | EP1675949A2 | NO20081376A  | AT354670T  | JP2008131952A  | US2009247613A1 | US2010099750A1 | US2005203040A1 | JP2009504190T  | JP9508018T  | EP1288296A2 | MX2008002369A  | CN100579111C  | WO2004097020A3 | EP1502950A3 | WO200116312A3 | GB2413557A  | EP1075508A2 | US2003050259A1 | US2009149408A1 | WO2002081628A2 | US2003064945A1 | US20030119017A1 | CA2160548A1 | US7404969B2 | WO2003070917A3 | CA2403243A1 | GB2413557B  | GB200511689D0 | US6127535A  | US5840876A  | KR20080036650A  | US6100027A  | AU2002344237B8 | JP2004215675A  | US6617438B1 | US5877021A  | NO963104D0 | AT452188T  | JP9504701T  | US5610054A  | US6566127B1 | EP1212416A2 | US2007099858A1 | US2004077565A1 | US2005020525A1 | EP1476574A2 | US2005182009A1 | CA2186526C  | AU3665799A  | CA2183992A1 | US2005277608A1 | WO2003070193A2 | EP1423404A4 | US7858769B2 | WO2007084865A3 | WO9955847A2 | US2009099120A1 | WO2005045032A2 | US5977343A  | US2005176665A1 | JP2005118056A  | US2003060611A1 | AU4221593A  | US2005267058A1 | US2006240554A1 | US7897753B2 | US2005176038A1 | JP2006502694T  | US2005176666A1 | US2005159381A1 | EP1682660A2 | AU2003216323A1 | SK97096A3 | US2006293271A1 | JP2005500025T  | WO2003070895A3 | WO2005045036A2 | US7662951B2 | US5817796A  | US2005261212A1 | US2006247428A1 | US5879938A  | EP748382B1 | AU2003215203A8 | AU697340B2 | EP1436314A4 | US2005158735A1 | US2005233329A1 | AU2003213057A8 | HK1086036A1 | WO2005078097A3 | JP2009000105A  | EP1713915A2 | US2007004667A1 | US2007032441A1 | US2009299045A1 | GB2406569B  | US2007167393A1 | US6432704B1 | EP1386004A4 | WO2003070966A3 | JP2008131951A  | EP1386004A2 | AU2003228667A1 | WO2007076328A2 | EP694044A4 | AU2003217594A1 | WO2003070918A2 | US2005159379A1 | US5837855A  | US2010145038A1 | WO2003009368A2 | US2006292691A1 | WO2003071569A9 | US6649751B2 | WO2005014811A2 | AU2007275365A1 | US6410224B1 | US2010099744A1 | AU2003213005A1 | US6017756A  | JP2005518803T  | GB2396864A  | EP1321521A1 | WO2003074654A3 | WO2005041859A2 | CA2543013A1 | US2005153916A1 | CA2457528A1 | AU4222993A  | WO2003071569A2 | WO9715662A2 | EP1495041A4 | WO2005044981A2 | WO2006078798A2 | EP1458741A4 | US2009023675A1 | CA2448320A1 | AU6516599A  | AU2003217594A8 | AU2003216255A1 | AU2002307099A1 | US2008188430A1 | CA2633684A1 | US2009137510A1 | JP2005517427T  | JP2008283975A  | US2002013458A1 | WO2003070884A3 | US7893248B2 | WO2002081628A8 | US2005119211A1 | WO9955857A2 | US2008020058A1 | CA2181791A1 | US2007185049A1 | US7897756B2 | US2005227936A1 | EP1493818A3 | AU2003215161A1 | JP8509128T  | GB2397062A  | AU2003216311A8 | EP1383782A1 | WO2003070887A3 | US7022828B2 | US7517864B2 | US2004219671A1 | US2010168208A1 | JP4280788B2 | US5795778A  | US2003148985A1 | US2009156533A1 | US2005142578A1 | US7915400B2 | CA2468048A1 | US5646020A  | CN101426912A  | EP1448590A2 | WO2005003350A2 | EP1476458A2 | US6482932B1 | US2009247606A1 | US2007203333A1 | WO9850530A2 | WO2003070896A2 | JP4280789B2 | AU751480B2 | US2010113564A1 | AU2010212416A1 | WO2007147143A3 | CA2180740A1 | US6555668B2 | US2009137513A1 | WO2003070897A2 | AU2003219833A8 | GB2406568A  | AU2004266311A1 | EP1432725A4 | US2010317717A1 | WO200159103A2 | US5831071A  | US2006217334A1 | WO2007086881A2 | US2010228018A1 | US2003003469A1 | EP1470256A2 | US2007161596A1 | US2006217332A1 | AU744191B2 | EP1710307A2 | US7662952B2 | EP1694838A2 | EP755406A1 | US6661037B2 | WO9506731A3 | EP1470257A4 | US2008033156A1 | WO2008011431A8 | US2006276635A1 | US2007049543A1 | US2005124569A1 | US2003143708A1 | GB2397062B  | EP1476457A2 | EP1741781A3 | US2010144842A1 | WO2005045035A2 | US2009099115A1 | US2003113891A1 | US2005233344A1 | AT397347T  | WO9528421A1 | WO2005035759A2 | WO200166721A2 | EP1682661A2 | EP1423404A2 | US2006241075A1 | WO2003070968A2 | EP1432724A1 | US5498692A  | JP4358521B2 | AT174600T  | US2005130181A1 | WO2003070969A2 | US2005191618A1 | WO2003072704A2 | EP1602725A3 | AU2006279454A1 | EP1572067A4 | US2009137507A1 | EP1987145A2 | WO2002096927A3 | US2003165900A1 | WO2004097020A2 | CA2554212A1 | GB2396616B  | WO9519429A3 | EP1572067A2 | EP1522583A2 | AU2003211058A1 | WO2005045035A3 | US6333170B1 | AU687479B2 | WO2003070970A2 | US2009253772A1 | PT748382E  | US6852535B1 | EP1260586A3 | DE69432189D1 | US2007004665A1 | WO2005003350A3 | AU2003216245A1 | US2008249040A1 | AU5209698A  | EP747489A2 | US2009093437A1 | EP1390472A2 | AU2003219712A8 | JP2005517436T  | AU2003216324B2 | JP4127850B2 | US6132967A  | EP1458741A2 | US7897755B2 | AU2003219818A8 | US5685756A  | US2009233983A1 | US2005282188A1 | HU75180A2 | CA2476112A1 | WO2007086883A3 | US5618855A  | GB200427955D0 | IL192182D0 | WO2003070888A3 | AU2005212433A1 | EP748382A1 | CA2455447A1 | JP9501318T  | AU7290598A  | WO2003070881A2 | US2009170197A1 | US2005176025A1 | WO9523225A2 | IL189540D0 | AT431411T  | US5616488A  | BR9408512A  | US5902880A  | FI962997A  | US2008032942A1 | US2005182006A1 | JP2001525667T  | PL178568B1 | CN101605892A  | MX9302726A  | EP2278004A1 | US5646042A  | WO2003070903A3 | AU2003216324A1 | US2010227912A1 | WO9513380A3 | US5837542A  | US2011015251A1 | EP799313A2 | US2002193579A1 | US2009156528A1 | US2004054156A1 | US2003088087A1 | WO2003072705A3 | EP1476457A4 | US2008207542A1 | CA2330574A1 | JP3980609B2 | EP1572128A4 | WO2005040379A2 | EP1472269A4 | US6541201B1 | AU2003210895A1 | US2005209179A1 | EP1670915A2 | WO2002094185A2 | WO2007120527A3 | AU2003216255A8 | US5672501A  | WO2003070885A2 | EP1470257A2 | EP755406A4 | WO2005045040A2 | EP1251170A3 | CA2526831A1 | US2005239739A1 | FI962997D0 | US2003092003A1 | US2009298914A1 | WO2003102131A3 | WO2003070972A2 | US6818447B1 | AU6708598A  | US2005261219A1 | EP1675951A2 | WO2004092383A3 | US2009137509A1 | US2009137512A1 | US2005153914A1 | US2010099743A1 | AU2003219817B2 | WO2005028650A2 | US6528640B1 | US2003125270A1 | WO2007067981A2 | WO2005044981A3 | EP1767632A2 | US2004192626A1 | US2005222066A1 | US2010311812A1 | US2009264636A1 | US2003165969A1 | US7897757B2 | US2005119212A1 | US2005124566A1 | WO2003070918A3 | JP2007505605T  | US2005288242A1 | WO2003009396A2 | US2001012618A1 | AU703070B2 | EP1408111A2 | US2005079610A1 | AU8017794A  | EP2287305A1 | WO2007084865A2 | WO2003070972A9 | FI954894D0 | CA2597724A1 | WO2005019453A2 | US6146886A ,374,30,Yes,Grant,Yes
259,WO2002099387,A2,MEANS AND METHODS FOR MONITORING PROTEASE INHIBITOR ANTIRETROVIRAL THERAPY AND GUIDING THERAPEUTIC DECISIONS IN THE TREATMENT OF HIV/AIDS,US19990338323,United States,1999-06-22T00:00:00Z,1999,2002-06-04T00:00:00Z,2002-12-12T00:00:00Z,2002,VIROLOGIC INC,PARKIN NEIL T      | ZEIRMANN RAINER A,C12Q00170 | C12Q00137 | C07K01416 | G01N033569,EP1407042A2 | WO2002068618A1 | US6869759B1 | WO2002099387A3 | US2002064838A1 | EP1322779A2 | CA2375905A1 | EP1322779A4 | EP1194587A1 | BR200011939A  | US2006035249A1 | EP1373479A1 | US7186506B1 | WO200078996A1 | AU200057582A  | WO200222076A2 | WO200078996A9 | EP1373479A4 | AU200190923A  | CA2422815A1 | US7138231B2 | EP1407042A4 | US2008044810A1 | EP1194587A4 | US2003108857A1 | WO200222076A3,19,6,Yes,Grant,Yes
260,WO2002102169,A2,SYNTHETIC FAT COMPOSITION,IL20000133968 | IL20000133969,Israel,2000-01-10T00:00:00Z,2000,2002-06-18T00:00:00Z,2002-12-27T00:00:00Z,2002,FOAMIX LTD,TAMARKIN DOV  IL  | EINI MEIR  IL  | PELED MICHA  IL,A23K00116 | A61K03120 | A61K03123 | A61K03125 | A61K04714 | A23D009007 | A23D00701 | A61K04710 | A23D007005 | A61K04506 | A23G00952 | A23D009013 | A23L001314 | A23L00130 | A23G00100 | A23G00334,US6967023B1 | IL133968D0 | AU200123936A  | EP1250116A1 | CA2397068A1 | US2002132035A1 | EP1246538A1 | US6911211B2 | US2004253275A1 | US2010137198A1 | US2003157138A1 | US2006088561A1 | WO200151014A1 | IL150664D0 | JP2004500075T  | EP1246538A4 | EP1250116A4 | AU200123937A  | AU782515B2 | IL133969D0 | WO2002102169A3 | US2003099747A1 | IL137051D0 | US6348229B1 | US6994863B2 | US7682623B2 | IL150644D0 | WO200150873A1 | US2003143312A1 | JP2003528821T  | CA2396071A1 | NZ520014A  | IL137052D0,22,8,Yes,Grant,Yes
261,WO2003005826,A1,AQUEOUS TAR SOLUTION AND TAR&minus;CONTAINING COATING,JP20010209762,Japan,2001-07-10T00:00:00Z,2001,2002-07-08T00:00:00Z,2003-01-23T00:00:00Z,2003,"YOSHIMATSU, MICHIHARU",YOSHIMATSU MICHIHARU  JP  | SUETAKE YUZURU  JP,B27K00312 | B05D00706 | A01N06102 | C09D00514 | C09D00712,CN1233242C  | AU2002315809B2 | AU2002315809B8 | AU2002315809B9 | EP1405563A1 | US6995199B2 | US2004186204A1 | CN1525820A ,5,5,Yes,Grant,Yes
262,WO2003006506,A2,PROTEASE INHIBITOR CONJUGATES AND ANTIBODIES USEFUL IN IMMUNOASSAY,US20010305192P,United States,2001-07-13T00:00:00Z,2001,2002-07-15T00:00:00Z,2003-01-23T00:00:00Z,2003,F. HOFFMANN-LA ROCHE AG,"DERAS, INA | HUI, Raymond | SIGLER, Gerald, F. | HUBER, Erasmus, J. | VON DER ELTZ, Herbert, W. | GHOSHAL, Mitali | ROOT, Richard, Terry | METZ, Sigrun",C12N000999 | A61K003900 | C07D040114 | C07D040312 | C07D040512 | C07D041714 | C07K001400 | C07K001600 | C07K001638 | C12N000510 | C12P002108,AT442388T | AU2323692A | AU1526299A | AU1820200A | AU3522500A | AU1958801A | AU5964001A | AU2002321216A1 | CA2449243A1 | CA2482232A1 | CA2578154A1 | CA2585546A1 | CA2586491A1 | CN101094841A | CN101151279A | DE10084638T0 | DE10149206A1 | DE19882381T0 | DE19983715T0 | DE4447960B4 | DE4492128C2 | DE4492128T0 | DE602005016587D1 | DE69828585D1 | DE69828585T2 | EP1069000A1 | EP1409546A2 | EP1519192A2 | EP1519192A3 | EP1809672A1 | EP1809672B1 | EP1809672B8 | EP1812410A2 | EP1894160A2 | EP1894160A4 | EP0952933A1 | EP0952933A4 | EP0952933B1 | ES2331143T3 | GB9509088D0 | GB9509090D0 | GB9510402D0 | GB9510408D0 | GB9611795D0 | GB9611810D0 | GB9624734D0 | GB9802263D0 | GB9816593D0 | GB9927633D0 | GB0111362D0 | GB0116062D0 | GB0117003D0 | GB0123688D0 | GB0200235D0 | GB0307874D0 | GB0422015D0 | GB0426923D0 | GB0426924D0 | GB0426925D0 | GB0426926D0 | GB2289332A | GB2289332B | GB2289542A | GB2289542B | GB2289653A | GB2289653B | GB2289786A | GB2289786B | GB2301906A | GB2301906B | GB2301922A | GB2301922B | GB2308102A | GB2308102B | GB2323340A | GB2323340B | GB2324864A | GB2324864B | GB2340978A | GB2340978B | GB2360097A | GB2360097B | GB2363638A | GB2363638B | GB2363769A | GB2363769B | GB2369737A | GB2369737B | GB2373117A | GB2373117B | GB2383415A | GB2383415B | GB2405279A | GB2405279B | GB2405931A | GB2405931B | GB2406170A | GB2406170B | GB2406171A | GB2406171B | GB2406646A | GB2406646B | JP03960394B2 | JP03993253B2 | JP4307252B2 | JP2001508732T | JP2002501459T | JP2003532959T | JP2004518104T | JP2004522932T | JP2005097307A | JP2005306376A | JP2005508877T | JP2008518897T | JP2008519793T | JP08175305A | JP08198044A | JP09175316A | JP09189710A | JP09240407A | JP9501120T | SE0100186A | SE0100186D0 | SE0100186L | SE523753C2 | TW541255B | US20010000886A1 | US20010002451A1 | US20010003168A1 | US20010015547A1 | US20010015548A1 | US20010020777A1 | US20010024032A1 | US20010028163A1 | US20010029416A1 | US20010035634A1 | US20010037903A1 | US20010037904A1 | US20010038698A1 | US20010042976A1 | US20010042977A1 | US20010048215A1 | US20010054516A1 | US20020005778A1 | US20020027339A1 | US20020027346A1 | US20020029103A1 | US20020059022A1 | US20020082756A1 | US20020089157A1 | US20020092693A1 | US20020093180A1 | US20020095980A1 | US20020101067A1 | US20020116106A1 | US20020121132A1 | US20020125050A1 | US20020140214A1 | US20020140215A1 | US20020166710A1 | US20020179822A1 | US20020188392A1 | US20020198632A1 | US20030001368A1 | US20030002690A1 | US20030009270A1 | US20030015898A1 | US20030023362A1 | US20030036835A1 | US20030039173A1 | US20030056997A1 | US20030075223A1 | US20030100088A1 | US20030116362A1 | US20030121704A1 | US20030125855A1 | US20030136600A1 | US20030155753A1 | US20030168838A1 | US20030176959A1 | US20030184065A1 | US20030191568A1 | US20030198767A1 | US20030209893A1 | US20030227382A1 | US20040036261A1 | US20040039509A1 | US20040066287A1 | US20040079150A1 | US20040127689A1 | US20040129478A1 | US20040130442A1 | US20040148057A1 | US20040183287A1 | US20040202049A1 | US20040215382A1 | US20040256842A1 | US20050017488A1 | US20050046584A1 | US20050060069A1 | US20050064517A1 | US20050082799A1 | US20050125117A1 | US20050131607A1 | US20050134440A1 | US20050137786A1 | US20050148596A1 | US20050156417A1 | US20050156457A1 | US20050192727A1 | US20050195383A1 | US20050242555A1 | US20050248136A1 | US20050269810A1 | US20050273218A1 | US20050278098A1 | US20060025897A1 | US20060097494A1 | US20060132350A1 | US20060144630A1 | US20060167595A1 | US20060180371A1 | US20060186713A1 | US20060202452A1 | US20060208169A1 | US20060211107A1 | US20060212193A1 | US20060212194A1 | US20060217864A1 | US20060220842A1 | US20060232052A1 | US20060243043A1 | US20060244246A1 | US20060244581A1 | US20060251293A1 | US20060261579A1 | US20060264618A1 | US20060273556A1 | US20060273558A1 | US20060282204A1 | US20060284839A1 | US20070005202A1 | US20070005609A1 | US20070021915A1 | US20070025597A1 | US20070035114A1 | US20070040363A1 | US20070057781A1 | US20070075919A1 | US20070085697A1 | US20070086624A1 | US20070096445A1 | US20070096446A1 | US20070096565A1 | US20070109111A1 | US20070114292A1 | US20070116327A1 | US20070120347A1 | US20070126561A1 | US20070132219A1 | US20070132220A1 | US20070135982A1 | US20070135984A1 | US20070139216A1 | US20070141643A1 | US20070142641A1 | US20070148708A1 | US20070149565A1 | US20070152804A1 | US20070154063A1 | US20070155959A1 | US20070156312A1 | US20070156317A1 | US20070156320A1 | US20070168050A1 | US20070182528A1 | US20070193811A1 | US20070205881A1 | US20070228703A1 | US20070251749A1 | US20070262574A1 | US20070271014A1 | US20070280505A1 | US20070282506A1 | US20070299587A1 | US20080015771A1 | US20080018475A1 | US20080021201A1 | US20080036185A1 | US20080036187A1 | US20080036252A1 | US20080036580A1 | US20080037803A1 | US20080040004A1 | US20080040005A1 | US20080040023A1 | US20080040029A1 | US20080042408A1 | US20080042409A1 | US20080042410A1 | US20080042418A1 | US20080042477A1 | US20080042815A1 | US20080046149A1 | US20080046150A1 | US20080046200A1 | US20080047329A1 | US20080047770A1 | US20080048421A1 | US20080048930A1 | US20080051946A1 | US20080051957A1 | US20080054603A1 | US20080061959A1 | US20080061984A1 | US20080064413A1 | US20080065290A1 | US20080065291A1 | US20080067792A1 | US20080069403A1 | US20080082237A1 | US20080086240A1 | US20080088441A1 | US20080088462A1 | US20080094212A1 | US20080100706A1 | US20080106436A1 | US20080108372A1 | US20080114502A1 | US20080119966A1 | US20080119993A1 | US20080125940A1 | US20080129475A1 | US20080133136A1 | US20080140278A1 | US20080140318A1 | US20080142713A1 | US20080143085A1 | US20080144944A1 | US20080147253A1 | US20080147265A1 | US20080147271A1 | US20080147278A1 | US20080147280A1 | US20080150786A1 | US20080154495A1 | US20080154629A1 | US20080156406A1 | US20080157510A1 | US20080157940A1 | US20080158096A1 | US20080161986A1 | US20080161987A1 | US20080161989A1 | US20080162036A1 | US20080165018A1 | US20080167819A1 | US20080167821A1 | US20080174423A1 | US20080180280A1 | US20080186205A1 | US20080189053A1 | US20080195261A1 | US20080215202A1 | US20080215231A1 | US20080216567A1 | US20080234899A1 | US20080236275A1 | US20080243342A1 | US20080250869A1 | US20080262646A1 | US20080270076A1 | US20080272579A1 | US20080272580A1 | US20080272906A1 | US20080272923A1 | US20080276191A1 | US20080277911A1 | US20080282817A1 | US20080284145A1 | US20080284575A1 | US20080292146A1 | US20080294315A1 | US20090015400A1 | US20090030605A1 | US20090033540A1 | US20090039625A1 | US20090043441A1 | US20090043506A1 | US20090046538A1 | US20090048750A1 | US20090058593A1 | US20090066065A1 | US20090092284A1 | US20090132129A1 | US20090143923A1 | US20090228157A1 | US20090261979A1 | US20100052945A1 | US20100057305A1 | US20100138008A1 | US20100141435A1 | US20100169009A1 | US20100207754A1 | US20100268423A1 | US20100280751A1 | US20100283626A1 | US5155307A | US5231253A | US5233141A | US5326133A | US5389751A | US5441301A | US5505485A | US5629681A | US5653462A | US5653464A | US5684701A | US5694320A | US5746446A | US5748473A | US5772238A | US5809437A | US5822707A | US5829782A | US5835613A | US5842716A | US5845000A | US5848802A | US5863068A | US5901978A | US5943295A | US6009970A | US6039139A | US6078854A | US6081757A | US6088640A | US6116639A | US6134492A | US6141432A | US6149194A | US6168198B1 | US6175787B1 | US6179326B1 | US6186537B1 | US6206129B1 | US6209909B1 | US6234519B1 | US6234520B1 | US6242701B1 | US6250668B1 | US6253134B1 | US6254127B1 | US6270116B1 | US6279946B1 | US6283503B1 | US6324453B1 | US6325414B2 | US6326704B1 | US6328126B2 | US6330501B1 | US6343810B1 | US6370475B1 | US6393133B1 | US6397136B1 | US6405132B1 | US6412813B1 | US6419265B1 | US6422595B1 | US6442465B2 | US6442504B1 | US6445988B1 | US6452870B1 | US6459973B1 | US6474683B1 | US6484080B2 | US6507779B2 | US6513830B2 | US6513833B2 | US6517107B2 | US6526352B1 | US6529809B1 | US6532408B1 | US6533316B2 | US6553296B2 | US6555766B2 | US6557889B2 | US6609053B1 | US6615656B1 | US6623033B2 | US6648367B2 | US6653577B2 | US6662642B2 | US6685218B1 | US6689962B2 | US6712387B1 | US6715790B2 | US6720920B2 | US6731569B2 | US6733036B2 | US6735506B2 | US6736231B2 | US6738697B2 | US6746078B2 | US6748797B2 | US6749218B2 | US6755273B2 | US6757602B2 | US6768944B2 | US6772057B2 | US6778672B2 | US6782316B2 | US6784379B2 | US6792342B2 | US6793242B2 | US6805404B1 | US6820897B2 | US6823244B2 | US6833516B2 | US6850824B2 | US6856873B2 | US6856876B2 | US6869100B2 | US6875976B2 | US6885968B2 | US6892572B2 | US6899134B2 | US6905135B2 | US6910711B1 | US6918459B2 | US6919803B2 | US6942248B2 | US6950022B2 | US6958451B2 | US6984818B1 | US6988026B2 | US7025379B2 | US7040653B1 | US7049945B2 | US7050897B2 | US7052038B2 | US7070202B2 | US7079450B2 | US7082359B2 | US7085637B2 | US7089099B2 | US7097201B2 | US7103460B1 | US7110880B2 | US7126583B1 | US7134687B2 | US7147246B2 | US7157561B2 | US7164117B2 | US7193065B2 | US7202092B2 | US7202776B2 | US7209221B2 | US7243945B2 | US7253725B2 | US7284769B2 | US7295925B2 | US7313467B2 | US7324039B2 | US7330784B2 | US7334657B2 | US7338069B2 | US7359527B2 | US7359782B2 | US7379800B2 | US7386372B2 | US7387183B2 | US7391752B1 | US7401807B2 | US7407029B2 | US7408453B2 | US7413048B2 | US7415126B2 | US7418346B2 | US7421321B2 | US7426437B2 | US7444210B2 | US7467034B2 | US7467809B2 | US7477758B2 | US7481453B2 | US7482437B2 | US7511833B2 | US7523803B2 | US7527288B2 | US7549327B2 | US7555370B2 | US7569678B2 | US7570785B2 | US7575248B2 | US7580782B2 | US7588115B2 | US7596242B2 | US7602313B2 | US7603894B2 | US7604080B2 | US7610146B2 | US7620521B2 | US7629899B2 | US7630802B2 | US7630806B2 | US7635043B2 | US7647180B2 | US7648164B2 | US7649085B2 | US7650210B2 | US7650212B2 | US7655895B2 | US7657354B2 | US7659813B2 | US7660437B2 | US7663502B2 | US7672756B2 | US7676062B2 | US7693626B2 | US7695015B2 | US7712777B2 | US7726684B2 | US7734061B2 | US7738678B2 | US7740273B2 | US7744122B2 | US7760080B2 | US7762580B2 | US7762582B2 | US7766383B2 | US7768380B2 | US7769513B2 | US7770920B2 | US7774115B2 | US7779956B2 | US7783403B2 | US7786864B1 | US7788008B2 | US7791503B2 | US7796081B2 | US7815219B2 | US7819003B2 | US7831358B2 | US7832762B2 | US7840342B1 | US7840355B2 | US7852462B2 | US7860626B2 | US7880594B2 | US7887089B2 | US7889096B2 | US7899616B2 | US7899621B2 | US7900736B2 | US7906629B2 | US7911324B2 | US7912645B2 | US7918100B2 | US7920102B2 | US7928839B2 | USRE37260E1 | USRE37736E1 | USRE39868E1 | USRE40073E1 | WO9010302A1 | WO9301071A1 | WO9301605A1 | WO9422693A1 | WO9854638A1 | WO9925581A1 | WO0029257A2 | WO00029257A3 | WO0038949A2 | WO00038949A3 | WO0038949A8 | WO0054008A1 | WO0114910A2 | WO0114910A3 | WO0145080A1 | WO0185491A1 | WO0220287A1 | WO03006506A3 | WO2006048300A1 | WO2006050964A2 | WO2006050964A3 | WO2007082204A2 | WO2007082204A3,27,9,Yes,Grant,Yes
263,WO2003013424,A2,USE OF R-NSAID COMPOUNDS FOR ANTI-HIV TREATMENT,US20010302533P ,United States,2001-06-29T00:00:00Z,2001,2002-07-01T00:00:00Z,2003-02-20T00:00:00Z,2003,"MYRIAD GENETICS, INC",ZAVITZ KENTON  US,A61K000,CA2451691A1 | WO2003013424A3 | US2003027867A1 | JP2004538319T  | EP1420745A2 | AU2002322481A1,6,6,Yes,Application,No
264,WO2003013534,A2,MEANS AND METHODS FOR IMPROVED TREATMENT OF CANCER BASED ON CYP3A5,EP20010117608,European Patent Office,2001-07-23T00:00:00Z,2001,2002-07-23T00:00:00Z,2003-02-20T00:00:00Z,2003,EPIDAUROS BIOTECHNOLOGIE AG,HEINRICH GUENTHER    DE  | KERB REINHOLD    DE,C12N01509 | A61P01100 | A61K0314152 | C07D491052 | A61K04500 | A61K031575 | C07D49122 | A61P00118 | A61K03149 | C12Q00168 | A61K031496 | A61K031566 | A61P00100 | A61K03800 | A61K031341 | A61K031277 | A61P04300 | A61K031565 | A61P01500 | A61K031235 | A61P02500 | A61K031519 | A61K031409 | A61K031343 | A61K0314709 | A61K031352 | A61K031353 | A61K0314745 | A61P03500 | A61K0314741,WO2003013535A9 | AU2002328953A1 | EP1408973A2 | WO2003013536A2 | WO2003013536A3 | EP1408972A2 | WO2003013535A2 | AU2002328950A1 | JP2005504759T  | WO2003013533A9 | WO2003013537A9 | CA2454640A1 | WO2003013534A9 | WO2003013536A9 | JP2005505526T  | JP2005506971T  | EP1438050A2 | WO2003013537A3 | CA2454648A1 | WO2003013533A2 | CA2454627A1 | CA2454643A1 | EP1408974A2 | AU2002331290A1 | EP1408975A2 | WO2003013535A3 | WO2003013534A3 | US2005032724A1 | WO2003013537A2 | JP2005501840T  | AU2002328952A1 | JP2005508312T  | WO2003013533A3 | CA2454637A1 | AU2002328945A1,26,6,Yes,Application,No
265,WO2003014105,A1,"BICYCLIC COMPOUND, PRODUCTION AND USE AS HIV INHIBITORS",JP20010240750,Japan,2001-08-08T00:00:00Z,2001,2002-08-07T00:00:00Z,2003-02-20T00:00:00Z,2003,"TOBIRA THERAPEUTICS, INC.","SHIRAISHI, Mitsuru | BABA, Masanori | AIKAWA, Katsuji | KANZAKI, Naoyuki | SETO, Masaki | IIZAWA, Yuji",A61P003118 | C07D022506 | C07D031320 | C07D040312 | C07D040512 | C07D040712,WO2003014105A9 | JP2003335776A  | AU2002328092A1 | AR034985A1 | JP2004123694A  | US2004259876A1 | JP4358851B2 | US2008161287A1 | EP1889839A1 | DK1423376T3 | DE60235632D1 | US2005107606A1 | CA2479071A1 | EP1484322A1 | EP2206702A1 | EP1484322A4 | CN1649847A  | EP1423376B1 | JP2007084578A  | JP2009209154A  | JP4316203B2 | WO2003014105A1 | US2009030032A1 | US7371772B2 | CA2459172A1 | AU2003213454A1 | PE03292003A1 | ES2339340T3 | CA2607992A1 | EP1423376A1 | AT460406T  | PT1423376E ,26,12,Yes,Grant,Yes
266,WO2003016306,A1,HIV INHIBITING PYRIMIDINES DERIVATIVES,EP20010203090 ,European Patent Office,2001-08-13T00:00:00Z,2001,2002-08-09T00:00:00Z,2003-02-27T00:00:00Z,2009,JANSSEN PHARMACEUTICA NV,JANSSEN PAUL ADRIAAN JAN    BE  | LEWI PAULUS JOANNES    BE  | VAN AKEN KOEN JEANNE ALFONS    BE  | DE JONGE MARC RENE    BE  | KOYMANS LUCIEN MARIA HENRICUS    BE  | PALANDJIAN PATRICE    FR  | VINKERS HENDRIK MAARTEN    BE  | DAEYAERT FREDERIK FRANS DESIRE    BE  | HEERES JAN    BE  | GUILLEMONT JEROME EMILE GEORGES    FR,C07D23946 | C07D40912 | A61P03118 | C07D40312 | A61K0315355 | C07D41312 | C07D40314 | A61K031505 | C07D41712 | C07D40114 | C07D23947 | A61K04500 | A61K031541 | C07C25542 | C07D40712 | C07D23948 | A61K031551 | C07D40512 | C07D23396 | A61K031506 | C07D40112 | C07C21100 | C07C25712 | A61K031675,AP1610A | AP200402993D0 | AP200603551D0 | AP200703933D0 | AP200703934D0 | AP2109A | AR036387A1 | AR046812A1 | AT508748T | AU2002329238B2 | AU2002329238C1 | AU2004268390A1 | AU2004268390B2 | AU2005279157A1 | AU2005279158A1 | AU2005279158B2 | AU2005279158C1 | AU2011201123A1 | BR0211909A | BRPI0414027A | BRPI0514861A | BRPI0514871A | CA2452217A1 | CA2452217C | CA2537095A1 | CA2577273A1 | CA2577288A1 | CA2577288C | CN100509801C | CN101056673A | CN101060844A | CN101068597A | CN101816658A | CN1541215A | CR9031A | CR9032A | EA011036B1 | EA013686B1 | EA014840B1 | EA200700534A1 | EA200700536A1 | EG24684A | EP1419152A1 | EP1419152B1 | EP1632232A1 | EP1632232B1 | EP1663240A1 | EP1789139A1 | EP2298761A1 | HK1070066A1 | HR20040096A2 | HU0401346A2 | HU0401346A3 | IL160328D0 | IL173438D0 | IL181649D0 | IL181650D0 | JP2005507380T | JP2007520443T | JP2008511591T | JP2008511592T | JP2010077140A | KR1020060090658A | KR1020070053284A | KR1020070074555A | KR1020070101409A | MXPA04001401A | MXPA06002437A | MX2007002594A | MX2007002595A | NO20040633A | NO20061374A | NO20071720A | NO20071745A | NO20083770A | NO327639B1 | NZ530951A | NZ545306A | NZ553322A | NZ553323A | OA12652A | PA8552901A1 | PL368270A1 | SG155885A1 | TWI272945B | UA78221C2 | US20040198739A1 | US20060111379A1 | US20060252764A1 | US20080200435A1 | US20090012108A1 | US20090215804A1 | US20100029591A1 | US20110008434A1 | US20110150996A1 | US7125879B2 | US7638522B2 | US7956063B2 | WO2005021001A1 | WO2006024667A1 | WO2006024668A1 | ZA200401159A | ZA200601820A | ZA200701826A,81,28,Yes,Grant,Yes
267,WO2003018045,A1,"A PHARMACEUTICAL BEING USED FOR TREATING HIV INFECTION, THE COMPOSITION AND USES THEREOF",CN20011030985,China,2001-08-29T00:00:00Z,2001,2002-06-06T00:00:00Z,2003-03-06T00:00:00Z,2003,"TIANJIN FUSOGEN BIOTECH CO., LTD.",ZHOU GENFA    CN  | TIAN WANGNI    CN,A61K04748 | A61P03118 | A61P04300 | A61K031496 | A61K031472 | C07K01416 | A61K031427 | A61K03800 | A61K0315513 | A61K04500 | A61K03821 | A61K0317048 | A61K0317072 | A61K03816 | C07K01401,EP1421946A1 | US2006100139A1 | HK1067531A1 | DE60228269D1 | AT404215T  | JP2004538334T  | CN1334122A  | US7335727B2 | US6962900B2 | RU2290197C2 | RU2004108858A  | DK1421946T3 | EP1421946A4 | EP1421946B1 | US2004248789A1 | CN1100564C ,10,9,Yes,Grant,Yes
268,WO2003020200,A2,A NOVEL PHARMACEUTICAL COMPOUND AND METHODS OF MAKING AND USING SAME,US19990123146P,United States,1999-03-05T00:00:00Z,1999,2001-11-16T00:00:00Z,2003-03-13T00:00:00Z,2003,NEW RIVER PHARMACEUTICALS INC,PICARIELLO THOMAS    US,A61K04748,WO2004062614A3 | EP1401374A4 | EA010295B1 | AT462412T  | WO2003020200A3 | WO200225328A3 | US2009131325A1 | JP2004523480T  | DE60141719D1 | EA200600696A1 | US2009306228A1 | DE60143090D1 | WO2003072046A3 | ZA200510383A  | US2009137672A1 | JP2005524677T  | US2002128177A1 | AU200186599A  | US7105486B2 | CN1476325A  | US2009186825A1 | EP1594513A4 | US2009131323A1 | US2009124700A1 | WO2002051432A1 | WO200052078A1 | US7375083B2 | US2009186945A1 | US7700561B2 | US7678770B2 | JP2006107460A  | US2010004336A1 | US7018654B2 | CN1925865A  | US2007066537A1 | KR100905628B1 | US2011046226A1 | US7659254B2 | US2009131322A1 | EP1865980A4 | AU200192764A  | CA2477004A1 | WO2003072047A3 | CA2512951A1 | US2009137674A1 | AU2004204804B2 | US2005176646A1 | US2009143307A1 | US2009137677A1 | US7659253B2 | US2007203055A1 | US7060708B2 | US7674774B2 | US2009137489A1 | US2005176645A1 | EP2080511A3 | KR20060102556A  | IL174683D0 | JP2005524648T  | WO2003079972A2 | JP2007507520T  | US2009124831A1 | MX2007012507A  | EP1644019A4 | AU2001298033B2 | US7375082B2 | EA008864B1 | US7687467B2 | EP1357928A2 | EP1531844A4 | US2006059255A1 | WO200234237A1 | US2009137491A1 | US6833954B2 | WO2003072047A2 | US2009143306A1 | AU2003216382A8 | WO2003072046A2 | EP1311242A4 | US7622441B2 | AU2008229978A1 | WO2007126832A2 | BRPI0414876A  | WO200225328A2 | US2009137675A1 | US2009143304A1 | AU2003240949A1 | RU2007136824A  | US2009131332A1 | EP1490090A4 | JP2008535860T  | AU2004202699A1 | JP2006515622T  | EP1401374B1 | KR100915284B1 | JP2007500242T  | EP1531844A2 | EP1311242A1 | US7662787B2 | US2009131526A1 | US2002102055A1 | WO2006121552A9 | US2009131516A1 | WO2003020200A8 | CA2367042A1 | BRPI0410792A  | US2009131476A1 | US2009209471A1 | WO2005032474A3 | CA2540678C  | EP2080511A2 | US7662788B2 | CA2422547A1 | EP1675555A2 | CA2540678A1 | AU2004204804A1 | US2004063628A1 | US7713936B2 | CN1649614A  | US2009143305A1 | IL155905D0 | JP2010229140A  | IL154583D0 | US2009131324A1 | AU2004277400A1 | US7427600B2 | EP1631006B1 | US2007232529A1 | US6707967B2 | CN101869713A  | IL155905A  | US2002099013A1 | WO200225327A2 | US2009186828A1 | US2009137487A1 | CN1720059A  | AU200196264A  | CA2428971A1 | CA2527646A1 | EP1257592A1 | IL163667D0 | US7169752B2 | US6716452B1 | EP1631006A1 | AU2003216382A1 | JP2006516947T  | US2009234002A1 | AU2008201969A1 | SG147485A1 | EP1675555A4 | MXPA05012850A  | US2009131533A1 | US7671031B2 | EP1644019A1 | KR20080006024A  | CA2477088A1 | AU2004277400B2 | IL155928D0 | JP2002540073T  | US2009137488A1 | AU2004251647B2 | WO2003034980A8 | JP2010189419A  | NZ546226A  | US2009137515A1 | WO2007126832A3 | WO2006121552A2 | US2009192093A1 | AU2009201958A1 | US7338939B2 | AU2004251647A1 | US2009137486A1 | EP1401374A1 | US2010105781A1 | US2005080012A1 | US2007042955A1 | US7223735B2 | US2007060500A1 | US7574503B2 | AU2001286599B2 | CN1816346A  | NZ544162A  | US2005038121A1 | US2005054561A1 | US2009137490A1 | WO2005000334A1 | AU2003219863C1 | IL169645D0 | BRPI0612440A2 | US2010197798A1 | AU2003217676B2 | US2005266070A1 | ZA200602598A  | KR20050098246A  | US2009131525A1 | CA2422460A1 | EP1865980A2 | US2004127397A1 | WO200225327A3 | NO20056211A  | MXPA06003619A  | KR20060073538A  | AT462411T  | KR20090057478A  | US2003086646A1 | US2009131534A1 | EP1311242B1 | AU2003219863A1 | US7718619B2 | AU2004204804C1 | US7163918B2 | CN101193650A  | EP2266590A3 | JP2006516948T  | AU2003219863B2 | US2008086016A1 | DE602005009453D1 | US7678771B2 | WO2004062614A2 | US2011009669A1 | WO2003034980A2 | US2009131333A1 | CA2603873A1 | CA2420590A1 | US7723305B2 | IL172212D0 | US2009124696A1 | WO2003079972A3 | CN1747737A  | US2006014697A1 | CA2429345A1 | US2009137461A1 | WO2005032474A2 | EP1357928A4 | US2009181898A1 | WO2006121552A3 | EP2266590A2 | US2009149392A1 | AU2009201552A1 | EP1364236A2 | US2004087483A1 | WO2003101476A1 | JP4625637B2 | AU2003217676A1 | AU771188B2 | US2007197451A1 | NO20061925A  | US2009137676A1 | AU2001297565B2 | US7687466B2 | US2009131326A1 | WO200053233A1 | US2005176644A1 | IL163666D0 | US2009131334A1 | AU200037239A  | US2009253792A1 | EP1490090A2 | US2009137673A1 | US7671030B2 | US2009131335A1 | EP1594513A2 | CN100413533C  | AU200036990A  | US7655630B2,177,18,Yes,Grant,Yes
269,WO2003020716,A1,PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS,US20010315683P,United States,2001-08-29T00:00:00Z,2001,2002-08-28T00:00:00Z,2003-03-13T00:00:00Z,2003,SCHERING CORP,PALANI ANANDAN      | MILLER MICHAEL W      | SCOTT JACK D,C07D40104 | A61P02500 | A61P03706 | A61P04300 | A61K04500 | A61K031506 | A61K0314545 | A61P01902 | A61P01106 | A61P02900 | A61P01700 | A61P01706 | C07D40114 | A61P03118,IL160060D0 | SI1421075T1 | JP2005502682T  | EP1421075A1 | RU2004109510A  | CN1304389C  | US7442703B2 | CA2457861A1 | ES2264491T3 | ZA200401594A  | JP4223950B2 | MXPA04001886A  | BR200212108A  | HU200402019A2 | US2008214575A1 | PT1421075E  | US2004092551A1 | DE60212146T2 | EP1421075B1 | AR036366A1 | DK1421075T3 | NO20041266A  | HK1061563A1 | HU200402019A3 | PL368827A1 | JP2008222722A  | US2004010008A1 | US7384948B2 | ECSP044993A  | US2004092745A1 | DE60212146D1 | AT328879T  | CN1551877A ,26,22,Yes,Grant,Yes
270,WO2003022252,A2,COMBINATORIAL TYPE CONTROLLED RELEASE DRUG DELIVERY DEVICE,US20010947464,United States,2001-09-07T00:00:00Z,2001,2002-09-05T00:00:00Z,2003-03-20T00:00:00Z,2003,"INTELLIPHARMACEUTICS, INC.",ODIDI AMINA  CA  | ODIDI ISA  CA,A61K00922 | A61K00948 | A61K0314422 | A61K03141 | A61K031137 | A61K031403 | A61K03155 | A61P03118 | A61P03500,AU2002325118A1 | WO2003022252A3 | US2003050620A1 | CA2459857C  | CA2459857A1,4,4,Yes,Grant,Yes
271,WO2003024932,A1,BIS-AMINO ACID SULFONAMIDES AS HIV PROTEASE INHIBITORS,US20010323042P,United States,2001-09-18T00:00:00Z,2001,2002-09-18T00:00:00Z,2003-03-27T00:00:00Z,2003,BRISTOL MYERS SQUIBB PHARMA CO,KALTENBACH ROBERT,C07K00506 | C07K00502 | A61K03800,US6562848B1,2,2,Yes,Grant,Yes
272,WO2003024995,A1,MOLECULES THAT BLOCK VIRAL INFECTIVITY AND METHODS OF USE THEREOF,US20010323650P,United States,2001-09-19T00:00:00Z,2001,2002-09-13T00:00:00Z,2003-03-27T00:00:00Z,2003,CHRONTECH PHARMA AB,VAHLNE ANDERS  SE  | GOOBAR-LARSSON LAURA  SE,C07K005083 | A61K03806 | A61P03118,US2004038908A1 | US7012129B2 | US2007037249A1 | EP1436317A1,4,3,Yes,Grant,Yes
273,WO2003035074,A1,"DRUGS COMPRISING COMBINATION OF TRIAZASPIRO[5,5]UNDECANE DERIVATIVE WITH CYTOCHROME P450 ISOZYME 3A4 INHIBITOR AND/OR P-GLYCOPROTEIN INHIBITOR",JP20010324435,Japan,2001-10-23T00:00:00Z,2001,2002-03-18T00:00:00Z,2003-05-01T00:00:00Z,2003,ONO PHARMACEUTICAL CO.,IMAWAKA HARUO    JP  | SHIBAYAMA SHIRO    JP  | TAKAOKA YOSHIKAZU    JP,A61K04500 | A61K0315377 | A61K031499 | A61K04506 | A61P04300 | C07D47110,PL370280A1 | IL161053D0 | EP1438962A4 | NO20041618A  | EP1438962A1 | CN1571671A  | CA2461545A1 | CZ20040500A3 | HU200500028A2 | MXPA04003816A  | ZA200403086A  | RU2004115621A  | BR200213372A ,12,12,Yes,Application,No
274,WO2003035077,A1,N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE,US20010339568P,United States,2001-10-26T00:00:00Z,2001,2002-10-21T00:00:00Z,2003-05-01T00:00:00Z,2003,ISTITUTE DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A,CRESCENZI BENEDETTA    IT  | GARDELLI CRISTINA    IT  | MURAGLIA ESTER    IT  | NIZI EMANUELA    IT  | ORVIETO FEDERICA    IT  | PACE PAOLA    IT  | PESCATORE GIOVANNA    IT  | PETROCCHI ALESSIA    IT  | POMA MARCO    IT  | ROWLEY MICHAEL    IT  | SCARPELLI RITA    IT  | SUMMA VINCENZO    IT,C07D23946 | A61K0315377 | A61K031513 | A61P03118 | A61P04300 | C07D51304 | C07D41312 | C07D40314 | C07D41704 | C07D40106 | C07D40112 | C07D40114 | C07D40312 | C07D41314 | C07D41304 | A61K031515 | C07D40310 | C07D40304 | A61K03900 | C07D40104 | C07D239557 | C07D23954,PL369223A1 | NO20042165A  | HR20040373A2 | US7217713B2 | US2008275004A1 | JP2005511543T  | US2011034449A1 | NZ533057A  | IS7213A  | IL161337A  | NL300340I2 | BR200213522A  | CA2463976A1 | US2007123524A1 | DE60209381T2 | HU200401740A2 | DE122009000048I1 | JP3927175B2 | UA77454C2 | NL300340I1 | NO2008007I1 | IS2436B  | US7820660B2 | DE60209381D1 | DK1441735T3 | NO2008007I2 | AU2002334207B2 | LU91428A9 | PT1441735E  | AT318140T  | EP1441735A1 | EP1441735B1 | YUP35604A  | CA2463976C  | US2005025774A1 | US2006258860A1 | ES2258668T3 | MXPA04003932A  | NO325206B1 | US7169780B2 | SI1441735T1 | CO5580777A2 | US7435734B2 | AU2002334207A2 | HU200401740A3 | IL161337D0 | ZA200402796A  | CN1700918A ,35,29,Yes,Grant,Yes
275,WO2003035111,A1,ANTIRETROVIRAL COMPOSITIONS COMPRISING THYMOSIN ALPHA PEPTIDES AND PROTEASE INHIBITORS,US20010330549P,United States,2001-10-24T00:00:00Z,2001,2002-10-23T00:00:00Z,2003-05-01T00:00:00Z,2003,"SCICLONE PHARMACEUTICALS, INC.",MARTINS EDUARDO BRUNO GUIMARAE  US  | PATON NICHOLAS  SG,A61K04700 | C07K00700,US2005020495A1,2,2,Yes,Application,No
276,WO2003037379,A1,USE OF GRANULAR MATERIALS BASED ON PYROGENICALLY PRODUCED SILICON DIOXIDE IN PHARMACEUTICAL COMPOSITIONS,DE20011053078,Germany,2001-10-30T00:00:00Z,2001,2002-07-06T00:00:00Z,2003-05-08T00:00:00Z,2003,"EVONIK DEGUSSA GMBH,",HASENZAHL STEFFEN      | MEYER JUERGEN      | HEYM JUERGEN,A61K04704 | A61K031616 | A61K00910 | A61K00906 | A61K00902 | A61K031167 | A61K00918 | A61K03100 | A61K03160 | A61P04300 | A61P03906 | A61P02900 | A61K00948 | A61K00914 | A61K031355 | A61K00920,US2004022844A1 | JP2005508977T  | DE10153078A1 | EP1439858A1 | US7815936B2 | CN1582169A  | JP4320254B2 | CA2465369A1,7,7,Yes,Grant,Yes
277,WO2003041694,A2,"USE OF COMPOUNDS COMPRISING IODINE, STRONTIUM AND ASCORBIC ACID AS WELL AS EITHER BISMUTH, ZINC OR POTASSIUM IN THE TREATMENT OF AIDS",US20010338225P,United States,2001-11-13T00:00:00Z,2001,2002-11-13T00:00:00Z,2003-05-22T00:00:00Z,2003,ALCHEMY INTERNATIONAL,SAKALOSKY GEORGE P  US,A61K03100 | A61K031375 | A61K031555 | A61P03118,WO2003041694A3 | AU2002360383A1 | US2003181436A1,3,3,Yes,Application,No
278,WO2003043602,A1,SOLID DISPERSIONS CONTAINING SUBSTITUTED CYCLODEXTRIN AND INSOLUBLE DRUG AND THEIR PREPARATIONS,KR20010072412,Korea,2001-11-20T00:00:00Z,2001,2002-11-18T00:00:00Z,2003-05-30T00:00:00Z,2003,"DDS TECH CO., LTD",CHANG SI-YOUNG  KR  | SONG JAE-SHIN  KR,A61K00914 | A61K00920 | A61K00916,AU2002366042A1 | KR20030041577A  | KR2003041577A ,3,3,Yes,Application,No
279,WO2003045404,A2,"METHODS FOR REGULATING LEVELS OF ZINC, CADMIUM AND CALCIUM IN HUMANS AND FOR DIAGNOSING, OR SCREENING FOR THE RISK OF DEVELOPING, DISEASES ASSOCIATED WITH ABNORMAL LEVELS OF CADMUIM, ZINC AND CALCIUM IN BODY FLUIDS AND TISSUES",US19990142926P,United States,1999-07-09T00:00:00Z,1999,2002-11-21T00:00:00Z,2003-06-05T00:00:00Z,2003,CANCER2 INC,WOODS GORDON L,A61K03324 | A61P00712 | A61P00912 | A61P01910 | A61P02510 | A61P02528 | A61P03500 | A61P04300,CA2378676C  | AU200059203A  | WO200104408A8 | JP2003504531T  | US7033615B2 | US2002114848A1 | CA2377920A1 | NZ516745A  | DE69940108D1 | US6811574B2 | EP1069233B1 | US2004123399A1 | US6852134B2 | WO2003045404A3 | US2002148049A1 | EP1069233A1 | AU777574B2 | WO200104408A1 | WO200103708A1 | EP1170414A1 | EP1200104A1 | NZ530205A  | US2004123398A1 | AT417955T  | US2002144353A1 | MXPA02000210A  | US2005198743A1 | CA2378676A1 | US2006068027A1 | CA2468154A1 | BR200012348A ,7,4,Yes,Grant,Yes
280,WO2003046559,A2,INDIVIDUALIZATION OF THERAPY WITH ANTIVIRAL AGENTS,US20010333500P,United States,2001-11-28T00:00:00Z,2001,2002-11-27T00:00:00Z,2003-06-05T00:00:00Z,2003,"XANTHUS LIFE SCIENCES, INC",LEYLAND-JONES BRIAN    US,G01N03350,AU2002349225A1 | WO2003046559A3 | US2003195350A1 | AU2002349225A8,3,3,Yes,Application,No
281,WO2003049746,A2,COMBINATION OF CYTOCHOME P>450< DEPENDENT PROTEASE INHIBITORS,EP20010204841,European Patent Office,2001-12-12T00:00:00Z,2001,2002-12-12T00:00:00Z,2003-06-19T00:00:00Z,2003,TIBOTEC PHARM LTD,VAN DER GEEST RONALD    NL  | STOFFELS PAUL    BE  | GROEN CORNELIS    NL  | JOCHMANS DIRK EDWARD DESIRE    BE,C07D49304 | A61P03112 | A61K0314164 | A61K03134 | A61K04500 | A61K031427 | A61P04300 | A61K031496 | A61K031365 | A61P03118 | A61K031635,ES2333206T3 | CA2469343C  | PL373072A1 | HU200402644A3 | MXPA04005755A  | CA2469343A1 | HR20040619A2 | HK1070008A1 | EP1458447B1 | SI1458447T1 | DK1458447T3 | NZ533826A  | HU200402644A2 | AU2002358713A1 | TWI286476B  | RU2329050C2 | NO20042666A  | AU2002358713B2 | BR200215043A  | AR037797A1 | ZA200404633A  | CN1604803A  | WO2003049746A3 | EP1458447A2 | DE60233677D1 | CN100335060C  | RU2004121144A  | JP2005511723T  | PT1458447E  | AT442189T  | IL162353D0 | US2005119338A1,24,23,Yes,Grant,Yes
282,WO2003051301,A2,USE OF dsRNAs IN STRATEGIC THERAPEUTIC INTERVENTION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY,US20010339390P,United States,2001-12-14T00:00:00Z,2001,2002-12-13T00:00:00Z,2003-06-26T00:00:00Z,2003,HEMISPHER BIOPHARMA,STRAYER DAVID R  US  | CARTER WILLIAM A  US,A61K000,AU2002364163A8 | EP1494684A2 | WO2003051301A3 | CN1617731A  | AU2002364163A1 | CA2470204A1 | US2005070489A1,6,6,Yes,Application,No
283,WO2003051361,A1,USE OF HIV-1 PROTEASE INHIBITORS AND THEIR DERIVATIVES IN THE TREATMENT OF INFLAMMATION,US20010340507P,United States,2001-12-14T00:00:00Z,2001,2002-11-27T00:00:00Z,2003-06-26T00:00:00Z,2003,CEDARS-SINAI MEDICAL CENTER,"ARDITI, Moshe  US | EQUILS, Ozlem US",A61K004500 | A61K003100 | A61K0031415 | A61K0031426 | A61K003147 | A61K0031472 | A61K0031496 | A61K0031513 | A61K0031551 | A61K003163 | A61K003170 | A61K00317064 | A61K0039395 | A61K004506 | A61P000100 | A61P000104 | A61P001902 | A61P002900 | A61P003104 | A61P003706 | A61P004300,AU2002346594A1 | EP1453504A1 | JP2005511767T | US20030138423A1,5,5,Yes,Application,No
284,WO2003053343,A2,NOVEL COMPOUNDS THAT ENHANCE DIMERIZATION OF THE SUBUNITS OF HIV-1 REVERSE TRANSCRIPTASE HAVING MUTATIONS ASSOCIATED WITH RESISTANCE TO NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS,US20010010129,United States,2001-12-06T00:00:00Z,2001,2002-12-06T00:00:00Z,2003-07-03T00:00:00Z,2003,PROGENICS PHARM INC,O'HARA BRYAN M,A61K000,US2003109468A1 | AU2002362093A8 | AU2002362093A1 | WO2003053343A3,3,3,Yes,Application,No
285,WO2003053347,A2,GALLIUMCOMPLEXES OF 3-HYDROXY-4-PYRONES TO TREAT MYCOBACTERIAL INFECTIONS,US19990157460P,United States,1999-10-04T00:00:00Z,1999,2002-12-11T00:00:00Z,2003-07-03T00:00:00Z,2003,BERNSTEIN LAWRENCE R,BERNSTEIN LAWRENCE R    US,A61K04506 | A61K0317036 | A61K031351 | C07D30940,US2003083308A1 | WO200124799A1 | WO2003053347A3 | DE60032915T2 | EP1218011A1 | AU2002364964A8 | CA2386325A1 | AU775459B2 | CA2386325C  | AU2002364964A1 | EP1218011A4 | US2006222628A1 | DE60032915D1 | EP1218011B1 | US2002068761A1 | JP2003510362T  | AU200111976A  | ES2280259T3 | MXPA02003463A ,14,9,Yes,Grant,Yes
286,WO2003057173,A2,BROAD SPECTRUM INHIBITORS,US20020344788P,United States,2002-01-07T00:00:00Z,2002,2003-01-07T00:00:00Z,2003-07-17T00:00:00Z,2003,SEQUOIA PHARMACEUTICALS,ERICKSON JOHN W    US  | EISSENSTAT MICHAEL    US  | SILVA ABELARDO    US  | GULNIK SERGEI    US,C07F0096584 | G06F01900 | G06F01916 | C07D30720 | C07D27503 | C07F0096571 | C07D49104 | C12N00988 | C12N00950 | C07D49304 | C07D49504 | G06F01918 | C07D27502,AU2008258152A1 | EP1483254A4 | EP1472536A4 | CA2472580A1 | ZA200405528A  | EP1483254A1 | US2005107342A1 | EP1472536A2 | US2004009890A1 | US2006258737A1 | WO2003064406A1 | CA2473231A1 | WO2003057173A3 | US2010009935A1 | US7285566B2 | US7109230B2 | US2003171423A1 | AU2003202914A1 | US2006293286A1,15,6,Yes,Grant,Yes
287,WO2003062238,A1,TRICYCLIC 2-PYRIMIDONE COMPOUNDS USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS,US20020349641P,United States,2002-01-18T00:00:00Z,2002,2003-01-16T00:00:00Z,2003-07-31T00:00:00Z,2003,BRISTOL MYERS SQUIBB PHARMA CO,TARBY CHRISTINE M    US,A61K031519 | A61P04300 | C07D48714 | A61P03118 | A61K03153 | C07D48704 | C07D47104 | C07D47114,RU2004125151A  | HR20040643A2 | NO20043424A  | BR200306927A  | PE09872003A1 | JP2005519910T  | EP1474424A1 | PL371418A1 | IL162743D0 | CN1642954A  | US6844340B2 | AR038164A1 | IS7341A  | YUP62504A  | US2004266778A1 | MXPA04006948A  | CA2473420A1 | ZA200405139A  | CO5590961A2 | US7186830B2 | US2003162800A1 | EP1474424A4,19,18,Yes,Grant,Yes
288,WO2003066028,A1,MANUFACTURE OF ORAL DOSAGE FORMS DELIVERING BOTH IMMEDIATE-RELEASE AND SUSTAINED-RELEASE DRUGS,US20020066146,United States,2002-02-01T00:00:00Z,2002,2003-01-28T00:00:00Z,2003-08-14T00:00:00Z,2003,"DEPOMED, INC.",LIM JONG      | SHELL JOHN N,A61K04726 | A61K04724 | A61P00310 | A61K04738 | A61K031155 | A61K0314015 | A61K00926 | A61K00924 | A61K00922 | A61K00936,EP1469838A1 | US2003147952A1 | EP1469838A4 | TWI280141B  | MXPA04007371A  | US6682759B2 | NZ534312A  | CA2417686A1 | IL163205A  | JP2005521674T  | AU2003207755B2 | CA2417686C  | AU2003207755A1,10,10,Yes,Grant,Yes
289,WO2003066830,A2,HUMAN MONOCLONAL ANTIBODIES AGAINST MEMBRANE PROTEINS,US20020071866,United States,2002-02-08T00:00:00Z,2002,2003-02-07T00:00:00Z,2003-08-14T00:00:00Z,2003,"ADIMAB, LLC",HUA SHAOBING    US  | PAULING MICHELLE H    US  | ZHU LI    US,C07K01628 | C07K01600 | A61K039395,US2003206909A1 | US2003152913A1 | AU2003209059A8 | US7138496B2 | US7700302B2 | US7005503B2 | AU2003209059A1 | US2003165988A1 | US2007059308A1 | WO2003066830A3 | US2005123973A1 | US2010227774A1,8,3,Yes,Grant,Yes
290,WO2003072766,A1,ANTI-CCR5 ANTIBODY,US20020081128,United States,2002-02-22T00:00:00Z,2002,2003-02-21T00:00:00Z,2003-09-04T00:00:00Z,2003,PROGENICS PHARM INC,OLSON WILLIAM C    US  | MADDON PAUL J    US,C12P02108 | A61P03118 | A61K03944 | C12N01563 | C07K01608 | C12N01513 | A61K039395 | C07K01628,IL163655D0 | EP1478738B1 | CA2476901A1 | AU2003217674A1 | DE60324664D1 | EP1478738A1 | AT414142T  | NO20043971A  | MXPA04008153A  | ES2316740T3 | ZA200406765A  | PT1478738E  | NZ561465A  | JP2006508631T  | NZ534947A  | AU2003217674B2 | RU2004128252A  | EP2058006A1 | AU2003217674C1 | DK1478738T3 | EP1478738A4 | RU2322454C2 | HK1072272A1 | CN1780907A ,18,16,Yes,Grant,Yes
291,WO2003075010,A2,"NON-PEPTIDE IMMUNOLOGIC TRACER PRECURSORS COMPRISING A TYROSYL-(X)N OR LYSINE-(X)N TYROSINE MOTIF, METHOD FOR PREPARING SAME AND USES THEREOF",FR20020002783,France,2002-03-05T00:00:00Z,2002,2003-03-05T00:00:00Z,2003-09-12T00:00:00Z,2003,CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE,VINCENT JEAN-PIERRE  FR  | CUPO ANNY  FR  | LE SAINT CECILE  FR,G01N033532,WO2003075010A3 | FR2836996A1 | AU2003227812A8 | AU2003227812A1,3,3,Yes,Application,No
292,WO2003078438,A1,CARBAMATES AS HIV PROTEASE INHIBITORS,US20020363252P,United States,2002-03-12T00:00:00Z,2002,2003-03-07T00:00:00Z,2003-09-25T00:00:00Z,2003,BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS,OKAMITSU JEFFREY K,B29C03508 | B05D00306 | B29C03502,AU2003213770A1 | AU2003213776A1 | CA2478731A1 | CN100431717C | CN1845796A | DE03711461T1 | EP1485387A1 | EP1585843A2 | EP1585843A4 | EP1585843B1 | JP2006504621T | MXPA04008858A | US20030230831A1 | US20040039016A1 | US20070082883A1 | US6833154B2 | US7157489B2 | US7897635B2 | WO2003078675A2 | WO2003078675A3,14,9,Yes,Grant,Yes
293,WO2003082241,A2,CLARITHROMYCIN FORMULATIONS HAVING IMPROVED BIOAVAILABILITY,IN2002DE00425,India,2002-04-03T00:00:00Z,2002,2003-04-03T00:00:00Z,2003-10-09T00:00:00Z,2003,RANBAXY LABORATORIES LIMITED,PARUTHI MANOJ KUMAR  IN  | RAMPAL ASHOK  IN  | RAGHUVANSHI RAJEEV S  IN,A61K00900,ZA200408568A  | CA2481271A1 | US2005163857A1 | AU2003214506A1 | WO2003082241A3 | CN1652753A  | EP1492507A2 | BR200308989A ,8,8,Yes,Application,No
294,WO2003082248,A2,TASTE MASKED COMPOSITIONS OF ERYTHROMYCIN A AND DERIVATIVES THEREOF,IN2002DE00426,India,2002-04-03T00:00:00Z,2002,2003-04-03T00:00:00Z,2003-10-09T00:00:00Z,2003,RANBAXY LABORATORIES LIMITED,DABRE RAHUL    IN  | NAGAPRASAD VISHNUBHOTLA    IN  | MALIK RAJIV    IN,A61K03143 | A61K00950 | A61K00916 | A61K03855 | A61K0314439 | A61K0317048 | A61K031734,CA2481269A1 | US2007167380A1 | EP1492504A2 | BR200308990A  | WO2003082248A3 | AU2003214504A1 | ZA200408569A  | CN1652750A ,8,8,Yes,Application,No
295,WO2003085127,A2,METHOD FOR IDENTIFICATION OF INSULIN RECEPTOR KINASE ACTIVATORS,US20000239636P,United States,2000-10-11T00:00:00Z,2000,2003-03-31T00:00:00Z,2003-10-16T00:00:00Z,2003,"TELIK, INC.",LUM ROBERT T   US  | SCHOW STEVEN R   US  | MANCHEM PRASAD V V S V   US,C12Q00148 | G01N03366,WO200230514A3 | EP1355698A2 | US6528037B2 | WO2003085127A3 | US2002151542A1 | AU2003222133A8 | AU2003222133A1 | AR035350A1 | US2002061927A1 | AU200211922A  | CA2421622A1 | ITTO20010950A1 | WO200230514A2 | CN1723059A  | FR2814953A1 | JP2004510831T ,13,10,Yes,Grant,Yes
296,WO2003099851,A2,METHODS AND COMPOSITIONS FOR INHIBITING HIV REPLICATION,US20020383409P,United States,2002-05-24T00:00:00Z,2002,2003-05-23T00:00:00Z,2003-12-04T00:00:00Z,2003,THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA,WEINER DAVID B    US,A61K03821 | A61K031551 | A61K03342 | A61K031496 | A61K0314725 | A61P03118 | A61K031472 | A61K031635 | A61K031536 | A61K031513 | A61K0317068 | A61K031567 | A61K031519 | A61K031522 | A61K0317072 | A61K031704 | A61K03157 | A61K031573 | A61K031569 | A61K03158 | A61K04506,CA2487655A1 | AU2003234637B2 | US2006068389A1 | JP2005531589T  | AU2003234637A1 | EP1523328A2 | EP1523328A4 | WO2003099851A3,6,6,Yes,Application,No
297,WO2003101481,A1,TREATMENT OF NEURODEGENERATIVE DISEASES USING PROTEASOME MODULATORS,US20020385489P | US20020385625P,United States,2002-06-03T00:00:00Z,2002,2003-06-03T00:00:00Z,2003-12-11T00:00:00Z,2003,"ALS THERAPY DEVELOPMENT FOUNDATION, INC.",RAMESH TENNORE M      | SCOTT SEAN,A61K031635 | A61K031472 | A61K031427 | A61P02528 | A61P03100 | A61K03100 | A61K031551 | A61K0314725 | A61P02516 | A61K03855 | A61K031496 | A61K031513,US7902185B2 | AU2003249682A1 | US2004138153A1,3,3,Yes,Grant,Yes
298,WO2003105826,A2,SOLUBLE STABLE PHARMACEUTICAL COMPOSITION FOR THE ADMINISTRATION OF HIV PROTEASE INHIBITORS AND A PROCESS FOR THE PREPARATION OF CONCENTRATED PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF HIV PROTEASE INHIBITORS.',BR20020002252,Brazil,2002-06-12T00:00:00Z,2002,2003-06-12T00:00:00Z,2003-12-24T00:00:00Z,2003,CRISTALIA PRODUTOS QUIMICOS FARMACEUTICOS LTDA,PACHECO OGARI    BR  | RUSSO ELISA    BR  | RUSSO VALTER    BR,A61K04710 | A61K031225 | A61K00900 | A61K04714 | A61K04722 | A61K04744,US7632853B2 | EP1513512A4 | US2005250764A1 | CN1668292A  | WO2003105826A3 | AU2003232535A1 | BR200202252A  | EP1513512A2 | CN1289076C  | WO2003105826B1,6,6,Yes,Grant,Yes
299,WO2004002410,A2,"2,4-DISUBSTITUTED-PYRIDINE N-OXIDES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS",US20020392092P,United States,2002-06-27T00:00:00Z,2002,2003-06-25T00:00:00Z,2004-01-08T00:00:00Z,2004,BRISTOL MYERS SQUIBB PHARMA CO,RODGERS JAMES D    US  | WANG HAISHENG    US,C07D21389 | A61K03144,AU2003243765A1 | PE06102004A1 | WO2004002410A3 | US2004019047A1 | AU2003243765A8 | AR040456A1 | US6809109B2 | EP1523476A2,6,6,Yes,Grant,Yes
300,WO2004002428,A2,DERIVATIVES OF GAMBOGIC ACID AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS,US20020392358P,United States,2002-07-01T00:00:00Z,2002,2003-07-01T00:00:00Z,2004-01-08T00:00:00Z,2004,CYTOVIA INC,TSENG BEN    US  | SIRISOMA NILANTHA SUDATH    US  | CAI SUI XIONG      | ZHANG HAN-ZHONG      | KASIBHATLA SHAILAJA      | OLLIS KRISTIN P      | DREWE JOHN A,C12N00502 | C07D49320,WO2004002428A3 | AU2003267977B2 | CA2491698A1 | US2004082066A1 | US7176234B2 | CN1738620A  | AU2003267977A1 | EP1562598A2 | JP2006507227T  | AU2003267977B8 | EP1562598A4 | CN1738620B ,7,7,Yes,Grant,Yes
301,WO2004003512,A2,COMPOSITIONS AND METHODS FOR DETERMINING THE SUSCEPTIBILITY OF A PATHOGENIC VIRUS TO PROTEASE INHIBITORS,US20020393234P,United States,2002-07-01T00:00:00Z,2002,2003-07-01T00:00:00Z,2004-01-08T00:00:00Z,2004,"MONOGRAM BIOSCIENCES, INC.",PARKIN NEIL T      | PAXINOS ELLEN      | CHAPPEY COLOMBE      | WRIN MARY T      | GAMARNIK ANDREA V      | PETROPOULOS CHRISTOS J,G01N03350 | C12Q00168 | C12N01509 | G01N03315 | C12Q00137 | G01N033569,US2004106106A1 | CA2491388A1 | AR040370A1 | CN1688719A  | JP2005536200T  | WO2004003512A3 | AU2003247790A1 | EP1552023A4 | EP1552023A2 | US7553618B2,8,8,Yes,Grant,Yes
302,WO2004004658,A2,METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS,US20020394856P,United States,2002-07-09T00:00:00Z,2002,2003-07-09T00:00:00Z,2004-01-15T00:00:00Z,2004,"POINT THERAPEUTICS, INC.",ADAMS SHARLENE      | MILLER GLENN T      | JESSON MICHAEL I      | JONES BARRY,A61K000,AU2003248921A1 | CA2491474A1 | JP2006507352T  | EP1578434A2 | WO2004004661A2 | US2004077601A1 | CN1826129A  | JP2006506442T  | WO2004004661A3 | CN1802090A  | EP1578362A2 | IL166157D0 | AU2003265264A1 | CA2491466A1 | US2005084490A1 | WO2004004658A3 | EP1578362A4 | IL166156D0,14,7,Yes,Application,No
303,WO2004004660,A2,COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS,US19990143767P,United States,1999-07-13T00:00:00Z,1999,2003-07-09T00:00:00Z,2004-01-15T00:00:00Z,2004,ALPHA RESEARCH GROUP,NELSON JODI,A61K03147 | A61K031375 | A61K031355 | A61K0314706,JP2006514917T  | AT431141T  | US6417177B1 | AU2003248893A8 | EP1261340A2 | CA2416233A1 | WO2004004660A3 | AU2003248893A1 | CA2531810A1 | DE60042215D1 | US2004229908A1 | AU200073865A  | EP1261340B1 | EP1581167A2 | WO200103649A3 | EP1581167A4 | EP1261340A4 | US2002198231A1 | AU779955B2 | JP2004500331T  | WO200103649A2,15,7,Yes,Grant,Yes
304,WO2004004711,A1,"USE OF AT LEAST TWO ANTICANCER COMPOUNDS, ONE OF WHICH AT LEAST MODULATES PROTEASOME ACTIVITY FOR MAKING A MEDICINE FOR CANCER TREATMENT",FR20020008458,France,2002-07-05T00:00:00Z,2002,2003-07-04T00:00:00Z,2004-01-15T00:00:00Z,2004,BIOMERIEUX | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ,ANDRE PATRICE  FR  | EVLACHEV ALEXEI  FR  | LOTTEAU VINCENT  FR,A61K031427 | A61K0314375 | A61K031704 | A61P03500,AU2003263263A8 | FR2841785A1 | AU2003263263A1,3,3,Yes,Application,No
305,WO2004005313,A2,"NOVEL COMPOUNDS, COMPOSITIONS AS CARRIERS FOR STEROID/NON-STEROID ANTI-INFLAMMATORY, ANTINEOPLASTIC AND ANTIVIRAL ACTIVE MOLECULES",US20020395190P,United States,2002-07-08T00:00:00Z,2002,2003-07-08T00:00:00Z,2004-01-15T00:00:00Z,2004,GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O.,MERCEP MLADEN    HR  | MESIC MILAN    HR  | TOMASKOVIC LINDA    HR  | MARKOVIC STRIBOR    HR,A61K04748 | A61P03708 | A61P01108 | A61P03112 | A61P00100 | A61P03118 | A61P03104 | C07K005103 | C07K005083 | A61P03702 | A61P02702 | A61P01706 | A61P01902 | A61P04300 | A61P02100 | A61P01106 | A61P00104 | A61P01704 | A61P01906 | A61P02900 | A61P01700 | A61P00910 | A61P03500 | A61P01100 | C07K00510 | C07J04300 | A61K03158 | C07J01700,NO329867B1 | WO2004005313A3 | EP1551865B1 | NO20050575A  | AU2003264917A1 | IS7685A  | US7157433B2 | IL165653D0 | IL165653A  | AR043103A1 | DE60327341D1 | HR20050002A2 | JP4530851B2 | US2004077612A1 | PL375162A1 | EP1551865A2 | RSP20050006A  | AU2003264917A8 | CN1665831A  | ES2325495T3 | JP2005538070T  | AT429441T ,15,15,Yes,Grant,Yes
306,WO2004006847,A2,SELECTED ANTIBODIES AND DURAMYCIN PEPTIDES BINDING TO ANIONIC PHOSPHOLIPIDS AND AMINOPHOSPHOLIPIDS AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER,US20020396263P,United States,2002-07-15T00:00:00Z,2002,2003-07-15T00:00:00Z,2004-01-22T00:00:00Z,2004,"BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM",THORPE PHILIP E    US  | SOARES MELINA M    US  | HUANG XIANMING    US  | HE JIN    US  | RAN SOPHIA    US,A61K04500 | A61P03702 | A61P00910 | A61P03112 | A61P00304 | A61P03122 | A61P03110 | A61P03500 | A61P02706 | A61P01710 | A61P01902 | A61P04300 | A61P02702 | A61P00706 | A61P00310 | A61P01700 | A61P01906 | A61P02900 | A61P01508 | A61P00514 | A61P03300 | A61P00704 | C07K01644 | A61K039395 | C07K01628,US7615223B2 | AU2003247869A1 | US2005059578A1 | US7455833B2 | EP1537146A2 | CN101653603A  | AU2009222538A1 | IL165267D0 | US2004175378A1 | US2005129696A1 | CA2491310A1 | DE60335383D1 | AT491725T  | US2004170620A1 | US7879801B2 | CN1668644A  | US2004208868A1 | US2010310638A1 | WO2004006847A3 | US7622118B2 | EP1537146A4 | EP2263697A2 | US7714109B2 | US7611704B2 | EP2263697A3 | US2004213779A1 | JP2010254723A  | US2005031620A1 | US2004131622A1 | US7511124B2 | US7572442B2 | US2004147440A1 | EP2269656A3 | US7906115B2 | EP2283869A2 | US7378386B2 | IL195328D0 | AU2003247869B2 | US7247303B2 | US2004219155A1 | JP2005537267T  | EP2269656A2 | EP2266624A2 | NZ574146A  | US7678386B2 | EP2283868A2 | DK1537146T3 | EP2283868A3 | EP2281578A2 | NZ537690A  | US2004131621A1 | US7572448B2 | US7625563B2 | US2004214764A1 | EP1537146B1 | US7790159B2 | US2005136059A1 | AU2003247869C1 | BR200312692A  | ZA200500363A  | US2004131610A1 | EP2266624A3 | KR20050027107A  | US7384909B2 | MXPA05000652A  | US2005002941A1 | US2011033454A1 | CN100506846C  | EP2281578A3 | US2005025761A1 | US2004265367A1 | US2004161429A1,48,16,Yes,Grant,Yes
307,WO2004009073,A1,P-GLYCOPROTEIN INHIBITOR COMPRISING OCTILONIUM BROMIDE AS AN EFFECTIVE INGREDIENT,KR20020042794,Korea,2002-07-20T00:00:00Z,2002,2003-07-21T00:00:00Z,2004-01-29T00:00:00Z,2004,"DAEHWA PHARM. CO., LTD.",CHUNG HESSON    KR  | JEONG SEO-YOUNG    KR  | KWON ICK-CHAN    KR  | PARK YEONG-TAEK    KR  | LEE IN-HYUN    KR  | YUK SOON-HONG    KR,A61K03114 | A61K00950 | A61K00900 | A61K031245 | A61K04506,KR100503889B1 | US2006141033A1 | EP1545495A4 | KR20040009018A  | EP1545495A1 | US2010029755A1 | AU2003281468A1,6,5,Yes,Grant,Yes
308,WO2004010937,A2,METHOD OF TREATING CANCER,US20020399573P,United States,2002-07-26T00:00:00Z,2002,2003-07-28T00:00:00Z,2004-02-05T00:00:00Z,2004,INDIANA UNIVERSITY,POTTER DAVID A   US,A61K000,AU2003256847A8 | US2004167139A1 | AU2003256847A1 | WO2004010937A3 | US2007009593A1,4,3,Yes,Application,No
309,WO2004011019,A1,USE OF A PROTEASOME INHIBITOR IN THE TREATMENT OF FIBROTIC DISEASES,DE20021033929,Germany,2002-07-25T00:00:00Z,2002,2003-07-25T00:00:00Z,2004-02-05T00:00:00Z,2004,CHARITE-UNIVERSITAETSMEDIZIN,STANGL KARL    DE  | MEINERS SIKE    DE  | HOCHER BERTHOLD    DE,A61K03807 | A61K03806 | A61K03100 | A61K03808 | A61K03813,EP1524988A1 | AT392212T  | EP1524988B1 | AU2003255287A1 | US2005222043A1 | JP2006502998T  | DE50309647D1,6,6,Yes,Grant,Yes
310,WO2004012699,A2,MODIFIED RELEASE COMPOSITION COMPRISING COATED MICRO MATRIY PARTICLES CONTAINING THE HIGH SOLUBLE ACTIVE INGREDIENT AND A RELEASE CONTROLLING AGENT,IN2002MU00696 | IN2002MU00698,India,2002-08-05T00:00:00Z,2002,2003-08-01T00:00:00Z,2004-02-12T00:00:00Z,2004,TORRENT PHARMACEUTICALS LIMITED,VAYA NAVIN  IN  | KARAN RAJESH SINGH  IN  | NADKARNI SUNIL SADANAND  IN,A61K00900,US2006018934A1 | AU2003274680A8 | AU2003274680A1 | US2006018933A1 | US2004096501A1 | WO2004012699A3 | US7976871B2,5,3,Yes,Grant,Yes
311,WO2004012700,A2,NOVEL DOSAGE FORM,IN2002MU00697 | IN2002MU00699,India,2002-08-05T00:00:00Z,2002,2003-08-01T00:00:00Z,2004-02-12T00:00:00Z,2004,TORRENT PHARMACEUTICALS LIMITED,VAYA NAVIN    IN  | KARAN RAJESH SINGH    IN  | NADKARNI SUNIL SADANAND    IN,A61K031455 | A61K00924 | A61K00922 | A61K00920 | A61K0314025 | A61K031155 | A61K03153 | A61K03119 | A61K03122,US2006024365A1 | WO2004012700A3 | AU2003274681A8 | US2004096499A1 | AU2003274681A1 | BR200313424A  | US2006153916A1 | EP1528917A2 | US7985422B2,7,5,Yes,Grant,Yes
312,WO2004012732,A2,USE OF A PROTEASOME INHIBITOR IN THE TREATMENT OF ENDOTHELIAL DYSFUNCTION AND/OR IN A LOW-DOSE PROTEASOME INHIBITOR THERAPY,EP20020017234,European Patent Office,2002-07-31T00:00:00Z,2002,2003-07-31T00:00:00Z,2004-02-12T00:00:00Z,2004,CHARITE-UNIVERSITAETSMEDIZIN,STANGL VERENA    DE  | STANGL KARL    DE  | LORENZ MARIO    DE,C12N00999 | A61K04800 | A61K03800 | A61K0317088 | A61P04300 | A61K04500 | A61P00904 | C07D20746 | A61K0314015 | A61K03805 | A61P00910 | C07D26314 | A61K03806 | A61K03807,US2006199772A1 | JP2005537292T  | AU2003261652A1 | WO2004012732A3 | EP1524977A2,5,5,Yes,Application,No
313,WO2004013110,A1,"4,4-DISUBSTITUTED-3,4-DIHYDRO-2(1H)-QUINAZOLINIONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS",US20020400409P,United States,2002-08-01T00:00:00Z,2002,2003-07-31T00:00:00Z,2004-02-12T00:00:00Z,2004,BRISTOL MYERS SQUIBB PHARMA CO,CORBETT JEFFREY    US,A61P03118 | A61K04506 | A61K031517 | C07D23980,US2004063734A1 | AU2003263838A1,3,3,Yes,Application,No
314,WO2004021969,A2,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS,EP20020019997,European Patent Office,2002-09-05T00:00:00Z,2002,2003-09-05T00:00:00Z,2004-03-18T00:00:00Z,2004,MEDIVIR AB,ANTONOV DMITRY    SE  | SUND CHRISTIAN    SE  | LINDSTROEM STEFAN    SE  | SAHLBERG CHRISTER    SE,C07D21384 | C07D40912 | A61K03144 | C07D40514 | A61K031425 | A61K0314433 | A61K0315377 | A61K04500 | C07D21365 | A61K031426 | C07D33506 | C07D30793 | C07D33378 | A61P03118 | C07D21375 | C07D31194 | C07D40512 | C07D21373,AU2003260492A1 | EP1534276B1 | CA2501924A1 | US2006167055A1 | AT413174T  | ZA200501805A  | US7517992B2 | CN1694700A  | EP1534276A2 | KR20050033663A  | DE60324568D1 | WO2004021969A3 | JP2005538155T  | MXPA05002545A ,11,11,Yes,Grant,Yes
315,WO2004022066,A2,METHOD AND MEANS FOR THE TREATMENT OF VASCULAR AND CARDIAC DISEASES,EP20020090315,European Patent Office,2002-09-04T00:00:00Z,2002,2003-08-20T00:00:00Z,2004-03-18T00:00:00Z,2004,FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG,BORLAK JUERGEN  DE  | THUM THOMAS  DE,A61K031565,US2004110733A1 | EP1402924A1 | AT419037T  | WO2004022066A3 | EP1402924B1 | AU2003283227A8 | AU2003283227A1 | DE50213170D1 | US2006258632A1,6,5,Yes,Grant,Yes
316,WO2004024683,A2,COMPOSITIONS FOR INDUCING INCREASED LEVELS OF beta-CHEMOKINES AND METHODS OF USE THEREFOR,US20020410714P,United States,2002-09-13T00:00:00Z,2002,2003-09-12T00:00:00Z,2004-03-25T00:00:00Z,2004,UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE,REDFIELD ROBERT R    US  | AMOROSO ANTHONY    US  | DAVIS CHARLES E    US  | HEREDIA ALONSA    US,A61K031505 | A61K03136 | A61K03134 | A61K03819,CA2498934C  | AU2003266152A8 | EP1545539A2 | WO2004024683A3 | CA2498934A1 | EP1545539A4 | US2006099170A1 | AU2003266152A1,5,5,Yes,Grant,Yes
317,WO2004025267,A2,METHOD FOR TESTING DRUG SUSCEPTIBILITY OF HIV,US19990117136P,United States,1999-01-25T00:00:00Z,1999,2003-09-15T00:00:00Z,2004-03-25T00:00:00Z,2004,MUSC FOUNDATION FOR RESEARCH DEVELOPMENT,DONG JIAN-YUN    US  | HARKABI DAN    IL  | WEINGARTEN NEHEMIAH    IL,C12Q00170 | A61K04800 | A61K03921 | A01N06300 | C12Q00168 | C12N00700 | C12N00701 | C12Q00104,WO200043515A2 | US6900010B2 | ZA200207644A  | US2003064054A1 | BR200007690A  | CN1452661A  | CA2403916A1 | US6884576B2 | WO200181608A3 | EP1144626A2 | AU777953B2 | US6410013B1 | US2002168345A1 | AU2003273335A1 | JP2003530889T  | AU200028484A  | JP2002534979T  | EP1276907A2 | AU200155565A  | WO2004025267A3 | ZA200105521A  | US2004106136A1 | WO200043515A3 | EP1144626A3 | AU2003273335A8 | WO200181608A2 | CA2358929A1 | US6406911B1 | CN1451042A  | US6967076B2 | US2002132347A1 | BR200110221A ,25,9,Yes,Grant,Yes
318,WO2004029201,A2,PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV INFECTION,US20020412797P,United States,2002-09-24T00:00:00Z,2002,2003-09-23T00:00:00Z,2004-04-08T00:00:00Z,2004,"FRONTIER BIOTECHNOLOGIES CO., LTD.",XIE DONG    US  | JIANG HE    US,C07K01416 | A61K03800,ZA200503118A  | AP200503291D0 | US2005089840A1 | NZ539539A  | JP2006505536T  | EP1542718A2 | JP2010209097A  | AU2003275116A1 | EP1542718A4 | US7575750B2 | CA2500248A1 | CN1327897C  | EA007918B1 | BR200314657A  | US2011003735A1 | CN1668330A  | AU2010200823A1 | WO2004029201A3,14,11,Yes,Grant,Yes
319,WO2004032718,A2,CYTOKINE ANTAGONISTS FOR NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS,US19990256388,United States,1999-02-24T00:00:00Z,1999,2003-10-07T00:00:00Z,2004-04-22T00:00:00Z,2004,"TACT IP, LLC",TOBINICK EDWARD LEWIS    US,A61K03820 | A61K03817 | A61K00900 | C07K01624,US6471961B1 | US6177077B1 | US2001026801A1 | US6623736B2 | AU200126043A  | US2007196375A1 | EP1161260A1 | WO200050079A1 | US2001016195A1 | JP2002537356T  | US2003113318A1 | CA2364130A1 | US6982089B2 | US6015557A  | AU200026161A  | US6419944B2 | US2010150933A1 | US6423321B2 | US2001004456A1 | US6428787B1 | US6419934B1 | US7214658B2 | US6379666B1 | EP1161260A4 | NZ514247A  | US7629311B2 | US2003007972A1 | WO200149321A1 | US6537549B2 | US2003185826A1 | US2010129359A1 | US2002131954A1 | US2003049256A1 | US2006051381A1 | AU2003287045A1 | US2002131955A1 | US2006009450A1 | AU758523B2,30,7,Yes,Grant,Yes
320,WO2004041118,A2,THERAPEUTIC COMPOSITIONS FOR DRUG DELIVERY TO AND THROUGH COVERING EPITHELIA,US20020382644P,United States,2002-05-23T00:00:00Z,2002,2003-10-31T00:00:00Z,2004-05-21T00:00:00Z,2004,"UMD, INC",PAULETTI GIOVANNI M      | DESAI KISHORKUMAR J      | ROWETON SUSAN L      | HARRISON DONALD C      | SANDERS LYNDA M,A61K031337 | A61K04506 | A61K00912 | A61K00902 | A61K03828 | A61K03820 | A61K0315415 | A61K031616 | A61K00900 | A61K03811 | A61K031277 | A61K00970 | A61K031407 | A61K031663 | A61K03827 | A61K031405 | A61K031192 | A61K031196,NZ540318A  | WO2003099264A1 | MXPA05004578A  | NO20051964D0 | HK1081844A1 | CN1662228A  | AU2003233653A1 | MXPA04011584A  | BR200311530A  | WO2004041118A3 | CN100522245C  | CN1720024A  | CA2486909A1 | NO20045140A  | EP1509209A1 | CA2504283A1 | AU2003233653B2 | JP2006512409T  | WO2004041118A8 | NO20051964A  | EP1556001A2 | JP2005531570T  | US2004151774A1 | BR200315194A  | US2003219472A1 | AU2003286796A1 | US7939098B2,22,12,Yes,Grant,Yes
321,WO2004041247,A2,GEODATE DELIVERY VEHICLES,US20020422989P,United States,2002-11-01T00:00:00Z,2002,2003-11-03T00:00:00Z,2004-05-21T00:00:00Z,2004,"BIODELIVERY SCIENCES INTERNATIONAL, INC",MANNINO RAPHAEL J    US  | KRAUSE SARA L    US  | GOULD-FOGERITE SUSAN    US  | DELMARRE DAVID    US  | LU RUYING    US,A61K009127 | A61K009107 | A23L00130 | A61K00916,WO2004041247A3 | US2004146551A1 | JP2006514103T  | CA2504329A1 | AU2003296923B2 | EP1562557A2 | AU2003296923A1,6,6,Yes,Application,No
322,WO2004041818,A1,ANTI-INFECTIVE AGENTS,US20020285714,United States,2002-11-01T00:00:00Z,2002,2003-10-31T00:00:00Z,2004-05-21T00:00:00Z,2004,ABBOTT LAB,PRATT JOHN K      | BETEBENNER DAVID A      | DONNER PAMELA L      | GREEN BRIAN E      | KEMPF DALE J      | MCDANIEL KEITH F      | MARING CLARENCE J      | STOLL VINCENT S      | ZHANG RONG,C07D49504 | C07D21522 | C07D21369 | A61P03100 | C07D47104 | C07D40104 | C07D51900 | C07D51304 | C07D41704 | C07D41714,MXPA05004670A  | BR200315897A  | EP1560827A1 | ZA200504413A  | US2005075331A1 | PL376823A1 | KR20050065670A  | US2004087577A1 | JP2006509042T  | ES2357230T3 | AU2003291670A1 | US2004162285A1 | US2004097492A1 | CA2504385A1 | AT493408T  | EP1560827B1 | CN100376572C  | DE60335564D1 | CN1735612A ,20,17,Yes,Grant,Yes
323,WO2004045519,A2,INDUCTION OF APOPTOSIS BY HIV-1 INFECTED MONOCYTIC CELLS,US20020426103P,United States,2002-11-14T00:00:00Z,2002,2003-11-13T00:00:00Z,2004-06-03T00:00:00Z,2004,MOUNT SINAI SCHOOL OF MEDICINE,SPERBER KIRK    US  | GELMAN IRWIN H,C12Q00168 | C07K01447 | G01N033569 | A61K03800,EP1572104A3 | AU2003290876A8 | US2004197770A1 | AU2003290876A1 | WO2004045519A3 | EP1572104A4 | EP1572104A2,4,4,Yes,Application,No
324,WO2004046309,A2,METHODS FOR INHIBITING VIRAL REPLICATION IN VIVO,US20020427497P,United States,2002-11-18T00:00:00Z,2002,2003-09-29T00:00:00Z,2004-06-03T00:00:00Z,2004,POLARIS GROUP,CLARK MIKE A    US,A61K03845 | A61K04506 | A61K03850 | A61K04748 | C12Q00118,CN1809378A  | AU2003282883A1 | EP1599217A4 | AU2003282883B2 | CN1809378B  | WO2004046309A3 | HK1091126A1 | US2007172469A1 | CA2506244A1 | JP2006515281T  | US2004131604A1 | US7204980B2 | EP1599217A2,9,8,Yes,Grant,Yes
325,WO2004052296,A2,DIOXOLANE THYMINE AND COMBINATIONS FOR USE AGAINST 3TC/ AZT RESISTANT STRAINS OF HIV,US20020431812P,United States,2002-12-09T00:00:00Z,2002,2003-12-08T00:00:00Z,2004-06-24T00:00:00Z,2004,"THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC | EMORY UNIVERSITY",CHU CHUNG K    US  | SCHINAZI RAYMOND F    US,A61K03165 | A61K03152 | A61K031505 | A61K03170 | A61K04506,EP1569659A4 | CA2502625A1 | MXPA05003637A  | AU2003296360A8 | AU2003296360A1 | CN100406017C  | BR200317113A  | US7615542B2 | WO2004052296A3 | CN1723025A  | US2005209196A1 | EP1569659A2,8,8,Yes,Grant,Yes
326,WO2004052862,A1,NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF,JP20020357446,Japan,2002-12-10T00:00:00Z,2002,2003-12-09T00:00:00Z,2004-06-24T00:00:00Z,2004,ONO PHARMACEUTICAL CO.,HABASHITA HIROMU    JP  | KOKUBO MASAYA    JP  | SHIBAYAMA SHIRO    JP  | TADA HIDEAKI    JP  | TANIHIRO TATSUYA    JP,A61P03700 | C07D40512 | A61P02500 | A61P00900 | C07D49310 | C07D40314 | C07D40114 | C07D22122 | C07D23948 | A61P00300 | C07D40112 | A61P03500 | A61P02900 | A61P04300 | C07D23995 | C07D40312 | A61P03708 | A61P03100 | A61P03118,US2010221259A1 | JP2011001368A  | EP1571146A4 | US2007167459A1 | AU2003288994A1 | US7759336B2 | EP1571146A1,7,5,Yes,Grant,Yes
327,WO2004054581,A2,CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS,US20020433552P,United States,2002-12-13T00:00:00Z,2002,2003-12-12T00:00:00Z,2004-07-01T00:00:00Z,2004,GSK LLC,DUAN MAOSHENG    US  | KAZMIERSKI WIESLAW MIECZYSLAW    US  | AQUINO CHRISTOPHER JOSEPH    US,C07D21166 | C07D20712 | A61P03118 | C07D45104 | C07D40104 | C07D40112 | A61P03104 | C07D41304 | C07D21158 | C07D21126 | C07D26120 | C07D40904 | C07D47110 | C07D23508 | C07D21128 | C07D21134,US7589207B2 | AU2003297048A8 | US2006122166A1 | ES2311755T3 | EP1569647B1 | DE60323133D1 | AT405269T  | WO2004054581A3 | AU2003297048A1 | JP2006514646T  | EP1569647A2,7,7,Yes,Grant,Yes
328,WO2004054586,A1,"USE OF A COMBINATION CONTAINING A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) WITH AN INHIBITOR OF CYTOCHROME P450, SUCH AS PROTEASE INHIBITORS",US20020433690P,United States,2002-12-16T00:00:00Z,2002,2003-12-15T00:00:00Z,2004-07-01T00:00:00Z,2004,BOEHRINGER INGELHEIM INTERNATIONAL GMBH,CORDINGLEY MICHAEL GRAHAM    CA,A61P03118 | A61K03155 | A61K031427 | A61K031353 | A61K03813 | A61K031551 | A61K031554 | A61K0317048,RSP20050461A  | BR200317095A  | UA81003C2 | KR20050085681A  | NZ541187A  | US2004152625A1 | ZA200502947A  | HR20050557A2 | ECSP055854A  | IL169099D0 | MXPA05005773A  | PL376900A1 | NO20053455A  | JP2006511538T  | AU2003296647A1 | CA2510143A1 | EP1575595A1 | CN1726041A  | US2008096832A1,19,18,Yes,Application,No
329,WO2004054974,A2,CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS,US20020433634P,United States,2002-12-13T00:00:00Z,2002,2003-12-12T00:00:00Z,2004-07-01T00:00:00Z,2004,GSK LLC,KAZMIERSKI WIESLAW MIECZYSLAW    US  | AQUINO CHRISTOPHER JOSEPH    US  | BIFULCO NEIL    US  | BOROS ERIC EUGENE    US  | CHAUDER BRIAN ANDREW    US  | CHONG PEK YOKE    US  | DUAN MAOSHENG    US  | DEANDA JR FELIX    US  | KOBLE CECILIA SUAREZ    US  | MCLEAN ED WILLIAMS    US  | PECKHAM JENNIFER POOLE    US  | PERKINS ANGILIQUE C    US  | THOMPSON JAMES BENJAMIN    US  | VANDERWALL DANA    US,C07D45104 | A61P03118,NO20052739A  | MXPA05006354A  | WO2004054974A3 | AU2003300902A1 | EP1569646A2 | KR20050087832A  | CO5580771A2 | RU2005118407A  | ZA200505600A  | MA27647A1 | CN1744899A  | BR200317230A  | JP2006511554T  | US7645771B2 | CA2509711A1 | NO20052739D0 | US2006229336A1,15,15,Yes,Grant,Yes
330,WO2004055010,A2,CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS,US20020433626P,United States,2002-12-13T00:00:00Z,2002,2003-12-12T00:00:00Z,2004-07-01T00:00:00Z,2004,GSK LLC,PECKHAM JENNIFER POOLE    US  | AQUINO CHRISTOPHER JOSEPH    US  | KAZMIERSKI WIESLAW MIECZYSLAW    US,C07D41304 | C07D21158 | C07D21128 | C07D21114 | C07D40914 | C07D40104 | C07D47108 | C07D41314 | C07D40112 | C07D47110 | C07D40512,US7569579B2 | US2006052408A1 | WO2004055010A3 | DE60318891D1 | EP1569934B1 | AU2003296993A1 | ES2298627T3 | AU2003296993A8 | DE60318891T2 | JP2006514950T  | AT384724T  | EP1569934A2,8,8,Yes,Grant,Yes
331,WO2004055011,A1,HETEROCYCLIC COMPOUNDS AS CCR5 ANTAGONISTS,US20020433410P,United States,2002-12-13T00:00:00Z,2002,2003-12-12T00:00:00Z,2004-07-01T00:00:00Z,2004,GSK LLC,AQUINO CHRISTOPHER JOSEPH    US  | CHONG PEK YONG    US  | DUAN MAOSHENG    US  | KAZMIERSKI WIESLAW MIECZYSLAW    US,C07D41314 | C07D41306 | A61P03118 | C07D41714 | C07D45104 | C07D47110,US2009053172A1 | DE60324014D1 | AU2003300911A1 | US2006052595A1 | ES2312856T3 | EP1569931B1 | JP2006511555T  | AT410426T  | US7452992B2 | EP1569931A1,8,7,Yes,Grant,Yes
332,WO2004055012,A1,INDANE COMPOUNDS AS CCR5 ANTAGONISTS,US20020433378P,United States,2002-12-13T00:00:00Z,2002,2003-12-12T00:00:00Z,2004-07-01T00:00:00Z,2004,GSK LLC,YOUNGMAN MICHAEL    US  | KAZMIERSKI WIESLAW MIECZYSLAW    US  | YANG HANBIAO    US  | AQUINO CHRISTOPHER JOSEPH    US,C07D41304 | C07D21158 | A61P03118 | C07D45104 | C07D47110,US2009187021A1 | AU2003300952A1 | US2006047116A1 | US7531661B2 | EP1581530A1 | US7589204B2 | JP2006512339T ,6,5,Yes,Grant,Yes
333,WO2004055016,A1,PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS,US20020433372P,United States,2002-12-13T00:00:00Z,2002,2003-12-12T00:00:00Z,2004-07-01T00:00:00Z,2004,GSK LLC,YANG HANBIAO    US  | KAZMIERSKI WIESLAW MIECZYSLAW    US  | AQUINO CHRISTOPHER JOSEPH    US,C07D47110 | A61P03100 | A61P02900,EP1569933B1 | DE60322423D1 | US2006058284A1 | ES2309400T3 | EP1569933A1 | AT402176T  | AU2003296992A1 | US7271172B2 | JP2006511552T ,7,7,Yes,Grant,Yes
334,WO2004055163,A2,"SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO[1,2-A] QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS",US20020432608P,United States,2002-12-12T00:00:00Z,2002,2003-12-12T00:00:00Z,2004-07-01T00:00:00Z,2004,CYTOVIA INC,CAI SUI XIONG      | DREWE JOHN A      | JIANG SUNGCHUN      | KASIBHATLA SHAILAJA      | KUEMMERLE JARED DANIEL      | SIRISOMA NILANTHA SUDATH      | ZHANG HAN-ZHONG,A61K0314985 | A61K031496 | A61K0314745 | C07D47104 | C07D47114 | C07D48704,AU2003300883A1 | WO2004055163A3 | US7135480B2 | EP1578424A2 | AU2003300883A8 | US2005014759A1 | EP1578424A4,4,4,Yes,Grant,Yes
335,WO2004056181,A1,"ORGAN PRECONDITIONING, ARREST, PROTECTION, PRESERVATION AND RECOVERY (2)",AU20030291846,Australia,2002-12-23T00:00:00Z,2002,2003-12-22T00:00:00Z,2004-07-08T00:00:00Z,2004,HIBERNATION THERAPEUTICS LIMITED,DOBSON GEOFFREY PHILLIP    AU,A61K0314422 | A61K031167 | A01N00102 | A61K0317076 | A61K04506 | A61P04100,AU2003903127D0 | GB200711805D0 | GB2436255B  | GB2412067A  | AU2003291847A1 | AU2003291847B2 | GB200515048D0 | CA2551169A1 | US2009325878A1 | AU2003291846A1 | GB2412067B  | WO2004056180A1 | AU2003900296D0 | US2006034941A1 | GB2436255A ,9,5,Yes,Grant,Yes
336,WO2004056770,A2,PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS,US20020434306P,United States,2002-12-18T00:00:00Z,2002,2003-12-17T00:00:00Z,2004-07-08T00:00:00Z,2004,SCHERING CORP,MILLER MICHAEL W      | SCOTT JACK D,C07D40114 | A61P03700 | A61P03118,AU2003297400B2 | US2008095740A1 | US2004132711A1 | US7307081B2 | JP4589728B2 | AR042481A1 | JP2006515851T  | WO2004056770A3 | AU2003297400A1 | CN100591678C  | EP1581494A2 | PE07692004A1 | NZ540452A  | CN1729186A  | KR20050085700A  | ZA200504772A  | CA2510027A1 | CN101768152A  | CL26372003A1 | MXPA05006580A ,16,14,Yes,Grant,Yes
337,WO2004058253,A1,"3,5-DISUBSTITUTED-[1,2,4]-OXADIAZOLES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF",US20020433953P,United States,2002-12-18T00:00:00Z,2002,2003-12-18T00:00:00Z,2004-07-15T00:00:00Z,2004,CYTOVIA INC,CAI SUI XIONG      | ZHANG HAN-ZHONG      | KUEMMERLE JARED D      | ZHANG HONG      | KEMNITZER WILLIAM E,A61K0314439 | A61K0314245,EP1581213A4 | US2004127521A1 | JP2006516250T  | US7144876B2 | EP1581213A1 | US2007112003A1 | CA2509224A1 | AU2003303373A1 | US7317029B2 | AU2003303373B8 | AU2003303373B2 | CN100364531C  | CN1756547A ,8,7,Yes,Grant,Yes
338,WO2004060370,A1,TREATMENT OF HIV INFECTION THROUGH COMBINED ADMINISTRATION OF TIPRANAVIR AND CAPRAVIRINE,US20020433679P,United States,2002-12-16T00:00:00Z,2002,2003-11-24T00:00:00Z,2004-07-22T00:00:00Z,2004,BOEHRINGER INGELHEIM INTERNATIONAL GMBH,DREES ULRICH WALTER      | MAYERS DOUGLAS LYTLE      | MCCALLISTER SCOTT,A61P03118 | A61K04506 | A61K0317056,EP1575583A1 | CA2509731A1 | AU2003295940A1 | JP2006514045T  | US2005020517A1,6,6,Yes,Application,No
339,WO2004064846,A1,COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY,US20030440308P | US20030440246P,United States,2003-01-14T00:00:00Z,2003,2004-01-13T00:00:00Z,2004-08-05T00:00:00Z,2004,GILEAD SCIENCES INC,DAHL TERRENCE C    US  | MENNING MARK M    US  | OLIYAI REZA    US,A61K0317076 | A61K031675 | A61K031513 | A61K04506,DK1583542T3 | KR100860136B1 | AU2004206821C1 | US2009143314A1 | EP1923063A2 | CA2512319A1 | NO20053817D0 | EP1585527A1 | CN1738628A  | SI1583542T1 | US2004224916A1 | AP2089A  | US2009036408A1 | HK1079122A1 | US2006246130A1 | AU2004206821A1 | AR040805A1 | IS7977A  | WO2004064845A1 | HR20050619A2 | US2006234982A1 | PL378368A1 | AU2004206827A1 | AT398455T  | AU2009200414A1 | DE602004014470D1 | CA2512475C  | EP1583542B1 | JP2010120957A  | ES2308136T3 | MXPA05007016A  | CA2512475A1 | JP2006515624T  | EP1583542B9 | JP2006516570T  | NZ540728A  | KR20090053867A  | AR043332A1 | AP200503348D0 | EP1923063A3 | BRPI0406760A  | IL169243A  | UA81797C2 | NO20053817A  | EP1583542A1 | KR20050092755A  | KR20080032014A  | US2004224917A1 | WO2004064845A8 | AU2004206821B2 | ZA200505852A ,42,26,Yes,Grant,Yes
340,WO2004065563,A2,NDR KINASE MODULATORS,US20030441898P,United States,2003-01-22T00:00:00Z,2003,2004-01-22T00:00:00Z,2004-08-05T00:00:00Z,2004,"DANA-FARBER CANCER INSTITUTE, INC.",DEVROE ERIC   US  | ENGELMAN ALAN   US  | SILVER PAMELA   US,C12Q00168,US2007031822A1 | WO2004065563A3,2,2,Yes,Application,No
341,WO2004074218,A2,INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME,US20030448427P,United States,2003-02-14T00:00:00Z,2003,2004-02-13T00:00:00Z,2004-09-02T00:00:00Z,2004,AVANIR PHARMACEUTICALS,SIRCAR JAGADISH C    US  | KUMAR SUNIL K C    US  | YING WENBIN    US,C07D40512 | A61P02900 | A61K031496 | A61K0314709 | C07D40112 | A61P03500 | C07D41312 | C07D40912 | C07D21554 | C07D41712 | C07D40104,US2007270395A1 | CL18132008A1 | BR200407424A  | US2007054923A1 | US7312220B2 | CA2514862A1 | WO2004074218A3 | US2007054922A1 | EP1594501A2 | BRPI0407424A  | JP2006517977T  | US2007054920A1 | PL378113A1 | HR20050733A2 | NO20054218D0 | US2007179132A1 | US7312221B2 | RU2005128190A  | US2007238736A9 | AR043190A1 | KR20050106430A  | AU2004213408A1 | US2004204586A1 | ZA200507170A  | US7173036B2 | UY28187A1 | NO20054218A  | CN1750823A  | MXJL05000031A  | ECSP056020A  | US7235546B2 | CO5640090A2 | US2007054898A1 | PE02742005A1 | EP1594501A4,27,21,Yes,Grant,Yes
342,WO2004074257,A1,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS,US20030447974P,United States,2003-02-18T00:00:00Z,2003,2004-02-17T00:00:00Z,2004-09-02T00:00:00Z,2004,F. HOFFMANN-LA ROCHE AG,DUNN JAMES PATRICK    US  | HOGG JOAN HEATHER    US  | MIRZADEGAN TARANEH    US  | SWALLOW STEVEN    US,C07D40306 | A61K031454 | A61K0314192 | A61K0314155 | C07D40106 | A61K0315377 | C07D41302 | C07D40906 | A61P03118 | C07D41304 | C07D23120,AT370124T  | CL2702004A1 | PL378556A1 | JP4608480B2 | AU2004213134A1 | RU2305680C2 | CN1751028A  | CN100389109C  | CA2515151C  | DE602004008227T2 | MXPA05008748A  | DE602004008227D1 | RU2005128832A  | JP2006515339T  | EP1597235A1 | ES2291854T3 | US2004192666A1 | BRPI0407591A  | CA2515151A1 | US7241794B2 | AR043195A1 | KR100776093B1 | EP1597235B1 | KR20050105471A ,17,17,Yes,Grant,Yes
343,WO2004074270,A2,"INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME",US20030449088P,United States,2003-02-21T00:00:00Z,2003,2004-02-09T00:00:00Z,2004-09-02T00:00:00Z,2004,PFIZER,BORCHARDT ALLEN JOHN    US  | GONZALEZ JAVIER    US  | LI HUI    US  | LINTON MARIA ANGELICA    US  | TATLOCK JOHN HOWARD    US,C07D51304 | C07D49504 | C07D41310 | C07D26358 | C07D41710 | C07D40906 | A61K031496 | A61K031452 | C07D40910 | C07D47336 | C07D40712 | C07D41712 | C07D41706 | C07D47104 | C07D41306 | C07D40706 | C07D41702 | C07D40506 | C07D48704 | C07D40510 | C07D41312 | A61K0314025 | C07D41314 | C07D40514 | C07D47330 | A61P03114 | A61K031519 | C07D30932 | C07D40512 | C07D40710 | C07D28506 | A61K0315377 | C07D41302 | A61K031541,US2004224960A1 | US7473790B2 | JP3940430B2 | BR200407699A  | US2005176701A1 | UY28192A1 | MXPA05007133A  | NL1025544C2 | PE02892005A1 | WO2004074270B1 | AR044749A1 | US7148226B2 | AU2004213247A1 | BRPI0407699A  | EP1597246A2 | IS7896A  | NL1025544A1 | WO2004074270A3 | US2006189681A1 | JP2006518370T  | CA2516235A1 | PA8596001A1,17,14,Yes,Grant,Yes
344,WO2004076687,A1,METHOD FOR DETERMINING ANTIVIRAL ACTIVITY OF AHPS RELATED COMPOUNDS,EP20030075596,European Patent Office,2003-02-27T00:00:00Z,2003,2004-02-26T00:00:00Z,2004-09-10T00:00:00Z,2004,UNIVERSITEIT UTRECHT HOLDING B.V,NOTTET JOHANNES SERVATIUS LEON    NL,C12Q00125,EP1452605A1,2,2,Yes,Application,No
345,WO2004084876,A2,USE OF COMPOUNDS FOR THE PREVENTION OF DRUG-INDUCED CELL TOXICITY,DK20030000459,Denmark,2003-03-26T00:00:00Z,2003,2004-03-25T00:00:00Z,2004-10-07T00:00:00Z,2004,RECEPTICON APS,NYKJAER ANDERS    DK,A61K03153 | A61K031195 | A61K03116 | A61K031132 | A61K031445 | A61K031198 | A61K04506 | A61K0317008 | A61K0314192 | A61P03900 | A61K0314196,JP2006520761T  | US2007004727A1 | CN1794982A  | EP1610773A2 | ZA200508482A  | MXPA05010143A  | WO2004084876A3 | CA2560522A1 | CN100441175C  | BRPI0408699A  | AU2004224788A1,10,10,Yes,Grant,Yes
346,WO2004084892,A1,USE OF RITONAVIR FOR THE TREATMENT OF UNCONJUGATED HYPERBILIRUBINEMIA,US20030395772,United States,2003-03-24T00:00:00Z,2003,2004-03-19T00:00:00Z,2004-10-07T00:00:00Z,2004,ABBOTT LAB,KEMPF DALE J      | BERTZ RICHARD J      | WARING JEFFREY F,A61P00116 | A61K03821 | A61K031426,MXPA05010216A  | JP2007525432T  | US2004242509A1 | US2008138315A1 | EP1608366A1 | US2004192624A1 | US7320961B2 | US7547678B2 | CA2517831A1,8,6,Yes,Grant,Yes
347,WO2004085406,A1,BENZYL-PYRIDAZINONS AS REVERSE TRANSCRIPTASE INHIBITORS,US20030457144P,United States,2003-03-24T00:00:00Z,2003,2004-03-17T00:00:00Z,2004-10-07T00:00:00Z,2004,F. HOFFMANN-LA ROCHE AG,DUNN JAMES PATRICK      | DYMOCK BRIAN WILLIAM      | MIRZADEGAN TARANEH      | SJOGREN ERIC BRIAN      | SWALLOW STEVEN      | SWEENEY ZACHARY KEVIN,C07D23722 | C07D23714 | A61P03118 | C07D40112 | C07D40506 | C07D40906,MXPA05010081A  | AR043674A1 | EP1608629A1 | RU2005132630A  | KR20050119652A  | JP2006521310T  | CN100469769C  | JP4485520B2 | AU2004224191A1 | US7189718B2 | US2004198736A1 | RU2344128C2 | CA2518823A1 | CN1764649A  | BRPI0408704A ,12,12,Yes,Grant,Yes
348,WO2004085411,A1,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS I FOR TREATING HIV MEDIATED DISEASES,US20030457130P,United States,2003-03-24T00:00:00Z,2003,2004-03-22T00:00:00Z,2004-10-07T00:00:00Z,2004,F. HOFFMANN-LA ROCHE AG,DUNN JAMES PATRICK      | SWALLOW STEVEN      | SWEENEY ZACHARY KEVIN,C07D24912 | A61P03118 | C07D271113 | C07D28513 | C07D27110 | C07D28512,US7208509B2 | EP1608633A1 | CN1759104A  | BRPI0408767A  | RU2005132632A  | US2004192704A1 | CN100588650C  | US7348345B2 | NO20054264D0 | MXPA05010210A  | CO5601029A2 | CL5902004A1 | AR043673A1 | US2007179157A1 | RU2342367C2 | NO20054264A  | HR20050830A2 | CA2518437A1 | KR20050115294A  | JP2006521319T  | AU2004224153A1 | AU2004224153B2 | NZ541829A ,19,17,Yes,Grant,Yes
349,WO2004087139,A1,ANTIVIRAL COMBINATION OF TIPRANAVIR AND A FURTHER ANTIRETROVIRAL COMPOUND,EP20030007001,European Patent Office,2003-03-27T00:00:00Z,2003,2004-03-22T00:00:00Z,2004-10-14T00:00:00Z,2004,BOEHRINGER INGELHEIM INTERNATIONAL GMBH,KLAES HEINZ-GERD    DE  | MAYERS DOUGLAS LYTL    US  | VALDEZ HERNAN    US  | KOUNDOURAKIS ELENA    US,A61P03112 | A61K0317068 | A61K0314433 | A61K031427 | A61K04506 | A61K0317072 | A61P03118 | A61K0317076 | A61K031708,US2004235779A1 | EP1610781A1 | US7244716B2,3,3,Yes,Grant,Yes
350,WO2004087140,A1,ANTIVIRAL COMBINATION OF A DIPYRIDODIAZEPINONE AND A FURTHER ANTIRETROVIRAL COMPOUND,EP20030007071,European Patent Office,2003-03-27T00:00:00Z,2003,2004-03-24T00:00:00Z,2004-10-14T00:00:00Z,2004,BOEHRINGER INGELHEIM INTERNATIONAL GMBH,KLAES HEINZ-GERD    DE  | MAYERS DOUGLAS LYTL    US  | VALDEZ HERNAN    US  | KOUNDOURAKIS ELENA    US,A61P03112 | A61K0317068 | A61K031551 | A61K031427 | A61K04506 | A61K0317072 | A61P03118 | A61K0317076 | A61K031708,EP1610782A1 | US2008139495A1 | US2004235781A1,4,3,Yes,Application,No
351,WO2004091578,A2,"NOVEL ENCOCHLEATION METHODS, COCHLEATES AND METHODS OF USE",US20030461483P,United States,2003-04-09T00:00:00Z,2003,2004-04-09T00:00:00Z,2004-10-28T00:00:00Z,2004,"BIODELIVERY SCIENCES INTERNATIONAL, INC",MANNINO RAPHAEL J    US  | GOULD-FOGERITE SUSAN    US  | KRAUSE-ELSMORE SARA L    US  | DELMARRE DAVID    US  | LU RUYING    US,A61K0317048 | A61K03100 | A61K009127,WO2004091578A3 | WO2004091572A2 | US2008242625A1 | WO2005110361A2 | EP1624858A2 | US2007237814A1 | US2005013855A1 | EP1631669A2 | WO2004091572A3 | EP1737427A2 | AU2005244262A1 | WO2005110361A3 | US2005013854A1 | JP2007532573T  | WO2004091578A8 | CA2562499A1 | US2008009457A1 | JP2010508809T ,16,6,Yes,Application,No
352,WO2004092162,A1,"INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE",US20020371846P,United States,2002-04-11T00:00:00Z,2002,2004-04-09T00:00:00Z,2004-10-28T00:00:00Z,2004,VERTEX PHARMA,FARMER LUC J    US  | PERNI ROBERT P    US  | BHISETTI GOVINDA RAO    US  | WILSON KEITH P    US,A61K031425 | A61K0314155 | A61K031401 | A61K0314965 | C07D40312 | C07D41712,MXPA04009938A  | WO2004092161A1 | ZA200408243A  | JP2010241821A  | SG159385A1 | CN1795188A  | US2009022688A1 | US7365092B2 | EP1497282A2 | PL373399A1 | AR043859A1 | HK1090644A1 | CN100381440C  | CN100453553C  | RU2004133044A  | AR044513A1 | US2004018986A1 | JP2009185081A  | AU2004230946A1 | JP2005535574T  | CA2481369A1 | WO2003087092A2 | US2010173851A1 | US2008125376A1 | US2007292933A1 | NZ561851A  | CN101245097A  | US2005090450A1 | CN1649864A  | AU2003223602A1 | US7273885B2 | WO2003087092A3 | NZ575692A  | IL164455D0 | US7906550B2 | EP1613620A1 | AU2009233604A1 | CA2521678A1 | JP2006526011T  | US2005080017A1 | NO20044889A  | EP1636208A1 | AU2003223602B8 | HK1081196A1 | AU2003223602B2,40,17,Yes,Grant,Yes
353,WO2004098531,A2,INCREASED TRANSDUCTION USING ABC TRANSPORTER SUBSTRATES AND/OR INHIBITORS,US20030468207P,United States,2003-05-05T00:00:00Z,2003,2004-05-04T00:00:00Z,2004-11-18T00:00:00Z,2004,VIRXSYS CORPORATION,DAVIS BRIAN    US  | HUMEAU LAURENT    US  | DROPULIC BORO    US,C12Q00168 | A61K04800 | A61K0317056 | A61K031554 | C12N01587 | C12N00510 | C12Q00170 | C12N01563 | C12N015867,WO2004098531A3 | US2005123514A1 | EP1624899A4 | DE602004030105D1 | EP1624899A2 | AT488252T ,4,4,Yes,Grant,Yes
354,WO2004101512,A2,NAPHTHYRIDINE INTEGRASE INHIBITORS,US20030470059P,United States,2003-05-13T00:00:00Z,2003,2004-05-12T00:00:00Z,2004-11-25T00:00:00Z,2004,GSK LLC,JOHNS BRIAN A    US,C07D40314 | A61K031497 | A61K031496 | A61K0314375 | C07D40114 | A61K031506 | C07D41714 | C07D41314 | A61K0315377 | C07D47104 | A61K031541,US2007142365A1 | EP1622615A4 | WO2004101512A3 | US7812016B2 | US2011003794A1 | JP2006528694T  | EP1622615A2,5,4,Yes,Grant,Yes
355,WO2004104005,A2,IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES,US19990118295P | US19990118235P | US19990118282P,United States,1999-02-02T00:00:00Z,1999,2004-05-21T00:00:00Z,2004-12-02T00:00:00Z,2004,4 AZA BIOSCIENCE NV,WAER MARK JOZEF ALBERT    BE  | HERDEWIJN PIET ANDRE MAURITS M    BE  | PFLEIDERER WOLFGANG EUGEN    DE,A61K031535 | A61K03152 | A61K031505 | A61K03157 | A61K03813 | C07D47502,US6946465B2 | CA2526651A1 | AU780284B2 | WO200045800A3 | EP1187615A2 | US2007043000A1 | JP2006528224T  | CA2361561A1 | WO2004104005A3 | AU2004240760A1 | AU200024418A  | US2003236255A1 | EP1636232A2 | EP1479682A1 | JP2002536320T  | WO200045800A2,14,6,Yes,Grant,Yes
356,WO2004110401,A2,INHALATION ANTIVIRAL PATCH,US20010333109P,United States,2001-11-20T00:00:00Z,2001,2004-06-10T00:00:00Z,2004-12-23T00:00:00Z,2004,LECTEC CORPORATION,ROLF DAVID    US,A61K03600 | A61K00970,WO2004110401A3 | US2004071757A1,2,2,Yes,Application,No
357,WO2004112724,A2,COMPOSITIONS FOR AND METHODS FOR TREATING HIV,US20030480393P | US20030480500P,United States,2003-06-20T00:00:00Z,2003,2004-06-21T00:00:00Z,2004-12-29T00:00:00Z,2004,"VGX PHARMACEUTICALS, INC",KIM JONG JOSEPH    US,A61K00970 | A61K00900 | A61F01300 | A61K03821,JP2007524616T  | CA2529852A1 | WO2004112724A3 | US2007259014A1 | KR20060039867A  | EP1643946A2 | AU2004249295A1 | CN1838930A ,8,8,Yes,Application,No
358,WO2004112747,A2,METHOD FOR DELIVERING DRUGS TO THE BRAIN,US20030482096P,United States,2003-06-24T00:00:00Z,2003,2004-06-15T00:00:00Z,2004-12-29T00:00:00Z,2004,BAXTER INTERNATIONAL INC.,RABINOW BARRETT E    US  | GENDELMAN HOWARD E    US  | KIPP JAMES E    US,A61K04748 | A61K00951 | A61K00900,ZA200603062A  | WO2007124224A3 | WO2007124224A2 | EP1663158A2 | US2006280430A1 | AU2004249172A1 | NO20061537A  | CA2540695A1 | US2005048002A1 | WO2004112747A3,9,6,Yes,Application,No
359,WO2005000405,A2,P38 KINASE INHIBITOR COMPOSITIONS AND METHODS OF USING THE SAME,US20030476397P,United States,2003-06-06T00:00:00Z,2003,2004-06-04T00:00:00Z,2005-01-06T00:00:00Z,2005,THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA,WEINER DAVID B    US  | MUTHUMANI KARUPPIAH    US,A61K031415 | A01N04350 | A01N04340 | A61K03144 | A61P00100,WO2005000405A3 | JP2006527197T  | US2006241150A1 | CA2535980A1 | AU2004251681A1 | EP1631145A2 | EP1631145A4,6,6,Yes,Application,No
360,WO2005004873,A1,USE OF ANTIVIRALS AGAINST INFLAMMATORY BOWEL DISEASES,US20030618176,United States,2003-07-10T00:00:00Z,2003,2004-07-08T00:00:00Z,2005-01-20T00:00:00Z,2005,ICN PHARMACEUTICALS SWITZERLAND LTD,BRANTL VICTOR    DE,A61K031522 | A61K03152 | A61K0314745 | A61K03156 | A61K04506 | A61P00100,US2005009848A1,2,2,Yes,Application,No
361,WO2005004881,A1,USE OF RIBOFURANOSE DERIVATIVES AGAINST INFLAMMATORY BOWEL DISEASES,US20030618148,United States,2003-07-10T00:00:00Z,2003,2004-07-08T00:00:00Z,2005-01-20T00:00:00Z,2005,ICN PHARMACEUTICALS SWITZERLAND LTD,BRANTL VICTOR   DE,A61K0317056 | A61P00100,US2005009766A1 | US2005153908A1 | US2005153907A1 | US6930093B2 | US2005009768A1 | US2005009767A1,6,2,Yes,Grant,Yes
362,WO2005007070,A2,STABLE PHARMACEUTICAL COMPOSITION FOR THE ADMINISTRATION OF HIV PROTEASE INHIBITORS AND PROCESS FOR PREPARING A CONCENTRATE PHARMACEUTICAL COMPOSITION FOR THE ADMINISTRATION OF HIV PROTEASE INHIBITORS,BR20030002523,Brazil,2003-07-23T00:00:00Z,2003,2004-07-19T00:00:00Z,2005-01-27T00:00:00Z,2005,CRISTALIA PRODUTOS QUIMICOS FARMACEUTICOS LTDA,PACHECO OGARI    BR  | RUSSO ELISA    BR  | RUSSO VALTER    BR,A61P03118 | A61K031505 | A61K031425,BR200302523A  | WO2005007070A3,2,2,Yes,Application,No
363,WO2005007656,A1,SPIRO COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY,US20030487973P,United States,2003-07-18T00:00:00Z,2003,2004-07-16T00:00:00Z,2005-01-27T00:00:00Z,2005,VIROCHEM PHARMA INC,CHAN CHUN KONG LAVAL    CA  | ZHANG MING-QIANG    GB  | MOINET CHRISTOPHE    CA  | PROULX MELANIE    FR  | REDDY THUMKUNTA JAGADEESWAR    CA  | COURCHESNE MARC    CA,C07D47110 | A61P03118,EP1776362A1 | CA2573951A1 | US2005075326A1,4,4,Yes,Application,No
364,WO2005007681,A2,"INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE",US20030488535P,United States,2003-07-18T00:00:00Z,2003,2004-07-16T00:00:00Z,2005-01-27T00:00:00Z,2005,VERTEX PHARMA,BRITT SHAWN D    US  | COTTRELL KEVIN M    US  | PERNI ROBERT B    US  | PITLIK JANOS    US,C07K00706 | A61P03112,IL173180D0 | NZ544789A  | CN1852920B  | AU2004257288A2 | CA2532664A1 | UY28423A1 | AR045916A1 | AU200020102572A1 | US7109172B2 | BRPI0412761A  | WO2005007681A3 | AU2004257288A1 | NO20060706A  | EP1646642A2 | CN101724022A  | US2005107304A1 | KR20060052836A  | JP2008500265T  | ZA200601420A  | PE02512005A1 | US2006211629A1 | CN1852920A  | RU2006105002A ,22,14,Yes,Grant,Yes
365,WO2005009413,A1,DUAL DRUG DOSAGE FORMS WITH IMPROVED SEPARATION OF DRUGS,US20030623481,United States,2003-07-18T00:00:00Z,2003,2004-07-13T00:00:00Z,2005-02-03T00:00:00Z,2005,"DEPOMED, INC.",LIM JONG    US  | SHELL JOHN N    US  | LOUIE-HELM JENNY    US,A61K00924 | A61K00922,EP1646368A1 | KR20060064048A  | JP2007524644T  | EP1646368A4 | US2005013863A1 | CA2531721A1 | MXPA06000526A  | NZ544615A  | AU2004258903A1,9,9,Yes,Application,No
366,WO2005010011,A2,METHODS OF SYNTHESIS OF ACYLOXYALKYL COMPOUNDS,US20030487642P,United States,2003-07-15T00:00:00Z,2003,2004-07-15T00:00:00Z,2005-02-03T00:00:00Z,2005,"XENOPORT, INC.",GALLOP MARK A    US  | BHAT LAXMINARAYAN    US,C07C30330 | C07C06966 | C07C06806 | C07C06742 | C07C06996 | C07D21346 | C07C22900 | C07F00902 | C07C26906 | C07C27122 | C07C30975,US7662987B2 | WO2005010011A3 | US2010041882A1 | US2005070715A1,3,2,Yes,Grant,Yes
367,WO2005011567,A2,FOAM CARRIER CONTAINING AMPHIPHILIC COPOLYMERIC GELLING AGENT,IL20020152486,Israel,2002-10-25T00:00:00Z,2002,2004-08-04T00:00:00Z,2005-02-10T00:00:00Z,2005,FOAMIX LTD,TAMARKIN DOV    IL  | FRIEDMAN DORON    IL  | EINI MEIR    IL,A61K00912 | A61K009107,US2008031907A1 | US2008206155A1 | US2008050317A1 | US2006233721A1 | US2011002857A1 | US2005271598A1 | BRPI0612429A2 | WO2007102052A3 | WO2007072216A3 | US7645803B2 | CN1713891A  | AU2005204347A1 | AU2004321183B2 | WO2007007208A3 | CA2611577A1 | AU2003279493A1 | EP2029106A2 | WO2008038140A2 | CA2609953A1 | WO2005011567A3 | KR20060113657A  | MXPA06001381A  | AU2006273697A1 | IL187275D0 | EP1942870A2 | CA2610662A1 | WO2007039825A2 | JP2007503428T  | IL173094D0 | ZA200711243A  | US2010221195A1 | CA2711703A1 | EP1556009A2 | AU2004266502B2 | BRPI0412975A  | WO2008038147A2 | JP2008539222T  | US2007292359A1 | WO2008152444A3 | JP2008540509T  | WO2007007198A2 | ZA200507018A  | US2010040561A9 | WO2008110872A2 | US2008297083A1 | WO2007085902A2 | US2008138293A1 | US2006275221A1 | IL173095D0 | CA2534372A1 | US2009180970A1 | US2005271596A1 | ZA200502171A  | US7704518B2 | WO2009007785A3 | WO2007054818A3 | US7820145B2 | FR2884713A1 | ZA200710619A  | US2005244342A1 | AU2004321183A1 | BRPI0612428A2 | WO2009087578A2 | EP2051697A2 | US2010111879A1 | AU2006283225A1 | EP2257276A2 | WO2009007785A2 | IL196363D0 | US2007292355A1 | WO2007007208A2 | US2006269485A1 | US2007020213A1 | US2005205086A1 | WO2007039825A3 | EP1670435A2 | WO2004037225A2 | US2007280891A1 | US2010266510A1 | EP1699433A2 | CA2714015A1 | US2007020304A1 | CN1856294A  | WO2008110872A3 | AU2004313285A1 | US2008069779A1 | IL188602D0 | WO2005018530A2 | WO2007085899A2 | WO2007054818A2 | AU2007356328A1 | WO2009098595A3 | US2006140984A1 | ZA200503298A  | JP2008540508T  | EP1919448A2 | EP1919449A2 | WO2007085902A3 | AU2006339311A2 | US2008253973A1 | US2007253911A1 | MXPA06006923A  | MXPA06002163A  | US2008206159A1 | AU2007355106A1 | AU2006298442A1 | US7633251B2 | BRPI0417287A  | IL186923D0 | WO2006003481A2 | AU2004261063A1 | JP2007516265T  | WO2007099396A2 | WO2007012977A3 | EP1865923A2 | CA2606933A1 | US2005232869A1 | MXPA05004278A  | US2008292560A1 | IL168399D0 | US2007159123A1 | AU2006339311A1 | AU2006201878A1 | CA2502986A1 | CA2609948A1 | IL173093D0 | JP2006505583T  | ZA200706383A  | AU2010219295A1 | WO2007007198A3 | BR200314916A  | WO2007085899A3 | WO2006003481A3 | IL152486D0 | WO2007072216A2 | US2008317679A1 | US2008206161A1 | WO2008075207A3 | WO2007099396A3 | EP2097065A2 | ZA200710621A  | WO2004037225A3 | WO2008038147A3 | US2006193789A1 | WO2008152444A2 | US2006275218A1 | IL187277D0 | WO2005018530A3 | US2007292461A1 | JP2008540511T  | US2008260655A1 | CA2536482A1 | IL198688D0 | US2005074414A1 | WO2007023396A3 | CN101267804A  | EP1893396A2 | WO2008038140A3 | US2008152596A1 | WO2007023396A2 | IL187276D0 | US7423394B2 | US7700076B2 | US2005031547A1 | US2005075407A1 | US2008044444A1 | JP2007508243T  | AU2004266502A1 | EP1663148A2 | US2006018937A1 | US2008299220A1 | CA2549505A1 | WO2008075207A2 | US2005069566A1 | US2005186142A1 | IL198687D0 | MX2007014101A  | EP1888032A2 | ZA200502180A  | EP2073794A2 | AU2003279493B2 | CA2602042A1 | EP1863447A2 | NZ540166A  | WO2007102052A2 | AU2006313443A1 | US2008063607A1 | WO2009087578A3 | WO2007012977A2 | KR20050083826A  | US2008138296A1 | WO2009098595A2 | EP1890679A2 | BRPI0612448A2 | AU2009211147A1,149,13,Yes,Grant,Yes
368,WO2005011709,A1,"ANTI-VIRAL NUCLEOSIDE ANALOGS AND METHODS FOR TREATING VIRAL INFECTIONS, ESPECIALLY HIV INFECTIONS",US20030448554P,United States,2003-02-19T00:00:00Z,2003,2004-02-18T00:00:00Z,2005-02-10T00:00:00Z,2005,YALE UNIVERSITY,CHENG YUNG-CHI    US  | TANAKA HIROMICHI    JP  | BABA MASANORI    JP,C07H01916 | A61K0317072 | A61K031675 | A61K031522 | C07H01910 | A61K0317076 | C07H01920 | C07D40504 | C07H01906,KR20060026402A  | EP2298783A1 | EA012844B1 | US7589078B2 | EP1653976A1 | US2010048500A1 | NZ541594A  | BR200407374A  | BRPI0407374A  | JP2006528972T  | US2004167096A1 | MXPA05008736A  | EP1653976A4 | AU2004260630B2 | PL378354A1 | CN1777432A  | AU2004260630A1 | ZA200506630A  | CA2514466A1,16,14,Yes,Grant,Yes
369,WO2005012276,A2,INTERMEDIATE PRODUCTS OF THE SYNTHESIS OF FLUORIZED INHIBITORS OF ASPARTIC PROTEASES,FR20030009458,France,2003-07-31T00:00:00Z,2003,2004-07-30T00:00:00Z,2005-02-10T00:00:00Z,2005,CENTRE NATIONALE DE LA RECHERCHE SCIENTIFIQUE | UNIVERSITE DE PARIS SUD XI,BONNET-DELPON DANIELE    FR  | BEGUE JEAN-PIERRE    FR  | CROUSSE BENOIT    FR  | MAGUEUR GUILLAUME    FR,A61P03306 | A61P03118 | A61K031335 | C07D30336,FR2858322A1 | WO2005012276A3 | FR2858322B1,2,2,Yes,Grant,Yes
370,WO2005016386,A1,IMPROVED THERAPEUTIC PROTOCOLS,AU20030904462,Australia,2003-08-19T00:00:00Z,2003,2004-08-19T00:00:00Z,2005-02-24T00:00:00Z,2005,MEDITECH RESEARCH LIMITED,BROWN TRACEY   AU  | BROWNLEE GARY   AU  | FOX RICHARD   AU,A61P03100 | A61K04736 | A61K03100,None,1,1,Yes,Application,No
371,WO2005018611,A1,PARTICLE SIZE REDUCTION OF BIOACTIVE COMPOUNDS,GB20030019797,United Kingdom,2003-08-26T00:00:00Z,2003,2004-08-25T00:00:00Z,2005-03-03T00:00:00Z,2005,K.U. LEUVEN RESEARCH & DEVELOPMENT,VAN DEN MOOTER GUY    BE  | MARTENS JOHAN    BE  | NUYENS JAN    BE,A61K00914,JP2007503399T  | DE602004006000T2 | EP1658052A1 | US7666307B2 | DE602004006000D1 | AT359765T  | ES2286655T3 | GB200319797D0 | US2007082054A1 | EP1658052B1,7,7,Yes,Grant,Yes
372,WO2005027855,A2,METHODS FOR TREATMENT OF HIV OR MALARIA USING COMBINATIONS OF CHLOROQUINE AND PROTEASE INHIBITORS,US20030449517P,United States,2003-02-21T00:00:00Z,2003,2004-02-20T00:00:00Z,2005-03-31T00:00:00Z,2005,"JARROW FORMULAS, INC.",SAVARINO ANDREA    IT,A61K04506 | A61K0314706 | A61K03147 | A61K031427 | A61K031551 | A61K0314725 | A61K0314745 | A61K031496,US2005009810A1 | US7553844B2 | EP1599172A2 | CN1901914A  | EP2189159A1 | WO2005027855A3 | AU2004273773B2 | EP1599172A4 | CA2676567A1 | ZA200506667A  | US2011003764A1 | CA2516642A1 | AU2004273773A1 | CA2516642C  | CN101829327A ,11,7,Yes,Grant,Yes
373,WO2005028502,A1,"INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE",US20030504405P,United States,2003-09-18T00:00:00Z,2003,2004-09-17T00:00:00Z,2005-03-31T00:00:00Z,2005,VERTEX PHARMA,COTTRELL KEVIN M    US  | PERNI ROBERT P    US  | PITLIK JANOS    US  | SCHAIRER WAYNE C    US,C07K00510 | A61K03807 | A61K03805 | A61K03804 | C07K00508 | A61P03112 | C07K00706 | C07K00504 | C07K00506,CA2538791A1 | AR045769A1 | US2005119189A1 | JP2007536204T  | AU2004274468B2 | AU2004274468A1 | EP1664091A1 | US2009291902A1,9,7,Yes,Application,No
374,WO2005030790,A1,"NOVEL TRITERPENE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF",US20030505899P,United States,2003-09-26T00:00:00Z,2003,2004-09-27T00:00:00Z,2005-04-07T00:00:00Z,2005,PANACOS PHARMACEUTICALS INC | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL,WILD CARL T   US  | ROBINSON GARY N   US  | ASHTON MARK   GB  | THOMAS RUSSELL   IT,C07J00100 | C07J05300 | C07C069608 | A61K031225 | A61K03156,NO20061792A  | IL174317D0 | AU2004276307A1 | ZA200602758A  | US2005148561A1 | BRPI0415023A  | EP1675866A1 | CN1871251A  | JP2007506761T  | CA2540160A1 | KR20060096147A ,11,11,Yes,Application,No
375,WO2005035525,A2,"INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE",US20030500670P,United States,2003-09-05T00:00:00Z,2003,2004-09-07T00:00:00Z,2005-04-21T00:00:00Z,2005,VERTEX PHARMA,PERNI ROBERT B    US  | COURT JOHN J    US  | BRITT SHAWN D    US  | PITLIK JANOS    US  | VAN DRIE JOHN H    US,C07D40314 | A61K04506 | A61K031497 | A61K0314439 | A61K0314178 | C07K00510 | A61K031501 | C07D40114 | C07K00502 | C07D40112 | A61K031506 | C07D40312 | A61K031517 | A61K03800,US7378422B2 | NO20061426A  | AR045596A1 | US7745444B2 | IL173627D0 | CA2536436A1 | NZ545158A  | US2005137139A1 | UY28500A1 | BRPI0414176A  | AU2004279800A1 | CN1845920A  | WO2005035525A3 | US2008311079A1 | JP2007504251T  | MXPA06002476A  | RU2006110934A  | KR20060073610A  | EP1667998A2 | PE03742005A1,19,16,Yes,Grant,Yes
376,WO2005037196,A2,SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS,US20030508290P,United States,2003-10-06T00:00:00Z,2003,2004-10-05T00:00:00Z,2005-04-28T00:00:00Z,2005,CYTOVIA INC,CAI SUI XIONG    US  | PERVIN AZRA    US  | KASIBHATLA SHAILAJA    US  | NGUYEN BAO NGOC    US,A61K03116,WO2005037196A3 | US2007043076A1,2,2,Yes,Application,No
377,WO2005037246,A2,AQUEOUS AEROSOL PREPARATION,DE20031047994,Germany,2003-10-15T00:00:00Z,2003,2004-10-14T00:00:00Z,2005-04-28T00:00:00Z,2005,PARI GMBH,JAUERNIG JUERGEN    DE  | LINTZ FRANK-CHRISTOPHE    DE  | KELLER MANFRED    DE,A61K009107 | A61K00900 | A61K009127 | A61K00919,BRPI0415470A  | CA2542666A1 | US2005244339A1 | EP1673066A2 | AU2004281531A1 | WO2005037246A3 | DE10347994A1 | RU2006114451A  | RU2363449C2 | US7758886B2 | NZ546824A  | MXPA06004132A ,10,10,Yes,Grant,Yes
378,WO2005037860,A2,"INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE",US20030510156P,United States,2003-10-10T00:00:00Z,2003,2004-10-08T00:00:00Z,2005-04-28T00:00:00Z,2005,VERTEX PHARMA,COTTRELL KEVIN M    US  | PERNI ROBERT B    US  | PITLIK JANOS    US,A61K03808 | A61K03807 | A61K03805 | C07K00706 | C07K00506 | C07K00508 | C07K00510,ZA200602937A  | EP1692157A2 | IL174863D0 | KR20060130027A  | US2005137140A1 | CN101857631A  | AU2004282148A1 | RU2006115558A  | WO2005037860A3 | US7208600B2 | CA2541634A1 | CN1906208B  | NO20062101A  | MXPA06004006A  | US2007161789A1 | CN1906208A  | JP2007532474T  | NZ546663A ,15,13,Yes,Grant,Yes
379,WO2005039551,A2,SOLID PHARMACEUTICAL DOSAGE FORM,US20030650178,United States,2003-08-28T00:00:00Z,2003,2004-08-23T00:00:00Z,2005-05-06T00:00:00Z,2005,ABBOTT LAB,ROSENBERG JOEERG    DE  | REINHOLD ULRICH    DE  | LIEPOLD BERND    DE  | DERNDL GUNTHER    DE  | BREITENBACH JOERG    DE  | ALANI LAMAN    US  | GHOSH SOUMOJEET    US,A61K00928 | A61K00920 | A61K00914 | A61K031425,NO330282B1 | KR20060121837A  | AU2010238573A1 | MXPA06002346A  | EP1663183A2 | NZ545499A  | ECSP066397A  | EP2258344A3 | EP2258346A3 | WO2005039551A3 | ZA200801362A  | CA2689639A1 | JP2007504142T  | CA2536638A1 | EP2258344A2 | AU2007249115A1 | AU2004283087B2 | AU2007249115B2 | EA011924B1 | BRPI0413882A  | ZA200601718A  | AU2004283087A1 | RSP20060140A  | EP2258346A2 | NO20100367A  | IL173939D0 | NO20061342A  | NZ579622A  | CN101919858A  | EA200900292A1 | EA200600473A1 | EP2258345A2 | AU2004283087C1 | US2005048112A1 | CN1901884A  | SG145690A1 | EP2258345A3 | CA2536638C ,30,17,Yes,Grant,Yes
380,WO2005039587,A1,HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY,US19980113989P,United States,1998-12-28T00:00:00Z,1998,2004-10-18T00:00:00Z,2005-05-06T00:00:00Z,2005,4 AZA BIOSCIENCE NV,WAER MARK JOZEF ALBERT    BE  | HERDEWIJN PIET ANDRE MAURITS M    BE  | DE JONGHE STEVEN CESAR ALFONS    BE  | MARCHAND ARNAUD DIDIER MARIE    BE  | GAO LING-JIE    BE,C07D47510 | A61K031541 | A61K0315377 | A61K031519 | C07D47508 | A61K031551 | A61K04506 | C07D47504,EP1144412B1 | DE69920757T2 | GB200408955D0 | DK1673092T3 | AT369862T  | EP1673092B1 | PT1663244E  | GB2413324A  | GB2407089A  | US2004077859A1 | DK1663244T3 | DK1658081T3 | SI1663244T1 | DE602004009696D1 | WO2005021003A2 | US2007032477A1 | US7276506B2 | JP2002533464T  | CA2356380A1 | CA2534549A1 | DE602004008312T2 | DE602004008312D1 | JP2007533617T  | DE602004009696T2 | US2007004721A1 | CA2534151A1 | AT376421T  | EP1658081B1 | WO200039129A1 | US7501513B2 | US2006189620A1 | GB200321384D0 | JP2007533610T  | CA2356380C  | AU2004283479A1 | AT277929T  | SI1658081T1 | US2006287314A1 | GB200603585D0 | GB200324324D0 | JP2007508355T  | ES2293324T3 | EP1663244A2 | AU2004267885A1 | ES2293354T3 | GB2405793A  | AU200030429A  | AT369861T  | EP1663244B1 | AU770551B2 | ES2295897T3 | CA2537224A1 | SI1673092T1 | PT1658081E  | DE69920757D1 | WO2005025574A3 | WO2005021003A3 | DE602004008304T2 | ES2229803T3 | WO2005025574A2 | EP1673092A1 | PT1673092E  | AU2004271721A1 | EP1658081A2 | DE602004008304D1 | EP1144412A1,50,13,Yes,Grant,Yes
381,WO2005042020,A2,COMBINATIONS FOR HCV TREATMENT,US20030514853P,United States,2003-10-27T00:00:00Z,2003,2004-10-27T00:00:00Z,2005-05-12T00:00:00Z,2005,VERTEX PHARMA,TUNG ROGER D    US  | CHANDORKAR GURUDATT    US  | PERNI ROBERT B    US,A61K04500 | A61K03821 | A61K0317056 | A61K04506,ES2319775T3 | EP1677827A2 | KR20060120162A  | CA2543696A1 | WO2005042020A3 | AT416789T  | BRPI0415935A  | DE602004018363D1 | IL175211D0 | PT1677827E  | JP2007509950T  | CN1893978A  | US2006003942A1 | AU2004285503A1 | EP1677827B1 | MXPA06004723A  | EP1944042A1 | NO20062428A  | DK1677827T3 | RU2006118359A  | ZA200603863A  | SI1677827T1,20,18,Yes,Grant,Yes
382,WO2005042517,A2,BIPIPERIDINYL DERIVATIVES USEFUL AS INHIBITORS OF CHEMOKINE RECEPTORS,US20030516954P,United States,2003-11-03T00:00:00Z,2003,2004-11-01T00:00:00Z,2005-05-12T00:00:00Z,2005,SCHERING CORP,MILLER MICHAEL W    US  | SCOTT JACK D    US,C07D41314 | C07D40114 | A61K031445,ZA200603479A  | CN1898231A  | CA2544377A1 | KR20060100409A  | JP2008031180A  | CN101798299A  | PE05742005A1 | EP1687295A2 | JP2007510653T  | US2006025441A1 | US7652142B2 | IL175331D0 | AR046923A1 | WO2005042517A3 | AU2004285051A1 | CN1898231B ,13,11,Yes,Grant,Yes
383,WO2005042570,A1,HCV NS3-NS4A PROTEASE RESISTANCE MUTANTS,US20030514740P,United States,2003-10-27T00:00:00Z,2003,2004-10-27T00:00:00Z,2005-05-12T00:00:00Z,2005,VERTEX PHARMA,LIN CHAO    US  | LIN KAI    US,C12Q00170 | C12N01551 | A61K03816 | A61K03805 | A61K0314709 | G01N03368 | C12N00950 | C07H02104 | C12Q00137 | G01N03350 | G06F01750 | C12N01586 | C07K01418 | C12N00948 | C12Q00168,IL175218D0 | CA2551074A1 | CN1894276B  | US7494660B2 | AU2004285019A1 | RU2365624C2 | KR20060120166A  | US2005136400A1 | EP1678202A1 | JP2008502308T  | RU2006118332A  | US2009191555A1 | US2011086006A1 | US7884199B2 | HK1099318A1 | NO20062427A  | CN1894276A ,13,11,Yes,Grant,Yes
384,WO2005043118,A2,DRUG DISCOVERY METHOD,US20030515009P,United States,2003-10-27T00:00:00Z,2003,2004-10-27T00:00:00Z,2005-05-12T00:00:00Z,2005,VERTEX PHARMA,PERNI ROBERT B    US  | GATES CYNTHIA    US  | THOMSON JOHN A    US,C12Q00118 | A61K03855 | A61K03821,US2006003317A1 | WO2005043118A3,2,2,Yes,Application,No
385,WO2005051358,A1,COMPOSITION AND METHOD FOR ENHANCING BIOAVAILABILITY,US20030523421P,United States,2003-11-19T00:00:00Z,2003,2004-11-12T00:00:00Z,2005-06-09T00:00:00Z,2005,ALZA CORP,DONG LIANG C    US  | POLLOCK-DOVE CRYSTAL    US  | HAN JASMINE    US,A61K00920 | A61K00916,US2005181049A1 | PE05842005A1 | EP1684726A4 | ZA200604969A  | NO20062860A  | CN1905859A  | WO2005051358A8 | JP2007511608T  | MXPA06005630A  | IL175647D0 | KR20060109934A  | CA2546618A1 | AR048017A1 | EP1684726A1 | AU2004292415A1,13,13,Yes,Application,No
386,WO2005051419,A1,RETROVIRUS-LIKE PARTICLES AND RETROVIRAL VACCINES,WO2003US33897WO2003US33897,World Intellectual Property Organization,2003-10-25T00:00:00Z,2003,2003-10-25T00:00:00Z,2005-06-09T00:00:00Z,2005,"THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH",OTT DAVID    US,A61K03921,US2007099276A1 | AU2003304566A1,3,3,Yes,Application,No
387,WO2005054297,A2,CELLULOSE INTERPOLYMERS AND METHOD OF OXIDATION,US20030525787P,United States,2003-11-28T00:00:00Z,2003,2004-11-23T00:00:00Z,2005-06-16T00:00:00Z,2005,EASTMAN CHEMICAL COMPANY,BUCHANAN CHARLES MICHAEL      | BUCHANAN NORMA LINDSEY      | CARTY SUSAN NORTHROP      | KUO CHUNG-MING      | LAMBERT JUANELLE LITTLE      | POSEY-DOWTY JESSICA DEE      | WATTERSON THELMA LEE      | WOOD MATTHEW DAVIE      | MALCOLM MICHAEL ORLANDO      | LINDBLAD MARGARETHA SODERQVIST,C09D01700 | C08B00322 | C08B00318 | C08B01504 | C08B01500 | A61K04738 | C08B01506 | C08B00316 | A61K00928 | A61K00920 | A61K00919 | A61K00948,WO2005054297A3 | EP1689787A2 | US2005192434A1 | US7879994B2 | BRPI0415764A  | JP2007515515T  | CN1886427A ,7,6,Yes,Grant,Yes
388,WO2005058248,A2,A METHOD OF TREATING HIV INFECTION IN ATAZANAVIR RESISTANT PATIENTS USING A COMBINATION OF ATAZANAVIR AND ANOTHER PROTEASE INHIBITOR,US20030529678P,United States,2003-12-15T00:00:00Z,2003,2004-12-14T00:00:00Z,2005-06-30T00:00:00Z,2005,BRISTOL MYERS SQUIBB PHARMA CO,COLONNO RICHARD J    US  | FRIBORG JR JACQUES    US  | ROSE RONALD E    US,A61K0317056 | A61K031551 | A61K03144,EP1696918A2 | EP1696918A4 | US2005148523A1 | WO2005058248A3,3,3,Yes,Application,No
389,WO2005058841,A2,HIV PROTEASE INHIBITING COMPOUNDS,US20030733946,United States,2003-12-11T00:00:00Z,2003,2004-12-09T00:00:00Z,2005-06-30T00:00:00Z,2005,ABBOTT LAB,DEGOEY DAVID A    US  | FLENTGE CHARLES A    US  | FLOSI WILLIAM J    US  | GRAMPOVNIK DAVID J    US  | KEMPF DALE J    US  | KLEIN LARRY L    US  | YEUNG MING C    US  | RANDOLPH JOHN T    US  | WANG XIU C    US  | YU SU    US,C07D47104 | C07D40106 | C07D21340 | C07D21330 | C07D41714 | C07D40112 | C07D49304 | C07D40114 | C07D41706,WO2005058841A3 | EP1697344A2 | EP2266971A2 | JP2007516260T  | EP2266971A3 | CA2549098A1 | MXPA06006612A  | US2005131017A1,7,6,Yes,Application,No
390,WO2005060663,A2,DERIVATIVES OF GAMBOGIC ACID AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS,US20030530256P,United States,2003-12-18T00:00:00Z,2003,2004-12-17T00:00:00Z,2005-07-07T00:00:00Z,2005,CYTOVIA INC,CAI SUI XIONG    US  | JIANG SONGCHUN    US  | ZHANG HAN-ZHONG    US,A61K0315377 | A61K031496 | A61K031352 | C07D49322 | C07D26530 | C07D31178 | C07D40502,WO2005060663A3 | US2007093456A1 | US7622497B2,2,2,Yes,Grant,Yes
391,WO2005061450,A2,HIV PROTEASE INHIBITING COMPOUNDS,US20030733915,United States,2003-12-11T00:00:00Z,2003,2004-11-10T00:00:00Z,2005-07-07T00:00:00Z,2005,ABBOTT LAB,FLENTGE CHARLES A    US  | CHEN HUI-JU    US  | DEGOEY DAVID A    US  | FLOSI WILLIAM J    US  | GRAMPOVNIK DAVID J    US  | HUANG PEGGY P    US  | KEMPF DALE J    US  | KLEIN LARRY L    US  | KRUEGER ALLAN C    US  | MADIGAN DAROLD L    US  | RANDOLPH JOHN T    US  | SUN MINGHUA    US  | YEUNG MING C    US  | ZHAO CHEN    US,C07D40506 | C07C31117 | C07D47104 | C07D40106 | C07D30720 | C07D49304 | C07D40310 | C07D21378 | C07D23332 | C07D23372 | C07D27748 | C07D40306 | C07D30742 | A61K031195 | A61K03118 | C07D41714 | C07D27746 | C07D41706 | C07D40510 | A61K031175 | C07D40906 | C07D27728 | A61K04506 | A61K031277 | C07D21340 | C07D21330 | A61K0314168 | A61K03165,EP1709037B8 | AT452889T  | MXPA06006610A  | HK1100037A1 | EP1709037A2 | DE602004024830D1 | EP2216334A1 | EP1709037B1 | CA2549389A1 | ES2337581T3 | WO2005061450A3 | EP2264032A3 | EP2264032A2 | US2005131042A1 | JP2007513944T ,11,9,Yes,Grant,Yes
392,WO2005061487,A1,HIV PROTEASE INHIBITING COMPOUNDS,US20030733227 | US20030528679P,United States,2003-12-11T00:00:00Z,2003,2004-11-10T00:00:00Z,2005-07-07T00:00:00Z,2005,ABBOTT LAB,RANDOLPH JOHN T    US  | CHEN HUI-JU    US  | DEGOEY DAVID A    US  | FLENTGE CHARLES A    US  | FLOSI WILLIAM J    US  | GRAMPOVNIK DAVID J    US  | HUANG PEGGY P    US  | HUTCHINSON DOUGLAS K    US  | KEMPF DALE J    US  | KLEIN LARRY L    US  | YEUNG MING C    US,C07D41714 | C07D40514 | C07C24324 | A61K0314178 | A61K0314166 | C07D40306 | C07C27122 | C07D41314 | C07D40914 | C07D40106 | C07D41706 | C07D40114,US2005159469A1 | EP1697348A1 | MXPA06006609A  | JP2007516255T  | CA2549228A1 | US7696226B2,6,6,Yes,Grant,Yes
393,WO2005062952,A2,COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY,US20030532405P,United States,2003-12-23T00:00:00Z,2003,2004-12-22T00:00:00Z,2005-07-14T00:00:00Z,2005,THE J. DAVID GLADSTONE INSTITUTES,OTT MELANIE    US  | VERDIN ERIC M    US  | JUNG MANFRED    DE,C12Q00170 | C12Q00134,WO2005062952A3 | CA2550157A1 | US2005287597A1 | US7485416B2 | EP1709206A4 | EP1709206A2,4,4,Yes,Grant,Yes
394,WO2005062979,A2,"IMMUNOASSAYS, HAPTENS, IMMUNOGENS AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS",US20030531552P,United States,2003-12-19T00:00:00Z,2003,2004-12-20T00:00:00Z,2005-07-14T00:00:00Z,2005,"ARK DIAGNOSTICS, INC.",VALDEZ JOHNNY    US,G01N033569 | C07K01644,WO2005062979A3 | US2009068719A1 | EP1700122A2 | CA2550316A1 | AU2004308507A1 | US2005244816A1 | EP1700122A4,6,5,Yes,Application,No
395,WO2005063213,A1,RIGID LIPOSOMAL COCHLEATE AND METHODS OF USE AND MANUFACTURE,US20030531546P,United States,2003-12-19T00:00:00Z,2003,2004-12-20T00:00:00Z,2005-07-14T00:00:00Z,2005,"BIODELIVERY SCIENCES INTERNATIONAL, INC",KRAUSE-ELSMORE SARA L   US  | MANNINO RAPHAEL J   US,A61K04702 | A61K009127,None,1,1,Yes,Application,No
396,WO2005064008,A1,METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS,US20020375665P | US20020375834P | US20020375779P | US20020375622P,United States,2002-04-26T00:00:00Z,2002,2004-12-22T00:00:00Z,2005-07-14T00:00:00Z,2005,GILEAD SCIENCES INC,ARIMILLI MURTY N    US  | BECKER MARK M    US  | BIRKUS GABRIEL    US  | BRYANT CLIFFORD    US  | CHEN JAMES M    US  | CHEN XIAOWU    US  | CIHLAR TOMAS    US  | DASTGAH AZAR    US  | EISENBERG EUGENE J    US  | FARDIS MARIA,C12Q00144,US7649015B2 | AU2003291998A8 | AU2003231765B9 | NO20045152A  | CA2481261A1 | WO2003090691A3 | WO2003090691A2 | AU2003231765B2 | SI1509537T1 | HR20041113B1 | HR20041113A2 | CN101074242A  | CA2481285A1 | AU2003263068A1 | WO2002059545A8 | IL164491D0 | DE60315023T2 | US2005239054A1 | US2007010489A1 | US2006128692A1 | MXPA04010528A  | WO2003090690A3 | JP2005523912T  | EP1575486A4 | WO2003091264A3 | HK1073467A1 | WO2003091264A2 | WO200206767A1 | US2005209197A1 | US7462608B2 | AU2003228707A1 | ZA200409377A  | IS7555A  | WO2002059545A1 | US6700669B1 | WO2003090690A2 | HR20041114A2 | EP1509537B1 | PT1509537E  | EP1509537B9 | WO2004096818A3 | US6594539B1 | WO2004096818A2 | AU2003263067A1 | US2005197320A1 | UA80819C2 | JP2006508634T  | ES2290485T3 | US2004121316A1 | WO2004021862A3 | IL164490A  | CN1649885A  | AT367394T  | DK1509537T3 | WO2004021862A2 | CN1656109A  | AU200166840A  | WO2004021915A3 | CA2481449A1 | WO2004021915A2 | EP1620445A2 | US7107116B2 | EP1509537A2 | US2006115815A1 | US2004117053A1 | EP1301752A2 | US6937348B2 | US7017868B2 | US2007190523A1 | AU2003231766A1 | EP1501841A2 | PL374968A1 | ZA200409376A  | AU2003231765A1 | US6556706B1 | US2004087862A1 | PL374522A1 | IL164490D0 | US2007038122A1 | US2004117052A1 | CN1313472C  | JP2009112319A  | CN101041669A  | JP2006524487T  | MXPA04010527A  | NO20045150A  | DE60315023D1 | WO2005064008A9 | US7242997B2 | WO200206767A8 | US7099732B2 | NZ535828A  | IS7556A  | AU2003263067A8 | EP1354176A1 | BR200309557A  | EP1575486A2 | JP2005523922T  | US2003223083A1 | BR200309573A  | EA008775B1 | AU2001268281A1 | AU2003263068A8 | AU2003291998A1,80,26,Yes,Grant,Yes
397,WO2005066131,A1,NON-NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS,SE20040000021,Sweden,2004-01-08T00:00:00Z,2004,2004-12-30T00:00:00Z,2005-07-21T00:00:00Z,2005,MEDIVIR AB,SUND CHRISTIAN    SE  | ROUE NATHALIE    SE  | LINDSTROEM STEFAN    SE  | ANTONOV DMITRY    SE  | SAHLBERG CHRISTER    SE  | JANSSON KATARINA    SE,C07D40912 | C07D40514 | C07D40512 | C07D40914,US7915295B2 | SG149070A1 | AU2004312284A2 | NZ548367A  | CN1926108A  | JP2007519640T  | IL176740D0 | AU2004312284B2 | AT451357T  | EP1701942A1 | SE200400021D0 | EA009700B1 | DK1701942T3 | AU2004312284A1 | HK1101400A1 | ES2337794T3 | EP1701942B1 | ZA200605395A  | DE602004024584D1 | BRPI0418306A  | EA200601289A1 | CN1926108B  | SE200400585D0 | CA2550187A1 | US2008070951A1,16,16,Yes,Grant,Yes
398,WO2005072706,A2,NANOSUSPENSIONS OF ANTI-RETROVIRAL AGENTS FOR INCREASED CENTRAL NERVOUS SYSTEM DELIVERY,US20040540718P,United States,2004-01-29T00:00:00Z,2004,2005-01-21T00:00:00Z,2005-08-11T00:00:00Z,2005,BAXTER INTERNATIONAL INC.,WERLING JANE    US  | CHAUBAL MAHESH V    US  | KIPP JAMES E    US  | RABINOW BARRETT E    US,A61K00951 | A61K00914 | A61K00910 | A61K0317076 | A61K03100 | A61K031551 | A61K0317072,CN1913871A  | CA2554246A1 | AU2005209243A1 | JP2007519725T  | US2005202094A1 | ZA200606051A  | KR20060135729A  | BRPI0507308A  | RU2006130958A  | WO2005072706A3 | IL176719D0 | EP1713443A2,11,11,Yes,Application,No
399,WO2005076892,A2,METHOD FOR DETERMINING REDUCED SUSCEPTIBILITY OF HIV TO PROTEASE INHIBITOR TREATMENT,US20040542795P,United States,2004-02-06T00:00:00Z,2004,2005-02-04T00:00:00Z,2005-08-25T00:00:00Z,2005,"MONOGRAM BIOSCIENCES, INC.",CHAPPEY COLOMBE    US  | PETROPOULOS CHRISTOS J    US  | PARKIN NEIL T    US,C12Q00170 | G06F01900 | C12Q00168,EP1789579A4 | US2005214749A1 | WO2005076892A3 | CA2555138A1 | EP1789579A2,4,4,Yes,Application,No
400,WO2005077050,A2,HIV INTEGRASE INHIBITORS,US20040543670P,United States,2004-02-11T00:00:00Z,2004,2005-02-10T00:00:00Z,2005-08-25T00:00:00Z,2005,GSK LLC,JOHNS BRIAN ALVIN    US  | BOROS ERIC EUGENE    US  | KAWASUJI TAKASHI    JP  | KOBLE CECILIA S    US  | KUROSE NORIYUKI    JP  | MURAI HITOSHI    JP  | SHERRILL RONALD GEORGE    US  | WEATHERHEAD JASON GORDON    US,C07D47104,RU2006128848A  | CN1976915A  | US2007124152A1 | KR20070002006A  | EP1720856A4 | WO2005077050A3 | AU2005211733A1 | BRPI0507628A  | EP1720856A2 | NO20063958A  | IL177189D0 | CA2555176A1 | MXPA06009132A  | JP2007523086T ,13,13,Yes,Application,No
401,WO2005077406,A1,PROTEASE INHIBITORS FOR THE TREATMENT OF DIGESTIVE PATHOLOGIES,FR20040000446,France,2004-01-19T00:00:00Z,2004,2005-01-18T00:00:00Z,2005-08-25T00:00:00Z,2005,RYTEK,BUENO LIONEL    FR,A61K03855,BRPI0506953A  | EP1708740B1 | CA2552638A1 | FR2865133A1 | AT482718T  | IL176733D0 | EP1708740A1 | US2008286355A1 | DE602005023834D1 | FR2865133B1 | AU2005211965A1 | JP2007518779T  | CN1909919A  | KR20060127983A ,11,11,Yes,Grant,Yes
402,WO2005077969,A2,"INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE",US20040541738P,United States,2004-02-04T00:00:00Z,2004,2005-02-04T00:00:00Z,2005-08-25T00:00:00Z,2005,VERTEX PHARMA,COTTRELL KEVIN M    US  | COURT JOHN J    US  | DEININGER DAVID D    US  | FARMER LUC J    US  | PITLIK JANOS    US,C07K01418 | C07K00702 | C07K00502,CA2554999A1 | JP2008505849T  | WO2005077969A3 | US7683033B2 | CN1938332A  | EP2311851A2 | US2005215486A1 | US2010330109A1 | AU2005212257A1 | EP1711515A2,9,7,Yes,Grant,Yes
403,WO2005079752,A2,CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY,AU20040900661,Australia,2004-02-11T00:00:00Z,2004,2005-02-10T00:00:00Z,2005-09-01T00:00:00Z,2005,RUBICON RESEARCH PRIVATE LIMITED,PILGAONKAR PRATIBHA    IN,A61K031522 | A61K00920 | A61K00900,WO2005079752A3 | EP1750717A2 | US2007196396A1 | WO2005079752A8,3,3,Yes,Application,No
404,WO2005082331,A2,EXTENDED RELEASE TABLETS OF CLARITHROMYCIN,IN2004DE00306,India,2004-02-26T00:00:00Z,2004,2005-02-25T00:00:00Z,2005-09-09T00:00:00Z,2005,RANBAXY LABORATORIES LIMITED,MANDAOGADE PRASHANT MANOHAR    IN  | RAGHUVANSHI RAJEEV SINGH    IN  | RAMPAL ASHOK    IN,A61K00920 | A61K00916 | A61K00900 | A61K0317048,EP1720524A2 | WO2005082331A3,2,2,Yes,Application,No
405,WO2005082362,A1,THERAPEUTIC COMBINATIONS,US20040540749P,United States,2004-01-30T00:00:00Z,2004,2005-01-17T00:00:00Z,2005-09-09T00:00:00Z,2005,PFIZER,HAMMOND JENNIFER LOU    US  | PATICK AMY KAREN    US,A61K0317076 | A61K031426 | A61K03141 | A61K03140 | A61K0317072 | A61K031522 | A61K04506 | A61K031551 | A61K0317056,CN1938017A  | BRPI0506493A  | US2005171038A1 | JP2007519704T  | IL177155D0 | AU2005216710A1 | CA2555171A1 | MXPA06008632A  | EP1713470A1 | NO20063483A  | KR20060114374A  | RU2006128606A ,12,12,Yes,Application,No
406,WO2005082364,A1,COMPOSITIONS COMPRISING HIV PROTEASE INHIBITOR AND CYTOCHROME P450 ENZYME ACTIVITY INHIBITOR,US20040540746P,United States,2004-01-30T00:00:00Z,2004,2005-01-17T00:00:00Z,2005-09-09T00:00:00Z,2005,PFIZER,TRAN JONATHAN QUOC    US  | SMITH EVAN BURR    US,A61K031426 | A61K03140 | A61K03100 | A61K031496 | A61K0317056 | A61K04506,NO20063826A  | US2005171037A1 | AR047584A1 | IL176675D0 | EP1713478A1 | ZA200606135A  | CA2555173A1 | MXPA06008598A  | RU2006127429A  | CN1913889A  | KR20060127939A  | BRPI0506498A  | CO5700739A2 | AU2005216712A1 | JP2007519706T ,15,15,Yes,Application,No
407,WO2005086871,A2,"COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING OR TREATING HIV-1",US20040795505,United States,2004-03-09T00:00:00Z,2004,2005-03-09T00:00:00Z,2005-09-22T00:00:00Z,2005,CYTOKINE PHARMASCIENCES INC,HAFFAR OMAR K    US  | GODDEN JEFFREY W    US  | BAJORATH JURGEN    US,A61K03144 | A61K0314245 | A61K03141 | C07D27110 | C07D27112 | C07D40104,WO2005086871A3 | AU2005221106A1 | CA2559507A1 | EP1722782A4 | EP1722782A2 | US2006264475A1 | US2005203150A1 | WO2005086871A9,6,5,Yes,Application,No
408,WO2005090317,A1,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS,US20040555798P,United States,2004-03-23T00:00:00Z,2004,2005-03-16T00:00:00Z,2005-09-29T00:00:00Z,2005,F. HOFFMANN-LA ROCHE AG,DUNN JAMES PATRICK    US  | ELWORTHY TODD RICHARD    US  | HOGG JOAN HEATHER    US  | STEFANIDIS DIMITRIOS    US,C07D23714,JP4627315B2 | CA2559552A1 | US2005215554A1 | JP2007530477T  | CN1934092A  | AR048042A1 | US7288542B2 | EP1730120A1,7,7,Yes,Grant,Yes
409,WO2005097818,A2,AN ASSAY SYSTEM FOR SCREENING PROTEASE INHIBITORS,US20040553263P,United States,2004-03-15T00:00:00Z,2004,2005-03-15T00:00:00Z,2005-10-20T00:00:00Z,2005,KECK GRADUATE INSTITUTE,CHENG TING-JEN   US  | KAN CHEN-CHEN   US,C07H02100,WO2005097818A3 | US2005244819A1,2,2,Yes,Application,No
410,WO2005102328,A1,METHODS OF TREATING HIV INFECTION,US20040555768P,United States,2004-03-24T00:00:00Z,2004,2005-02-22T00:00:00Z,2005-11-03T00:00:00Z,2005,BRISTOL MYERS SQUIBB PHARMA CO,LIN PIN-FANG    US  | NOWICKA-SANS BEATA    US  | YAMANAKA GREGORY    US,A61K031522 | A61K031496 | A61K031435 | A61K031551,US2005215544A1 | PE01492006A1 | AR048324A1,4,4,Yes,Application,No
411,WO2005102391,A1,COMBINATIONS FOR THE TREATMENT OF AIDS OR HIV INFECTIONS,US20040555847P,United States,2004-03-24T00:00:00Z,2004,2005-02-18T00:00:00Z,2005-11-03T00:00:00Z,2005,BRISTOL MYERS SQUIBB PHARMA CO,LIN PIN-FANG   US  | NOWICKA-SANS BEATA   US  | YAMANAKA GREGORY   US,A61K04506 | A61K031496 | A61K0317076 | A61K0317072 | A61K0317068 | A61P03118,US2005215543A1 | AR048439A1 | PE11612005A1,4,4,Yes,Application,No
412,WO2005102392,A2,METHODS OF TREATING HIV INFECTION,US20040555767P,United States,2004-03-24T00:00:00Z,2004,2005-03-01T00:00:00Z,2005-11-03T00:00:00Z,2005,BRISTOL MYERS SQUIBB PHARMA CO,LIN PIN-FANG    US  | NOWICKA-SANS BEATA    US  | YAMANAKA GREGORY    US,A61K031551 | A61K031522 | A61K031496 | A61K04506,DE602005022420D1 | AU2005235116B2 | JP2007530540T  | US7776863B2 | DK1732604T3 | CN1956720B  | ES2347801T3 | AU2005235116A1 | PT1732604E  | PE01482006A1 | NZ549778A  | HK1096540A1 | EP1732604B1 | BRPI0509140A  | WO2005102392A3 | RU2006137555A  | AT474602T  | ZA200607959A  | RU2367439C2 | KR20070011322A  | AR048333A1 | CN1956720A  | IL178141D0 | IL178141A  | US2005215545A1 | NO20064547A  | CA2561146A1 | EP1732604A2 | HR20100434T1,23,23,Yes,Grant,Yes
413,WO2005107742,A1,NOVEL ANTIVIRAL HELIOXANTHIN ANALOGS,US20040568348P,United States,2004-05-05T00:00:00Z,2004,2005-05-02T00:00:00Z,2005-11-17T00:00:00Z,2005,YALE UNIVERSITY,YEO HOSUP    KR  | AUSTIN DAVID J    US  | LI LING    US  | CHENG YUNG-CHI    US,A61K031517 | A61K031365 | A61K03136 | C07D49304 | C07D40504 | C07D40704 | C07D49104,KR20070011451A  | US2008167353A1 | US7754718B2 | CN1980657A ,4,4,Yes,Grant,Yes
414,WO2005110411,A1,"COMBINATIONS OF SUBSTITUTED 1-PHENYL-1,5-DIHYDRO-PYRIDO- [3,2-B] INDOL-2-ONES AND OTHER HIV INHIBITORS",EP20040102173,European Patent Office,2004-05-17T00:00:00Z,2004,2005-05-17T00:00:00Z,2005-11-24T00:00:00Z,2005,TIBOTEC PHARM LTD,KESTELEYN BART RUDOLF ROMANIE    BE  | VAN DE VREKEN WIM    BE  | KINDERMANS NATALIE MARIA FRANC    BE  | CANARD MAXIME FRANCIS JEAN-MAR    BE  | HERTOGS KURT    BE  | BETTENS EVA    BE  | DE VROEY VERONIQUE CORINE PAUL    BE  | JOCHMANS DIRK EDWARD DESIRE    BE  | WIGERINCK PIET TOM BERT PAUL    BE  | WANG JING    BE  | TAHRI ABDELLAH    BE  | SURLERAUX DOMINIQUE LOUIS NEST    BE,A61K0315377 | A61K031496 | A61K031475 | A61K04506,US2007249655A1 | JP2007538053T  | EP1750708A1 | CA2563601A1 | KR20070011588A  | EA200602136A1 | MXPA06013316A  | AU2005244449A1 | ZA200610588A  | CN1953751A  | AR048962A1 | AP200603794D0 | BRPI0511144A ,13,13,Yes,Application,No
415,WO2005110428,A2,RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS,US20040568935P,United States,2004-05-07T00:00:00Z,2004,2005-05-09T00:00:00Z,2005-11-24T00:00:00Z,2005,SEQUOIA PHARMACEUTICALS,EISSENSTAT MICHAEL    US  | DELAHANTY GREG    US  | TOPIN ANDREY    US  | RAJENDRAN GNANA RAVI    US,A61K031665 | A61K031353 | A61K031343 | C07D49302,US7507763B2 | CN1997363A  | WO2005110428A3 | US7378441B2 | AU2005244121A1 | US2010056596A1 | EP1750696A2 | CA2566340A1 | EP1750696A4 | US2006258627A1 | US2005267074A1 | MXPA06012909A  | ZA200609247A  | IL179056D0 | JP2007536271T ,11,8,Yes,Grant,Yes
416,WO2005111006,A1,"RITONAVIR ANALOGOUS COMPOUND USEFUL AS RETROVIRAL PROTEASE INHIBITOR, PREPARATION OF THE RITONAVIR ANALOGOUS COMPOUND AND PHARMACEUTICAL COMPOSITION FOR THE RITONAVIR ANALOGOUS COMPOUND.",BR2004PI01742,Brazil,2004-05-13T00:00:00Z,2004,2005-05-11T00:00:00Z,2005-11-24T00:00:00Z,2005,CRISTALIA PRODUTOS QUIMICOS FARMACEUTICOS LTDA,BOCKELMANN MARIA ALICE    BR  | ROSATTO SIMONE SOARES    BR  | FUZETO CLAUDIO ROBERTO    BR  | VERNUCCI THIAGO BOSCARO    BR  | BAREL DANIELA CECILIA    BR  | OLIVEIRA KESLEY MORAES GODINHO    BR  | FREITAS MATHEUS PUGGINA DE    BR,C07D27728 | C07D27724,MXPA06013188A  | EP1751125B1 | US2007244168A1 | AT480526T  | BRPI0401742A  | DE602005023437D1 | CN1980907A  | US7763733B2 | HK1107699A1 | BR200401742A  | EP1751125A1 | JP2007537166T  | CN100584833C ,9,9,Yes,Grant,Yes
417,WO2005111112,A2,CELLULOSE AND ACRYLIC BASED POLYMERS AND THE USE THEREOF FOR THE TREATMENT OF INFECTIOUS DISEASES,US20040837153,United States,2004-05-03T00:00:00Z,2004,2005-05-03T00:00:00Z,2005-11-24T00:00:00Z,2005,"NOVA FLUX BIOSCIENCES, INC",RANDO ROBERT F    US  | LABIB MOHAMED E    US,C08B01120 | C08B00316 | A61K03174 | C08G06348 | C08B01300 | C08F21618 | C08F22206,JP2007536237T  | CA2565551A1 | US2005244365A1 | AU2005243219A1 | US2007148124A1 | EP1749041A2 | WO2005076794A3 | US2005176180A1 | US7015075B2 | MXPA06012780A  | CN1918702B  | WO2005111112A3 | EP1721332A2 | CN1918702A  | JP2007522675T  | BRPI0510628A  | WO2005076794A2,9,8,Yes,Grant,Yes
418,WO2005113059,A2,INHIBITION OF HIV-1 REPLICATION BY DISRUPTION OF THE PROCESSING OF THE VIRAL CAPSID-SPACER PEPTIDE 1 PROTEIN,US20030443180P,United States,2003-01-29T00:00:00Z,2003,2005-05-24T00:00:00Z,2005-12-01T00:00:00Z,2005,PANACOS PHARMACEUTICALS INC | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL,SALZWEDEL KARL    US  | LI FENG    US  | WILD CARL T    US  | ALLAWAY GRAHAM P    US  | FREED ERIC O    US,C07K01416 | A61M03700 | A61K03816 | C07K01610 | C12N00700 | G01N033569,EP1594435A2 | EP1758640A2 | AU2005245506A1 | EP1594435A4 | WO2004069166A2 | NO20065982A  | US2010221264A1 | MXPA06013698A  | CA2514563A1 | IL179494D0 | JP2008504808T  | BRPI0511514A  | ZA200610825A  | WO2005113059A3 | JP2006520756T  | EP1758640A4 | US2004265320A1 | US2008200550A1 | WO2004069166A3 | US2008233559A1 | US2005015039A1 | CA2568248A1 | CN101022834A  | US7537765B2 | ZA200506876A  | AU2004210162A1,21,11,Yes,Grant,Yes
419,WO2005115469,A2,ESTROGEN MODULATION OF IFN-GAMMA-MEDIATED CONDITIONS AND DISEASES,US20040573872P,United States,2004-05-24T00:00:00Z,2004,2005-05-24T00:00:00Z,2005-12-08T00:00:00Z,2005,CEDARS-SINAI MEDICAL CENTER,GONSKY RIVKAH    US  | TARGAN STEPHAN R    US,A61K04500 | A61K03526 | A61K03156,CA2567101A1 | AU2005247453B2 | WO2005115469A3 | EP1748793A2 | AU2005247453A1,4,4,Yes,Grant,Yes
420,WO2005116081,A2,STABLE PROTEIN STORAGE AND STABLE NUCLEIC ACID STORAGE IN RECOVERABLE FORM,US20040574274P,United States,2004-05-24T00:00:00Z,2004,2005-05-24T00:00:00Z,2005-12-08T00:00:00Z,2005,GENVAULT CORPORATION,HOGAN MICHAEL    US  | DAVIS JAMES C    US,C12N01510 | C07K01700 | C07K00104,US2006014177A1 | JP2008509226T  | CA2567720A1 | US2010178210A1 | EP1758937A2 | WO2005116081A3 | EP1758937B1 | EP2168975A2 | US7589184B2 | EP2168975A8 | AT441669T  | DE602005016402D1,8,6,Yes,Grant,Yes
421,WO2005121145,A2,HETEROCYCLIC ANTIVIRAL COMPOUNDS,US20040578759P,United States,2004-06-09T00:00:00Z,2004,2005-06-01T00:00:00Z,2005-12-22T00:00:00Z,2005,F. HOFFMANN-LA ROCHE AG,LEE EUN KYUNG    US  | MELVILLE CHRIS RICHARD    US  | ROTSTEIN DAVID MARK    US,C07D48704 | C07D48700,JP2008501743T  | US2006014767A1 | AU2005251891A1 | CN101001860A  | US2007117859A1 | US7164019B2 | AR049209A1 | PT1761542E  | ZA200609837A  | WO2005121145A3 | AT382623T  | CA2569910A1 | SI1761542T1 | DE602005004144T2 | US7714018B2 | ES2297727T3 | MXPA06014404A  | NO20070137A  | IL179534D0 | EP1761542A2 | EP1761542B1 | BRPI0511982A  | DE602005004144D1 | DK1761542T3,19,18,Yes,Grant,Yes
422,WO2005121378,A2,METHODS AND COMPOSITIONS FOR VACCINATION,US20040576840P,United States,2004-06-03T00:00:00Z,2004,2005-05-26T00:00:00Z,2005-12-22T00:00:00Z,2005,SAINT LOUIS UNIVERSITY,BULLER ROBERT MARK L    US,C12Q00170 | A61K039275,WO2005121378A3 | US2009087451A1,2,2,Yes,Application,No
423,WO2005122741,A2,ANTIBODIES AGAINST WEST NILE VIRUS AND THERAPEUTIC AND PROPHYLACTIC USES THEREOF,US20040581819P,United States,2004-06-21T00:00:00Z,2004,2005-06-21T00:00:00Z,2005-12-29T00:00:00Z,2005,WASHINGTON UNIVERSITY,DIAMOND MICHAEL    US  | OLIPHANT THEODORE    US  | DOANE CHRISTOPHER MICHAEL    US,C07K01610,EP1778879A4 | AU2005254110B2 | AU2005254110A1 | MXPA06014795A  | US2009258011A1 | JP2008504029T  | IL179874D0 | CA2571404A1 | US2006067940A1 | WO2005122741A3 | US7527973B2 | EP1778879A2,8,7,Yes,Grant,Yes
424,WO2005124563,A2,COMPOUNDS AND KITS FOR TREATING MUSCLE DISORDERS AND METHODS OF USE THEREOF,US20040578914P,United States,2004-06-12T00:00:00Z,2004,2005-06-13T00:00:00Z,2005-12-29T00:00:00Z,2005,CEPTOR CORPORATION,STRACHER ALFRED    US  | KESNER LEO    US  | BARTON NORMAN W    US  | CARVER THEODORE E    US,G06F01300,WO2005124563A3,1,1,Yes,Application,No
425,WO2006002248,A1,"MONOACYLATED BETULIN AND DIHYDROBETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF",US20020413451P,United States,2002-09-26T00:00:00Z,2002,2005-06-20T00:00:00Z,2006-01-05T00:00:00Z,2006,"NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SC | PANACOS PHARMACEUTICALS, INC. | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL",ALLAWAY GRAHAM P    US  | WILD CARL T    US  | KASHIWADA YOSHIKI    JP  | LEE KUO-HSIUNG    US,C07J05300,NZ538896A  | WO2004028455A3 | EP1551790A4 | WO2004028455A2 | CA2499038A1 | ZA200502824A  | AU2003278930A1 | US2005020548A1 | EP1551790A2 | US7365221B2 | US2004131629A1 | JP2006504704T ,10,8,Yes,Grant,Yes
426,WO2006005529,A1,PARAPOXVIRUSES IN COMBINATION WITH OTHER ANTIVIRAL AGENTS FOR THE TREATMENT OF HIV/AIDS,EP20040016414,European Patent Office,2004-07-13T00:00:00Z,2004,2005-07-08T00:00:00Z,2006-01-19T00:00:00Z,2006,AICURIS GMBH & CO. KG,PAULSEN DANIELA    DE  | RUEBSAMEN-WAIGMANN HELGA    DE  | KUREISHI AMAR    DE  | HUNSMANN GERHARD    DE  | STAHL-HENNIG CHRISTIANE    DE  | MEYERHANS ANDREAS    DE  | SCHUETZ ALEXANDRA    DE  | WEBER OLAF    DE,A61K03576 | A61K03170,CN1984666A  | PT1765370E  | BRPI0513321A  | JP2008505952T  | EP1765370B1 | AT442155T  | US2010255032A1 | ES2330540T3 | EP1765370A1 | DK1765370T3 | HK1097467A1 | CA2573204A1 | DE602005016552D1,12,12,Yes,Grant,Yes
427,WO2006005720,A1,COMBINATION OF ANTI-HIV REVERSE TRANSCRIPTASE AND PROTEASE INHIBITORS,EP20040103256,European Patent Office,2004-07-08T00:00:00Z,2004,2005-07-08T00:00:00Z,2006-01-19T00:00:00Z,2006,TIBOTEC PHARM LTD,HOETELMANS RICHARD MARINUS WIL    NL,A61K031427 | A61K0317076 | A61K031343 | A61P03118,EP1765337B1 | SI1765337T1 | CA2572551A1 | CN1984654A  | DE602005009366D1 | RU2368380C2 | RU2007104774A  | NZ551841A  | BRPI0513051A  | AU2005261701A1 | HR20080612T3 | EP1765337A1 | AT406161T  | ES2313394T3 | DK1765337T3 | ZA200700176A  | MXPA06014930A  | JP2008505870T  | US2007208009A1,17,17,Yes,Grant,Yes
428,WO2006010545,A1,BENZYLTRIAZOLONE COMPOUNDS AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS,US20040591311P,United States,2004-07-27T00:00:00Z,2004,2005-07-20T00:00:00Z,2006-02-02T00:00:00Z,2006,F. HOFFMANN-LA ROCHE AG,DUNN JAMES PATRICK    US  | ELWORTHY TODD RICHARD    US  | STEFANIDIS DIMITRIOS    US  | SWEENEY ZACHARY KEVIN    US,C07D24912 | A61K0314196 | A61P03118,JP2008508211T  | AR050266A1 | US2006025462A1 | SG148179A1 | IL180495D0 | MX2007000788A  | US7666891B2 | RU2394028C2 | BRPI0513858A  | NO20070258A  | CN1993332A  | RU2007106928A  | CN1993332B  | CA2574308A1 | EP1773790A1 | AU2005266530A1,13,13,Yes,Grant,Yes
429,WO2006014282,A2,PRODRUGS OF HIV PROTEASE INHIBITORS,US20040585710P,United States,2004-07-06T00:00:00Z,2004,2005-06-29T00:00:00Z,2006-02-09T00:00:00Z,2006,ABBOTT LAB,DEGOEY DAVID A    US  | FLOSI WILLIAM J    US  | GRAMPOVNIK DAVID J    US  | KLEIN LARRY L    US  | KEMPF DALE J    US  | WANG XIU C    US,C07F00900,AU2005270124A1 | US7718633B2 | CA2571726A1 | US2007270383A1 | BRPI0512970A  | CN101023090A  | IL180433D0 | WO2006014282A3 | JP2008505898T  | MXPA06015108A  | EP1773850A2 | KR20070029244A  | ZA200700101A ,14,12,Yes,Grant,Yes
430,WO2006017341,A2,COATED VAGINAL DEVICES FOR VAGINAL DELIVERY OF THERAPEUTICALLY EFFECTIVE AND/ OR HEALTH-PROMOTING AGENTS,US19970049325P,United States,1997-06-11T00:00:00Z,1997,2005-07-12T00:00:00Z,2006-02-16T00:00:00Z,2006,"UMD, INC",WILSON MICHELLE  US  | DESAI KISHORKUMAR J  US  | PAULETTI GIOVANNI M  US  | ANTOON MITCHELL K JR  US  | CLENDENING CHRIS E  US,A61K00970,US2005163826A1 | AU2002329842B2 | CA2416122A1 | MXPA05007791A  | US7344732B2 | JP2009508869T  | JP2006514838T  | HU200303189A2 | AU2006292507A1 | US2005276836A1 | US2004043071A1 | IL154134D0 | US2005249774A1 | US2003139709A1 | US7744916B2 | AU2005271786A1 | JP2002515069T  | AU2001281287B2 | MXPA04006684A  | CN1201749C  | AU2001281287B8 | AU2005271865B2 | MXPA03000803A  | WO2006017341A3 | US2006002966A1 | CA2622746A1 | BRPI0406635A  | ZA200403724A  | WO2004067063A2 | US6572874B1 | BR200306513A  | BR200306501A  | NZ508130A  | IL169694D0 | EP1474105B1 | IL153719D0 | AU2001278920B2 | US6416779B1 | IL180241D0 | AU200178920A  | WO2007035515A2 | JP2004508296T  | EP1776071A2 | WO2003059318A2 | NZ502120A  | CA2416050A1 | MXPA04006683A  | JP2008506687T  | CA2573583A1 | US2004005345A1 | CA2293346C  | EP1587470A2 | CN1592600A  | IL180243D0 | US6197327B1 | IL190194D0 | EP988009A1 | EP1474106A1 | EP1427366A2 | BR200113134A  | US6982091B2 | NZ541776A  | NO20053657D0 | NO20030422A  | WO2007035515A3 | WO2006017238A1 | CN1741779A  | PL365884A1 | NZ524069A  | CA2514109A1 | US2007036834A1 | BR9810089A  | WO2003020210A3 | WO2003063829A1 | JP2008505977T  | CN1461207A  | WO2004067063A3 | AU7697698A  | IL153719A  | WO9856323A1 | EP1301150A1 | US6086909A  | EP1311213A1 | CA2293346A1 | MXPA02012819A  | AU2005271865A1 | EP1948103A2 | AU2004207456A1 | IL154134A  | US2003144639A1 | CA2470529A1 | AU2003214813B2 | CZ20030494A3 | WO200203896A1 | US6905701B2 | EP988009A4 | IL133431A  | US7341737B2 | CA2457526A1 | AU2003214813A1 | BR200112571A  | IL133431D0 | AU2003219653B2 | JP2006515994T  | JP2004519420T  | EP1771133A1 | NO20030422D0 | CN1306919C  | CA2578247A1 | WO2003020210A2 | HK1029914A1 | DE60324099D1 | ZA200403725A  | NO20053657A  | CN1263454A  | WO200209631A1 | NZ524047A  | US2003049302A1 | JP2006515889T  | JP2005507874T  | WO2003059318A3 | EP1301150A4 | AU20077354B2 | AU200181287A  | CA2470256A1 | CN1199621C  | EP1474105A2,98,17,Yes,Grant,Yes
431,WO2006020415,A1,CHEMICAL COMPOUNDS,US20040598030P,United States,2004-08-02T00:00:00Z,2004,2005-07-29T00:00:00Z,2006-02-23T00:00:00Z,2006,GSK LLC,GUDMUNDSSON KRISTJAN    US  | MILLER JOHN FRANKLIN    US  | TURNER ELIZABETH MADALENA    US,A61K03147 | C07D21538,MX2007001514A  | US2008096861A1 | CA2575560A1 | JP2008508357T  | EP1778231A4 | EP1778231A1,6,6,Yes,Application,No
432,WO2006021456,A1,COMBINATION COMPRISING A STAUROSPORINE AND A CYP3A4 INHIBITOR,GB20040019159,United Kingdom,2004-08-27T00:00:00Z,2004,2005-08-26T00:00:00Z,2006-03-02T00:00:00Z,2006,NOVARTIS AG,COHEN PAMELA SARAH    US,A61K03100 | A61K031553 | A61K031496 | A61P03500 | A61P03502,GB200419159D0,1,1,Yes,Application,No
433,WO2006022759,A1,COMPRESSED COMPOSITE DELIVERY SYSTEM FOR RELEASE-RATE MODULATION OF BIOACTIVES,US20040903267,United States,2004-07-30T00:00:00Z,2004,2004-10-06T00:00:00Z,2006-03-02T00:00:00Z,2006,"SCOLR PHARMA, INC.",FASSIHI REZA   US  | PILLAY VINESS   ZA,A61K00924 | A61K00920 | A61K00922,JP2008508270T  | CA2574981A1 | AU2004322707A1 | US2006024368A1 | EP1778199A1,6,6,Yes,Application,No
434,WO2006023400,A2,CHEMICAL COMPOUNDS,US20040601928P ,United States,2004-08-16T00:00:00Z,2004,2005-08-12T00:00:00Z,2006-03-02T00:00:00Z,2006,GSK LLC,GUDMUNDSSON KRISTJAN    US  | SEBAHAR PAUL RICHARD    US  | RICHARDSON LEAH D AURORA    US,C07D40302,EP1789045A2 | NO20071161A  | IL181160D0 | AU2005277638A1 | RU2007105823A  | ZA200701282A  | KR20070042568A  | PE06462006A1 | US2008045537A1 | WO2006023400A3 | BRPI0514438A  | CN101039672A  | JP2008510006T  | AR050522A1 | MX2007001958A  | CA2577100A1 | RU2350604C2,16,16,Yes,Grant,Yes
435,WO2006026703,A2,CHEMICAL COMPOUNDS,US20040606742P ,United States,2004-09-02T00:00:00Z,2004,2005-08-28T00:00:00Z,2006-03-09T00:00:00Z,2006,GSK LLC,GUDMUNDSSON KRISTJAN    US  | BOGGS SHARON DAVIS    US,C07D40102,WO2006026703A3 | RU2007106779A  | MX2007002615A  | EP1799671A2 | AU2005279835A1 | AR051565A1 | PE06562006A1 | MX2007002679A  | IL181419D0 | PE07122006A1 | ZA200701827A  | KR20070053313A  | CN101052399A  | NO20071366A  | EP1784185A2 | KR20070049682A  | JP2008511669T  | RU2351592C2 | US2007232615A1 | WO2006028896A2 | NO20071418A  | AR050302A1 | CN101052635A  | RU2352567C2 | RU2007106780A  | CA2579059A1 | ZA200701829A  | AU2005282753A1 | JP2008511668T  | CA2578746A1 | EP1799671A4 | WO2006026703A8 | BRPI0514881A  | US2007254910A1 | EP1784185A4 | WO2006028896A3,30,16,Yes,Grant,Yes
436,WO2006026924,A1,THE USE OF GINSENOSIDE IN THE TREATMENT OF AIDS,CN20041074307,China,2004-09-08T00:00:00Z,2004,2005-09-08T00:00:00Z,2006-03-16T00:00:00Z,2006,LI ZELIN | ZENG YUE | ZENG YI | ZENG XIN,LI ZELIN    CN  | ZENG YUE    CN  | ZENG YI    CN  | ZENG XIN    CN,A61K031704 | A61K03578 | A61P03118,CN100411623C  | US2008318876A1 | KR20070110250A  | JP2008512400T  | CN1745756A ,5,5,Yes,Grant,Yes
437,WO2006027711,A2,PRODRUGS CONTAINING NOVEL BIO-CLEAVABLE LINKERS,US20040604632P,United States,2004-08-26T00:00:00Z,2004,2005-08-26T00:00:00Z,2006-03-16T00:00:00Z,2006,PIRAMAL LIFE SCIENCES LIMITED,SATYAM APPARAO    IN,A61K04748,RU2007110846A  | AU2005281359A1 | KR20070053214A  | AT478685T  | ZA200701332A  | CA2577490A1 | BRPI0515218A  | DE602005023185D1 | EP2266623A2 | MX2007002210A  | EP1789091B1 | AR054181A1 | EP2269657A2 | US2006046967A1 | EP2266622A2 | IL181504D0 | EP2266625A2 | JP2008510795T  | EP1789091A2 | EP2075011A2 | WO2006027711A3 | US2006205674A2 | CN101039701A ,20,15,Yes,Grant,Yes
438,WO2006028229,A1,BENZONAPHTHACENEGLYCOSIDE DERIVATIVE AND USE THEREOF,JP20040258886,Japan,2004-09-06T00:00:00Z,2004,2005-09-05T00:00:00Z,2006-03-16T00:00:00Z,2006,FUJIFILM CORPORATION,OKI TOSHIKAZU    JP  | IGARASHI YASUHIRO    JP  | FURUMAI TAMOTSU    JP,C07H015252,EP1810976A1 | US2008027144A1 | US7732582B2 | AU2005280911A1 | CA2579315A1 | CN101048422A  | CN101048422B  | EP1810976A4,6,6,Yes,Grant,Yes
439,WO2006030297,A1,"TASTE MASKED GRANULES COMPRISING CLARITHROMYCIN, HYDROCOLLOIDS AND A COATING",IN2004DE01768,India,2004-09-17T00:00:00Z,2004,2005-09-15T00:00:00Z,2006-03-23T00:00:00Z,2006,RANBAXY LABORATORIES LIMITED,MATHUR RAJEEV SHANKER   IN  | MEHTA KAMAL   IN  | PRABAGARAN CHANDRASEKARAN   IN,A61K00916 | A61P03104,WO2006030297B1,1,1,Yes,Application,No
440,WO2006031825,A2,HUMANIZED ANTIBODIES AGAINST WEST NILE VIRUS AND THERAPEUTIC AND PROPHYLACTIC USES THEREOF,US20040609766P,United States,2004-09-13T00:00:00Z,2004,2005-09-13T00:00:00Z,2006-03-23T00:00:00Z,2006,"MACROGENICS, INC.",JOHNSON LESLIE S   US  | HUANG LING   US,A61K03942 | C07K01608,MX2007002883A  | US2009324593A1 | US2006057149A1 | WO2006031825A3 | US7572456B2 | IL181477D0 | CA2579142A1,5,4,Yes,Grant,Yes
441,WO2006034001,A2,METHODS OF TREATING HIV INFECTION,US20040610343P,United States,2004-09-16T00:00:00Z,2004,2005-09-16T00:00:00Z,2006-03-30T00:00:00Z,2006,BRISTOL MYERS SQUIBB PHARMA CO,KRYSTAL MARK    US  | DEMINIE CAROL A    US  | BOLLINI SAGARIKA    US  | TERRY BRIAN J    US,A61K031551 | A61K031522 | A61K031513 | A61K031195,US2006058286A1 | WO2006034001A3,2,2,Yes,Application,No
442,WO2006034643,A1,"A TRADITIONAL CHINESE MEDICINE COMPOSITION WITH ANTI-HIV ACTIVITY, PREPARATION, AND USE THEREOF",CN20041080516,China,2004-09-30T00:00:00Z,2004,2005-09-27T00:00:00Z,2006-04-06T00:00:00Z,2006,BEIJING CENTURY HEALTH MEDICAL & PHARMACEUTICAL DEVELOPMENT LTD,LI ZELIN    CN  | ZENG YUE    CN  | ZENG YI    CN  | ZENG XIN    CN,A61K03578 | A61P03118,KR20070074557A  | JP2008514654T  | ZA200702619A  | US2009011052A1 | CN1754559A  | CN100581565C ,6,6,Yes,Grant,Yes
443,WO2006035418,A2,COMBINATION PRODUCTS,US20040612784P | US20040612785P | US20040612786P,United States,2004-09-27T00:00:00Z,2004,2005-09-27T00:00:00Z,2006-04-06T00:00:00Z,2006,SIGMOID PHARMA LIMITED,MOODLEY JOEY    IE  | COULTER IVAN    IE,A61K00950 | A61K0314422,CA2581775A1 | WO2006035416A2 | EP1802287A2 | US2008113031A1 | EP2153824A1 | CA2581764A1 | US2008020018A1 | WO2006035417A3 | AT413165T  | WO2006035417A2 | WO2006035418A3 | CA2581816A1 | US2007292523A1 | EP1814530A2 | EP2156826A1 | EP1811979A2 | EP1811979B1 | WO2006035416A3 | DE602005010899D1,16,5,Yes,Grant,Yes
444,WO2006036816,A2,CHEMCIAL COMPOUNDS,US20040612844P,United States,2004-09-24T00:00:00Z,2004,2005-09-23T00:00:00Z,2006-04-06T00:00:00Z,2006,GSK LLC,GUDMUNDSSON KRISTJAN    US  | BOGGS SHARON DAVIS    US,A61K031445,EP1793825A2 | WO2006036816A3 | EP1793825A4 | US2008171740A1 | JP2008514622T ,4,4,Yes,Application,No
445,WO2006037335,A2,USE OF COMPOUNDS FOR THE PREVENTION OF DRUG-INDUCED CELL TOXICITY,DK20040001529,Denmark,2004-10-06T00:00:00Z,2004,2005-10-05T00:00:00Z,2006-04-13T00:00:00Z,2006,RECEPTICON APS,NYKJAER ANDERS    DK,A61P04300 | A61K031435 | A61K03114 | A61K031137 | A61K031132 | A61K0314035 | A61K03115 | A61K031444 | A61K031439 | A61K031155 | A61K031495 | A61K031351,CN101076372A  | EP1809381A2 | WO2006037335A3 | US2009110720A1 | JP2008515821T  | CA2581489A1,6,6,Yes,Application,No
446,WO2006037418,A1,PHARMACEUTICAL COMBINATION COMPRISING DESOXYPEGANINE AND CYP2D6 INHIBITORS,DE200410048927,Germany,2004-10-06T00:00:00Z,2004,2005-09-08T00:00:00Z,2006-04-13T00:00:00Z,2006,LTS LOHMANN THERAPIE-SYSTEME AG,HOFFMANN HANS-RAINER   DE  | MATUSCH RUDOLF   DE,A61K04506 | A61P02530,DE102004048927A1,2,2,Yes,Application,No
447,WO2006037827,A1,"SOLID PHARMACEUTICAL COMPOSITION COMPRISING THE THIAZOLYL METHYL ESTER OF [5S-(5R*,8R*,10R*,11R*)]-10-HYDROXY-2-METHYL-5-(1-METHYLETHYL)-1-[2-1(1-M ETHYLETHYL)-4-THIAZOLYL]-3,6-DIOXO-8,11-BIS(PHENYLMETHYL)-2,4,7,12-TETRAA ZATRIDECAN-13-OIC ACID AND PRE",AR2004P103504,Argentina,2004-09-28T00:00:00Z,2004,2005-09-28T00:00:00Z,2006-04-13T00:00:00Z,2006,COLL FARMA S.L,ZINI ELVIRA BEATRIZ    AR  | RODRIGUEZ FERNANDO JAVIER    AR  | PAGANITTS CECILIA    AR,A61K031426 | A61K04704,EP1800681A1 | BRPI0515293A  | MX2007003431A  | AR045841A1,5,5,Yes,Application,No
448,WO2006039356,A2,SUBSTITUTED N-ARYL-9-OXO-9H-FLUORENE-1-CARBOXAMIDES AND ANALOGS AS ACTIVATOR OF CASPASES AND INDUCERS OF APOPTOSIS,US20040613817P,United States,2004-09-29T00:00:00Z,2004,2005-09-29T00:00:00Z,2006-04-13T00:00:00Z,2006,CYTOVIA INC,KEMNITZER WILLIAM E    US  | CAI SUI XIONG    US  | DREWE JOHN A    US  | SIRISOMA NILANTHA SUDATH    US,A61K031165,WO2006039356A8 | US2008096848A1 | EP1804786A2 | EP1804786A4 | WO2006039356A3,3,3,Yes,Application,No
449,WO2006039488,A2,HCV NS3-NS4A PROTEASE INHIBITION,US20040615412P,United States,2004-10-01T00:00:00Z,2004,2005-09-30T00:00:00Z,2006-04-13T00:00:00Z,2006,VERTEX PHARMA,LIN CHAO    US  | TAYLOR WILLIAM P    US,A61K03805,KR20070061570A  | AU2005291918A1 | EP1804821A4 | SG155967A1 | US2011059886A1 | EP1804821A2 | NZ554351A  | CA2583472A1 | WO2006039488A3 | ZA200703484A  | NO20072286A  | CN101072575A  | IL182339D0 | MX2007003812A  | BRPI0516825A  | US2008267915A1 | JP2008514723T ,15,14,Yes,Application,No
450,WO2006041538,A2,A MIXTURE FOR TRANSDERMAL DELIVERY OF LOW AND HIGH MOLECULAR WEIGHT COMPOUNDS,US19980092061P,United States,1998-07-08T00:00:00Z,1998,2005-05-25T00:00:00Z,2006-04-20T00:00:00Z,2006,"ORYXE ENERGY INTERNATIONAL, INC.",JORDAN FREDERICK    US  | DOLBEAR GEOFF E    US,A61K00970,EP1765310A2 | US2006193901A1 | US7201919B2 | US6759056B2 | AU2005294805A1 | CA2566354A1 | US2006188531A1 | WO200002601A2 | US7316820B2 | WO2005039464A1 | US2008064640A1 | US7300666B2 | AU5093199A  | US2004170676A1 | WO2006041538A3 | US2006188532A1 | AU2004283067A1 | EP1684681A1 | MXPA06003887A  | US2005019384A1 | US2003064093A1 | US6946144B1 | US7220427B2 | US2008154210A1 | CN1874740A  | WO200002601A3 | JP2007508297T  | CA2540539A1,22,8,Yes,Grant,Yes
451,WO2006041900,A2,"SUBSTITUTED N-ARYL-1H-PYRAZOLO[3,4-b]QUINOLIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS",US20040616539P,United States,2004-10-07T00:00:00Z,2004,2005-10-06T00:00:00Z,2006-04-20T00:00:00Z,2006,CYTOVIA INC,ZHANG HAN-ZHONG    US  | CAI SUI XIONG    US  | DREWE JOHN A    US,A61K0314745 | C07D47102,WO2006041900A8 | AU2005294430A1 | US2007253957A1 | WO2006041900A3 | EP1807426A2,4,4,Yes,Application,No
452,WO2006044968,A2,COMBINATION THERAPY FOR TREATING VIRAL INFECTIONS,US20040620023P,United States,2004-10-19T00:00:00Z,2004,2005-10-18T00:00:00Z,2006-04-27T00:00:00Z,2006,ACHILLION PHARMACEUTICALS INC,POTTAGE JOHN    US,A61K03170 | A61K03155 | A61K031535 | A61P03114 | A61P03118,CA2584670A1 | EP2266579A1 | WO2006044968A3 | US2006084628A1 | EP1802315A2,5,4,Yes,Application,No
453,WO2006046134,A2,METHOD OF SCREENING BY USING CONFORMATION SENSITIVE PEPTIDES,EP20040292224,European Patent Office,2004-09-16T00:00:00Z,2004,2005-09-16T00:00:00Z,2006-05-04T00:00:00Z,2006,VIVALIS,MEHTALI MAJID    FR,G01N03368 | G01N033566 | C07K01416,EP1637885A1 | WO2006046134A3 | US2008076669A1 | EP1789799A2,4,3,Yes,Application,No
454,WO2006050165,A2,METHODS AND COMPOSITIONS FOR REDUCING NEURODEGENERATION IN AMYOTROPHIC LATERAL SCLEROSIS,US20040624100P,United States,2004-11-01T00:00:00Z,2004,2005-10-31T00:00:00Z,2006-05-11T00:00:00Z,2006,YOO SEO HONG,YOO SEO HONG    US,A61K031575 | A61K04736 | A61K00900 | A61P02516 | A61P02528,JP2008518935T  | KR20070089926A  | AU2005302452B2 | AT491456T  | IL182805D0 | CN101048164A  | DE602005025391D1 | EP1814558A2 | EP2255812A1 | CA2585471A1 | US2006142241A1 | AU2005302452A1 | WO2006050165A3 | EP1814558B1,11,10,Yes,Grant,Yes
455,WO2006050930,A2,CONJUGATE MOLECULE COMPOUNDS WITH ENHANCED CELL UPTAKE ACTIVITY,EP20040026934,European Patent Office,2004-11-12T00:00:00Z,2004,2005-11-09T00:00:00Z,2006-05-18T00:00:00Z,2006,"XIGEN S.A,",BONNY CHRISTOPHE    CH  | COQUOZ DIDIER    CH  | CHEN JIANHUA    CN,A61K04748 | A61P03500 | A61P03118 | C07K00706,WO2006050930A3 | IL182760D0 | BRPI0517843A  | US2010256041A1 | AR051765A1 | JP2008519785T  | AU2005303949A1 | EP1656951A1 | EA200700976A1 | CN101072589A  | EP1809334A2 | CA2585421A1,11,10,Yes,Application,No
456,WO2006052452,A1,NON-GELATIN SOFT CAPSULE SYSTEM,US20040984205,United States,2004-11-08T00:00:00Z,2004,2005-10-26T00:00:00Z,2006-05-18T00:00:00Z,2006,CATALENT PHARMA SOLUTIONS,SHELLEY RICKEY S    US  | STROUD NORMAN    US  | YOUNGBLOOD ELIZABETH    US  | TANNER KEITH    US,A61K00948 | A61K00966,EP1809261A4 | UY29200A1 | BRPI0517674A  | JP2008519075T  | AR051237A1 | US2006099246A1 | CA2585721A1 | EP1809261A1 | EP2289496A3 | MX2007005403A  | PE11362006A1 | AU2005305232A1 | AU2005305232B2 | EP2289496A2,12,11,Yes,Application,No
457,WO2006053255,A2,"NOVEL BETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF",US20040626886P,United States,2004-11-12T00:00:00Z,2004,2005-11-14T00:00:00Z,2006-05-18T00:00:00Z,2006,"MYREXIS, INC.",ROBINSON GARY N    US  | WILD CARL T    US  | ASHTON MARK    GB  | THOMAS RUSSELL    IT  | MONTALBETTI CHRISTIAN    GB  | COULTER THOMAS STEPHEN    GB  | MAGARACI FILIPPO    GB  | TOWNSEND ROBERT JAMES    GB  | NITZ THEODORE JOHN    US,A61K03166 | C07J05100 | A61K03158 | C07J05300,JP2008519857T  | CN101142227A  | NO20072978A  | ZA200704806A  | EP1828223A2 | MX2007005694A  | WO2006053255A3 | US2006205697A1 | KR20070101851A  | AR051768A1 | EP1828223A4 | IL183102D0 | AU2005304323A1 | CA2587498A1 | BRPI0517343A ,13,13,Yes,Application,No
458,WO2006057637,A1,DRIED FORMS OF AQUEOUS SOLUBILIZED BILE ACID DOSAGE FORMULATION: PREPARATION AND USES THEREOF,WO2004US39507,WIPO,2004-11-24T00:00:00Z,2004,2004-11-24T00:00:00Z,2006-06-01T00:00:00Z,2006,YOO SEO HONG,YOO SEO HONG    US,A61K00916,AU2004325203A1 | CN101065110A  | BRPI0419213A  | JP2008521800T  | EP1819318A1 | CA2588168A1,7,7,Yes,Application,No
459,WO2006057945,A2,"2,3,4,6-SUBSTITUTED PYRIDYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE",US20040563612P,United States,2004-04-20T00:00:00Z,2004,2005-11-18T00:00:00Z,2006-06-01T00:00:00Z,2006,MERCK & CO INC,NANTERMET PHILIPPE G    US  | STANTON MATTHEW G    US  | RAJAPAKSE HEMAKA A    US  | SELNICK HAROLD G    US  | BARROW JAMES C    US  | STAUFFER SHAUN R    US  | VACCA JOSEPH P    US  | MOORE KEITH P    US  | STACHEL SHAWN J    US,A61K0314439 | C07D40302,EP1817311A4 | CA2587360A1 | EP1817311A2 | WO2005103043A1 | CN101061113A  | US2005242069A1 | AU2005236063A1 | US7094987B2 | JP2008520718T  | US2007293497A1 | CN1942467A  | EP1740581A4 | EP1740581A1 | US2008015233A1 | CA2563639A1 | AU2005309760A1 | JP2007533757T  | WO2006057945A3,15,7,Yes,Grant,Yes
460,WO2006058920,A1,USE OF OMEGA-3 FATTY ACID(S) FOR TREATING HYPERCHOLESTEROLEMIA CAUSED BY ANTI-RETROVIRAL TREATMENT OF HIV-INFECTED PATIENTS,FR20040012862,France,2004-12-03T00:00:00Z,2004,2005-12-02T00:00:00Z,2006-06-08T00:00:00Z,2006,PIERRE FABRE MEDICAMENT,GARDETTE JEAN    FR,A61K031202 | A61K03600 | A61K03560 | A61P00306,CA2589797A1 | FR2878747B1 | RU2007123368A  | CN101068542A  | JP2008521863T  | EP1827414A1 | AU2005311266A1 | NO20073318A  | BRPI0515823A  | MX2007006561A  | KR20070089216A  | US2008113046A1 | IL183349D0 | FR2878747A1 | ZA200705392A ,14,14,Yes,Grant,Yes
461,WO2006060918,A1,NOVEL SPIROTROPANE COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY,US20040634257P,United States,2004-12-09T00:00:00Z,2004,2005-12-09T00:00:00Z,2006-06-15T00:00:00Z,2006,VIROCHEM PHARMA INC,CHAN CHUN KONG LAVAL    CA  | MOINET CHRISTOPHE    CA  | COURCHESNE MARC    CA  | VAILLANCOURT LOUIS    CA  | BUBENIK MONICA    CA,C07D47120 | A61K031438,CA2590737A1 | US2009047238A1 | EP1824853A4 | EP1824853A1,4,4,Yes,Application,No
462,WO2006060919,A1,NOVEL SPIROTROPANE COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY,US20040634266P,United States,2004-12-09T00:00:00Z,2004,2005-12-09T00:00:00Z,2006-06-15T00:00:00Z,2006,VIROCHEM PHARMA INC,CHAN CHUN KONG LAVAL    CA  | MOINET CHRISTOPHE    CA  | COURCHESNE MARC    CA  | VAILLANCOURT LOUIS    CA  | BLAIS CHARLES    CA  | BUBENIK MONICA    CA,C07D47120 | C07D49820 | A61K031439,ZA200705033A  | CN101098871A  | US2008267906A1 | EA200701248A1 | CA2587508A1 | KR20070095310A  | EP1831222A4 | AU2005313813A1 | BRPI0518859A2 | SG158111A1 | MX2007006776A  | JP2008522986T  | NZ555624A  | AP200704058D0 | EP1831222A1 | US7960403B2,14,14,Yes,Grant,Yes
463,WO2006065377,A2,METHODS OF TREATING LENTIVIRUS INFECTION,US20040624664P,United States,2004-11-02T00:00:00Z,2004,2005-10-31T00:00:00Z,2006-06-22T00:00:00Z,2006,THE J. DAVID GLADSTONE INSTITUTES,GRANT ROBERT M    US  | BOURARA KHAOULA    US,A61K04900 | C12Q00168 | A61K03800,WO2006065377A3 | US2009105187A1,2,2,Yes,Application,No
464,WO2006065947,A1,METHOD FOR TREATMENT OF HIV INFECTION,US20040015631,United States,2004-12-17T00:00:00Z,2004,2005-12-15T00:00:00Z,2006-06-22T00:00:00Z,2006,"NIPPON ZOKI PHARMACEUTICAL CO., LTD.",ANSARI AFTAB A    US  | GERSHWIN M ERIC    US,A61K03802 | A61K03800 | A61K03536 | A61K03512 | A61K04700,KR20070089924A  | US2006134646A1 | EP1827475A4 | CA2591087A1 | US2008112978A1 | JP2008524234T  | EP1827475A1,7,6,Yes,Application,No
465,WO2006066414,A1,"HYDROXYDIHYDROPYRIDOPY RAZINE-1,8-DIONES AND METHODS FOR INHIBITING HIV INTEGRASE",US20040638180P,United States,2004-12-23T00:00:00Z,2004,2005-12-22T00:00:00Z,2006-06-29T00:00:00Z,2006,VIROCHEM PHARMA INC,CHAN CHUN KONG LAVAL    CA  | LIU BINGCAN    CA  | NGUYEN-BA NGHE    CA  | CADILHAC CAROLINE    CA  | TURCOTTE NATHALIE    CA,C07D47104 | A61K0317072 | A61K031522 | A61K0314985 | A61P03118,EP1973906A1 | CA2634499A1,3,3,Yes,Application,No
466,WO2006074147,A2,COMPOUNDS AND THERAPEUTICAL USE THEREOF,US20030484325P,United States,2003-07-03T00:00:00Z,2003,2006-01-03T00:00:00Z,2006-07-13T00:00:00Z,2006,"MYREXIS, INC.",CAI SUI XIONG    US  | ANDERSON MARK B    US  | WILLARDSEN ADAM    US  | SIRISOMA NILANTHA SUDATH    US  | ZHANG HONG    US  | SUZUKI KAZUYUKI    US,A61K031541,AU2004253967A1 | US2008032974A1 | US2007244113A1 | US2007208044A1 | CN1984660B  | JP2007524637T  | US2007244114A1 | WO2005003100A2 | US7618975B2 | CA2592900A1 | WO2006074147A3 | US2008004297A1 | NZ544472A  | CN1984660A  | AU2004253967A8 | EP1660092A2 | EP1833482A4 | US2005137213A1 | US2010069383A1 | WO2005003100A3 | KR20060052775A  | US2008039479A1 | US2007249601A1 | EP1833482A2 | AU2004253967B2 | CA2531327A1,20,9,Yes,Grant,Yes
467,WO2006076131,A2,CHEMICAL COMPOUNDS,US20040636933P,United States,2004-12-17T00:00:00Z,2004,2005-12-16T00:00:00Z,2006-07-20T00:00:00Z,2006,GSK LLC,GUDMUNDSSON KRISTJAN    US,A61K0314741 | C07D49102,US2008207634A1 | JP2008524255T  | EP1838312A2 | WO2006076131A3 | EP1838312A4,4,4,Yes,Application,No
468,WO2006078876,A2,COMPOSITIONS AND METHODS RELATING TO MITOCHONDRIAL HYPERPOLARIZATION IN NEUROLOGICAL DISEASE,US20050645426P,United States,2005-01-20T00:00:00Z,2005,2006-01-19T00:00:00Z,2006-07-27T00:00:00Z,2006,UNIVERSITY OF ROCHESTER,PERRY SETH W    US  | NORMAN JOHN PHILLIP    US  | DEWHURST STEPHEN    US  | GELBARD HARRIS A    US,A61K031203,WO2006078876A9 | EP1845969A4 | CA2594910A1 | AU2006206399A1 | EP1845969A2 | US2008269161A1 | WO2006078876A3,5,5,Yes,Application,No
469,WO2006089546,A1,TABLETS COMPRISING A HIGH LOAD OF STRONTIUM,DK20030000691,Denmark,2003-05-07T00:00:00Z,2003,2005-11-07T00:00:00Z,2006-08-31T00:00:00Z,2006,OSTEOLOGIX A/S,CHRISTGAU STEPHAN    DK,A61K00920 | A61K03324 | A61K03128,EP1855654A1 | EP1758652A2 | US2010143473A1 | EP1622629A2 | CA2524603A1 | EP2266585A2 | EP2266584A3 | WO2004098618A2 | WO2005123192A3 | JP2009263381A  | CN101010087A  | AU2005240257A1 | ES2275218T3 | AU2004237438B2 | JP2008502608T  | AT342722T  | AU2010249227A1 | US2007282127A1 | DK1732575T3 | WO2004098619A3 | AU2004237437B2 | US2006122274A1 | DE602005025616D1 | AT493137T  | WO2005123193A2 | WO2005108339A2 | JP2006525243T  | AU2004237439A1 | WO2004098619A2 | WO2004098617A2 | EP1758653A2 | EP2266584A2 | JP2008502609T  | EP1534305B9 | EP1534305B1 | AU2005216596A1 | CA2565840A1 | EP1745791A3 | US2009035315A1 | WO2004098617A3 | EP1622630A2 | US2009191282A1 | WO2005082385A1 | US7595342B2 | AU2004237437A1 | JP4354984B2 | AU2005216596B2 | AU2004237439B2 | CA2519189A1 | WO2005123193A3 | EP1732575A1 | JP2006525241T  | WO2005123192A2 | US2008221213A1 | US2010048697A1 | PT1534305E  | CA2570503A1 | DK1534305T3 | DE602004002832T2 | AU2004237438A1 | JP2007523916T  | US2006275503A1 | EP1744770A2 | KR20060125861A  | AU2005254154A1 | EP1534305A2 | US2006216358A1 | WO2005108339A3 | CA2557324A1 | AU2011200693A1 | US2009291926A1 | EP1745791A2 | DE602004002832D1 | AU2005254155A1 | US7589235B2 | CA2570389A1 | US2008167513A1 | US2008317849A1 | CA2524610A1 | WO2004098618A3 | EP1732575B1 | JP2006525242T  | JP2007536288T ,68,14,Yes,Grant,Yes
470,WO2006090264,A1,"A PROCESS FOR THE SYNTHESIS OF 2-AMINO-5-PROTECTED AMINO-3-HYDROXY-1, 6-DIPHENYLHEXANE OR A SALT THEREOF - AN INTERMEDIATE FOR ANTIVIRAL DRUGS",IN2005DE00430,India,2005-02-28T00:00:00Z,2005,2006-02-28T00:00:00Z,2006-08-31T00:00:00Z,2006,RANBAXY LABORATORIES LIMITED,BOSE PROSENJIT    IN  | BISWAS SUJOY    IN  | RATHORE RAMENDRA SINGH    IN  | SACHDEVA YOGINDER PAL    IN  | KUMAR YATENDRA    IN,C07C27120 | C07C26904 | C07C21300 | C07D23910 | C07D27728,None,1,1,Yes,Application,No
471,WO2006090270,A1,ACID ADDITION SALT OF 2-ISOPROPYL-4-(((N-METHYL)AMINO)METHYL)THIAZOLE AND ITS?USE IN THE PREPARATION OF RITONAVIR,IN2005DE00437,India,2005-02-28T00:00:00Z,2005,2006-02-28T00:00:00Z,2006-08-31T00:00:00Z,2006,RANBAXY LABORATORIES LIMITED,BOSE PROSENJIT    IN  | SACHDEVA YOGINDER PAL    IN  | BISWAS SUJAY    IN  | RATHORE RAMENDRA SINGH    IN  | KUMAR YATENDRA    IN,C07D27728 | A61K03141,None,1,1,Yes,Application,No
472,WO2006091529,A2,A SOLID PHARMACEUTICAL DOSAGE FORMULATION,US20030498412P,United States,2003-08-28T00:00:00Z,2003,2006-02-21T00:00:00Z,2006-08-31T00:00:00Z,2006,ABBOTT LAB,ROSENBERG JOEERG    DE  | REINHOLD ULRICH    DE  | LIEPOLD BERND    DE  | BERNDL GUNTHER    DE  | BREITENBACH JOERG    DE  | ALANI LAMAN    US  | GHOSH SOUMOJEET    US,A61K031513 | A61K031426 | A61K00928 | A61K00920,AR055734A1 | WO2006091529A3 | IL185390D0 | CA2598827A1 | EA200701790A1 | US2008299203A1 | UY29391A1 | US2005084529A1 | KR20070114294A  | NO20074807A  | US2005143404A1 | EP1855683A2 | CN101163479A  | ZA200707022A  | PE10162006A1 | JP2008531565T  | MX2007010275A  | BRPI0609173A2 | US2011015216A1 | SV2007002427A  | EA014446B1 | EP2206500A1 | NZ560829A  | US2011008430A1 | US2007249643A1 | EP2283844A1 | PE01232010A1 | AU2006216856A1,28,18,Yes,Grant,Yes
473,WO2006091534,A1,PIPERIDINYL PIPERIDINE DERIVATIVES USEFUL AS INHIBITORS OF CHEMOKINE RECEPTORS,US20050655538P,United States,2005-02-23T00:00:00Z,2005,2006-02-21T00:00:00Z,2006-08-31T00:00:00Z,2006,SCHERING CORP,CHAN TZE-MING    US  | COX KATHLEEN    US  | FENG WENQING    US  | MILLER MICHAEL W    US  | WESTON DANIEL    GB  | MCCOMBIE STUART    US,C07D40114 | A61P03118 | A61K0314545,EP1858886A1 | CN101133050A  | CA2598568A1 | US2006223856A1 | MX2007010257A  | US7705019B2 | AR055313A1 | JP2008531566T  | PE10742006A1,9,9,Yes,Grant,Yes
474,WO2006091692,A1,PIPERIDINYL PIPERAZINE DERIVATIVES USEFUL AS INHIBITORS OF CHEMOKINE RECEPTORS,US20050655572P,United States,2005-02-23T00:00:00Z,2005,2006-02-21T00:00:00Z,2006-08-31T00:00:00Z,2006,SCHERING CORP,CHAN TZE-MING    US  | COX KATHLEEN    US  | FENG WENQING    US  | MILLER MICHAEL W    US  | WESTON DANIEL    GB  | MCCOMBIE STUART W    US,C07D40114 | C07D40106 | A61P03118 | A61K031496,CA2598651A1 | ZA200707019A  | MX2007010258A  | RU2007135126A  | PE10122006A1 | AU2006216731A1 | JP2008531575T  | CN101163695A  | NO20074825A  | AR054740A1 | IL185395D0 | US7659275B2 | BRPI0609251A2 | EP1858887A1 | KR20070107085A  | US2006223821A1,15,15,Yes,Grant,Yes
475,WO2006091798,A2,VACCINES AND METHODS FOR PREVENTION AND TREATMENT OF DRUG-RESISTANT HIV-1 AND HEPATITIS B VIRUS,US20050655984P,United States,2005-02-22T00:00:00Z,2005,2006-02-22T00:00:00Z,2006-08-31T00:00:00Z,2006,"THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH",CATANZARO ANDREW    US  | YARCHOAN ROBERT    US  | BERZOFSKY JAY A    US  | OKAZAKI TAKAHIRO    JP  | SNYDER JAMES T II    US  | BRODER SAMUEL    US,A61K03921 | A61K03912 | A61K03100 | C07K01418 | A61K03929 | C07K01402 | C07K01416,WO2006091798A3 | US2009317418A1,2,2,Yes,Application,No
476,WO2006096444,A2,CHEMICAL COMPOUNDS,US20050658530P,United States,2005-03-04T00:00:00Z,2005,2006-03-01T00:00:00Z,2006-09-14T00:00:00Z,2006,GSK LLC,GUDMUNDSSON KRISTJAN    US  | CATALANO JOHN G    US  | SVOLTO ANGILIQUE    US,A61K0314745,US2009093454A1 | WO2006096444A3 | EP1853604A4 | JP2008531716T  | EP1853604A2,4,4,Yes,Application,No
477,WO2006097323,A1,TETRAHYDRO-ISOQUINOLIN-l-ONES FOR THE TREATMENT OF CANCER,DE200510012680,Germany,2005-03-18T00:00:00Z,2005,2006-03-17T00:00:00Z,2006-09-21T00:00:00Z,2006,WEBER LUTZ,WEBER LUTZ    DE,C07D21724 | A61P03500 | A61K031435,US2009068144A1,2,2,Yes,Application,No
478,WO2006101920,A2,COMPOSITIONS AND METHODS RELATED TO THE MANIPULATION OF ADENOSINE 2A RECEPTOR SIGNALING FOR THE TREATMENT OF HIV ASSOCIATED NEURONAL DAMAGE,US20050663059P,United States,2005-03-18T00:00:00Z,2005,2006-03-16T00:00:00Z,2006-09-28T00:00:00Z,2006,UNIVERSITY OF ROCHESTER,DEWHURST STEPHEN    US  | RAMIREZ SERVIO    US  | LU SHAO-MING    US  | GELBARD HARRIS A    US  | MAGGIRWAR SANJAY B    US  | FAN SHONGSHAN    US,A61K031522,WO2006101920A3,1,1,Yes,Application,No
479,WO2006104646,A1,HIV PROTEASE INHIBITORS,US20050660706P,United States,2005-03-11T00:00:00Z,2005,2006-03-07T00:00:00Z,2006-10-05T00:00:00Z,2006,GSK LLC,MCLEAN ED W    US  | MILLER JOHN FRANKLIN    US,A61K031427 | C07D41714,JP2008533017T  | EP1855672A1 | US2008194554A1,4,4,Yes,Application,No
480,WO2006105374,A2,OPTIMIZING PHARMACODYNAMICS OF THERAPEUTIC AGENTS FOR TREATING VASCULAR TISSUE,US20050096241,United States,2005-03-30T00:00:00Z,2005,2006-03-30T00:00:00Z,2006-10-05T00:00:00Z,2006,CARTER ANDREW J,CARTER ANDREW J    US,A61K03820 | A61K031496 | A61K0314745 | A61K0314178 | A61K0317048 | A61K031551 | A61K031553 | A61K03156,WO2006105374A3 | EP1874281A2 | US2006222627A1 | EP1874281A4,3,3,Yes,Application,No
481,WO2006108556,A2,PHARMACEUTICAL AEROSOL COMPOSITION,EP20050008322,European Patent Office,2005-04-15T00:00:00Z,2005,2006-04-06T00:00:00Z,2006-10-19T00:00:00Z,2006,PARI GMBH,KELLER MANFRED    DE  | FRIEDRICH INGO    DE  | JAUERNIG JUERGEN    DE  | LINTZ FRANK-CHRISTOPHE    DE,A61K00912 | A61K03813 | A61K03158 | A61M01500 | A61P01100 | A61P03702,CA2604327A1 | EP1712220A1 | BRPI0607574A2 | MX2007012802A  | WO2006108556A3 | RU2007141868A  | AU2006233604A1 | EP1874270A2,8,7,Yes,Application,No
482,WO2006108666,A1,"MEFLOQUINE, NELFINAVIR AND SAQUINAVIR AS NOVEL AGENTS FOR NEURODEGENERATIVE AND (NEURO-) INFLAMMATORY DISEASES",US20050670648P,United States,2005-04-13T00:00:00Z,2005,2006-04-13T00:00:00Z,2006-10-19T00:00:00Z,2006,PROTEOSYS AG,SCHRATTENHOLZ ANDRE    DE,A61K0314709 | A61P01706 | A61K0314725 | A61P02506 | A61P02528,None,1,1,Yes,Application,No
483,WO2006108828,A1,"(1, 10B-DIHYDRO-2-(AMINOALKYL- PHENYL)-5H-PYRAZ0L0 [1,5-C] [1,3] BENZ0XAZIN-5-YL) PHENYL METHANONE DERIVATIVES AS HIV VIRAL REPLIATION INHIBITORS",EP20050102847,European Patent Office,2005-04-11T00:00:00Z,2005,2006-04-11T00:00:00Z,2006-10-19T00:00:00Z,2006,TIBOTEC PHARM LTD,TAHRI ABDELLAH    BE  | HU LILI    BE  | SURLERAUX DOMINIQUE LOUIS NEST    BE  | WIGERINCK PIET TOM BERT PAUL    BE,C07D49804 | A61P03100 | A61K0315365,MX2007012630A  | JP2008535894T  | RU2007141639A  | CA2604686A1 | US2009048242A1 | US2008214534A1 | AU2006233922A1 | CN101155816A  | EP1871777A1 | US7745432B2 | US7465727B2 | AR056652A1,11,10,Yes,Grant,Yes
484,WO2006108879,A2,USE OF A SULFONAMIDE COMPOUND FOR IMPROVING THE PHARMACOKINETICS OF A DRUG,EP20050103035,European Patent Office,2005-04-15T00:00:00Z,2005,2006-04-14T00:00:00Z,2006-10-19T00:00:00Z,2006,TIBOTEC PHARM LTD,VAN T KLOOSTER GERBEN ALBERT E    NL  | WIGERINCK PIET TOM BERT PAUL    BE  | DE MEYER SANDRA    BE  | BAERT LIEVEN ELVIRE COLETTE    BE  | DE KOCK HERMAN AUGUSTINUS    BE,A61K031426 | A61P03118,CA2604799A1 | AU2006234335A1 | CN101175491A  | BRPI0608322A2 | US2008287488A1 | EP1874307A2 | JP2008535896T  | ZA200708811A  | AR053845A1 | EA200702242A1 | WO2006108879A3,11,11,Yes,Application,No
485,WO2006114001,A1,METHOD FOR IMPROVING PHARMACOKINETICS OF PROTEASE INHIBITORS AND PROTEASE INHIBITOR PRECURSORS,US20050675082P,United States,2005-04-27T00:00:00Z,2005,2006-04-26T00:00:00Z,2006-11-02T00:00:00Z,2006,AMBRILIA BIOPHARMA INC.,WU JINZI J    CA  | STRANIX BRENT RICHARD    CA  | GE MICHAEL    CA  | MILOT GUY    CA  | PETRELLA MARCO    CA  | PANCHAL CHANDRA    CA,A61K04506 | A61K031513 | A61K0314196 | A61K031135 | A61P03118 | A61K0315375 | A61K031661,US2006287316A1 | EP1877091A1 | EP1877091A4 | CA2606025A1,4,4,Yes,Application,No
486,WO2006120495,A1,"PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIVIRAL AGENT, AN ANTITUMOUR AGENT OR AN ANTIPARASITIC AGENT AND AN ACTIVE SUBSTANCE SELECTED FROM CARVEOL, THYMOL, EUGENOL, BORNEOL AND CARVACROL",WO2005IB01314,WIPO,2005-05-13T00:00:00Z,2005,2005-05-13T00:00:00Z,2006-11-16T00:00:00Z,2006,ADVANCED SCIENTIFIC DEVELOPMENTS,REMMAL ADNANE  MA,A61P03112 | A61K04506 | A61K03105 | A61K031045 | A61P03500 | A61P03300 | A61P03310,JP2008540505T  | WO2006120568A3 | CA2608061A1 | CA2606887A1 | CN101175532A  | WO2006120568A2 | US2008171768A1 | CN101193682A  | ZA200710785A  | AP200704228D0 | EP1883452A2 | WO2006120564A1 | EA200702486A1 | US2008171709A1 | EP1879656A1,16,9,Yes,Application,No
487,WO2006125042,A1,METHOD FOR THE TREATMENT OF DRUG-INDUCED SEXUAL DYSFUNCTION,US20050682760P,United States,2005-05-19T00:00:00Z,2005,2006-05-17T00:00:00Z,2006-11-23T00:00:00Z,2006,BOEHRINGER INGELHEIM INTERNATIONAL GMBH,PYKE ROBERT    US,A61K031496 | A61P01510 | A61P01500,CA2608363A1 | US2006264511A1 | JP2008540673T  | EP1888071A1,5,5,Yes,Application,No
488,WO2006129134,A1,SYNERGIC COMBINATIONS COMPRISING A STYRYLQUINOLINE COMPOUND AND OTHER HIV INFECTION THERAPEUTIC AGENTS,WO2005IB01538,WIPO,2005-06-01T00:00:00Z,2005,2005-06-01T00:00:00Z,2006-12-07T00:00:00Z,2006,BIOALLIANCE PHARMA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE | ECOLE NORMALE SUPERIEURE DE CACHAN | UNIVERSITE DE PARIS,LEH HERVE    FR  | ZOUHIRI FATIMA    FR  | MOUSCADET JEAN-FRANCOIS    FR  | THOMAS CLAIRE-MARIE    FR,A61K03147 | A61K031506 | A61K031402 | A61K031551 | A61P03118 | C07D21548,JP2008542352T  | CA2610029A1 | US2008280849A1,4,4,Yes,Application,No
489,WO2006129276,A1,PROCESSES FOR THE PREPARATION OF STABLE POLYMORPHIC FORM I OF RITONAVIR,IN2005DE01385,India,2005-05-30T00:00:00Z,2005,2006-05-30T00:00:00Z,2006-12-07T00:00:00Z,2006,RANBAXY LABORATORIES LIMITED,SACHDEVA YOGINDER PAL    IN  | BOSE PROSENJIT    IN,C07D27728 | A61P03118 | A61K031426,EP1891027A1 | US2008312300A1,3,3,Yes,Application,No
490,WO2006130426,A2,MODULATORS OF CCR-5 ACTIVITY,US20050685147P,United States,2005-05-27T00:00:00Z,2005,2006-05-25T00:00:00Z,2006-12-07T00:00:00Z,2006,"KEMIA, INC",BOMAN ERIK    US  | DAHL RUSSELL    US  | DELAET NANCY G J    US  | ERNST JUSTIN    US  | LUM CHRISTOPHER    US  | SEBO LUBOMIR    US  | URBAN JAN    US,A01N04358 | A01N04360 | A01N04342 | A61K03150 | A61K03144 | A61K031495 | A61K0314965,WO2006130426A3,1,1,Yes,Application,No
491,WO2006130477,A2,METHODS AND COMPOSITIONS FOR DETERMINING RESISTANCE OF HIV-1 TO PROTEASE INHIBITORS,US20050685336P,United States,2005-05-27T00:00:00Z,2005,2006-05-25T00:00:00Z,2006-12-07T00:00:00Z,2006,"MONOGRAM BIOSCIENCES, INC.",PARKIN NEIL T    US,C12Q00168,WO2006130477A3 | CA2609910A1 | US2009087841A1 | EP1896618A4 | EP1896618A2,4,4,Yes,Application,No
492,WO2006133194,A2,METHODS FOR TREATING VIRAL INFECTION WITH ORAL OR INJECTIBLE DRUG SOLUTION,US20050687813P,United States,2005-06-06T00:00:00Z,2005,2006-06-06T00:00:00Z,2006-12-14T00:00:00Z,2006,"VGX PHARMACEUTICALS, INC",KIM JONG JOSEPH    US  | MATHARU RAJINDER    US,A61K00914,WO2006133194A3 | US2009074721A1,2,2,Yes,Application,No
493,WO2006136175,A2,PHARMACEUTICAL COMPOSITIONS COMPRISING TACROLIMUS AND A CYP3A4 INHIBITOR,DK20050000917,Denmark,2005-06-22T00:00:00Z,2005,2006-06-22T00:00:00Z,2006-12-28T00:00:00Z,2006,LIFECYCLE PHARMA A/S,RANKLOEVE LISBET BOENLOEKKE    DK,A61K04506 | A61K0314523 | A61K031366 | A61K031352 | A61K031496 | A61P03500,EP1896075A2 | CA2612829A1 | WO2006136175A3,3,3,Yes,Application,No
494,WO2007000234,A1,MOXIFLOXACIN THERAPEUTIC USE FOR TREATING IMMUNE SYSTEM FUNCTIONAL DISTURBANCES,DE200510029370,Germany,2005-06-24T00:00:00Z,2005,2006-06-09T00:00:00Z,2007-01-04T00:00:00Z,2007,BAYER AG,WEBER OLAF   DE  | SEILER PETER   DE,A61K0314709 | A61P03704 | A61K031496,DE102005053679A1,2,2,Yes,Application,No
495,WO2007000779,A2,NOVEL PHARMACEUTICAL SUSTAINED RELEASE COMPOSITIONS AND PROCESSES THEREOF,IN2005DE01680,India,2005-06-29T00:00:00Z,2005,2006-06-29T00:00:00Z,2007-01-04T00:00:00Z,2007,PANACEA BIOTEC LTD,JAIN RAJESH    IN  | JINDAL KOUR CHAND    IN  | SINGH SUKHJEET    IN  | BOLDHANE SANJAY    IN,A61K00920 | A61K031522 | A61K00916 | A61P03112,CN101212957A  | EA200800162A1 | AU2006263338A2 | WO2007000779A3 | US2009099154A1 | JP2009500318T  | BRPI0613070A2 | EP1912628A2 | CA2613407A1 | NO20080399A  | AU2006263338A1 | RSP20070512A  | MX2008000084A  | AR055070A1,13,13,Yes,Application,No
496,WO2007002172,A2,HIV-1 PROTEASE INHIBITORS,US20050693134P,United States,2005-06-22T00:00:00Z,2005,2006-06-21T00:00:00Z,2007-01-04T00:00:00Z,2007,UNIVERSITY OF MASSACHUSETTS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | UNIVERSITY OF MARYLAND,SCHIFFER CELIA    US  | RANA TARIQ M    US  | GILSON MICHAEL    US  | TIDOR BRUCE    US,C07C31115 | C07D21302 | C07D30702 | C07D33304 | A61K03142 | A61K03134 | A61K03118 | C07C31122 | A61K031426 | C07D27708 | C07D26106 | A61P03118,EP1937631A2 | JP2008546790T  | CN101309911A  | AU2006262275A1 | WO2007002173A1 | WO2007002172A3 | CA2667445A1 | EP1937655A1 | CA2667449A1 | CN101296901A  | AU2006262274A1 | JP2008546789T ,17,7,Yes,Application,No
497,WO2007002238,A2,DRUG/POLYMER COMPOSITE MATERIALS AND METHODS OF MAKING THE SAME,US20050158724,United States,2005-06-22T00:00:00Z,2005,2006-06-21T00:00:00Z,2007-01-04T00:00:00Z,2007,MICELL TECHNOLOGIES INC,MCCLAIN JIM    US  | DEYOUNG JAMES    US,A61K00914 | A61F00202,US2007009564A1 | WO2007002238A3 | CA2613280A1 | EP1898878A2,4,4,Yes,Application,No
498,WO2007004236,A2,IMPROVED DRUG OR PHARMACEUTICAL COMPOUNDS AND A PREPARATION THEREOF,IN2005CH00861,India,2005-07-04T00:00:00Z,2005,2006-06-29T00:00:00Z,2007-01-11T00:00:00Z,2007,KRISHNAN RAMU,KRISHNAN RAMU    IN,A61K031426,US2008200533A1 | EP1898922A2 | WO2007004236A3 | AU2006264407A1 | CA2613875A1,5,5,Yes,Application,No
499,WO2007008499,A1,TREATMENT OF CANCER PATIENTS EXHIBITING ACTIVATION OF THE P-GLYCOPROTEIN EFFLUX PUMP MECHANISM,US20050696913,United States,2004-06-14T00:00:00Z,2004,2006-06-30T00:00:00Z,2007-01-18T00:00:00Z,2007,KANISA PHARMACEUTICALS INC | SIKIC BRANIMIR | HOTH DANIEL | SOCKS DAVID | GLENN SCOTT | MARCELLETTI JOHN | WALSH MICHAEL J | MULTANI PRATIK S,SIKIC BRANIMIR    US  | HOTH DANIEL    US  | SOCKS DAVID    US  | GLENN SCOTT    US  | MARCELLETTI JOHN    US  | WALSH MICHAEL J    US  | MULTANI PRATIK S    US,G01N03353 | G01N033566 | G01N03348 | G01N033574,US2006015911A1 | RU2008101016A  | EP1898916A4 | JP2009500416T  | WO2005125178A1 | CA2630087A1 | US2007009534A1 | WO2007008498A3 | JP2009518881T  | AU2006269481A1 | AU2006269492A1 | EP1955543A4 | JP2009501707T  | WO2007008496A1 | CA2614321A1 | WO2007008498A2 | US2007009533A1 | CN101257921A  | AU2006269501A1 | EP1899728A4 | US2007010465A1 | WO2007008490A2 | EP1898946A1 | US2007022464A1 | US2007009535A1 | KR20080030659A  | WO2007008498A8 | EP1898916A2 | US2007009531A1 | CN101252933A  | WO2007008479A1 | EP1899728A1 | KR20080034151A  | US2007010478A1 | CA2614324A1 | EP1898957A1 | US2007010487A1 | US2007009532A1 | CA2630799A1 | EP1955543A2 | US2007010466A1 | WO2007008490A3 | US2007010486A1 | AU2006269498A1 | CA2614392A1 | US2007010485A1 | RU2008101019A ,34,9,Yes,Application,No
500,WO2007008539,A2,CHEMICAL COMPOUNDS,US20050698110P,United States,2005-07-11T00:00:00Z,2005,2006-07-05T00:00:00Z,2007-01-18T00:00:00Z,2007,GSK LLC,GUDMUNDSSON KRISTJAN    US,C07D49104 | A61P03112 | A61K031436,US2008214562A1 | JP2009500451T  | WO2007008539A3 | EP1904501A2,4,4,Yes,Application,No
501,WO2007008780,A2,COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE TO ESCAPE MUTANTS OF TARGETED THERAPIES,US20050698381P,United States,2005-07-11T00:00:00Z,2005,2006-07-10T00:00:00Z,2007-01-18T00:00:00Z,2007,"GLOBEIMMUNE, INC.",APELIAN DAVID    US  | FRANZUSOFF ALEX    US  | RODELL TIMOTHY C    US,A61K03800,IL188717D0 | US2010034840A1 | JP2009500454T  | CA2614884A1 | AU2006268333A1 | BRPI0613025A2 | CN101262883A  | EP1906997A2 | WO2007008780A3 | KR20080043775A  | SG163572A1,10,10,Yes,Application,No
502,WO2007011833,A2,SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE,US20050700090P,United States,2005-07-18T00:00:00Z,2005,2006-07-14T00:00:00Z,2007-01-25T00:00:00Z,2007,"SUNESIS PHARMACEUTICALS, INC. | MERCK SHARP & DOHME CORP.",COBURN CRAIG A    US  | EGBERTSON MELISSA S    US  | GRAHAM SAMUEL L    US  | MCGAUGHEY GEORGIA B    US  | STAUFFER SHAUN R    US  | RAJAPAKSE HEMAKA A    US  | NANTERMET PHILIPPE G    US  | STACHEL SHAWN R    US  | YANG WENJIN    US  | LU WANLI    US  | FAHR BRUCE    US,C07D47110 | A61P02528 | A61K031438,CN101238124A  | AU2006270084A1 | US2007021454A1 | JP2009502786T  | WO2007011810A1 | EP1910364A2 | AR054560A1 | PE03672007A1 | CA2615656A1 | WO2007011833A3,11,9,Yes,Application,No
503,WO2007013047,A2,WATER-DISPERSIBLE ANTI-RETROVIRAL PHARMACEUTICAL COMPOSITIONS,IN2005DE02019,India,2005-07-29T00:00:00Z,2005,2006-07-31T00:00:00Z,2007-02-01T00:00:00Z,2007,RANBAXY LABORATORIES LIMITED,JAISWAL ASHISH    IN  | GARG MUKESH    IN  | SINGLA AJAY KUMAR    IN,A61K00920 | A61K0317072 | A61K031551 | A61K0317076,WO2007013047A3 | US2007059360A1,2,2,Yes,Application,No
504,WO2007014918,A1,MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS,EP20050107066,European Patent Office,2005-07-29T00:00:00Z,2005,2006-07-28T00:00:00Z,2007-02-08T00:00:00Z,2007,TIBOTEC BVBA | MEDIVIR AB,DE KOCK HERMAN AUGUSTINUS    BE  | RABOISSON PIERRE JEAN-MARIE BE    BE  | SIMMEN KENNETH ALAN    BE  | LINDSTROEM MATS STEFAN    SE  | KAHNBERG PIA CECILIA    SE  | ANTONOV DMITRY    SE  | NILSSON KARL MAGNUS    SE  | SAMUELSSON BENGT BERTIL    SE  | ROSENQUIST AASA ANNICA KRISTIN    SE,C07K005078 | C07K00506 | A61P03114 | A61K0314709,SG163610A1 | MX2008001394A  | NZ564542A  | EA200800485A1 | PE02102007A1 | CN101233147A  | GT200600340A  | IL188281D0 | CA2616954A1 | AR054881A1 | ZA200800856A  | AU2006274857A1 | AT496934T  | JP2009502881T  | DE602006019879D1 | BRPI0614515A2 | EP1913014A1 | EP1913014B1 | NO20081074A  | KR20080039430A  | US2008200503A1 | UY29702A1,25,25,Yes,Grant,Yes
505,WO2007014919,A1,MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS,EP20050107067,European Patent Office,2005-07-29T00:00:00Z,2005,2006-07-28T00:00:00Z,2007-02-08T00:00:00Z,2007,TIBOTEC PHARM LTD,RABOISSON PIERRE JEAN-MARIE BE    BE  | DE KOCK HERMAN AUGUSTINUS    BE  | VENDEVILLE SANDRINE MARIE HELE    BE  | HU LILI    BE  | VAN DE VREKEN WIM    BE  | MC GOWAN DAVID CRAIG    BE  | TAHRI ABDELLAH    BE  | SURLERAUX DOMINIQUE LOUIS NEST    BE  | SIMMEN KENNETH ALAN    BE,C07D48704 | A61P03114 | A61K03805 | C07K00506 | C07K005078,UY29705A1 | PE02212007A1 | AU2006274858A1 | BRPI0614670A2 | CN101233137A  | AR055104A1 | EP1912995A1 | SV2008002639A  | IL188283D0 | ZA200800860A  | EA200800484A1 | MX2008001395A  | US2010240698A1 | CA2617095A1 | GT200600341A  | JP2009502882T  | NO20081071A  | NZ564541A  | EA014646B1 | KR20080041651A  | SG163613A1,20,20,Yes,Grant,Yes
506,WO2007014920,A1,MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS,EP20050107068,European Patent Office,2005-07-29T00:00:00Z,2005,2006-07-28T00:00:00Z,2007-02-08T00:00:00Z,2007,TIBOTEC BVBA | MEDIVIR AB,DE KOCK HERMAN AUGUSTINUS    BE  | RABOISSON PIERRE JEAN-MARIE BE    BE  | TAHRI ABDELLAH    BE  | SIMMEN KENNETH ALAN    BE  | NILSSON KARL MAGNUS    SE  | SAMUELSSON BENGT BERTIL    SE  | ROSENQUIST AASA ANNICA KRISTIN    SE  | ANTONOV DMITRY    SE,C07D48704 | A61P03114 | A61K03805 | A61K03133 | C07D41312 | C07K005078,AR055105A1 | RU2008107738A  | EP1912996A1 | BRPI0614621A2 | JP2009502883T  | CN101273042A  | US2010120855A1,8,8,Yes,Application,No
507,WO2007014921,A1,MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS,EP20050107069,European Patent Office,2005-07-29T00:00:00Z,2005,2006-07-28T00:00:00Z,2007-02-08T00:00:00Z,2007,TIBOTEC BVBA | MEDIVIR AB,RABOISSON PIERRE JEAN-MARIE BE    BE  | DE KOCK HERMAN AUGUSTINUS    BE  | DORANGE ISMET    FR  | VENDEVILLE SANDRINE MARIE HELE    BE  | SURLERAUX DOMINIQUE LOUIS NEST    BE  | TAHRI ABDELLAH    BE  | SIMONNET YVAN    FR  | VAN DE VREKEN WIM    BE  | HU LILI    BE  | SIMMEN KENNETH ALAN    BE  | NILSSON KARL MAGNUS    SE  | SAMUELSSON BENGT BERTIL    SE  | ROSENQUIST AASA ANNICA KRISTIN    SE  | WALLBERG HANS KRISTIAN    SE,C07D40114 | A61P03114 | A61K0314725 | C07K005078,JP2009502884T  | BRPI0614638A2 | CN101273030A  | US2009281141A1 | EP1919904A1 | RU2008107727A  | AR054882A1,8,8,Yes,Application,No
508,WO2007014922,A1,MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS,EP20050107070,European Patent Office,2005-07-29T00:00:00Z,2005,2006-07-28T00:00:00Z,2007-02-08T00:00:00Z,2007,TIBOTEC BVBA | MEDIVIR AB,RABOISSON PIERRE JEAN-MARIE BE    BE  | DE KOCK HERMAN AUGUSTINUS    BE  | SIMMEN KENNETH ALAN    BE  | JOENSSON CARL ERIK DANIEL    SE  | NILSSON KARL MAGNUS    SE  | ROSENQUIST AASA ANNICA KRISTIN    SE  | SAMUELSSON BENGT BERTIL    SE  | ANTONOV DMITRY    SE  | SALVADOR ODEN LOURDES    SE  | AYESA ALVAREZ SUSANA    SE  | CLASSON BJOERN OLOF    SE,C07D40112 | C07D24504 | A61P03114 | A61K0314523 | C07D40312,AU2006274861A1 | JP2009502885T  | CA2617096A1 | US7666834B2 | EP1919898B1 | DE602006019883D1 | AR055360A1 | CN101273027A  | EA014293B1 | KR20080039938A  | AT496908T  | BRPI0614242A2 | EP1919898A1 | EA200800477A1 | US2009105302A1,15,15,Yes,Grant,Yes
509,WO2007014923,A1,MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS,EP20050107071 ,European Patent Office,2005-07-29T00:00:00Z,2005,2006-07-28T00:00:00Z,2007-02-08T00:00:00Z,2007,TIBOTEC PHARM LTD,DE KOCK HERMAN AUGUSTINUS    BE  | SIMMEN KENNETH ALAN    BE  | JOENSSON CARL ERIK DANIEL    SE  | AYESA ALVAREZ SUSANA    SE  | CLASSON BJOERN OLOF    SE  | NILSSON KARL MAGNUS    SE  | ROSENQUIST AASA ANNICA KRISTIN    SE  | SAMUELSSON BENGT BERTIL    SE  | WALLBERG HANS KRISTIAN    SE,C07D40112 | A61P03114 | A61K031538 | C07D40312 | C07D41312,DE602006019741D1 | AU2006274862A1 | BRPI0614620A2 | KR20080039422A  | EA200800478A1 | EA013475B1 | AR057703A1 | JP2009502886T  | CN101273028A  | US2009247512A1 | EP1919899B1 | EP1919899A1 | AT496042T  | CA2617099A1,15,14,Yes,Grant,Yes
510,WO2007014924,A1,MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS,EP20050107072,European Patent Office,2005-07-29T00:00:00Z,2005,2006-07-28T00:00:00Z,2007-02-08T00:00:00Z,2007,TIBOTEC PHARM LTD,RABOISSON PIERRE JEAN-MARIE BE    BE  | DE KOCK HERMAN AUGUSTINUS    BE  | VAN DE VREKEN WIM    BE  | SURLERAUX DOMINIQUE LOUIS NEST    BE  | SIMMEN KENNETH ALAN    BE,C07K005078 | A61P03114 | A61K03805 | A61K03141 | C07D40304,MX2008001402A  | CN101273052A  | RU2008107726A  | BRPI0614696A2 | JP2009502887T  | US2008262058A1 | AR057704A1 | EP1913015A1,9,9,Yes,Application,No
511,WO2007014925,A1,MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS,EP20050107073,European Patent Office,2005-07-29T00:00:00Z,2005,2006-07-28T00:00:00Z,2007-02-08T00:00:00Z,2007,TIBOTEC PHARM LTD,RABOISSON PIERRE JEAN-MARIE BE    BE  | DE KOCK HERMAN AUGUSTINUS    BE  | HU LILI    BE  | SURLERAUX DOMINIQUE LOUIS NEST    BE  | SIMMEN KENNETH ALAN    BE  | SALVADOR ODEN LOURDES    SE  | NILSSON KARL MAGNUS    SE  | ROSENQUIST AASA ANNICA KRISTIN    SE  | SAMUELSSON BENGT BERTIL    SE,C07D48704 | A61P03114 | A61K03805 | A61K03133 | C07K005078 | C07D24504 | C07K00506,RU2008107768A  | EP1912997A1 | BRPI0614637A2 | JP2009502888T  | AR055361A1 | CN101282978A  | US2009062311A1,8,8,Yes,Application,No
512,WO2007014926,A1,MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS,EP20050107074,European Patent Office,2005-07-29T00:00:00Z,2005,2006-07-28T00:00:00Z,2007-02-08T00:00:00Z,2007,TIBOTEC PHARM LTD,RABOISSON PIERRE JEAN-MARIE BE    BE  | DE KOCK HERMAN AUGUSTINUS    BE  | HU LILI    BE  | VENDEVILLE SANDRINE MARIE HELE    BE  | TAHRI ABDELLAH    BE  | SURLERAUX DOMINIQUE LOUIS NEST    BE  | SIMMEN KENNETH ALAN    BE  | NILSSON KARL MAGNUS    SE  | SAMUELSSON BENGT BERTIL    SE  | ROSENQUIST AASA ANNICA KRISTIN    SE  | IVANOV VLADIMIR    SE  | PELCMAN MICHAEL    SE  | BELFRAGE ANNA KARIN GERTRUD LI    SE  | JOHANSSON PER-OLA MIKAEL    SE,C07D48704 | A61P03114 | A61K03805 | A61K03133 | C07K005078 | C07D24504 | C07K00506,SV2008002642A  | DE602006019439D1 | CA2616580A1 | UY29703A1 | CA2616580C  | JP2009502889T  | WO2007014851A2 | US7781436B2 | AU2006274865B2 | IL188227D0 | BRPI0614654A2 | CN101277945A  | NZ564550A  | ZA200800523A  | KR20080042084A  | KR20080027897A  | AU2006274865A1 | CA2616937A1 | EP1912999A1 | EP1912999B1 | ECSP088150A  | NO20080316A  | RU2008101962A  | BRPI0614692A2 | SG163617A1 | CN101228169A  | NO20081073A  | AU2006274884A1 | US2010222357A1 | IL188928D0 | US2007027163A1 | AT494288T  | AR055359A1 | EP1917255A2 | PE02112007A1 | AR057086A1 | JP2009502859T  | WO2007014851A3 | MX2008001292A  | EA200800476A1 | US2009281140A1,26,25,Yes,Grant,Yes
513,WO2007015824,A2,NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION,US20050702195P,United States,2005-07-25T00:00:00Z,2005,2006-07-17T00:00:00Z,2007-02-08T00:00:00Z,2007,INTERMUNE INC | ARRAY BIOPHARMA INC,SEIWERT SCOTT D    US  | BLATT LAWRENCE M    US  | ANDREWS STEVEN W    US  | MARTIN PIERRE    CH  | SCHUMACHER ANDREAS    DE  | BARNETT BRADLEY R    US  | EARY TODD C    US  | KAUS ROBERT    US  | KERCHER TIMOTHY    US  | LIU WEIDONG    US  | LYON MICHAEL    US  | NICHOLS PAUL    US  | WANG BIN    US  | SAMMAKIA TAREK    US  | KENNEDY APRIL    US  | JIANG YUTONG    US,C07K00512 | C07C23102 | A61P03114 | A61K03800 | C07C26900 | C07D20716 | C07D20944,EP2305696A2 | AR055095A1 | EP2103623A2 | WO2007015824A3 | US2007054842A1 | EP2103623A3 | EP1924594A2 | EP2305698A2 | EP2305695A2 | EA200800413A1 | IL188693D0 | CA2615666A1 | ECSP088208A  | EP2305697A2 | AU2006276246A1 | CN101263156A  | MX2008001166A  | BRPI0613962A2 | KR20080039434A  | NO20080875A  | US2009148407A1 | ZA200800715A  | US2009169510A1 | JP2009502920T ,24,17,Yes,Grant,Yes
514,WO2007016589,A2,INHIBITORS OF SERINE PROTEASES,US20050704772P,United States,2005-08-02T00:00:00Z,2005,2006-08-01T00:00:00Z,2007-02-08T00:00:00Z,2007,VERTEX PHARMA,LYONS STEVE    US  | PERNI ROBERT B    US,C07D40312 | A61P03112 | A61K031501,NO20081012A  | CA2617679A1 | EP1910341A2 | WO2007016589A3 | AU2006275413A1 | AR057716A1 | RU2008108024A  | MX2008001528A  | CN101277950A  | IL189192D0 | US2007105781A1 | KR20080033481A  | EP2256113A1 | ZA200801114A  | JP2009505966T ,16,14,Yes,Application,No
515,WO2007018943,A2,SOLID CARRIERS FOR IMPROVED DELIVERY OF ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS,US19990258654,United States,1999-02-26T00:00:00Z,1999,2006-07-12T00:00:00Z,2007-02-15T00:00:00Z,2007,LIPOCINE INC | PATEL MAHESH,PATEL MAHESH    US,A61K00950 | A61K00916,WO2004087052A3 | US7374779B2 | EP1233756A1 | AU200053131A  | EP1158959A4 | NZ513810A  | AU200216701A  | EP1194120A1 | US2003180352A1 | JP2003506476T  | US2002032171A1 | US6761903B2 | WO2003068186A1 | US2003077297A1 | US2010137271A1 | WO200112155A1 | CA2391923A1 | CA2365536A1 | WO200239983A3 | US6267985B1 | AU200060838A  | WO200101960A1 | WO2004105694A2 | AU2004243013B2 | CA2526616A1 | EP1194120A4 | US6248363B1 | US2009074859A1 | NZ517659A  | EP1210063A1 | NZ516521A  | EP1624855A4 | US2003236236A1 | CA2375083A1 | WO2002053100A2 | JP2003503440T  | JP2003517470T  | AU2002243387A1 | AU780877B2 | US6309663B1 | US6458383B2 | EP1158959A1 | WO2002053100A3 | EP1210063A4 | US6569463B2 | US2003215496A1 | US2005171193A1 | US2010136105A1 | US2003064097A1 | US6923988B2 | CA2706113A1 | AU2004243013A1 | CA2380642A1 | WO200137808A1 | AU2003213020A1 | CA2375083C  | WO2004105694A3 | WO2007018943A3 | JP2007508296T  | WO200239983A2 | US2003235595A1 | AU771659B2 | JP2002537317T  | NZ543571A  | WO2004087052A2 | EP2000130A1 | US2003104048A1 | AU783077B2 | AU200022242A  | EP1624855A2 | AU200117981A  | US2002012680A1 | US2001024658A1 | US6982281B1 | WO200050007A1 | US2006034937A1 | EP1233756A4 | US6294192B1 | US6451339B2,64,7,Yes,Grant,Yes
516,WO2007019098,A2,HIV INTEGRASE INHIBITORS,US20050705346P,United States,2005-08-04T00:00:00Z,2005,2006-07-28T00:00:00Z,2007-02-15T00:00:00Z,2007,GSK LLC,JOHNS BRIAN A    US,A61K0317072 | A61K0317076,WO2007019098A3 | US2008214527A1 | EP1910363A4 | EP1910363A2 | JP2009503081T ,4,4,Yes,Application,No
517,WO2007019100,A2,HIV INTEGRASE INHIBITORS,US20050705327P,United States,2005-08-04T00:00:00Z,2005,2006-07-28T00:00:00Z,2007-02-15T00:00:00Z,2007,GSK LLC,JOHNS BRIAN A    US  | SPALTENSTEIN ANDREW    US,A61K031675,WO2007019100A3 | US2008194523A1 | EP1910355A2 | JP2009503082T  | EP1910355A4,4,4,Yes,Application,No
518,WO2007019130,A2,HIV INTEGRASE INHIBITORS,US20050705342P,United States,2005-08-04T00:00:00Z,2005,2006-07-28T00:00:00Z,2007-02-15T00:00:00Z,2007,GSK LLC,JOHNS BRIAN A    US  | SPALTENSTEIN ANDREW    US,A61K031675,JP2009503089T  | WO2007019130A3 | US2008234231A1 | EP1909578A4 | EP1909578A2,4,4,Yes,Application,No
519,WO2007022255,A2,PHARMACEUTICAL FORMULATIONS FOR SUSTAINED RELEASE,US20010277195P,United States,2001-03-19T00:00:00Z,2001,2006-08-15T00:00:00Z,2007-02-22T00:00:00Z,2007,GSK LLC,BARKER NICHOLAS    US  | WOLFE JANET L    CA,A61K04748 | A61K00914,WO2007022255A3 | US2006198815A1 | US2006293217A1 | EP1383376A2 | JP2005511477T  | WO2002074247A3 | US2002176841A1 | WO2002074247A2 | AU2002258563A1 | WO2002074247A8 | EP1383376A4,8,5,Yes,Application,No
520,WO2007025307,A2,INHIBITORS OF SERINE PROTEASES,US20050711530P,United States,2005-08-26T00:00:00Z,2005,2006-08-28T00:00:00Z,2007-03-01T00:00:00Z,2007,VERTEX PHARMA,COTTRELL KEVIN M    US  | MAXWELL JOHN    US  | TANG QING    US  | GRILLOT ANNE-LAURE    US  | LE TIRAN ARNAUD    US  | PEROLA EMANUELE    US,C07D49810 | C07K00508,JP2009506078T  | EP1917269A2 | CN101316852A  | MX2008002606A  | AR055395A1 | BRPI0615223A2 | ZA200801793A  | AU2006282771A1 | CA2620621A1 | WO2007025307A3 | IL189668D0 | US2007179167A1 | NO20081467A  | KR20080041715A  | EA200800670A1 | ECSP088258A | US7964624B1 | US7985762B2,32,18,Yes,Grant,Yes
521,WO2007027999,A2,CHEMICAL COMPOUNDS,US20050713134P ,United States,2005-08-31T00:00:00Z,2005,2006-08-30T00:00:00Z,2007-03-08T00:00:00Z,2007,GSK LLC,GUDMUNDSSON KRISTJAN    US  | BOGGS SHARON DAVIS    US,A61K0314745,US2008234318A1 | JP2009507795T  | EP1919872A2 | WO2007027999A3 | EP1919872A4,4,4,Yes,Application,No
522,WO2007033208,A2,USE OF INDIRUBIN AND ITS DERIVATIVES IN THE TREATMENTS OF HIV INFECTION AND HEART FAILURE,US20050716097P,United States,2005-09-12T00:00:00Z,2005,2006-09-12T00:00:00Z,2007-03-22T00:00:00Z,2007,UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE,REDFIELD ROBERT    US  | HEREDIA ALONSO    US  | DAVIS CHARLES E    US,A61K031404,WO2007033208A3,1,1,Yes,Application,No
523,WO2007034312,A2,THERAPEUTIC COMPOUNDS,US20050720151P,United States,2005-09-23T00:00:00Z,2005,2006-09-11T00:00:00Z,2007-03-29T00:00:00Z,2007,PFIZER,PATTERSON BRIAN DOUGLAS    US  | SAKATA SYLVIE KIM    US  | NAMBU MITCHELL DAVID    US  | PATEL LEENA BHARAT KUMAR    US  | TATLOCK JOHN HOWARD    US,C07D21376 | A61P03900 | A61K0314406,RSP20080118A  | EP1937639B1 | EA200800542A1 | EP1937639A2 | PT1937639E  | US2007167497A1 | IL189666D0 | ES2340200T3 | NZ566136A  | SI1937639T1 | JP4336738B2 | HR20100272T1 | US7868026B2 | ECSP088296A  | WO2007034312A3 | KR20080038431A  | CA2621805A1 | HR20100272T2 | ZA200801677A  | AT459603T  | JP2009508931T  | NO20081844A  | EA014329B1 | DE602006012713D1 | AU2006293605A1 | DK1937639T3 | CN101287708A ,22,22,Yes,Grant,Yes
524,WO2007035957,A2,METHODS FOR TREATING VIRAL INFECTIONS USING POLYAMINE ANALOGS,US20050719573P,United States,2005-09-23T00:00:00Z,2005,2006-09-25T00:00:00Z,2007-03-29T00:00:00Z,2007,PATHOLOGICA LLC,MCGRATH MICHAEL S    US  | HADLOCK KENNETH G    US,A61K031155 | A61K03113,AU2006292063A1 | EP1937235A2 | CN101300004A  | US7879914B2 | CA2623203A1 | US2007078187A1 | WO2007035957A3 | EP1937235A4,7,6,Yes,Grant,Yes
525,WO2007039463,A1,NNRT INHIBITORS,US20050722335P,United States,2005-09-30T00:00:00Z,2005,2006-09-20T00:00:00Z,2007-04-12T00:00:00Z,2007,F. HOFFMANN-LA ROCHE AG,SAITO YOSHIHITO DAVID    US  | SMITH MARK    US  | SWEENEY ZACHARY KEVIN    US,C07D23704 | A61K031535 | A61K03153 | A61K03150 | C07D27304 | A61P03118 | C07D25306,ES2317584T3 | US7625897B2 | CN101273020A  | KR20080064957A  | AT418545T  | EP1937651B1 | DE602006004473D1 | AR055666A1 | IL190081D0 | AU2006298853A1 | CA2623728A1 | US2007078128A1 | JP2009510013T  | EP1937651A1,12,12,Yes,Grant,Yes
526,WO2007042037,A1,TACROLIMUS COMBINATION PRODUCTS,DK20050001411,Denmark,2005-10-07T00:00:00Z,2005,2006-10-09T00:00:00Z,2007-04-19T00:00:00Z,2007,LIFECYCLE PHARMA A/S,LISBET BOENLOEKKE RANKLOEVE    DK  | MIKKELSEN JAN MOELLER    DK,A61K031436 | A61K031365 | A61K031357 | A61K031496 | A61K03813,CA2624825A1 | EP1942887A1 | US2009011013A1,4,4,Yes,Application,No
527,WO2007045572,A1,N-PHENYL PHENYLACETAMIDE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INIHIBITORS,US20050728609P,United States,2005-10-19T00:00:00Z,2005,2006-10-09T00:00:00Z,2007-04-26T00:00:00Z,2007,F. HOFFMANN-LA ROCHE AG,SILVA TANIA    US  | SWEENEY ZACHARY KEVIN    US,C07C25554 | C07D21340 | C07C31728 | A61K03140 | A61K031381 | A61K031277 | C07D31728 | C07C31151 | A61K031541 | C07D21138 | C07D29512 | C07D33348 | C07D20712 | C07D21146 | C07C27922,DE602006005699D1 | IL190443D0 | CN101287702A  | KR20080047479A  | AU2006303367A1 | AR057159A1 | US2007088015A1 | EP1940782A1 | ZA200803174A  | ES2320042T3 | CA2625039A1 | JP2009512659T  | EP1940782B1 | AT425138T  | RU2008119412A  | US7754919B2,14,14,Yes,Grant,Yes
528,WO2007045573,A1,PHENYL-ACETAMIDE NNRT INHIBITORS,US20050728443P,United States,2005-10-19T00:00:00Z,2005,2006-10-09T00:00:00Z,2007-04-26T00:00:00Z,2007,F. HOFFMANN-LA ROCHE AG,MIRZADEGAN TARANEH    US  | SILVA TANIA    US,C07C25550 | C07C31116 | A61K031277 | A61K03118 | A61K031167 | C07C25551 | A61P03118 | C07C23311,JP2009515826T  | IL190442D0 | AR058094A1 | KR20080056220A  | US2007088053A1 | US7388111B2 | CN101291905A  | AU2006303368A1 | EP1940781A1 | CA2625047A1,10,9,Yes,Grant,Yes
529,WO2007047371,A2,ORAL DOSAGE COMBINATION PHARMACEUTICAL PACKAGING,US20010294786P,United States,2001-05-31T00:00:00Z,2001,2006-10-13T00:00:00Z,2007-04-26T00:00:00Z,2007,MICRODOSE TECHNOLOGIES INC,ABRAMS ANDREW L    US  | GUMASTE ANAND V    US  | SISON RAYMUNDO A    US,A61K00948,ZA200402466A  | JP2005514966T  | WO2007047371A3 | AU2002303840A1 | EP1933815A2 | CA2614899A1 | WO2002096347A3 | AU2006304180A1 | CN101309675A  | EP1408907A4 | CA2448997A1 | CA2625776A1 | WO2002096347A2 | US2004156903A1 | EP1408907A2 | NZ529696A  | US2007087048A1 | JP2009511191T  | CA2614902A1,17,9,Yes,Application,No
530,WO2007049265,A2,ANTI MINERALOCORTICOID THERAPY OF INFECTION,IE20050000723,Ireland,2005-10-28T00:00:00Z,2005,2006-10-31T00:00:00Z,2007-05-03T00:00:00Z,2007,PRENDERGAST PATRICK T,PRENDERGAST PATRICK T    AU,A61K031565 | A61K03157 | A61K031567 | A61K031573 | A61K03158 | A61K031585,WO2007049265A3 | CN101277702A  | CA2627463A1 | US2009053294A1 | IE20050723A1 | EP1940414A2,6,6,Yes,Application,No
531,WO2007050375,A2,PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS,US19990305226,United States,1999-05-04T00:00:00Z,1999,2006-10-18T00:00:00Z,2007-05-03T00:00:00Z,2007,SCHERING CORP,RAMANTHAN RAGULAN    US  | GHOSAL ANIMA    US  | MILLER MICHAEL W    US  | CHOWDHURY SWAPAN K    US  | ALTON KEVIN B    US,C07D40114 | A61P03706 | A61P03118 | A61K031506 | C07H01702,SK15692001A3 | PE07112007A1 | NO322045B1 | AR057107A2 | DE60045528D1 | RU2008119652A  | ZA200803454A  | SK286641B6 | DE60021370D1 | NO20015366D0 | SK200101569A3 | DK1175401T3 | AR057786A2 | EP1175401B1 | KR20080058486A  | AU200045009A  | AT299865T  | CZ20013940A3 | AR057873A2 | AU780888B2 | JP2002543185T  | ES2244437T3 | CA2371583A1 | DE60021370C5 | PL203116B1 | EP1951708A2 | RU2299206C9 | ZA200108868A  | CN1636567A  | CH1175401H1 | CN1450992A  | US2008188485A1 | WO200066558A1 | US6391865B1 | AR057106A2 | US2004067961A1 | EP1632479B1 | NO20082297A  | IL145741D0 | EG24136A  | US6289745B1 | SI1175401T1 | CN101326178A  | SK287418B6 | IL190902D0 | DE60021370T2 | TWI285200B  | JP2006052225A  | PL351388A1 | AU2005202357B2 | HU200202867A2 | CH1175401H9 | AR058105A1 | ECSP088378A  | BR200010304A  | CA2626565A1 | WO2007050375A3 | CN1182114C  | HU200202867A3 | AT495154T  | JP3722700B2 | NO20015366A  | CO5170523A1 | JP2009512705T  | US7384944B2 | EP1632479A2 | US2006105964A1 | HK1039930A1 | US6689765B2 | AU2005202357A1 | EP1632479A3 | RU2299206C2 | CN100490811C  | EP1175401A1 | US7825121B2 | AU2006306491A1 | CA2371583C  | US2003069252A1 | TR200103214T2,4,30,Yes,Grant,Yes
532,WO2007056083,A2,BIOSYNTHETIC POLYPEPTIDE FUSION INHIBITORS,US20050733339P,United States,2005-11-02T00:00:00Z,2005,2006-11-01T00:00:00Z,2007-05-18T00:00:00Z,2007,AMBRX INC,MARIANI ROBERTO    US  | KIMMEL BRUCE E    US,A61K03817,EP1954302A4 | US2008112943A1 | CN101489571A  | AU2006311938A1 | KR20080074924A  | CA2626675A1 | EP1954302A2 | JP2009514533T  | WO2007056083A3 | US2009088365A1 | US2008113408A1 | IL190692D0,10,8,Yes,Application,No
533,WO2007056208,A2,N-ARYLALKYL-THIENOPYRIMIDIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF,US20050732139P,United States,2005-11-02T00:00:00Z,2005,2006-11-02T00:00:00Z,2007-05-18T00:00:00Z,2007,CYTOVIA INC,CAI SUI XIONG    US  | DREWE JOHN A    US  | KEMNITZER WILLIAM E    US  | SIRISOMA NILANTHA SUDATH    US,A61K031519 | C07D49802,US2007099941A1 | WO2007056208A3,2,2,Yes,Application,No
534,WO2007056214,A2,N-ALKYL-N-ARYL-THIENOPYRIMIDIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF,US20050732131P,United States,2005-11-02T00:00:00Z,2005,2006-11-02T00:00:00Z,2007-05-18T00:00:00Z,2007,CYTOVIA INC,CAI SUI XIONG    US  | SIRISOMA NILANTHA SUDATH    US  | KEMNITZER WILLIAM E    US,A61K031519,US2007213305A1 | WO2007056214A8 | WO2007056214A3,2,2,Yes,Application,No
535,WO2007056215,A2,N-ARYL-THIENOPYRIMIDIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF,US20050732140P,United States,2005-11-02T00:00:00Z,2005,2006-11-02T00:00:00Z,2007-05-18T00:00:00Z,2007,CYTOVIA INC,CAI SUI XIONG    US  | KEMNITZER WILLIAM E    US  | SIRISOMA NILANTHA SUDATH    US  | ZHANG HAN-ZHONG    US,A61K031655 | C07D49802 | A61K031519,US2007099877A1 | WO2007056215A9 | WO2007056215A3,2,2,Yes,Application,No
536,WO2007060682,A1,EFFERVESCENT GRANULAR FORMULATIONS OF ANTIRETROVIRAL DRUGS,WO2005IN00385,WIPO,2005-11-28T00:00:00Z,2005,2005-11-28T00:00:00Z,2007-05-31T00:00:00Z,2007,STRIDES ARCOLAB LTD,IYER VENKAT SUBRAMANIAN    IN  | SRINIVAS SATHYA C H    IN,A61K03100,None,1,1,Yes,Application,No
537,WO2007061454,A1,COMPOSITIONS COMPRISING AZELASTINE AND METHODS OF USE THEREOF,US20040630274P,United States,2004-11-24T00:00:00Z,2004,2006-07-14T00:00:00Z,2007-05-31T00:00:00Z,2007,MEDA PHARMACEUTICALS INC.,DANG PHUONG GRACE    US  | LAWRENCE BRIAN D    US  | BALWANI GUL    US  | D ADDIO ALEXANDER D    US,C07D40312,AU2005309657A1 | IL183372D0 | EP1827499A1 | WO2006058022A1 | CA2588338A1 | ZA200704902A  | MX2007006233A  | BRPI0517891A  | NZ555501A  | US2006110331A1 | EP1827499A4 | CN101098714A  | KR20070104884A  | US2007020330A1 | US2010152147A1 | JP2008521812T ,15,12,Yes,Application,No
538,WO2007061529,A1,LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY,US20050282507,United States,2005-11-18T00:00:00Z,2005,2006-10-13T00:00:00Z,2007-05-31T00:00:00Z,2007,SCIDOSE PHARMA INC,PALEPU NAGESWARA    US,A61K00914,AU2006317563A1 | KR20080067705A  | JP2009515958T  | CA2628178A1 | EP1954244A1 | US2007116729A1 | CN101330905A ,8,8,Yes,Application,No
539,WO2007062528,A1,POLYCYCLIC PHENOLIC COMPOUNDS AND USE IN TREATING VIRAL INFECTIONS,US20050742058P,United States,2005-12-01T00:00:00Z,2005,2006-12-01T00:00:00Z,2007-06-07T00:00:00Z,2007,MIGENIX CORP,DUGOURD DOMINIQUE    CA,A61K03821 | A61K0317056 | A61K031565 | A61K031435 | A61P03112,US2007161611A1,2,2,Yes,Application,No
540,WO2007065016,A2,METHODS AND COMPOSITIONS TO IMPROVE ACTIVITY AND REDUCE TOXICITY OF STENTS,US20050741855P,United States,2005-12-02T00:00:00Z,2005,2006-12-04T00:00:00Z,2007-06-07T00:00:00Z,2007,AU JESSIE L S | WIENTJES GUILLAUME M,AU JESSIE L S    US  | WIENTJES GUILLAUME M    US,A61F00202,WO2007065016A3,1,1,Yes,Application,No
541,WO2007065256,A1,NOVEL SPIROPIPERIDINE COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY,US20050742545P,United States,2005-12-06T00:00:00Z,2005,2006-12-05T00:00:00Z,2007-06-14T00:00:00Z,2007,VIROCHEM PHARMA INC,MOINET CHRISTOPHE    CA  | COURCHESNE MARC    CA,C07D49810 | C07D47110 | A61K0314523,None,1,1,Yes,Application,No
542,WO2007068380,A1,DIARYL UREA FOR TREATING VIRUS INFECTIONS,EP20050027453 | EP20050027463 | EP20050027461 | EP20050027459 | EP20050027457 | EP20050027455 | EP20050027472 | EP20050027470 |EP20050027466 | EP20050027464 ,European Patent Office,2005-12-15T00:00:00Z,2005,2006-12-06T00:00:00Z,2007-06-21T00:00:00Z,2007,BAYER AG,WEBER OLAF    DE  | RIEDL BERND    DE,A61K03144 | A61P03112,CA2633400A1 | EP1962841A1 | JP2009519265T  | US2010129321A1,5,5,Yes,Application,No
543,WO2007068383,A1,DIARYL UREAS FOR TREATING VIRUS INFECTIONS,EP20050027451 | EP20050027452 | EP20050027462 | EP20050027460 | EP20050027458 | EP20050027456 | EP20050027454 | EP20050027467 | EP20050027465 | EP20050027471 ,European Patent Office,2005-12-15T00:00:00Z,2005,2006-12-06T00:00:00Z,2007-06-21T00:00:00Z,2007,BAYER AG,WEBER OLAF    DE  | RIEDL BERND    DE,A61K03133 | A61P03112,EP1962829A1 | JP2009524585T  | US2009227637A1 | CA2633417A1,6,5,Yes,Application,No
544,WO2007072503,A2,COMBINATIONS FOR MANAGING INFLAMMATION AND ASSOCIATED DISORDERS,IN2005DE03431,India,2005-12-21T00:00:00Z,2005,2006-12-18T00:00:00Z,2007-06-28T00:00:00Z,2007,PANACEA BIOTEC LTD,JAIN RAJESH    IN  | JINDAL KOUR CHAND    IN,A61K04506 | A61K031415 | A61K031407 | A61P02102 | A61P02900 | A61P03112,WO2007072503A3,1,1,Yes,Application,No
545,WO2007073583,A1,A METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME,AU20050907328,Australia,2005-12-29T00:00:00Z,2005,2006-12-21T00:00:00Z,2007-07-05T00:00:00Z,2007,THE UNIVERSITY OF SYDNEY,ROUFOGALIS BASIL    AU  | MARKS DENESE    AU  | DUKE RUJEE    AU,A61K031353 | A61K031704 | A61K031475 | A61P03500 | A61P03104 | A61P03112 | A61P03300,None,1,1,Yes,Application,No
546,WO2007075377,A2,"CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS",US20050751032P,United States,2005-12-15T00:00:00Z,2005,2006-12-13T00:00:00Z,2007-07-05T00:00:00Z,2007,CYTOKINETICS INC,MORGAN BRADLEY P    US  | MALIK FADY    US  | MORGANS DAVID J JR    US,A61K031195,US2009247544A1 | EP1959947A2 | WO2007075377A3 | US2007197505A1,4,3,Yes,Application,No
547,WO2007076372,A2,TREATMENT OF NEUROAIDS USING INHIBITORS OF GLYCOGEN SYNTHASE KINASE (GSK)-3,US20050753614P,United States,2005-12-23T00:00:00Z,2005,2006-12-19T00:00:00Z,2007-07-05T00:00:00Z,2007,UNIVERSITY OF ROCHESTER,GELBARD HARRIS A    US  | MAGGIRWAR SANJAY B    US  | DEWHURST STEPHEN    US  | SCHIFITTO GIOVANNI    US,A61K031195,US2009081318A1 | EP1976976A2 | CA2634932A1 | WO2007076372A3 | EP1976976A4,4,4,Yes,Application,No
548,WO2007079260,A1,METHODS FOR IMPROVING THE PHARMACOKINETICS OF HIV INTEGRASE INHIBITORS,US20050755039P,United States,2005-12-30T00:00:00Z,2005,2006-12-29T00:00:00Z,2007-07-12T00:00:00Z,2007,GILEAD SCIENCES INC | JAPAN TOBACCO INC,KEARNEY BRIAN P    US  | KAKEE ATSUYUKI    JP  | KAWAGUCHI ISAO    JP,A61K031426 | A61P03118 | A61K03147,EP2308490A1 | US2009233964A1 | ZA200806222A  | IL192208D0 | AP200804522D0 | AU2006332664A1 | HR20080313A2 | NO20083333A  | US2007219243A1 | EA200801619A1 | KR20080081358A  | CN101336107A  | JP2009525265T  | EP1976517A1 | WO2007079260A9 | CA2635468A1 | JP4676536B2,14,12,Yes,Grant,Yes
549,WO2007083316,A2,DELIVERY SYSTEM FOR ACTIVE AGENTS,US20060760935P,United States,2006-01-23T00:00:00Z,2006,2007-01-23T00:00:00Z,2007-07-26T00:00:00Z,2007,YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM,BENITA SHIMON    IL  | ROM ALONA    IL  | NASSER TAHER    IL,A61K00951 | A61K031436 | A61K00962 | A61K0314523 | A61K0317048,EP2026771B1 | JP2009523843T  | CA2639921A1 | KR20080108426A  | DE602007002905D1 | CN101410098A  | WO2007083316A3 | IL192998D0 | AT446087T  | BRPI0706949A2 | US2009011009A1 | AU2007206582A1 | EP2026771A2,10,10,Yes,Grant,Yes
550,WO2007086039,A1,A METHOD OF PRODUCING POROUS MICROPARTICLES,IE20060000052,Ireland,2006-01-27T00:00:00Z,2006,2007-01-29T00:00:00Z,2007-08-02T00:00:00Z,2007,TRINITY COLLEGE DUBLIN,HEALY ANNE MARIE    IE  | MCDONALD BERNARD    IE  | CORRIGAN OWEN I    IE  | TAJBER LIDIA    IE,A61K00916,US2010226990A1 | CA2640165A1 | EP1976486A1 | AU2007208998A1 | IE20070049A1 | US2010092453A1 | JP2009524646T ,8,7,Yes,Application,No
551,WO2007087548,A2,CHEMICAL COMPOUNDS,US20060761883P,United States,2006-01-25T00:00:00Z,2006,2007-01-24T00:00:00Z,2007-08-02T00:00:00Z,2007,GSK LLC,GUDMUNDSSON KRISTJAN    US  | TURNER ELIZABETH MADALENA    US,A61K0314745,JP2009524689T  | EP1984375A2 | WO2007087548A9 | WO2007087548A3 | US2010227880A1,4,4,Yes,Application,No
552,WO2007087549,A2,CHEMICAL COMPOUNDS,US20060761892P,United States,2006-01-25T00:00:00Z,2006,2007-01-24T00:00:00Z,2007-08-02T00:00:00Z,2007,GSK LLC,GUDMUNDSSON KRISTJAN    US  | BOGGS SHARON DAVIS    US  | MILLER JOHN FRANKLIN    US  | SVOLTO ANGILIQUE CHRISTINA    US,A61K0314745,PE09462007A1 | JP2009524690T  | EP1984376A2 | WO2007087549A3 | EP1984376A4 | US2010280010A1 | AR059197A1,6,6,Yes,Application,No
553,WO2007089030,A1,"USE OF 6-(3-CHLORO-2-FLUOROBENZYL)-1-[(2S)-1-HYDROXY-3-METHYLBUTAN-2-YL]-7-METHO XY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID OR SALT THEREOF FOR TREATING RETROVIRUS INFECTION",US20060763900P,United States,2006-02-01T00:00:00Z,2006,2007-02-01T00:00:00Z,2007-08-09T00:00:00Z,2007,JAPAN TOBACCO INC,MATSUZAKI YUJI    JP  | KANO MITSUKI    JP  | IKEDA SATORU    JP,A61K03147 | A61K031506 | A61K031472 | A61P03118 | C07D21556,EP1978960A1 | JP2009525261T  | JP2011037857A  | EP1978960A4 | US2009018162A1,5,4,Yes,Application,No
554,WO2007089745,A2,NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX,US20030491331P,United States,2003-07-29T00:00:00Z,2003,2007-01-29T00:00:00Z,2007-08-09T00:00:00Z,2007,SIGNATURE R & D HOLDINGS LLC,CHANDRAN V RAVI    US,A61K03816,IL173382D0 | US7589233B2 | ZA200600660A  | WO2005046575A3 | CA2534342A1 | KR20060073584A  | SG145693A1 | US2010004481A1 | AU2004289174A1 | EP1660017A2 | EP1660017A4 | AU2004289174A2 | JP2007510621T  | US2006287244A1 | WO2007089745A3 | US2010069489A1 | WO2005046575A2 | US2006241017A1 | CN101123878A  | US2010069446A1,15,10,Yes,Grant,Yes
555,WO2007089906,A2,CATIONIC STEROID ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE,US20060764129P,United States,2006-02-01T00:00:00Z,2006,2007-01-31T00:00:00Z,2007-08-09T00:00:00Z,2007,BRIGHAM YOUNG UNIVERSITY | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER,SAVAGE PAUL B    US  | LEUNG DONALD    US,A61K03156 | A61K03157 | A61K031568 | G01N03315 | A61K031575 | A61K04506 | A61P03116,WO2007089906A3 | US2010330086A1 | US2007190558A1,3,2,Yes,Application,No
556,WO2007089907,A2,CATIONIC STEROID ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE,US20060763999P,United States,2006-02-01T00:00:00Z,2006,2007-01-31T00:00:00Z,2007-08-09T00:00:00Z,2007,BRIGHAM YOUNG UNIVERSITY | VANDERBILT UNIVERSITY,SAVAGE PAUL B    US  | UNUTMAZ DERYA    US,A61K03156 | A61K03157 | A61K031568 | G01N03315 | A61K031575 | A61K04506 | A61P03118,US2007190067A1 | AU2007211279A1 | WO2007089907A3 | EP1978968A2 | CN101378761A  | CA2640584A1 | ZA200805763A ,7,7,Yes,Application,No
557,WO2007090721,A1,PHARMACEUTICAL COMPOSITIONS CONTAINING MIXTURES OF POLYMERS AND ACTIVE AGENTS POORLY SOLUBLE IN WATER,DE200610005485,Germany,2006-02-03T00:00:00Z,2006,2007-01-17T00:00:00Z,2007-08-16T00:00:00Z,2007,EVONIK ROEHM GMBH,MEIER CHRISTIAN    DE  | NOLLENBERGER KATHRIN    DE  | GRYCZKE ANDREAS    DE  | PETEREIT HANS-ULRICH    DE  | DRESSMAN JENNIFER    DE,A61K00916 | A61K00950 | A61K00920,EP1978936A1 | KR20080090494A  | US2009011007A1 | JP2009525300T  | CA2641351A1 | IL191604D0 | CN101370480A ,8,8,Yes,Application,No
558,WO2007092645,A2,NOVEL HCV INHIBITOR COMBINATIONS AND METHODS,US20060771927P,United States,2006-02-09T00:00:00Z,2006,2007-02-09T00:00:00Z,2007-08-16T00:00:00Z,2007,SCHERING CORP | VIROPHARMA INC | WYETH CORP,EMINI EMILIO ANTHONY    US  | FLINT MICHAEL JAMES    US  | HOWE ANITA YEE MEI    US  | MALCOLM BRUCE A    US  | MULLEN STANLEY L    US  | RALSTON ROBERT ORVILLE    US  | TONG XIAO    US,A61K03806 | A61P03114 | A61K031343,WO2007092616A3 | AR059430A1 | PE01972008A1 | US2007274951A1 | MX2008010355A  | EP1981523A2 | EP1981524A2 | PE12302007A1 | AR059429A1 | US2007224167A1 | JP2009526070T  | CA2641859A1 | WO2007092645A3 | WO2007092616A2,13,8,Yes,Application,No
559,WO2007093515,A1,HETEROCYCLIC ANTIVIRAL COMPOUNDS,US20060773984P,United States,2006-02-15T00:00:00Z,2006,2007-02-05T00:00:00Z,2007-08-23T00:00:00Z,2007,F. HOFFMANN-LA ROCHE AG,LEMOINE REMY    US  | MELVILLE CHRIS RICHARD    US  | PADILLA FERNANDO    US  | ROTSTEIN DAVID MARK    US  | WANNER JUTTA    US,C07D48704 | A61P03118 | A61P03112 | A61K031407,EP1987035A1 | AR059490A1 | US2007191406A1 | ZA200806845A  | AU2007214602A1 | KR20080102386A  | IL193108D0 | RU2008136763A  | CN101384599A  | NO20083583A  | CA2641382A1 | JP2009526802T ,13,13,Yes,Application,No
560,WO2007093520,A1,HETERO-BYCYCLIC ANTIVIRAL COMPOUNDS,US20060773942P,United States,2006-02-15T00:00:00Z,2006,2007-02-06T00:00:00Z,2007-08-23T00:00:00Z,2007,F. HOFFMANN-LA ROCHE AG,LEMOINE REMY    US  | MELVILLE CHRIS RICHARD    US  | ROTSTEIN DAVID MARK    US  | WANNER JUTTA    US,C07D48704 | A61P03118 | A61P02900 | A61K031407,CN101384596A  | AU2007216543A1 | IL193107D0 | JP2009526803T  | KR20080102387A  | ZA200806756A  | US2007191335A1 | EP1987036A1 | AR059571A1 | CA2641389A1 | RU2008136756A  | NO20083585A ,12,12,Yes,Application,No
561,WO2007094825,A2,"METAXALONE PRODUCTS, METHOD OF MANUFACTURE, AND METHOD OF USE",US20050726861P,United States,2005-10-14T00:00:00Z,2005,2006-10-11T00:00:00Z,2007-08-23T00:00:00Z,2007,MUTUAL PHARMACEUTICAL COMPANY,DU JIE    US  | ROBERTS RICHARD H    US,A61K03142 | A61K031335,US2011065721A1 | US7378434B2 | US2007088066A1 | US2007088065A1 | US7122566B1 | WO2007094825A3 | CA2626027A1 | US2008292584A1,7,3,Yes,Grant,Yes
562,WO2007097936,A2,PROTEIN HYDROLYSATE EXCIPIENTS,US20060354974,United States,2006-02-16T00:00:00Z,2006,2007-02-13T00:00:00Z,2007-08-30T00:00:00Z,2007,WYETH CORP,MARK WILLIAM ANTONIO    US  | HALL LLOYD THOMAS    US,A61K00920 | A61K00916,EP1986614A2 | US2007190130A1 | WO2007097936A3,4,3,Yes,Application,No
563,WO2007098247,A2,SUBSTITUTED TARAXASTANES USEFUL FOR TREATING VIRAL INFECTIONS,US20060775138P,United States,2006-02-21T00:00:00Z,2006,2007-02-20T00:00:00Z,2007-08-30T00:00:00Z,2007,ACHILLION PHARMACEUTICALS INC,BRADBURY BARTON JAMES    US  | HUANG MINGJUN    US,A61K03156 | C07J06300 | A61P03118,JP2009527563T  | CA2643028A1 | EP1986654A2 | WO2007098247A3 | US2007197646A1,5,5,Yes,Application,No
564,WO2007100739,A1,CCR5 ANTAGONISTS USEFUL FOR TREATING HIV,US20060776355P,United States,2006-02-24T00:00:00Z,2006,2007-02-22T00:00:00Z,2007-09-07T00:00:00Z,2007,SCHERING CORP,RAMANATHAN RAGULAN    US  | MILLER MICHAEL W    US  | CHOWDHURY SWAPAN K    US  | ALTON KEVIN B    US  | GROTZ DIANE    US  | RINDGEN DIANE    US  | TENDOLKAR AMOL    US,C07D40114 | C07D40914 | C07D40306 | C07D41714,JP2009527573T  | AU2007221194A1 | IL193616D0 | MX2008010927A  | CA2643323A1 | EP1996576A1 | CN101426781A  | AR059612A1 | US2007203149A1 | KR20080098541A  | ZA200807281A ,11,11,Yes,Application,No
565,WO2007103670,A2,NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS,US20050658002P,United States,2006-03-02T00:00:00Z,2006,2007-02-27T00:00:00Z,2007-09-13T00:00:00Z,2007,ABBOTT LAB,KEMPF DALE J    US  | FLENTGE CHARLES A    US  | RANDOLPH JOHN T    US  | HUANG PEGGY    US  | KLEIN LARRY L    US,B29D09900 | A61K031427 | A61K031426 | C07D27738 | C07D41702,MX2008011222A  | JP2009528378T  | US2010280248A1 | EP1993820A4 | US7786153B2 | US2006199851A1 | EP1993820A2 | CA2643988A1 | CN101432129A  | WO2007103670A3,8,7,Yes,Grant,Yes
566,WO2007103740,A2,"IMMUNOASSAYS, HAPTENS, IMMUNOGENS AND ANTIBODIES FOR ANTI-HIV THERAPEUTICS",US20060777923P,United States,2006-03-01T00:00:00Z,2006,2007-03-01T00:00:00Z,2007-09-13T00:00:00Z,2007,ARK DIAGNOSTICS,VALDEZ JOHNNY    US,C12Q00170 | C12Q00168,WO2007103740A3 | EP1994184A2 | US2007218486A1,3,3,Yes,Application,No
567,WO2007103934,A2,COMPOSITIONS AND METHODS OF USE OF RITONAVIR FOR TREATING HCV,US20060779501P,United States,2006-03-06T00:00:00Z,2006,2007-03-06T00:00:00Z,2007-09-13T00:00:00Z,2007,ABBOTT LAB,KEMPF DALE J    US  | MARSH KENNAN C    US,A61K03821 | A61K031497 | A61K0314965 | A61K031407 | A61K0317056,US2007207122A1 | JP2009529537T  | WO2007103934A3 | MX2008011429A  | EP2007381A2 | CN101460166A  | CA2645684A1,8,7,Yes,Application,No
568,WO2007106450,A2,DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE IN COMBINATION THERAPY,US20060781520P,United States,2006-03-10T00:00:00Z,2006,2007-03-09T00:00:00Z,2007-09-20T00:00:00Z,2007,"UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC",NAIR VASU    US  | CHI GUOCHEN    US  | UCHIL VINOD R    US,A61K0317072,WO2007106450A3,1,1,Yes,Application,No
569,WO2007111866,A2,"COMBINATIONS OF HCV PROTEASE INHIBITOR(S) AND CYP3A4 INHIBITOR(S), AND METHODS OF TREATMENT RELATED THERETO",US20060785761P,United States,2006-03-23T00:00:00Z,2006,2007-03-19T00:00:00Z,2007-10-04T00:00:00Z,2007,SCHERING CORP,RALSTON II ROBERT O    US  | STRIZKI JULIE M    US  | VLACH JAROMIR    US  | GUPTA SAMIR K    US  | O'MARA EDWARD M    US  | GHOSAL ANIMA    US  | TREITEL MICHELLE A    US  | MCLEOD JAMES F    US  | WHITE RONALD E    US,A61K03116 | A61K03806 | A61K031427 | A61K031196 | A61K031192 | A61K04506 | A61K031403 | A61K031343 | A61K031496 | A61K03807 | A61P03112 | A61K031454 | A61K031395 | A61K0314965 | A61K03140,US2007287664A1 | CA2647158A1 | EP1998759A2 | JP2009530382T  | PE01712008A1 | US2010291034A1 | WO2007111866A3 | AR060003A1 | MX2008012225A ,9,8,Yes,Application,No
570,WO2007112345,A2,USE OF CYCLOSPORIN ALKENE ANALOGUES FOR PREVENTING OR TREATING VIRAL-INDUCED DISORDERS,US20060391027,United States,2006-03-28T00:00:00Z,2006,2007-03-26T00:00:00Z,2007-10-04T00:00:00Z,2007,AMR TECHNOLOGY INC,MOLINO BRUCE F    US,A61K03813,WO2007112345A8 | US2007232532A1 | WO2007112345A3,2,2,Yes,Application,No
571,WO2007112352,A2,USE OF CYCLOSPORIN ALKYNE/ALKENE ANALOGUES FOR PREVENTING OR TREATING VIRAL-INDUCED DISORDERS,US20060391023,United States,2006-03-28T00:00:00Z,2006,2007-03-26T00:00:00Z,2007-10-04T00:00:00Z,2007,AMR TECHNOLOGY INC,MOLINO BRUCE F    US,A61K03813,US7696166B2 | US2007232531A1 | WO2007112352A3,2,2,Yes,Grant,Yes
572,WO2007112357,A2,USE OF CYCLOSPORIN ALKYNE ANALOGUES FOR PREVENTING OR TREATING VIRAL-INDUCED DISORDERS,US20060391020,United States,2006-03-28T00:00:00Z,2006,2007-03-26T00:00:00Z,2007-10-04T00:00:00Z,2007,AMR TECHNOLOGY INC,MOLINO BRUCE F    US,A61K03813,WO2007112357A3 | US7696165B2 | US2007232530A1,2,2,Yes,Grant,Yes
573,WO2007113856,A2,ORALLY DISINTEGRATING TABLETS,IN2006MU00498,India,2006-03-31T00:00:00Z,2006,2007-03-30T00:00:00Z,2007-10-11T00:00:00Z,2007,RUBICON RESEARCH PRIVATE LIMITED,PILGAONKAR PRATIBHA S    IN  | RUSTOMJEE MAHARUKH T    IN  | GANDHI ANILKUMAR S    IN  | BAGDE PRADNYA    IN  | MORVEKAR HETAL N    IN,A61K00920 | A61K04726 | A61K04702 | A61K04738,JP2009532343T  | AU2007232098A1 | CN101460150A  | KR20090008307A  | US2009208576A1 | US2009087485A1 | NZ572106A  | EP2001450A2 | IL194355D0 | WO2007113856A3 | CA2650498A1 | MX2008012299A  | NO20084612A ,13,12,Yes,Application,No
574,WO2007115132,A2,RADIOPHARMACEUTICAL IN SELF-FORMING LIPOSOMAL FORMULATION CAPABLE OF MULTIPATH ADMINISTRATION INCLUDING OTHER INGREDIENTS,US20010338267P,United States,2001-11-09T00:00:00Z,2001,2007-03-29T00:00:00Z,2007-10-11T00:00:00Z,2007,GUILFORD F. TIMOTHY | SCHUMM BROOKE,GUILFORD F TIMOTHY  US  | SCHUMM BROOKE  US,A61K003532,CA2628777A1 | EP1817006A2 | EP1817006A4 | EP1868572A2 | EP1868572A4 | IL182950D0 | IL191278D0 | JP2008518976T | US20040022873A1 | US20060099244A1 | US20070053970A1 | US20070065497A1 | US20070077258A1 | US20090047340A1 | US20100233193A1 | US20100233297A1 | US20100291196A1 | US20100316700A1 | US20110129523A1 | WO2006060120A2 | WO2006060120A3 | WO2006105155A2 | WO2006105155A3 | WO2006128133A1 | WO2007053810A2 | WO2007053810A3 | WO2007053810A2 | WO2007115131A2 | WO2007115131A3 | WO2007115132A3 | WO2008052184A1,22,5,Yes,Application,No
575,WO2007115181,A2,COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF,US20060788053P,United States,2006-04-03T00:00:00Z,2006,2007-03-30T00:00:00Z,2007-10-11T00:00:00Z,2007,EASTMAN CHEMICAL COMPANY,WEMPE MICHAEL FITZPATRICK    US  | EDGAR KEVIN JOSEPH    US  | ZIMA GEORGE CHESTER    US  | HYATT JOHN ANTHONY    US,A61B00505,US2007254859A1 | WO2007115181A3 | WO2007115181A9,2,2,Yes,Application,No
576,WO2007115381,A2,ENHANCING SOLUBILITY AND DISSOLUTION RATE OF POORLY SOLUBLE DRUGS,GB20060007105,United Kingdom,2006-04-10T00:00:00Z,2006,2007-04-10T00:00:00Z,2007-10-18T00:00:00Z,2007,K.U.LEUVEN RESEARCH & DEVELOPMENT,JANSSENS SANDRIEN    BE  | VAN DEN MOOTER GUY    BE,A61K00914 | A61K04734 | A61K031496,WO2007115381A3 | WO2007115381B1 | CN101460148A  | US2011059175A9 | US2009311325A1 | GB200607105D0 | CA2642757A1 | IL194635D0 | ZA200808556A  | JP2009533357T  | EP2004142A2,7,7,Yes,Application,No
577,WO2007117482,A2,RENIN INHIBITORS,US20060789823P | US20060789703P,United States,2006-04-05T00:00:00Z,2006,2007-04-05T00:00:00Z,2007-10-18T00:00:00Z,2007,VITAE PHARMACEUTICALS INC ,BALDWIN JOHN J    US  | CLAREMON DAVID A    US  | TICE COLIN M    US  | CACATIAN SALVACION    US  | DILLARD LAWRENCE W    US  | ISHCHENKO ALEXEY V    US  | YUAN JING    US  | XU ZHENRONG    US  | MCGEEHAN GERARD    US  | ZHAO WEI    US  | SIMPSON ROBERT D    US  | SINGH SURESH B    US  | FLAHERTY PATRICK T    US  | KALLANDER LARA S    US  | LEACH COLIN A    US  | LAWHORN BRIAN    US  | LU QING    US  | TERRELL LAMONT R    US  | GHAVINI-ALAGHA BAHMAN    US  | ZHANG JING    US  | GHIRLANDA DAMIANO    US  | HOU XIAOPING    US  | SEMUS SIMON    US,C07D21122 | A61P00912 | A61K0315375 | A61K03144 | C07D26530 | C07D40106,WO2007117559A3 | EP2010488A2 | WO2007117559A2 | US2009264428A1 | WO2007117482A3 | US2009275581A1 | WO2007117559A8,5,3,Yes,Application,No
578,WO2007119006,A1,NEW MEDICINES FOR TREATMENTS AGAINST RETROVIRUSES,FR20060003370,France,2006-04-14T00:00:00Z,2006,2007-04-13T00:00:00Z,2007-10-25T00:00:00Z,2007,LABORATOIRES GOEMAR,YVIN JEAN-CLAUDE    FR  | CHERMANN JEAN-CLAUDE    FR,A61K031716 | A61K04506 | A61K031737 | A61P03114 | A61P03118 | A61P03500,EP2007400A1 | FR2899815B1 | US2008269162A1 | FR2899815A1,4,4,Yes,Grant,Yes
579,WO2007120595,A2,ORGANIC COMPOUNDS AND THEIR USES,US20060791320P,United States,2006-04-11T00:00:00Z,2006,2007-04-09T00:00:00Z,2007-10-25T00:00:00Z,2007,NOVARTIS AG,RIGOLLIER PASCAL    FR  | EHRHARDT CLAUS    DE  | PARKER DAVID THOMAS    US  | COTTENS SYLVAIN    CH  | RADETICH BRANKO    US  | SEEPERSAUD MOHINDRA    US  | RANDL STEFAN ANDREAS    CH  | RAMAN PRAKASH    US  | FU JIPING    US  | PATANE MICHAEL    US,C07D24124 | A61P03112 | A61K031505 | A61K031395 | C07D40312 | C07D41314,WO2007120595A3,1,1,Yes,Application,No
580,WO2007121124,A2,ORGANIC COMPOUNDS AND THEIR USES,US20060791611P,United States,2006-04-11T00:00:00Z,2006,2007-04-09T00:00:00Z,2007-10-25T00:00:00Z,2007,NOVARTIS AG,BRANDL TRIXI    CH  | BRITT SHAWN D    US  | COTTENS SYLVAIN    CH  | EHRHARDT CLAUS    DE  | FU JIPING    US  | KARUR SUBRAMANIAN    US  | LI HONGJU    US  | LU PEICHAO    US  | PARKER DAVID THOMAS    US  | PATANE MICHAEL    US  | RADETICH BRANKO    US  | RAMAN PRAKASH    US  | RANDL STEFAN ANDREAS    CH  | RIGOLLIER PASCAL    FR  | SEEPERSAUD MOHINDRA    US  | SIMIC OLIVER    CH  | TICHKULE RITESH BHANUDASJI    US  | ZHU YANYI    US,C07K00506 | A61P03114 | A61K03800 | C07K00508 | C07K00510,MX2008013136A  | CA2648298A1 | JP2009533463T  | AR060402A1 | AU2007238252A1 | EP2007787A2 | US2008045530A1 | CL10032007A1 | WO2007121124A3 | RU2008144298A  | EP2272858A2 | KR20080111127A  | PE12222007A1 | US2007235275A1 | CN101466728A  | US7597406B2,16,13,Yes,Grant,Yes
581,WO2007121125,A2,ORGANIC COMPOUNDS AND THEIR USES,US20060791578P,United States,2006-04-11T00:00:00Z,2006,2007-04-09T00:00:00Z,2007-10-25T00:00:00Z,2007,NOVARTIS AG,COTTENS SYLVAIN    CH  | EHRHARDT CLAUS    DE  | FU JIPING    US  | PARKER DAVID THOMAS    US  | PATANE MICHAEL    US  | RADETICH BRANKO    US  | RAMAN PRAKASH    US  | RANDL STEFAN ANDREAS    CH  | RIGOLLIER PASCAL    FR  | SEEPERSAUD MOHINDRA    US  | SIMIC OLIVER    CH  | WAN DONGPENG    US,C07K00506 | A61P03114 | A61K03800 | C07K00508 | C07K00510,EP2007788A2 | US2007265281A1 | AR060385A1 | MX2008013125A  | AU2007238253A1 | WO2007121125A3 | RU2008144294A  | PE03552008A1 | JP2009536158T  | KR20080104366A  | CN101421292A  | CA2648678A1 | CL10042007A1,13,13,Yes,Application,No
582,WO2007121418,A2,CHEMICAL COMPOUNDS,US20060792543P | US20060792496P ,United States,2006-04-17T00:00:00Z,2006,2007-04-17T00:00:00Z,2007-10-25T00:00:00Z,2007,GSK LLC,AQUINO CHRISTOPHER JOSEPH    US  | FREEMAN GEORGE ANDREW    US  | MARTIN MICHAEL TOLAR    US,A61K031277,WO2007121415A2 | AR060491A1 | WO2007121415A3 | WO2007121416A3 | WO2008054857A1 | PE12262007A1 | AR060492A1 | WO2007121416A2 | WO2007121418A3 | AR060490A1,8,3,Yes,Application,No
583,WO2007124104,A2,NEEDLE-FREE DELIVERY OF HIV THERAPEUTICS,US20060745374P,United States,2006-04-21T00:00:00Z,2006,2007-04-20T00:00:00Z,2007-11-01T00:00:00Z,2007,ZOGENIX INC,CIPOLLA DAVID    US,A61M01502,WO2007124104A3,1,1,Yes,Application,No
584,WO2007124383,A2,"1,1'-BINAPHTHYL-BASED INHIBITORS OF NAD+-DEPENDENT DEACETYLASE ACTIVITY AND SIR2-FAMILY MEMBERS",US20060793430P,United States,2006-04-19T00:00:00Z,2006,2007-04-19T00:00:00Z,2007-11-01T00:00:00Z,2007,OREGON HEALTH & SCIENCE UNIVERSITY,GOODMAN RICHARD H    US  | FJELD CLARK C    US  | JACKSON MICHAEL D    US,A61K031277,WO2007124383A3,1,1,Yes,Application,No
585,WO2007126812,A2,PROCESS FOR PREPARATION OF HIV PROTEASE INHIBITORS,US20060787126P,United States,2006-03-29T00:00:00Z,2006,2007-03-29T00:00:00Z,2007-11-08T00:00:00Z,2007,GILEAD SCIENCES INC,CRAWFORD KENNETH R    US  | DOWDY ERIC D    US  | GUTIERREZ ARNOLD    US  | POLNIASZEK RICHARD P    US  | YU RICHARD HUNG CHIU    US,C07D49304 | C07F00902 | C07C32742,EA200802074A1 | NO20084547A  | JP2009531441T  | HR20080554A2 | US2011065631A1 | KR20080108322A  | MX2008012398A  | EP1999133A2 | ZA200808046A  | AP200804641D0 | AU2007245194A1 | CN101448838A  | US2008004242A1 | WO2007126812A3 | CA2647316A1,14,13,Yes,Application,No
586,WO2007127683,A2,ADMINISTRATION OF AGONIST-ANTAGONIST IN OPIOID-DEPENDENT PATIENTS,RU20060113790,Russia,2006-04-25T00:00:00Z,2006,2007-04-20T00:00:00Z,2007-11-08T00:00:00Z,2007,VORONKOV MICHAEL VICTOR | NEZHINSKY EFIM DAVID | ISAKULYAN LEVON GEVORKOVICH | OCHERET DARIA ALEXANDROVNA,VORONKOV MICHAEL VICTOR    US  | NEZHINSKY EFIM DAVID    RU  | ISAKULYAN LEVON GEVORKOVICH    RU  | OCHERET DARIA ALEXANDROVNA    RU,A61K00914,EP2018178A4 | US2009060871A1 | WO2007127683A3 | RU2006113790A  | EP2018178A2 | EA200802159A1,5,5,Yes,Application,No
587,WO2007128349,A1,USE OF ROLL COMPACTED PYROGENICALLY PRODUCED SILICON DIOXIDE IN PHARMACEUTICAL COMPOSITIONS,WO2006EP62215,WIPO,2006-05-10T00:00:00Z,2006,2006-05-10T00:00:00Z,2007-11-15T00:00:00Z,2007,EVONIK DEGUSSA GMBH,GRAY ANN    DE  | DRECHSLER MARGARETE    DE  | HOFMANN RALPH    DE,A61K00916,EP2023898A1 | CN101522174A  | US2009306224A1 | JP2009536164T ,5,5,Yes,Application,No
588,WO2007129274,A2,COMBINATION THERAPY,JP20060126096 ,Japan,2006-04-28T00:00:00Z,2006,2007-05-04T00:00:00Z,2007-11-15T00:00:00Z,2007,MEDIVIR AB,ZHANG HONG    SE  | OBERG BO    SE,A61K0317072 | A61P03118,WO2007129274A3 | ES2349486T3 | WO2007126157A8 | WO2007129274A9 | US7893145B2 | KR20090016568A  | EP2015759A2 | AU2007244150A1 | EP2017308A1 | AT476187T  | DE602007008226D1 | AU2007246644B2 | CN101432370A  | US2009170806A1 | PT2015759E  | EA200870501A1 | EA014778B1 | CN101437525A  | GB200608876D0 | JP2009536192T  | CA2651232A1 | ZA200809110A  | AU2007246644A1 | MX2008013491A  | CA2649683A1 | WO2007126157A1 | US2009169902A1 | DK2015759T3 | EP2015759B1,21,15,Yes,Grant,Yes
589,WO2007133865,A2,ORGANIC COMPOUNDS AND THEIR USES,US20060791318P,United States,2006-04-11T00:00:00Z,2006,2007-04-09T00:00:00Z,2007-11-22T00:00:00Z,2007,NOVARTIS AG,BRANDL TRIXI    CH  | FU JIPING    US  | LENOIR FRANCOIS    US  | PARKER DAVID THOMAS    US  | PATANE MICHAEL    US  | RADETICH BRANKO    US  | RAMAN PRAKASH    US  | RIGOLLIER PASCAL    FR  | SEEPERSAUD MOHINDRA    US  | SIMIC OLIVER    CH  | YIFRU AREGAHEGN    US  | ZHENG RUI    US,C07K00506 | C07K00510 | C07K005078 | A61K03807 | A61K03806 | A61K03805 | C07K005107 | A61P03112 | C07K005083 | C07K005103 | C07K00508 | A61P03114 | C07K005087 | A61P03118,US2007286842A1 | PE00722008A1 | MX2008013119A  | CL10052007A1 | ZA200808226A  | KR20080111123A  | AU2007249668B2 | WO2007133865A3 | US7825152B2 | JP2009533464T  | ECSP088811A  | US2010331243A1 | AU2007249668A1 | CN101466727A  | RU2008144299A  | AR060405A1 | EP2007789A2 | NO20084749A  | CA2643680A1,18,17,Yes,Grant,Yes
590,WO2007134037,A2,METHODS AND COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION WITH CONJUGATED ANTIBODIES OR ANTIBODY FRAGMENTS,US19970041506P,United States,1997-03-24T00:00:00Z,1997,2007-05-08T00:00:00Z,2007-11-22T00:00:00Z,2007,IMMUNOMEDICS INC,GOLDENBERG DAVID M    US  | CHANG CHIEN HSING    US  | ROSSI EDMUND A    US  | MCBRIDE WILLIAM J    US,H04M00342,US2010015048A1 | EP1959993A2 | US7772373B2 | US7612180B2 | US2008166342A1 | JP2010088439A  | US2008138333A1 | DE69830570D1 | EP2117604A2 | US7282567B2 | EP1937851A4 | CN1770373A  | WO2006107617A3 | JP2009531325T  | CA2675202A1 | US2009291093A1 | EP1459768A3 | US2005191300A1 | JP2006502699T  | US2010261885A1 | WO2004110390A2 | EP2291678A2 | US2010068137A1 | WO2008088648A2 | US2004115193A1 | JP2010516675T  | IL163851A  | DE602004031714D1 | JP4472351B2 | EP1572242A1 | MXPA05007851A  | US2007140966A1 | JP2006515892T  | CA2529496A1 | US2011064754A1 | AU2005220212A1 | KR20060040042A  | IL163852D0 | AU2006218454A1 | US2010189641A1 | US2008050311A1 | EP1720996A4 | US2004219203A1 | US7312318B2 | EP1483295A2 | AT417067T  | US2011008251A1 | AU6761098A  | US2010008858A1 | WO2006107786A3 | WO2010017500A2 | US2003124058A1 | EP1994057A2 | AU2003277087A1 | US2009202487A1 | JP2006502698T  | AT297759T  | WO2009055653A1 | EP1194167B1 | WO9842378A1 | WO2009100194A3 | US2006057136A1 | EP1720996A1 | AU2009279503A1 | WO2006107786A2 | US7642239B2 | US2011076233A1 | WO2009079024A1 | US2010189689A1 | AU2009243494A1 | ES2241129T3 | WO2007075270A3 | US2006091803A1 | JP2007523857T  | WO2004110390A3 | AU2006302848A1 | BR200406574A  | CA2284829A1 | US2007020265A1 | DK0969866T3 | US2010221210A1 | WO2006107617A2 | US7550143B2 | AU2009282830A1 | US2009202433A1 | CA2604032A1 | JP2001518930T  | WO2007134037A3 | WO2011025904A1 | WO2006094192A2 | WO2003106495A3 | RU2349343C2 | BRPI0406574A  | AU2007230822A1 | CA2478047A1 | WO2010022225A1 | SG153825A1 | EP1644729A4 | US6183744B1 | EP1431311A1 | AU2004207494C1 | CN101951939A  | US2010074840A1 | US7534866B2 | AU2003209447B8 | US7521056B2 | EP2200657A4 | US2008171067A1 | JP2008532949T  | WO2009126558A1 | US2004185053A1 | WO2009135015A8 | US2007230195A1 | WO2009135015A2 | WO2008088648A3 | AT439860T  | JP2007524686T  | IL169045A  | CN101171034A  | US2008166363A1 | WO2003074567A2 | CA2375912A1 | CN101534865A  | US2010272636A1 | MX2010004547A  | US2008170989A1 | JP4354280B2 | WO200074718A1 | KR100647630B1 | EP1937724A4 | CN101568352A  | EP1874358A2 | CA2489467A1 | US2006228357A1 | CN101824090A  | CN1675245A  | US2007087001A1 | US7597876B2 | US7901680B2 | AT500845T  | EP1543839A1 | US2007086942A1 | PL378012A1 | EP1594548A1 | IL172402D0 | WO2007075270A2 | CA2510664A1 | EP2271364A1 | US2011020273A1 | EP2308898A1 | CA2696260A1 | DE69830570T2 | WO2007046893A2 | JP2006513695T  | EP1959993A4 | CN101374546A  | US7871622B2 | US2010266497A1 | US2009304580A1 | CN101484182A  | AU728325B2 | AU2006232310A1 | AU2005220212B2 | US2005271671A1 | WO2003074566A2 | DE05075555T1 | AU2008338917A1 | CN1675245B  | MXPA04012656A  | EP1459768A2 | US7910103B2 | CA2675014A1 | AU2007343600A1 | US7544487B2 | KR20080097995A  | JP2010031032A  | CA2647130A1 | CA2373618A1 | AU2008212083A1 | JP2011507863T  | AU2005220211A1 | US2007212350A1 | US2003133930A1 | AU2003215732A1 | CN101534849A  | EP969866B2 | AU2008316741A1 | US2011070155A1 | IL163851D0 | US2004202666A1 | AU2006330051A1 | AU2004207494A1 | WO200067795A1 | CA2720935A1 | JP4584363B2 | CA2625992A1 | AU2009212436A1 | ES2331644T3 | DK1483294T3 | DE60333732D1 | CN101583376A  | EP1594548B1 | WO2010093395A1 | WO2007112193A2 | JP4286483B2 | CA2731438A1 | US7641901B2 | US7906121B2 | WO2003074566A3 | DE69830570T3 | CA2713933A1 | CN1649903A  | JP2006511526T  | WO2009135015A3 | AU2003209447A1 | JP2006134874A  | EP1483294A2 | US7919087B2 | US2007264265A1 | EP2197468A1 | US2009191225A1 | EP1937851A2 | EP2121030A2 | AU200048296A  | HK1046635A1 | US6306393B1 | US7527787B2 | US7563433B2 | EP1874358A4 | US2008131363A1 | JP2008542194T  | AU2005214361A1 | BR200311799A  | AU2009212806A1 | US7238785B2 | AU2005214361B2 | EP1874824A4 | EP2271359A2 | ES2241129T5 | DE60325184D1 | US7666400B2 | CA2508831A1 | AU200056005A  | JP2002544173T  | CA2633486A1 | JP2008538747T  | US2004001825A1 | CN100360567C  | EP1483295B1 | US2009060862A1 | WO2008088658A2 | JP2011012083A  | JP2010515732T  | WO2011026026A1 | KR20100132484A  | US2008253964A1 | WO2007047609A3 | DK1194167T3 | US2010284906A1 | ZA9802438A  | US2009269277A1 | IN189313A1 | PT1194167E  | US2006051349A1 | US2002041847A1 | US7517964B2 | EP1483294B1 | US2006210475A1 | WO2003074567A3 | BRPI0607486A2 | EP1194167A1 | AU2004207494B2 | EP1644729A2 | EP2287201A2 | US2006202597A1 | EP1853313A4 | AU2005220211B2 | JP4373387B2 | US2010216662A1 | CN1649902A  | EP2289551A1 | US2002071807A1 | AU2004247270A1 | CN1764478A  | AU2009242641A1 | WO2004054622A1 | US2010196266A1 | US7837995B2 | EP2301968A2 | JP2003501401T  | CN101264325A  | EP1937724A2 | US2006193865A1 | EP1519958A2 | WO2007112193A3 | WO2003106495A2 | KR20050104354A  | US7829064B2 | JP2009519931T  | CA2604034A1 | JP2009514813T  | US7906118B2 | AU2003288467A1 | US2010266496A1 | AU782160B2 | DE60042785D1 | WO2007046893A3 | EP1853313A2 | US2010221177A1 | HK1071576A1 | US7332863B2 | AU2006232920A1 | MX2010006728A  | US7585491B2 | US2009155166A1 | CN1649902B  | EP1874824A2 | WO2010017500A3 | WO2006094192A3 | US2010015046A1 | KR20080055932A  | EP969866A1 | US2009246130A1 | US7591994B2 | US2009299033A1 | WO2004067038A1 | US2010233779A1 | US2011070156A1 | AU2003215732B2 | DK0969866T4 | CA2599734A1 | AU2005220209A1 | US7858070B2 | JP2010227099A  | CA2555661A1 | EP969866B1 | AU2006304418A1 | CA2478012A1 | AU2003209447B2 | AU2003277087B2 | AU774044B2 | WO2005080586A1 | US2009246214A1 | EP2200657A1 | WO2007047609A2 | AU2007343610A1 | WO2010117984A1 | ES2350477T3 | KR20100085932A  | RU2005126717A  | US2006228300A1 | AT477276T  | AU2007230822A8 | US2006014245A1 | CN101506358A  | EP1178826A1 | WO2008088658A3 | CA2734265A1 | AU2004247270B2 | WO2009100194A2 | CA2696160A1 | US7074403B1 | JP2011500842T  | US2010196267A1 | AU2009233925A1 | US2010104589A1 | JP2009517337T  | CA2720748A1 | US2005014207A1 | CA2607056A1,290,21,Yes,Grant,Yes
591,WO2007143433,A1,NANOPOROUS STENTS WITH ENHANCED CELLULAR ADHESION AND REDUCED NEOINTIMAL FORMATION,US20020426106P,United States,2002-11-13T00:00:00Z,2002,2007-05-25T00:00:00Z,2007-12-13T00:00:00Z,2007,SETAGON INC | UNIVERSITY OF VIRGINIA PATENT FOUNDATION,OWENS GARY    US  | LYE WHYE-KEI    US  | REED MICHAEL    US  | SPRADLIN JOSHUA    US  | WAMHOFF BRIAN    US  | HUDSON MATTHEW    US  | LOOI KAREN    US,A61F00206,US2006193889A1 | US2006276879A1 | CN1725988A  | KR20070063511A  | EP1786363A2 | US2006193888A1 | JP2008509742T  | US2006121080A1 | WO2006020742A2 | WO2004043292A3 | US7713573B2 | US7294409B2 | AU2005272790A2 | US2006193886A1 | EP1786363A4 | US2008086198A1 | US2006193887A1 | WO2006020742A3 | US2006276877A1 | AT464025T  | US2006271169A1 | DE60322581D1 | US2006276885A1 | US2010260922A1 | WO2004043292A2 | EP1572032A4 | KR100826574B1 | EP1786363B1 | US2006276884A1 | CA2503625A1 | CA2577197A1 | AT402675T  | JP2006514848T  | US2005070989A1 | AU2005272790A1 | US2006193890A1 | EP1572032B1 | EP1572032A2 | AU2003295535A1 | AU2003295535B2 | DE602005020642D1 | CN101437467A  | EP1839626A1 | US2006276878A1 | US2004148015A1 | KR20050065643A ,34,9,Yes,Grant,Yes
592,WO2007143847,A1,SPIROTROPANE COMPOUNDS,US20060813366P | US20060813367P,United States,2006-06-14T00:00:00Z,2006,2007-06-14T00:00:00Z,2007-12-21T00:00:00Z,2007,VIROCHEM PHARMA INC,MOINET CHRISTOPHE    CA  | BLAIS CHARLES    CA  | BUBENIK MONICA    CA  | CHAN CHUN KONG LAVAL    CA  | COURCHESNE MARC    CA  | PEREIRA OSWY Z    CA  | DENIS REAL    CA  | VAILLANCOURT LOUIS    CA  | YANNOPOULOS CONSTANTIN G    CA,C07D45100 | A61K03146,CA2655203A1,3,3,Yes,Application,No
593,WO2007146695,A1,ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS,US20060811464P,United States,2006-06-06T00:00:00Z,2006,2007-06-06T00:00:00Z,2007-12-21T00:00:00Z,2007,ENANTA PHARM INC,OR YAT SUN    US  | SUN YING    US  | WANG ZHE    US,A01N03324 | A61K03115,WO2007143694A3 | US7728148B2 | KR20090017688A  | US2008187516A1 | AU2007256622A1 | CL16292007A1 | US2007281884A1 | ZA200810235A  | MX2008015495A  | AR061238A1 | US2008125444A1 | UY30391A1 | CA2653034A1 | CL16302007A1 | EP2037947A2 | RU2008152087A  | PE04572008A1 | CN101500596A  | WO2007143694A2 | AR063942A1 | JP2009539871T  | US2008181868A1 | US2007281885A1 | EP2037947A4 | UY30392A1,23,15,Yes,Grant,Yes
594,WO2007147884,A1,2-(SUBSTITUTED-AMINO)-BENZOTHIAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS,EP20060116003,European Patent Office,2006-06-23T00:00:00Z,2006,2007-06-22T00:00:00Z,2007-12-27T00:00:00Z,2007,TIBOTEC PHARM LTD,DE KOCK HERMAN    BE  | JONCKERS TIM HUGO MARIA    BE  | BOONANTS PAUL JOZEF GABRIEL MA    BE  | LAST STEFAAN JULIEN    BE  | DIERYNCK INGE    BE  | BAUMEISTER JUDITH EVA    BE  | VAN T KLOOSTER GERBEN ALBERT E    NL,C07D49304 | A61P03118 | A61K03134,MX2009000160A  | AP200804679D0 | AU2007262943A1 | CA2653233A1 | US2009209583A1 | KR20090024257A  | EA200970052A1 | JP2009541272T  | AR061619A1 | CN101479275A  | UY30416A1 | EP2035432A1 | ZA200810350A  | AP2069A  | IL195381D0 | PE03422008A1,15,15,Yes,Application,No
595,WO2008002924,A2,QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS,US20060872442P,United States,2006-06-26T00:00:00Z,2006,2007-06-26T00:00:00Z,2008-01-03T00:00:00Z,2008,ENANTA PHARM INC,OR YAT SUN    US  | MOORE JOEL D    US  | LIU DONG    US  | SUN YING    US  | GAI YONGHUA    US  | TANG DATONG    US  | NIU DEQIANG    US  | XU GUOYOU    US  | WANG ZHE    US,A61K031498 | A61P03112 | A61K03821 | C07D24504,ZA200810519A  | WO2008002924A3 | CA2654945A1 | IL195512D0 | PE09922008A1 | AU2007265157A1 | CN101478970A  | US2008008681A1 | US2007299078A1 | UY30437A1 | KR20090023732A  | MX2008016528A  | JP2009541491T  | AR061629A1 | RU2009102252A  | EP2066326A4 | US2009005387A1 | EP2066326A2,16,14,Yes,Application,No
596,WO2008005276,A2,MEDICAL DEVICE/DRUG DELIVERY SYSTEM FOR THE HEALING OF WOUNDS AND THE PREVENTION OF INFLAMMATION AND DISEASE,US20060817953P,United States,2006-06-30T00:00:00Z,2006,2007-06-28T00:00:00Z,2008-01-10T00:00:00Z,2008,DIRECTCONTACT LLC,SCHULTZ CLYDE L    US,A61K03818 | A61K00914,WO2008005276A3,1,1,Yes,Application,No
597,WO2008005511,A2,NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION,US20060818914P,United States,2006-07-05T00:00:00Z,2006,2007-07-05T00:00:00Z,2008-01-10T00:00:00Z,2008,INTERMUNE INC | ARRAY BIOPHARMA Inc,BLATT LAWRENCE M    US  | SEIWERT SCOTT    US  | BEIGELMAN LEONID    US  | KERCHER TIMOTHY    US  | KENNEDY APRIL L    US  | ANDREWS STEVEN W    US,C07D23156 | A61K031437 | A61K031416 | A61K0314035 | C07D47104 | A61P03114 | C07D40314,JP2009542690T  | CA2657035A1 | WO2008005511A3 | US7781474B2 | AU2007269606A1 | EP2044032A2 | AR061817A1 | CN101495457A  | KR20090024834A  | MX2008016369A  | US2010209391A1 | US2008019942A1 | RU2008152171A  | WO2008005511A8,12,11,Yes,Grant,Yes
598,WO2008008120,A1,SOLID FORM,US20060830912P,United States,2006-07-14T00:00:00Z,2006,2007-05-16T00:00:00Z,2008-01-17T00:00:00Z,2008,FMC CORP,DARMUZEY OLIVIA    BE  | MACLEOD GRAEME    BE  | CENGIC DZENANA    BE  | STOKES KEVIN M    US,A61K00920 | A61J00310 | A61J00300 | A61K00948 | B30B01102,EP2043613A1 | US2008014228A1,3,3,Yes,Application,No
599,WO2008009613,A1,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS,US20060832482P,United States,2006-07-21T00:00:00Z,2006,2007-07-12T00:00:00Z,2008-01-24T00:00:00Z,2008,F. HOFFMANN-LA ROCHE AG,SWEENEY ZACHARY KEVIN    US,C07C25554 | C07D23372 | A61K03163 | A61K0314166 | A61K031277 | C07C31151 | A61P03118 | C07C31146,US2008020981A1 | IL196144D0 | EP2046731A1 | AU2007276180A1 | AR061943A1 | CL21052007A1 | KR20090031584A  | ZA200900071A  | MX2009000574A  | PE05582008A1 | CA2657723A1 | JP2009544645T  | CN101484418A ,13,13,Yes,Application,No
600,WO2008009689,A1,PHARMACEUTICALLY ACCEPTABLE SOLUBILIZING COMPOSITION AND PHARMACEUTICAL DOSAGE FORM CONTAINING SAME,EP20060015076 | US20060832074P,European Patent Office and United States,2006-07-19T00:00:00Z,2006,2007-07-17T00:00:00Z,2008-01-24T00:00:00Z,2008,ABBOTT LAB,ROSENBERG JOERG    DE  | BREITENBACH JOERG    DE  | MARSH KENNAN    US  | LIEPOLD BERND    DE  | SCHMIDT CHRISTOPH    DE  | LANDER UTE    DE,A61K00920 | A61K031427 | A61K00914 | A61K031513 | A61K04714 | A61K04722,KR20090033342A  | EP2046298A1 | CN101489537A  | AU2007275177A1 | CA2658395A1 | ZA200901110A  | MX2009000048A  | EP1880715A1 | US2010247635A1 | RU2009105479A  | JP2009543849T ,12,11,Yes,Application,No
601,WO2008010953,A2,PYRIDINONE DIKETO ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY,US20060831990P,United States,2006-07-19T00:00:00Z,2006,2007-07-13T00:00:00Z,2008-01-24T00:00:00Z,2008,"UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC",NAIR VASU    US  | SEO BYUNG I    US  | UCHIL VINOD R    US  | CHI GUOCHEN    US,A61K0314412 | A61K00972 | A61K00902 | A61P03118 | C07D21186,US2010092427A1 | AU2007275805A1 | EP2046328A4 | CA2657034A1 | MX2009000661A  | US2008020010A1 | EP2046328A2 | WO2008010953A3 | JP2009543865T  | CN101516369A  | US7888375B2,9,8,Yes,Grant,Yes
602,WO2008011045,A2,"3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF",US20060831458P,United States,2006-07-18T00:00:00Z,2006,2007-07-18T00:00:00Z,2008-01-24T00:00:00Z,2008,CYTOVIA INC,CAI SUI XIONG    US  | DREWE JOHN A    US  | ZHANG HAN-ZHONG    US  | KASIBHATLA SHAILAJA    US  | CLAASSEN GISELA    US  | SIRISOMA NILANTHA SUDATH    US  | KEMNITZER WILLIAM EDWARD    US,A61K03153 | A61P03500 | A61K031542 | C07D48704 | C07D51304,US2008045514A1 | EP2046336A4 | CA2657931A1 | WO2008011045A3 | EP2046336A2,4,4,Yes,Application,No
603,WO2008011116,A2,AZA-PEPTIDE PROTEASE INHIBITORS,US20060832459P,United States,2006-07-21T00:00:00Z,2006,2007-07-19T00:00:00Z,2008-01-24T00:00:00Z,2008,GILEAD SCIENCES INC,CANNIZZARO CARINA E    US  | CHEN JAMES M    US  | DESAI MANOJ C    US  | MITCHELL MICHAEL L    US  | SWAMINATHAN SUNDARAMOORTHI    US  | XU LIANHONG    US,C07D49304 | A61P03118 | A61K031443 | A61K03134 | C07D40512 | C07D51900,US2009099096A1 | US7741345B2 | WO2008011116A3 | AU2007275689A1 | EP2049547A2 | JP2009544612T  | CA2657821A1,6,6,Yes,Grant,Yes
604,WO2008011117,A2,ANTIVIRAL PROTEASE INHIBITORS,US20060832624P,United States,2006-07-21T00:00:00Z,2006,2007-07-19T00:00:00Z,2008-01-24T00:00:00Z,2008,GILEAD SCIENCES INC,CANNIZZARO CARINA E    US  | YANG ZHENG-YU    US  | DESAI MANOJ C    US  | MITCHELL MICHAEL L    US  | XU LIANHONG    US  | SWAMINATHAN SUNDARAMOORTHI    US  | CHEN JAMES M    US,C07D21356 | C07D40512 | C07D40112 | C07D40514 | C07D40712 | C07D40912,US2009306112A1 | AU2007275690A1 | CA2657936A1 | US7723380B2 | EP2069303A2 | WO2008011117A3 | US2009105279A1 | JP2009544613T ,7,6,Yes,Grant,Yes
605,WO2008016522,A2,NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS,US20060832806P,United States,2006-07-24T00:00:00Z,2006,2007-07-24T00:00:00Z,2008-02-07T00:00:00Z,2008,GILEAD SCIENCES INC | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY,GUO HONGYAN    US  | KIM CHOUNG U    US  | KIM HAE SOO    KR  | LEE CHONG-KYO    KR  | LEE III YOUNG    KR  | MITCHELL MICHAEL L    US  | SON JONG CHAN    KR  | XU LIANHONG    US,C07D23954 | A61P03100 | A61K031513 | C07D40106 | C07D40306 | C07D41306,NO20090835A  | HR20090114A2 | EP2044037A2 | US2010034827A1 | AU2007281604A1 | CN101495461A  | WO2008016522A3 | EA200900213A1 | US2008070920A1 | AP200904759D0 | MX2009000871A  | IL196675D0 | KR20090040449A  | JP2009544710T  | CA2658479A1,13,12,Yes,Application,No
606,WO2008017867,A2,ANTIRETROVIRAL SOLID ORAL COMPOSITION,IN2006MU01269,India,2006-08-10T00:00:00Z,2006,2007-08-10T00:00:00Z,2008-02-14T00:00:00Z,2008,CIPLA LTD,LULLA AMAR    IN  | MALHOTRA GEENA    IN,A61P03118 | A61K04500 | A61K031513 | A61K031427 | A61K04706 | A61K04732 | A61K04738,CL23312007A1 | UY30535A1 | CA2660374A1 | WO2008017867A3 | US2010173921A1 | PE04222008A1 | AU2007283196A1 | ZA200901001A ,8,8,Yes,Application,No
607,WO2008019289,A2,TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS,US20060499245,United States,2006-08-04T00:00:00Z,2006,2007-08-02T00:00:00Z,2008-02-14T00:00:00Z,2008,ENANTA PHARM INC,SUN YING    US  | LIU DONG    US  | OR YAT SUN    US  | WANG ZHE    US,A61K03812 | C07K00512,AR062224A1 | CL22842007A1 | US2009035271A1 | CA2656816A1 | CN101674844A  | PE13122008A1 | UY30527A1 | ECSP077648A  | US2009130059A1 | WO2008019289A3 | CO6020003A1,11,10,Yes,Application,No
608,WO2008019968,A1,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS,US20060838272P,United States,2006-08-16T00:00:00Z,2006,2007-08-06T00:00:00Z,2008-02-21T00:00:00Z,2008,F. HOFFMANN-LA ROCHE AG,KENNEDY-SMITH JOSHUA    US  | PALMER WYLIE SOLANG    US  | SWEENEY ZACHARY KEVIN    US,C07D23112 | A61P03118 | A61K0314162 | A61K031415 | C07D48704 | C07D23156 | C07D47104,PE07342008A1 | CA2658984A1 | CN101501002A  | CL23462007A1 | EP2057125B1 | NO20090405A  | IL196655D0 | KR20090040438A  | RU2009109354A  | JP2010500392T  | US2011059975A1 | EP2057125A1 | AU2007286345A1 | US7713974B2 | AT503744T  | MX2009001198A  | AR062366A1 | US2008045511A1,19,18,Yes,Grant,Yes
609,WO2008021456,A2,"N-ARYL-5,7-DIHYDROFURO[3,4-D]PYRIMIDIN-4-AMINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF",US20060837921P,United States,2006-08-16T00:00:00Z,2006,2007-08-16T00:00:00Z,2008-02-21T00:00:00Z,2008,CYTOVIA INC,ZHANG HAN-ZHONG    US  | CAI SUI XIONG    US  | KEMNITZER WILLIAM E    US,A61K04800,WO2008021456A3 | US2008113946A1,2,2,Yes,Application,No
610,WO2008021733,A2,TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS,US20060934927P,United States,2006-08-11T00:00:00Z,2006,2007-08-02T00:00:00Z,2008-02-21T00:00:00Z,2008,ENANTA PHARM INC,SUN YING    US  | LIU DONG    US  | OR YAT SUN    US  | WANG ZHE    US,A61K03806,WO2008021733A3 | US2009035268A1 | US2009098085A1,3,2,Yes,Application,No
611,WO2008022242,A2,SYNTHESIS OF PROPYL PHENOXY ETHERS AND USE AS DELIVERY AGENTS,US20060838637P,United States,2006-08-18T00:00:00Z,2006,2007-08-16T00:00:00Z,2008-02-21T00:00:00Z,2008,"EMISPHERE TECHNOLOGIES, INC",SONG JIANFENG    US,A61K0314745,CA2661018A1 | US2010062970A1 | WO2008022242A3 | JP2010501489T  | EP2053918A4 | EP2053918A2,5,5,Yes,Application,No
612,WO2008022956,A1,METHOD FOR DETERMINING TRANSPORT ACTIVITY OF A TRANSPORT PROTEIN,EP20060119511,European Patent Office,2006-08-25T00:00:00Z,2006,2007-08-15T00:00:00Z,2008-02-28T00:00:00Z,2008,BOEHRINGER INGELHEIM INTERNATIONAL GMBH,CUI YUNHAI    DE,G01N033542 | G01N03360,EP2064548A1 | CA2660512A1 | JP2010501837T  | EP1892530A1,6,5,Yes,Application,No
613,WO2008029417,A2,PHARMACEUTICAL FORMULATION FOR USE IN HIV THERAPY,IN2006CH01597,India,2006-09-04T00:00:00Z,2006,2007-08-31T00:00:00Z,2008-03-13T00:00:00Z,2008,MATRIX LAB LTD,VELAVENI KIRAN KUMAR NARSAIAH    IN  | VERMA SANJAY DESHRAJ    IN  | DIXIT AKHILESH ASHOK    IN  | DESHMUKH ABHIJIT MUKUND    IN  | SETHI SANJEEV MEHARCHAND    IN  | MITRA SOURAV DILIPKUMAR    IN,A61K00920,WO2008029417A3 | US2009281132A1 | EP2063862A2,3,3,Yes,Application,No
614,WO2008033389,A2,ORGANIC COMPOUNDS AND THEIR USES,US20060825509P,United States,2006-09-13T00:00:00Z,2006,2007-09-11T00:00:00Z,2008-03-20T00:00:00Z,2008,NOVARTIS AG,BRANDL TRIXI    CH  | COTTENS SYLVAIN    CH  | EHRHARDT CLAUS    DE  | FU JIPING    US  | KARUR SUBRAMANIAN    US  | PARKER DAVID THOMAS    US  | PATANE MICHAEL A    US  | RAMAN PRAKASH    US  | RANDL STEFAN ANDREAS    CH  | RIGOLLIER PASCAL    FR  | SEEPERSAUD MOHINDRA    US  | SIMIC OLIVER    CH,C07K00506 | A61P03118 | A61P03112 | A61P03100 | C07K00508,EP2066688A2 | WO2008033389A3 | CN101541826A  | MX2009002688A  | AU2007294872A1 | JP2010503671T  | KR20090049600A  | CA2663159A1 | US2010204159A1,10,10,Yes,Application,No
615,WO2008033466,A2,COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES,US20060844463P,United States,2006-09-14T00:00:00Z,2006,2007-09-13T00:00:00Z,2008-03-20T00:00:00Z,2008,COMBINATORX SINGAPORE PRE LTD,JOHANSEN LISA M    US  | OWENS CHRISTOPHER M    US  | MAWHINNEY CHRISTINA    US  | CHAPPELL TODD W    US  | BROWN ALEXANDER T    US  | FRANK MICHAEL G    US  | ALTMEYER RALF    SG,A61K0314704,WO2008033466A3 | CL26782007A1 | AR062794A1 | US2008161324A1,4,4,Yes,Application,No
616,WO2008034039,A2,NOVEL TETRAHYDRO-ISOQUINOLINES,US20060845095P,United States,2006-09-15T00:00:00Z,2006,2007-09-14T00:00:00Z,2008-03-20T00:00:00Z,2008,NEXUSPHARMA INC,WEBER LUTZ    DE  | KHAZAK VLADIMIR    US  | ROSS GUNTHER    DE  | KALINSKI CEDRIC    DE  | BURDACK CHRISTOPH    DE,A61K0314704,WO2008034039A3 | US2009306130A1,2,2,Yes,Application,No
617,WO2008034731,A1,"OCTAHYDROPYRROLO [3, 4-C] PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS",US20060845334P,United States,2006-09-18T00:00:00Z,2006,2007-09-10T00:00:00Z,2008-03-27T00:00:00Z,2008,F. HOFFMANN-LA ROCHE AG,LEMOINE REMY    US  | MELVILLE CHRIS RICHARD    US  | ROTSTEIN DAVID MARK    US  | WANNER JUTTA    US,C07D48704 | A61P03118 | A61K031407,CN101516884A  | JP2010503714T  | ES2345130T3 | EP2066674B1 | AT472549T  | AR062798A1 | US2008103125A1 | PE13752008A1 | EP2066674A1 | CA2662835A1 | US7625905B2 | CL26712007A1 | DE602007007497D1,11,11,Yes,Grant,Yes
618,WO2008041176,A2,PROCESS FOR THE PREPARATION OF FORM I AND FORM II OF RITONAVIR,IN2006DE02173,India,2006-10-03T00:00:00Z,2006,2007-10-01T00:00:00Z,2008-04-10T00:00:00Z,2008,RANBAXY LABORATORIES LIMITED,SHARMA MUKESH KUMAR    IN  | KHANDURI CHANDRA HAS    IN  | SINGH PANKAJ KUMAR    IN  | SACHDEVA YOGINDER PAL    IN,A61P03118,US2010099885A1 | EP2077903A2 | WO2008041176A3,3,3,Yes,Application,No
619,WO2008046052,A1,PHARMACEUTICAL FORMULATIONS,US20050669699P,United States,2005-04-08T00:00:00Z,2005,2007-10-12T00:00:00Z,2008-04-17T00:00:00Z,2008,FOURNIER LABORATORIES IRELAND LTD,GAO YI    US  | TZUCHI R JU    US  | LEE DENNIS Y    US  | NGUYEN NICOLE    US  | WU HAUILIANG    US,A61K031192 | A61K00928 | A61K00920 | A61K00916,US2007148234A1 | EP1868587A2 | WO2006135480A3 | BRPI0609636A2 | IL198160D0 | CN101217944A  | US2006280791A1 | US2007128278A1 | JP2010506855T  | MX2007012443A  | US2007185199A1 | EP2081563A1 | CA2672686A1 | WO2006135480A9 | AU2007307641A1 | KR20080008352A  | ECSP099251A  | CN101677981A  | IL186435D0 | US2010310607A1 | NO20075628A  | US2006280790A1 | WO2006135480A2 | EA200702198A1 | MX2009003815A  | SG161256A1 | AU2006258217A1 | JP2008535851T  | CA2604078A1 | ZA200902488A  | US2008152714A1 | KR20090119959A  | US2007264334A1 | EP2074992A1 | EA200900531A1,32,15,Yes,Application,No
620,WO2008051039,A1,METHOD FOR DETECTING NUCLEOTIDE VARIATIONS,KR20060103745,South Korea,2006-10-25T00:00:00Z,2006,2007-10-25T00:00:00Z,2008-05-02T00:00:00Z,2008,SEEGENE INC,CHUN JONG YOON    KR,C12N01510 | C12N01509,EP2084281A1 | KR20080037128A  | JP2010504752T ,4,4,Yes,Application,No
621,WO2008052737,A2,IMMUNOCHEMICALLY EQUIVALENT HIV DRUG ANALOGS,US20060863442P,United States,2006-10-30T00:00:00Z,2006,2007-10-30T00:00:00Z,2008-05-08T00:00:00Z,2008,F. HOFFMANN-LA ROCHE AG,SIGLER GERALD    US  | GHOSHAL MITALI    US  | HUI RAYMOND    US  | SORIANO GLENDA    US,C07D21342 | A61P03118 | A61K031536 | A61K031513 | C07K01638 | C07D23910 | C07D26518,WO2008052737A3 | CA2664430A1 | EP2094660A2 | JP2010508250T ,4,4,Yes,Application,No
622,WO2008052770,A2,(BASE-)MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN,DE200610051516,Germany,2006-10-31T00:00:00Z,2006,2007-10-31T00:00:00Z,2008-05-08T00:00:00Z,2008,CUREVAC GMBH,HOERR INGMAR    DE  | VON DER MUELBE FLORIAN    DE,A61K03900 | C12N01567 | A61K04800,EP2083851A2 | DE102006051516A1 | US2010047261A1 | WO2008052770A3 | JP2010508014T ,5,5,Yes,Application,No
623,WO2008054454,A2,"NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF AS ANTIVIRAL AGENTS",US20060772309P,United States,2006-02-10T00:00:00Z,2006,2007-02-09T00:00:00Z,2008-05-08T00:00:00Z,2008,TRANSTECH PHARMA INC,MJALLI ADNAN M M    US  | COOPER JEREMY T    US  | ARIMILLI MURTY N    US  | ANDREWS ROBERT C    US  | ROTHLEIN ROBERT    US  | ALTEL TALEB H    US,C07D23364 | A61K0314725 | A61K0314178 | A61K0314164 | C07D40114 | A61P03112 | C07D40102,US2007219239A1 | WO2008054454A3,2,2,Yes,Application,No
624,WO2008055995,A2,METHODS AND COMPOSITIONS FOR DETECTING RECEPTOR LIGAND MIMETICS,US20060858033P,United States,2006-11-10T00:00:00Z,2006,2007-11-09T00:00:00Z,2008-05-15T00:00:00Z,2008,ALPHAPTOSE GMBH,KHAZAK VLADIMIR    US  | WEBER LUTZ    DE,G01N03350 | C12Q00168 | A61K03166,EP2089711A2 | CN101606061A  | CA2669012A1 | WO2008055995A3 | JP2010508836T  | AU2007316587A1 | US2010111930A1,7,7,Yes,Application,No
625,WO2008057402,A2,N-ARYL-ISOXAZOLOPYRIMIDIN-4-AMINES AND RELATED COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF,US20060856004P,United States,2006-11-02T00:00:00Z,2006,2007-11-02T00:00:00Z,2008-05-15T00:00:00Z,2008,CYTOVIA INC,CAI SUI XIONG    US  | KEMNITZER WILLIAM E    US  | SIRISOMA NILANTHA SUDATH    US  | ZHANG HAN-ZHONG    US,A61K031519,WO2008057402A3,1,1,Yes,Application,No
626,WO2008059046,A1,MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS,EP20060124359,European Patent Office,2006-11-17T00:00:00Z,2006,2007-11-16T00:00:00Z,2008-05-22T00:00:00Z,2008,TIBOTEC PHARM LTD,RABOISSON PIERRE JEAN-MARIE BE    BE  | DE KOCK HERMAN AUGUSTINUS    BE  | MC GOWAN DAVID CRAIG    BE  | VAN DE VREKEN WIM    BE  | HU LILI    BE  | TAHRI ABDELLAH    BE  | VENDEVILLE SANDRINE MARIE HELE    BE,C07D40112 | A61P03114 | A61K0314741 | A61K0314709 | C07D49104,CN101535294A  | AU2007321182A1 | US2010022578A1 | KR20090079881A  | EA200970493A1 | EP2097402A1 | CA2661338A1 | JP2010510192T  | AR064258A1 | CL32992007A1 | MX2009005219A ,12,12,Yes,Grant,Yes
627,WO2008060578,A2,"3-ARYL-6-ARYL-[1,2,4] TRIAZOLO[3,4-B][1,3,4] THIADIAZOLES AND RELATED COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF",US20060858936P,United States,2006-11-15T00:00:00Z,2006,2007-11-15T00:00:00Z,2008-05-22T00:00:00Z,2008,CYTOVIA INC,CAI SUI XIONG    US  | DREWE JOHN A    US  | SIRISOMA NILANTHA SUDATH    US  | ZHANG HAN-ZHONG    US,A61K0315377 | A61K0314709 | A61K0314245,US2008113984A1 | WO2008060578A3 | US7732468B2,2,2,Yes,Grant,Yes
628,WO2008062385,A2,ANTIRETROVIRAL DRUG RESISTANCE TESTING,ZA20060010003,South Africa,2006-11-24T00:00:00Z,2006,2007-11-26T00:00:00Z,2008-05-29T00:00:00Z,2008,CILLIERS REGINALD ANTHONY | LOUBSER ALISTAIR SHAYNE,CILLIERS REGINALD ANTHONY    ZA  | LOUBSER ALISTAIR SHAYNE    ZA,C12Q00168,ZA200903519A  | WO2008062385A3,2,2,Yes,Application,No
629,WO2008062429,A2,"PARTICLES FOR DELIVERY OF ACTIVE INGREDIENTS, PROCESS OF MAKING AND COMPOSITIONS THEREOF",IN2006MU01276,India,2006-08-11T00:00:00Z,2006,2007-08-10T00:00:00Z,2008-05-29T00:00:00Z,2008,PANACEA BIOTEC LTD,SINGH AMARJIT    IN  | SINGH SARABJIT    IN  | SINGH PARAMJIT    IN  | JAIN RAJESH    IN,B82B00300 | A61K00900,CN101500937A  | WO2008062429A3 | MX2009001533A  | RU2009108646A  | JP2010500340T  | AR062334A1 | EP2054339A2 | ZA200900506A  | AU2007323007A1 | CL23362007A1 | US2010172993A1 | CA2657829A1 | KR20090041426A ,13,13,Yes,Application,No
630,WO2008063493,A2,COMPOSITIONS AND METHODS RELATED TO TOLL-LIKE RECEPTOR-3,US20060858891P,United States,2006-11-14T00:00:00Z,2006,2007-11-15T00:00:00Z,2008-05-29T00:00:00Z,2008,THE TEXAS A & M UNIVERSITY SYSTEM,KAO CHENG C    US  | KUMAR RANJITH    US,A61K03817,JP2010509398T  | EP2094726A2 | WO2008063493A3 | US2009142300A1 | AU2007322105A1 | CA2669558A1,6,6,Yes,Application,No
631,WO2008067164,A2,SOLID PHARMACEUTICAL DOSAGE FORMULATIONS,US20060859271P,United States,2006-11-15T00:00:00Z,2006,2007-11-14T00:00:00Z,2008-06-05T00:00:00Z,2008,ABBOTT LAB,BERNDL GUNTHER    DE  | ROSENBERG JOERG    DE  | FASTNACHT KATJA    DE  | LIEPOLD BERND    DE  | BREITENBACH JOERG    DE  | JUNG TINA    DE  | ROTH WOLFGANG    DE  | MORRIS JOHN    US  | KLEIN CHERI E    US  | CAI YAN    US  | ALANI LAMAN    US  | GHOSH SOUMOJEET    US,A61K00920 | A61K031427,CA2669938A1 | WO2008067164A3 | US2008181948A1 | EP2112925A2,4,4,Yes,Application,No
632,WO2008070625,A2,SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL,US20040780424,United States,2004-02-17T00:00:00Z,2004,2007-12-03T00:00:00Z,2008-06-12T00:00:00Z,2008,"UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC",BRENNAN ANTHONY B    US  | BANEY RONALD H    US  | CARMAN MICHELLE L    US  | ESTES THOMAS G    US  | FEINBERG ADAM W    US  | WILSON LESLIE H    US  | SCHUMACHER JAMES F    US,B63B00132,CA2556662A1 | JP2007529090T  | US7650848B2 | US2010126404A1 | EP1716451A2 | US2005178286A1 | US2010226943A1 | WO2006025857A3 | US7117807B2 | AU2005280637A1 | AU2005280637B8 | EP1716451A4 | US2006219143A1 | WO2008070625A3 | AU2005280637B2 | US2007227428A1 | WO2006025857A2 | US7143709B2,11,6,Yes,Grant,Yes
633,WO2008071587,A2,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS,US20060874673P,United States,2006-12-13T00:00:00Z,2006,2007-12-04T00:00:00Z,2008-06-19T00:00:00Z,2008,F. HOFFMANN-LA ROCHE AG,BROTHERTON-PLEISS CHRISTINE E    US  | KERTESZ DENIS JOHN    US  | YANG MINMIN    CN,C07D40312 | C07D40114 | A61P03118 | A61K031502 | C07D40314 | C07D47110,JP2010513240T  | AU2007332654A1 | CL35652007A1 | EP2089384A2 | CN101553483A  | AR064221A1 | WO2008071587A3 | MX2009005881A  | KR20090087512A  | US2008146595A1 | PE15092008A1 | CA2671478A1 | US7998969B2,12,12,Yes,Grant,Yes
634,WO2008073138,A2,"TEREPHTHALAMATE COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS HIV INTEGRASE INHIBITORS",US20060747262P,United States,2006-05-15T00:00:00Z,2006,2007-04-18T00:00:00Z,2008-06-19T00:00:00Z,2008,IRM LLC,HE YUN    US  | WANG ZHIWEI    US  | WU BAOGEN    US,A61K0314412,CN101443007A  | JP2009537521T  | RU2008149246A  | MX2008014616A  | WO2008073138A3 | KR20080110905A  | EP2018166A2 | AU2007333021A1 | CA2650329A1,10,10,Yes,Application,No
635,WO2008073558,A2,"WATER-DISPERSIBLE ORAL, PARENTERAL, AND TOPICAL FORMULATIONS FOR POORLY WATER SOLUBLE DRUGS USING SMART POLYMERIC NANOPARTICLES",US20060849684P,United States,2006-10-05T00:00:00Z,2006,2007-10-05T00:00:00Z,2008-06-19T00:00:00Z,2008,THE JOHNS HOPKINS UNIVERSITY,MAITRA ANIRBAN    US  | FELDMANN GEORG    US  | BISHT SAVITA    US,A61K04748 | A61K04732 | A61K00919,US2008107749A1 | EP2073848A2 | CN101583379A  | AU2007333528A1 | CA2665343A1 | JP2010505877T  | MX2009003680A  | WO2008073558A3,9,9,Yes,Application,No
636,WO2008077649,A1,"PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTONS",US20060871905P,United States,2006-12-26T00:00:00Z,2006,2007-12-24T00:00:00Z,2008-07-03T00:00:00Z,2008,GILEAD SCIENCES INC,WATKINS WILLIAM JOHN    US  | CHONG LEE SHUN    US  | ZHANG JENNIFER R    US,C07D47104 | A61P03112 | A61K031519,US2009324543A1,2,2,Yes,Application,No
637,WO2008077650,A1,"PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS",US20060871916P,United States,2006-12-26T00:00:00Z,2006,2007-12-24T00:00:00Z,2008-07-03T00:00:00Z,2008,GILEAD SCIENCES INC,BONDY STEVEN S    US  | WATKINS WILLIAM JOHN    US  | CHONG LEE SHUN    US  | HERDEWIJN PIET ANDRE MAURITS M    BE  | DE JONGHE STEVEN CESAR ALFONS    BE,C07D47104 | A61P03112 | A61K031519,US2010048559A1,2,2,Yes,Application,No
638,WO2008090287,A2,USE OF AT LEAST ONE BOTULISM NEUROTOXIN FOR TREATING THE PAIN INDUCED BY THERAPEUTIC TREATMENTS FOR THE AIDS VIRUS,FR20060011244,France,2006-12-22T00:00:00Z,2006,2007-12-17T00:00:00Z,2008-07-31T00:00:00Z,2008,IPSEN PHARMA S.A.S.,FAVRE CHRISTINE    FR  | AUGUET MICHEL    FR  | CHABRIER DE LASSAUNIERE PIERRE    FR,A61K03848,WO2008090287A3 | US2010029566A1 | FR2910327A1 | EP2104510A2,4,4,Yes,Application,No
639,WO2008092006,A2,ANTIMICROBIAL COMPOSITIONS,US20070897147P,United States,2007-01-24T00:00:00Z,2007,2008-01-24T00:00:00Z,2008-07-31T00:00:00Z,2008,CERNOFINA LLC,MITTELMAN MARC W    US  | ALBERTE RANDALL S    US,A61K031185,US2009016990A1 | WO2008092006A3,2,2,Yes,Application,No
640,WO2008097924,A2,PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN ANALOGS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS,US20070899472P,United States,2007-02-05T00:00:00Z,2007,2008-02-04T00:00:00Z,2008-08-14T00:00:00Z,2008,AVANIR PHARMACEUTICALS,SIRCAR JAGADISH    US  | KUMAR KC SUNIL    US,A61K031473,WO2008097924A3,1,1,Yes,Application,No
641,WO2008098789,A2,DUAL ACTING PRODRUGS,EP20070003342,European Patent Office,2007-02-16T00:00:00Z,2007,2008-02-15T00:00:00Z,2008-08-21T00:00:00Z,2008,KTB TUMORFORSCHUNGSGESELLSCHAFT MBH,KRATZ FELIX    DE  | MERFORT IRMGARD    DE,A61K04748 | A61P03700 | A61P03500,JP2010518135T  | EP2131866A2 | US2010144647A1 | WO2008098789A3 | CA2678427A1 | AU2008214801A1,6,6,Yes,Application,No
642,WO2008100867,A2,NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION,US20070889433P,United States,2007-02-12T00:00:00Z,2007,2008-02-11T00:00:00Z,2008-08-21T00:00:00Z,2008,"INTERMUNE INC | ARRAY BIOPHARMA, INC.",BEIGELMAN LEONID    US  | BUCKMAN BRAD    US  | WANG GUANGYI    US  | MATULIC-ADAMIC JASENKA    US  | STOYCHEVA ANTITSA DIMITROVA    US  | ANDREWS STEVEN W    US  | MISIALEK SHAWN MAURICE    US  | RAJAGOPALAN P T RAVI    US  | FRYER ANDREW M    US  | GUNAWARDANA INDRANI    US  | HAAS JULIA    US  | HUANG LILY    US  | MADDURU MACHENDER R    US  | ZHANG GAN    US  | KOSSEN KARL    US  | SEREBRYANY VLADIMIR    US,C07D20918 | C07D40906 | C07D40310 | C07D20932 | C07D20930 | C07D40914 | C07D40306 | C07D30779 | C07D40706 | C07D40912 | C07D41306 | C07D40312 | C07D33360 | C07D40904 | C07D40110,EP2134683A2 | WO2008100867A3 | CA2676906A1 | JP2010518125T  | US2009047246A1 | AU2008216382A1 | CN101687789A  | MX2009008439A ,8,8,Yes,Application,No
643,WO2008101665,A1,MACROCYCLIC COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS,US20070890754P ,United States,2007-02-20T00:00:00Z,2007,2008-02-19T00:00:00Z,2008-08-28T00:00:00Z,2008,NOVARTIS AG,BRITT SHAWN D    US  | FU JIPING    US  | PARKER DAVID THOMAS    US  | PATANE MICHAEL A    US  | RAMAN PRAKASH    US  | RADETICH BRANKO    US  | SEEPERSAUD MOHINDRA    US  | YIFRU AREGAHEGN    US  | ZHENG RUI    US  | BRANDL TRIXI    CH  | COTTENS SYLVAIN    CH  | EHRHARDT CLAUS    DE  | RANDL STEFAN ANDREAS    CH  | RIGOLLIER PASCAL    FR  | SCHIERING NIKOLAUS    DE  | SIMIC OLIVER    CH,C07D25702 | C07D51304 | A61P03114 | A61K031395 | C07D49804 | C07D28500 | C07D51900 | C07D51504 | C07D48704 | C07K00502 | C07D48708,US2010240638A1 | EA200901101A1 | MX2009008872A  | EP2125757A1 | JP2010519266T  | CN101663284A  | CA2677843A1 | AU2008217187A1,6,9,Yes,Application,No
644,WO2008103899,A1,PREPARATION AND UTILITY OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS,US20070891436P,United States,2007-02-23T00:00:00Z,2007,2008-02-22T00:00:00Z,2008-08-28T00:00:00Z,2008,AUSPEX PHARMACEUTICALS INC,GANT THOMAS G    US  | SARSHAR SEPEHR    US,C07D47114 | A61P03100 | A61K031551,US2008241289A1 | AR065468A1,3,3,Yes,Application,No
645,WO2008109154,A1,CHEMOKINE RECEPTOR MODULATORS,US20070905580P,United States,2007-03-08T00:00:00Z,2007,2008-03-07T00:00:00Z,2008-09-12T00:00:00Z,2008,METASTATIX INC,CLARK MICHAEL P    US  | LOCKWOOD MARK A    US  | WAGNER FLORENCE F    US  | NATCHUS MICHAEL G    US,A61K03104,US2008261978A1,2,2,Yes,Application,No
646,WO2008109462,A2,SUSTAINED RELEASE COMPOSITIONS USING WAX-LIKE MATERIALS,US20070904456P,United States,2007-03-02T00:00:00Z,2007,2008-02-29T00:00:00Z,2008-09-12T00:00:00Z,2008,FARNAM COMPANIES INC,CHEN ANDREW XIAN    US  | KIGIN PATRICIA D    US,A61K00916 | A61K00950 | A01N02534 | A61K031135 | A61K031522 | A61K0317008,WO2008109462A3 | EP2144599B1 | CN101652128A  | AT476176T  | EP2144599A2 | DE602008002073D1 | JP2010520226T  | AU2008223091A1 | ES2350029T3 | US2008220079A1 | CA2678367A1,9,9,Yes,Grant,Yes
647,WO2008109483,A1,PARTICULATE DRUG DELIVERY,US20070892834P,United States,2007-03-02T00:00:00Z,2007,2008-03-02T00:00:00Z,2008-09-12T00:00:00Z,2008,THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS,CHENG JIANJUN    US  | TONG RONG    US,B82B00100 | B82B00300,EP2132133A1 | JP2010520227T  | CN101679021A  | US2008248126A1,5,5,Yes,Application,No
648,WO2008112156,A1,CHEMOKINE RECEPTOR MODULATORS,US20070905610P,United States,2007-03-08T00:00:00Z,2007,2008-03-07T00:00:00Z,2008-09-18T00:00:00Z,2008,METASTATIX INC,CLARK MICHAEL P    US  | LOCKWOOD MARK A    US  | WAGNER FLORENCE F    US  | NATCHUS MICHAEL G    US  | DOROH BRANDON C    US,A61K03104,US2008293711A1,2,2,Yes,Application,No
649,WO2008112289,A2,OLIGOMER-PROTEASE INHIBITOR CONJUGATES,US20070906330P | US20070906329P,United States,2007-03-12T00:00:00Z,2007,2008-03-12T00:00:00Z,2008-09-18T00:00:00Z,2008,NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER    US  | CHENG LIN    US  | VIEGAS TACEY X    US  | GU XUYUAN    US  | DUARTE FRANCO J    US  | ZHANG WEN    US,A61K04748 | A61P03118,JP2010521465T  | US2010317705A1 | AU2008226823A1 | EP2131865A2 | CA2679482A1 | CA2679473A1 | WO2008112286A9 | WO2008112261A1 | MX2009009850A  | WO2009067175A2 | WO2008112286A2 | KR20090118965A  | WO2009032286A2 | WO2008112286A3 | IL200846D0 | WO2008112289A3 | AU2008226820A1 | WO2009067175A3 | US2010168232A1 | EP2134370A1 | US2010184989A1 | JP2010522142T  | EP2125027A2 | CN101631568A ,22,9,Yes,Application,No
650,WO2008113177,A1,COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF AND USES THEREOF,US20070895795P,United States,2007-03-20T00:00:00Z,2007,2008-03-19T00:00:00Z,2008-09-25T00:00:00Z,2008,CENTRE DE RECHERCHE SUR LES BIOTECHNOLOGIES MARINE,FORTIN SAMUEL    CA,A61K04744 | A61K04722 | A61K0369066 | A61K03112 | A61K031047 | A61K009127 | A61K036282 | A61K031122 | A61K04716 | A61K04724 | A61K04714 | A61K03556 | A61K04718 | A61K03602,CA2677670A1 | CA2677670C  | US2010196496A1 | US2009291102A1 | EP2136844A1 | AU2008229604A1,6,5,Yes,Grant,Yes
651,WO2008113364,A2,PREVENTION OF NEPHROTOXICITY III,DK20070000424,Denmark,2007-03-20T00:00:00Z,2007,2008-03-19T00:00:00Z,2008-09-25T00:00:00Z,2008,RECEPTICON APS,BOYE SOEREN VALDGAARD    DK  | THINGGAARD JACOB    DK,A61K031132 | A61K0314045 | A61K031195 | A61K031136 | A61K031133 | A61K031417 | A61K03118 | A61K03114 | A61K031381 | A61K0314164 | A61K0314412 | A61K031198 | A61K031155 | A61K0314035 | A61K031166,WO2008113364A3 | EP2139461A2,2,2,Yes,Application,No
652,WO2008116165,A2,METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION,US20060826271P,United States,2006-09-20T00:00:00Z,2006,2008-03-21T00:00:00Z,2008-09-25T00:00:00Z,2008,NEXT SAFETY INC,LEMAHIEU EDWARD    US  | JONES CHARLES    US  | STERN TOM    US  | HEBRANK JACK    US  | HUNTER CHARLES ERIC    US  | DUVALL LYNDELL    US  | HARTLEY CHRIS    US  | BALLOU BERNARD L JR    US  | HUNTER JOCELYN    US  | MCNEIL LAURIE    US  | WETZEL PAUL    US  | CRISS RON    US,A61M01102,US2008271732A1 | US2008078382A1 | WO2008036801A2 | WO2008116165A9 | US2008066741A1 | EP1911481A2 | EP1911481A3 | WO2008036798A2 | EP1902742A1 | JP2010504171T  | WO2008036798A3 | US2008066739A1 | WO2008116165A3 | CA2662777A1 | US2008142010A1 | CN101553210A  | WO2008036801A3,13,6,Yes,Application,No
653,WO2008118991,A1,METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS BY STIMULATING ER STRESS,US20070908107P,United States,2007-03-26T00:00:00Z,2007,2008-03-26T00:00:00Z,2008-10-02T00:00:00Z,2008,UNIVERSITY OF SOUTHERN CALIFORNIA,SCHONTHAL AXEL H    US  | PETASIS NICOS A    US  | HOFMAN FLORENCE M    US  | LOUIE STAN G    US  | CHEN THOMAS C    US,G01N033574 | C12N00500,JP2010522763T  | AU2008230816A1 | US2009062227A1 | EP2137536A1 | CN101918843A | US7981917B2,6,6,Yes,Grant,Yes
654,WO2008119662,A1,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS,US20070920635P,United States,2007-03-29T00:00:00Z,2007,2008-03-18T00:00:00Z,2008-10-09T00:00:00Z,2008,F. HOFFMANN-LA ROCHE AG,SWEENEY ZACHARY KEVIN    US  | WELCH MICHAEL    US,C07D24912 | A61P03118 | A61K0314196,AR067271A1 | MX2009009920A  | CN101657433A  | JP2010522706T  | AU2008233929A1 | IL200748D0 | EP2142520A1 | US2008249151A1 | CA2682637A1 | KR20090127178A  | PE00672009A1 | US7906540B2,11,11,Yes,Grant,Yes
655,WO2008122534,A2,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS,US20070922449P,United States,2007-04-09T00:00:00Z,2007,2008-03-31T00:00:00Z,2008-10-16T00:00:00Z,2008,F. HOFFMANN-LA ROCHE AG,BILLEDEAU ROLAND J    US  | PALMER WYLIE SOLANG    US  | SWEENEY ZACHARY KEVIN    US  | WU JEFFREY    US,C07D47104 | A61P03118 | A61K0314353 | A61K0314162 | C07D48704,CN101679414A  | US2008293664A1 | MX2009010932A  | CL9962008A1 | CA2683046A1 | KR20100015435A  | AU2008235549A1 | AR066404A1 | PE01432009A1 | JP2010523613T  | IL200886D0 | WO2008122534A3 | EP2134711A2,12,12,Yes,Application,No
656,WO2008127291,A2,ADVANCED DRUG DEVELOPMENT AND MANUFACTURING,US20010859701,United States,2001-05-16T00:00:00Z,2001,2007-10-10T00:00:00Z,2008-10-23T00:00:00Z,2008,"LOS ALAMOS NATIONAL SECURITY, LLC",BIRNBAUM EVA R    US  | KOPPISCH ANDREW T    US  | BALDWIN SHARON M    US  | WARNER BENJAMIN P    US  | MCCLESKEY MARK T    US  | BERGER JENNIFER A    US  | STEWART JEFFREY J    US  | HARRIS MICHAEL N    US  | BURRELL ANTHONY K    US,G01N03353 | G01N023223 | G01N02176 | G01N03368,US6858148B2 | US2004017884A1 | EP2084519A2 | EP1644095A1 | JP2010509566T  | US2004235059A1 | US2008220441A1 | EP2084519A4 | AU2003267973A8 | WO2004011898A2 | US2005011818A1 | WO2007142772A2 | JP2006503268T  | US7519145B2 | US7858385B2 | EP1525458A4 | JP2007527524T  | EP1644095A4 | WO2007142772A3 | US2005214847A1 | WO2008127291A3 | WO2005009584A1 | AU2003267973A1 | US7241381B2 | WO2004011898A3 | EP1525458A2 | US2007003008A1 | US2005095636A1 | US2003027129A1 | US2009175410A1,20,5,Yes,Grant,Yes
657,WO2008129106,A2,NANOPARTICLES COMPRISING A CYCLODEXTRIN AND A BIOLOGICALLY ACTIVE MOLECULE AND USES THEREOF,ES20070001074,Spain,2007-04-20T00:00:00Z,2007,2008-04-18T00:00:00Z,2008-10-30T00:00:00Z,2008,"INSTITUTO CIENTIFICO Y TECNOLOGICO DE NAVARRA, S.A",AGUEEROS BAZO MAITE    ES  | SALMAN HESHAM H A    ES  | IRACHE GARRETA JUAN MANUEL    ES  | CAMPANERO MARTINEZ MIGUEL ANGE    ES,A61K00951 | A61K04748,JP2010524902T  | EP2153826A2 | MX2009011247A  | WO2008129106A3 | ES2310122A1 | CA2684560A1 | CN101686949A  | AU2008240545A1 | US2010136129A1 | ES2310122B1,9,9,Yes,Grant,Yes
658,WO2008131505,A1,OSMOTIC FORM FOR CONTROLLED RELEASE OF ACTIVE PRINCIPLES,BR2007PI01904,Brazil,2007-04-27T00:00:00Z,2007,2008-04-24T00:00:00Z,2008-11-06T00:00:00Z,2008,"LIBBS FARMACEUTICA LTDA,",FREITAS MILLER NUNES DE    BR,A61K00924 | A61K00944 | A61K00928,US2010143472A1 | CA2683068A1 | EP2155171A1 | BRPI0701904A2 | MX2009011520A ,6,6,Yes,Application,No
659,WO2008133982,A2,ADHESIVE PATCH WITH AVERSIVE AGENT,US20070926483P,United States,2007-04-27T00:00:00Z,2007,2008-04-25T00:00:00Z,2008-11-06T00:00:00Z,2008,LECTEC CORP | ROLF DAVID,ROLF DAVID    US,A61K00970,WO2008133982A3,1,1,Yes,Application,No
660,WO2008137779,A2,NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION,US20070915896P,United States,2007-05-03T00:00:00Z,2007,2008-05-02T00:00:00Z,2008-11-13T00:00:00Z,2008,INTERMUNE INC | ARRAY BIOPHARMA INC,BLATT LAWRENCE M    US  | PAN LIN    US  | SEIWERT SCOTT    US  | ANDREWS STEVEN W    US  | MARTIN PIERRE    CH  | SCHUMACHER ANDREAS    DE  | BEIGELMAN LEONID    US  | LIU JYANWEI    US  | CONDROSKI KEVIN    US  | JIANG YUTONG    US  | KAUS ROBERT    US  | KENNEDY APRIL    US  | KERCHER TIMOTHY    US  | LYON MICHAEL    US  | WANG BIN    US,C07D48704 | A61P03112 | A61K031407 | C08H00100,EA200971026A1 | US2009155209A1 | EP2160392A2 | AR066448A1 | KR20100024920A  | CO6251243A2 | WO2008137779A3 | MX2009011867A  | AP200905053D0 | CN101784549A  | ECSP099780A  | JP2010528987T  | IL201757D0 | EP2177523A1 | AU2008247509A1 | CA2686138A1,16,16,Yes,Application,No
661,WO2008140459,A1,SOLID FORM,WO2007US11707,WIPO,2007-05-16T00:00:00Z,2007,2007-05-16T00:00:00Z,2008-11-20T00:00:00Z,2008,FMC CORP,DARMUZEY OLIVIA    BE  | MACLEOD GRAEME    BE  | CENGIC DZENANA    BE,A61K00920 | A61K00948 | A61J00307,None,1,1,Yes,Application,No
662,WO2008140460,A1,SOLID FORM,WO2007US11762,WIPO,2007-05-16T00:00:00Z,2007,2007-05-16T00:00:00Z,2008-11-20T00:00:00Z,2008,FMC CORP,CENGIC DZENANA    BE  | DARMUZEY OLIVIA    BE  | MACLEOD GRAEME    BE,A61K00920 | A61K00948 | A61K00928,None,1,1,Yes,Application,No
663,WO2008140461,A1,SOLID FORM,WO2007US11768,WIPO,2007-05-16T00:00:00Z,2007,2007-05-16T00:00:00Z,2008-11-20T00:00:00Z,2008,FMC CORP,DARMUZEY OLIVIA    BE  | MACLEOD GRAEME    BE  | CENGIC DZENANA    BE  | STOKES KEVIN M    US,A61K00920 | A61K00928 | A61J00307 | A61K00948,None,1,1,Yes,Application,No
664,WO2008141227,A1,NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION,US20070917300P,United States,2007-05-10T00:00:00Z,2007,2008-05-09T00:00:00Z,2008-11-20T00:00:00Z,2008,INTERMUNE INC | ARRAY BIOPHARMA INC,ANDREWS STEVEN W    US  | SEIWERT SCOTT    US  | BEIGELMAN LEONID    US  | BLATT LAWRENCE    US  | BUCKMAN BRAD    US,C07D21726 | A61P03114 | A61K03116 | C07D40112 | C07D41714,US2009297476A1 | EA200971041A1 | IL201842D0 | CO6241100A2 | CN101679277A  | CA2686546A1 | AR066528A1 | AP200905057D0 | MX2009012093A  | AU2008251425A1 | KR20100027134A  | JP2010526834T  | EP2185524A1 | ECSP099792A  | US7932277B2,14,14,Yes,Grant,Yes
665,WO2008145562,A1,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS,US20070932251P,United States,2007-05-30T00:00:00Z,2007,2008-05-20T00:00:00Z,2008-12-04T00:00:00Z,2008,F. HOFFMANN-LA ROCHE AG,KENNEDY-SMITH JOSHUA    US  | SWEENEY ZACHARY KEVIN    US  | WU JEFFREY    US,C07D23372 | C07D239545 | A61P03118 | A61K031513 | A61K0314174 | C07D23954 | C07D239553 | C07D23378 | C07D23922,JP2010528083T  | PE02962009A1 | CA2687747A1 | US2009076045A1 | CN101679294A  | AR066743A1 | IL202143D0 | EA200901599A1 | MX2009012704A  | EP2155692A1 | KR20100028584A  | AU2008257771A1,12,12,Yes,Application,No
666,WO2008145606,A1,NEW MUTATIONAL PROFILE IN HIV-1 GAG CLEAVAGE SITE CORRELATED WITH PHENOTYPIC DRUG RESISTANCE,EP20070108899,European Patent Office,2007-05-25T00:00:00Z,2007,2008-05-23T00:00:00Z,2008-12-04T00:00:00Z,2008,TIBOTEC PHARM LTD,DIERYNCK INGE    BE  | DE MEYER SANDRA    BE,G01N033569 | C12Q00170 | C12N00700,AU2008257703A1 | EP2162745A1 | CA2688278A1 | US2010173282A1,5,5,Yes,Application,No
667,WO2008145733,A2,"NOVEL CHEMICAL COMPOUNDS, PRODUCTION THEREOF, AND USE THEREOF",DE200710026701,Germany,2007-06-01T00:00:00Z,2007,2008-05-30T00:00:00Z,2008-12-04T00:00:00Z,2008,UNIVERSITAET LEIPZIG,HEY-HAWKINS EVAMARIE    DE  | SCHOLZ MATTHIAS    DE,C07F00502,WO2008145733A3 | DE102007026701A1,2,2,Yes,Application,No
668,WO2008149228,A1,"AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE (2S,3S,5S)-5-AMINO-2-N,N-DIBENZYLAMINO-3-HYDROXY-1,6-DIPHENYLHEXANE",IN2007CH01184,India,2007-06-08T00:00:00Z,2007,2008-06-05T00:00:00Z,2008-12-11T00:00:00Z,2008,AUROBINDO PHARMA LTD,AMBATI V RAGHAVA REDDY    IN  | GARAGA SRINIVAS    IN  | DANDALA RAMESH    IN  | MEENAKSHISUNDERAM SIVAKUMARAN    IN,C07C21310 | C07C21528,US2010317855A1,2,2,Yes,Application,No
669,WO2008153610,A2,USE OF IL-23 ANTAGONISTS FOR TREATMENT OF INFECTION,US20070889475P,United States,2007-02-12T00:00:00Z,2007,2008-02-08T00:00:00Z,2008-12-18T00:00:00Z,2008,SCHERING CORP,KOPF MANFRED    CH  | ROMANI LUIGINA    IT  | KASTELEIN ROBERT A    US  | CHACKERIAN ALISSA A    US,A61K03900,US2010291084A1 | AU2008262544A1 | ZA200906126A  | WO2008153610A3 | MX2009008617A  | JP2010518087T  | EP2064246A2 | CN101668775A  | CA2677835A1,9,9,Yes,Application,No
670,WO2008154271,A1,CHEMICAL COMPOUNDS,US20070942266P,United States,2007-06-06T00:00:00Z,2007,2008-06-05T00:00:00Z,2008-12-18T00:00:00Z,2008,GSK LLC,PEAT ANDREW JAMES    US  | SEBAHAR PAUL RICHARD    US  | YOUNGMAN MICHAEL    US  | CHONG PEK YOKE    US  | ZHANG HUICHANG    US,A01N04350 | A61K031415,CN101790313A  | IL202217D0 | EA200901490A1 | AR066909A1 | MX2009013349A  | EP2166856A1 | JP2010529965T  | UY31132A1 | KR20100039301A  | US2010216746A1 | PE03302009A1 | AU2008261977A1 | CA2694871A1 | CR11196A  | CO6251246A2,17,17,Yes,Application,No
671,WO2008156632,A1,AZAPEPTIDE DERIVATIVES,US20070934201P,United States,2007-06-12T00:00:00Z,2007,2008-06-12T00:00:00Z,2008-12-24T00:00:00Z,2008,CONCERT PHARMACEUTICALS INC,HARBESON SCOTT L    US  | TUNG ROGER D    US,C07D21342 | A61P03118 | A61K031675 | A61K0314418 | C07F00958,CA2692028A1 | JP2010529196T  | EP2003120A1 | RS51226B  | SI2003120T1 | DK2003120T3 | AT447554T  | KR20100020033A  | ES2356334T3 | EP2003120B1 | HR20100065T1 | MX2009013565A  | AU2008267048A1 | PT2003120E  | CN101711237A  | US2009036357A1 | HK1127345A1 | CO6241121A2 | EP2116532A1 | AR066972A1 | US2011009355A1 | DE602008000255D1 | EP2003120B9,22,19,Yes,Grant,Yes
672,WO2008157273,A1,CHEMICAL COMPOUNDS,US20070943928P,United States,2007-06-14T00:00:00Z,2007,2008-06-13T00:00:00Z,2008-12-24T00:00:00Z,2008,GSK LLC,AQUINO CHRISTOPHER JOSEPH    US  | DICKSON HAMILTON    US  | PEAT ANDREW JAMES    US,A01N04382 | A61K03141,None,1,1,Yes,Application,No
673,WO2008157330,A1,CHEMICAL COMPOUNDS,US20070943931P,United States,2007-06-14T00:00:00Z,2007,2008-06-13T00:00:00Z,2008-12-24T00:00:00Z,2008,GSK LLC,AQUINO CHRISTOPHER JOSEPH    US  | DICKSON HAMILTON    US  | PEAT ANDREW JAMES    US,A01N04382 | A61K03141,None,1,1,Yes,Application,No
674,WO2009000663,A1,UREA AND CARBAMATE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS,US20070936956P,United States,2007-06-22T00:00:00Z,2007,2008-06-12T00:00:00Z,2008-12-31T00:00:00Z,2008,F. HOFFMANN-LA ROCHE AG,ELWORTHY TODD RICHARD    US  | HOGG JOAN HEATHER    US  | KENNEDY-SMITH JOSHUA    US  | O YANG COUNDE    US  | SMITH MARK    US  | SWEENEY ZACHARY KEVIN    US  | WU JEFFREY    US,C07D23526 | C07C25554 | A61P03118 | A61K0314166 | C07D47104 | C07D48704,KR20100039348A  | MX2009013865A  | CN101784529A  | AR067076A1 | PE04192009A1 | IL202737D0 | AU2008267895A1 | CA2692182A1 | US2009012034A1 | EP2170836A1 | JP2010530863T |US7947709B2,11,11,Yes,Grant,Yes
675,WO2009002821,A2,TABLETED COMPOSITIONS CONTAINING ATAZANAVIR,US20070945701P,United States,2007-06-22T00:00:00Z,2007,2008-06-20T00:00:00Z,2008-12-31T00:00:00Z,2008,BRISTOL MYERS SQUIBB PHARMA CO,KOO OTILIA MAY YUE    US  | NIKFAR FARANAK    US  | DIAZ STEVEN    US,A61K00920 | A61K04506 | A61K031551 | C07D21342,JP2010530888T  | EP2170292A2 | WO2009002821A3 | CN101778624A  | US2010183715A1 | AU2008268625A1 | MX2009013504A  | KR20100033380A ,8,8,Yes,Application,No
676,WO2009002823,A2,TABLETED COMPOSITIONS CONTAINING ATAZANAVIR,US20070945706P,United States,2007-06-22T00:00:00Z,2007,2008-06-20T00:00:00Z,2008-12-31T00:00:00Z,2008,BRISTOL MYERS SQUIBB PHARMA CO,KOO OTILIA MAY YUE    US  | NIKFAR FARANAK    US  | DIAZ STEVEN    US,A61K00920 | A61K04506 | A61K031551 | C07D21342,AU2008268627A1 | DE602008005316D1 | EP2178511B1 | JP2010530889T  | WO2009002823A3 | MX2009013462A  | US2010178339A1 | CN101801348A  | EP2178511A2 | KR20100033378A  | AT499927T ,10,10,Yes,Grant,Yes
677,WO2009002826,A2,TABLETED COMPOSITIONS CONTAINING ATAZANAVIR,US20070945691P,United States,2007-06-22T00:00:00Z,2007,2008-06-20T00:00:00Z,2008-12-31T00:00:00Z,2008,BRISTOL MYERS SQUIBB PHARMA CO,KOO OTILIA MAY YUE    US  | NIKFAR FARANAK    US  | DIAZ STEVEN    US,A61K00920 | A61K04506 | A61K031395 | C07D21342,KR20100033379A  | DE602008005462D1 | AT500820T  | WO2009002826A3 | CN101778625A  | AU2008268630A1 | EP2178512A2 | EP2178512B1 | MX2009013499A  | US2010178340A1 | JP2010530890T ,10,10,Yes,Grant,Yes
678,WO2009002829,A2,TABLETED COMPOSITIONS CONTAINING ATAZANAVIR,US20070945694P,United States,2007-06-22T00:00:00Z,2007,2008-06-20T00:00:00Z,2008-12-31T00:00:00Z,2008,BRISTOL MYERS SQUIBB PHARMA CO,KOO OTILIA MAY YUE    US  | NIKFAR FARANAK    US  | DIAZ STEVEN    US,A61K00920 | A61K04506 | A61K031551 | C07D21342,KR20100033377A  | CN101795674A  | AT503467T  | EP2178513B1 | WO2009002829A3 | AU2008268537A1 | JP2010530892T  | MX2009013461A  | EP2178513A2 | US2010183716A1,14,14,Yes,Grant,Yes
679,WO2009003669,A2,"PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT",GB20040028475,United Kingdom,2004-12-30T00:00:00Z,2004,2008-06-30T00:00:00Z,2009-01-08T00:00:00Z,2009,4 AZA IP NV | GILEAD SCIENCES INC,DE JONGHE STEVEN CESAR ALFONS    BE  | DOLUSIC EDUARD    BE  | GAO LING-JIE    BE  | HERDEWIJN PIET ANDRE MAURITS MARIA    BE  | PFLEIDERER WOLFGANG EUGEN    DE,C07D47104 | A61P03500 | A61K031519,EP1831217A2 | CA2594241A1 | US2008004285A1 | GB200428475D0 | WO2009003669A3 | US2009131414A1 | MX2007007901A  | US2009036430A1 | CA2612788A1 | KR20070102693A  | EP1899332A1 | US2009264415A2 | IL184131D0 | RU2007128961A  | JP2008526704T  | ZA200705281A  | AU2005321492A1 | GB200608766D0 | NO20072984A  | WO2006069805A2 | BRPI0516373A  | WO2006135993A1 | WO2006069805A3 | CN101365699A  | JP2008543888T  | AU2006261607A1,21,12,Yes,Application,No
680,WO2009005693,A1,NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS,US20070937756P,United States,2007-06-29T00:00:00Z,2007,2008-06-26T00:00:00Z,2009-01-08T00:00:00Z,2009,GILEAD SCIENCES INC | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY,HE GONG-XIN    US  | KIM CHOUNG U    US  | MITCHELL MICHAEL L    US  | XU LIANHONG    US,C07D23954 | A61P03118 | A61K031513,US2009075939A1 | EP2167476A2 | KR20100041799A  | CN101784532A  | AU2008271114A1 | MX2009013804A  | AR067181A1 | EA200971115A1 | WO2009005674A2 | US2011076276A1 | KR20100041798A  | WO2009005674A3,13,10,Yes,Application,No
681,WO2009006199,A1,THERAPEUTIC COMPOSITIONS AND THE USE THEREOF,US20070947306P,United States,2007-06-29T00:00:00Z,2007,2008-06-26T00:00:00Z,2009-01-08T00:00:00Z,2009,GILEAD SCIENCES INC,KEARNEY BRIAN P    US  | MATHIAS ANITA A    US  | RAMANATHAN SRINIVASAN    US,A61K03147 | A61P03118,AR067183A1 | US2009093467A1,15,14,Yes,Application,No
682,WO2009006203,A1,THERAPEUTIC COMPOSITIONS AND THE USE THEREOF,US20070947325P,United States,2007-06-29T00:00:00Z,2007,2008-06-26T00:00:00Z,2009-01-08T00:00:00Z,2009,GILEAD SCIENCES INC,KEARNEY BRIAN P    US  | MATHIAS ANITA A    US,A61K03147 | A61K03806 | A61K031505 | A61P03118,US2009093482A1 | AR067184A1,14,13,Yes,Application,No
683,WO2009008989,A1,MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS,US20060819315P,United States,2006-07-07T00:00:00Z,2006,2008-07-03T00:00:00Z,2009-01-15T00:00:00Z,2009,GILEAD SCIENCES INC,DESAI MONOJ C    US  | HUI HON CHUNG    US  | LIU HONGTAO    US  | SUN JIANYU    US  | XU LIANHONG    US,C07D27728 | A61P03112 | A61K031427 | C07D41714,CN101490023A  | MX2009008935A  | JP2009542696T  | EP2170851A1 | MX2009000234A  | US2009291952A1 | AR067412A1 | WO2008010921A3 | US2008207620A1 | CN101796040A  | AR065439A1 | CA2678907A1 | KR20090028821A  | AP200804720D0 | HR20090077A2 | AR061838A1 | AU2008218186A1 | US2009181902A1 | JP2010519314T  | AU2007275860A1 | IL200550D0 | EA200901155A1 | IL202624D0 | CA2692331A1 | KR20100040896A  | CA2653374A1 | CN101679325A  | US2008108617A1 | WO2008010921A2 | NO20090593A  | US2010189687A1 | EP2118082A1 | EP2049506A2 | KR20090122261A  | WO2008103949A1 | EA200900155A1 | IL195488D0 | US7939553B2,35,13,Yes,Grant,Yes
684,WO2009009531,A2,NOVEL PYRIMIDINECARBOXAMIDE DERIVATIVES,US20070948610P,United States,2007-07-09T00:00:00Z,2007,2008-07-08T00:00:00Z,2009-01-15T00:00:00Z,2009,CONCERT PHARMACEUTICALS INC,HARBESON SCOTT L    US,C07D41312 | A61P03118 | A61K031505,WO2009009531A3 | US2009035324A1 | CA2702317A1 | US2010152214A1 | US7687509B2,4,3,Yes,Grant,Yes
685,WO2009014638,A2,METHODS OF INHIBITING INFECTION BY DIVERSE SUBTYPES OF DRUG-RESISTANT HIV-1,US20070961326P,United States,2007-07-19T00:00:00Z,2007,2008-07-17T00:00:00Z,2009-01-29T00:00:00Z,2009,PROGENICS PHARM INC,OLSON WILLIAM C    US,A61K03940,WO2009014638A3 | WO2009014638A9,2,2,Yes,Application,No
686,WO2009017767,A2,COMPOSITIONS AND METHODS FOR DERMALLY TREATING NEUROPATHY WITH MINOXIDIL,US20040577536P,United States,2004-06-07T00:00:00Z,2004,2008-07-30T00:00:00Z,2009-02-05T00:00:00Z,2009,ZARS PHARMA INC,SANJAY SHARMA    US  | ZHANG JIE    US  | WARNER KEVIN S    US,A61K031165 | A61K031415 | A61K00912 | A61P01700 | A61K031445 | A61K031505 | A61K03156,WO2007070643A2 | CA2633515A1 | WO2007070695A2 | JP2009519958T  | EP1959930A2 | US2007196459A1 | WO2005120473A3 | US2007196293A1 | US2007196452A1 | JP2009519957T  | WO2007100376A3 | AU2005251805A1 | US2007196323A1 | US2007189980A1 | JP2009519940T  | CN101442987A  | AU2006326018A1 | CA2633464A1 | EP1959931A2 | KR20070027694A  | AU2006339350A1 | CA2633466A1 | AU2006326388A1 | CA2633489A1 | WO2007070679A2 | CN1993092A  | US2007190124A1 | WO2007070694A2 | AU2006326034A1 | CN101370453A  | WO2007100376A2 | CN101374488A  | EP1968541A2 | JP2008501805T  | JP2009519956T  | US2007280972A1 | US2007196453A1 | US2005276842A1 | WO2009017767A3 | US2007189978A1 | CA2633472A1 | US2008019927A1 | CA2569121A1 | JP2009524586T  | WO2007070679A3 | US2007189977A1 | US2007196458A1 | CN101494976A  | EP1959929A2 | WO2007070695A3 | CN101378729A  | WO2007070643A3 | US2007196457A1 | EP1959928A2 | WO2007070694A3 | US2007196325A1 | WO2005120473A2 | US2010267678A1 | AU2006326033A1 | EP1753380A2,54,8,Yes,Application,No
687,WO2009020457,A2,CHEMICAL COMPOUNDS,US20060817972P,United States,2006-06-30T00:00:00Z,2006,2007-06-13T00:00:00Z,2009-02-12T00:00:00Z,2009,GSK LLC,ANDREWS CLARENCE WEBSTER III    US  | CAO PING    US  | FREEMAN GEORGE ANDREW    US  | QU JUNYA    US,A61K031513,None,1,1,Yes,Application,No
688,WO2009027644,A2,COMPOSITION,US20070957764 | GB20070016591 ,United States,2007-08-24T00:00:00Z,2007,2008-08-22T00:00:00Z,2009-03-05T00:00:00Z,2009,SLOTERVAART PARTICIPATIES BV | STICHTING HET NEDERLANDS KANKER INSTITUUT,JONES NICHOLAS ANDREW    GB  | BEIJNEN JACOB HENDRIK    NL  | SCHELLENS JOHANNES HENRICUS MATTHIAS    NL  | MOES JOHANNES    NL  | NUIJEN BASTIAAN    NL,A61K00914 | A61K00948 | A61K00919 | A61P03500 | A61K031337 | A61K031426 | A61K04506,AR073123A1 | MX2010002179A  | AU2008291930A1 | WO2010020799A2 | JP2010536837T  | EP2190413A2 | WO2010020799A3 | WO2009027644A3 | CN101854919A  | KR20100044237A  | WO2009027644A8 | US2009054503A1 | CA2696622A1 | GB200716591D0,12,10,Yes,Application,No
689,WO2009035662,A1,DEUTERATED 4 -OXOQUINOLINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTION,US20070993428P,United States,2007-09-12T00:00:00Z,2007,2008-09-12T00:00:00Z,2009-03-19T00:00:00Z,2009,CONCERT PHARMACEUTICALS INC,HARBESON SCOTT L    US,C07D21556 | A61P03100 | A61K03147,AU2008299931A1 | US2009143427A1 | EP2197847A1 | CA2698825A1 | MX2010002679A | US7994194B2,6,6,Yes,Grant,Yes
690,WO2009036341,A2,COMPOSITIONS AND METHODS RELATING TO HIV PROTEASE INHIBITION,US20070972505P,United States,2007-09-14T00:00:00Z,2007,2008-09-12T00:00:00Z,2009-03-19T00:00:00Z,2009,THE REGENTS OF THE UNIVERSITY OF MICHIGAN,CARLSON HEATHER A    US  | DAMM KELLY L    US  | MEAGHER KRISTIN L    US,A61K0314168 | A61K03142 | A61K03141 | A61K03147,WO2009036341A3,2,2,Yes,Application,No
691,WO2009037855,A1,ORAL AND SKIN COMPOSITIONS,JP20070245657,Japan,2007-09-21T00:00:00Z,2007,2008-09-19T00:00:00Z,2009-03-26T00:00:00Z,2009,NIHON KODOIRYO KENKYUKAI CO LTD,NODA SATOSHI    JP,A61K04506 | A61P04300 | A61K04732 | A61K04704 | A61P01700 | A61K04736 | A61K04738 | A61P00102,CN101801414A  | US2010239690A1,3,3,Yes,Application,No
692,WO2009038663,A1,METHOD OF TREATING HEPATITIS C PATIENTS,US20070993753P,United States,2007-09-14T00:00:00Z,2007,2008-09-11T00:00:00Z,2009-03-26T00:00:00Z,2009,SCHERING CORP,ALBRECHT JANICE K    US  | BRASS CLIFFORD A    US  | RALSTON II ROBERT ORVILLE    US,A61K04506 | A61P03120,CA2699280A1 | AU2008301981A1 | US2010226885A1 | JP2010539165T  | MX2010002909A  | EP2061513A1 | EP2061513B1,8,8,Yes,Grant,Yes
693,WO2009040818,A1,COMPOSITIONS COMPRISING LIPOPHILIC ACTIVE COMPOUNDS AND METHOD FOR THEIR PREPARATION,US20070975045P | US20070975066P ,United States,2007-09-25T00:00:00Z,2007,2008-09-25T00:00:00Z,2009-04-02T00:00:00Z,2009,SOLUBEST LTD,TEMTSIN KRAYZ GALIA    IL  | AVERBUCH MARYANA    IL  | GITIS LARISA    IL  | ZELKIND ILYA    IL,A61K00916,AU2008303129A1 | EP2200588A1 | WO2009040818A9 | US2009098200A1 | IL204711D0 | CA2700426A1,5,5,Yes,Application,No
694,WO2009042960,A1,ORAL DOSAGE COMBINATION PHARMACEUTICAL PACKAGING,US20070863156,United States,2007-09-27T00:00:00Z,2007,2008-09-26T00:00:00Z,2009-04-02T00:00:00Z,2009,MICRODOSE TECHNOLOGIES INC,SISON RAYMUNDO A    US,A61K00954,EP2200594A1 | JP2011501736T  | US2009232886A1 | US2009087483A1 | CN101808625A ,6,5,Yes,Application,No
695,WO2009043296,A1,"GAMBOGIC GLYCOSIDE DERIVATIVES AND ANALOGS, THE PREPARATION AND THE APPLICATION THEREOF",CN20071157223,China,2007-09-29T00:00:00Z,2007,2008-09-26T00:00:00Z,2009-04-09T00:00:00Z,2009,LIAONING LIFENG SCIENTIFIC & TECHNOLOGY DEVELOPMENT COMPANY LTD,XU LIFENG    CN,C07H01704 | A61P03500 | A61K0317048,US2011038952A1 | EP2223929A1 | JP2010540471T  | CN101289482A ,5,5,Yes,Application,No
696,WO2009045975,A1,POTENT COMBINATIONS OF ZIDOVUDINE AND DRUGS THAT SELECT FOR THE K65R MUTATION IN THE HIV POLYMERASE,US20070997264P,United States,2007-10-02T00:00:00Z,2007,2008-09-29T00:00:00Z,2009-04-09T00:00:00Z,2009,EMORY UNIVERSITY,SCHINAZI RAYMOND F    US,A61K03170 | A61K0317072 | A61K031505 | A61P03118,EP2207553A4 | EP2207553A1 | MX2010003542A  | CN101878032A  | US2011053884A1 | CA2701356A1,6,6,Yes,Application,No
697,WO2009047264,A1,SPIROPYRROLIDINES AND THEIR USE AGAINST HCV AND HIV INFECTION,US20070978974P,United States,2007-10-10T00:00:00Z,2007,2008-10-08T00:00:00Z,2009-04-16T00:00:00Z,2009,NOVARTIS AG,BRITT SHAWN D    US  | CISZEWSKI LECH ANDRZEJ    US  | FU JIPING    US  | KARUR SUBRAMANIAN    US  | LIU YUGANG    US  | PARKER DAVID THOMAS    US  | PRASHAD MAHAVIR    US  | RAMAN PRAKASH    US  | SEEPERSAUD MOHINDRA    US  | ZHENG RUI    US  | LU PEICHAO    US  | RIGOLLIER PASCAL    FR  | YIFRU AREGAHEGN    US,C07D40112 | A61K031497 | A61K03144 | A61K031403 | A61P03112 | C07D40312,MX2010003916A  | JP2011500528T  | CR11310A  | KR20100051749A  | CA2702132A1 | PE12372009A1 | AR068756A1 | AU2008309589A1 | US2009137495A1 | EP2205584A1 | CN101868452A  | EA201000556A1,15,15,Yes,Application,No
698,WO2009051782,A1,DEUTERATED ETRAVIRINE,US20070980869P,United States,2007-10-18T00:00:00Z,2007,2008-10-17T00:00:00Z,2009-04-23T00:00:00Z,2009,CONCERT PHARMACEUTICALS INC,MASSE CRAIG E    US,C07D23948 | A61P03118 | A61K031505,US2009105147A1 | EP2212298A1,3,3,Yes,Application,No
699,WO2009051840,A2,COMPOSITIONS AND METHODS FOR REDUCING HEPATOTOXICITY ASSOCIATED WITH DRUG ADMINISTRATION,US20070999413P,United States,2007-10-18T00:00:00Z,2007,2008-10-20T00:00:00Z,2009-04-23T00:00:00Z,2009,YALE UNIVERSITY,MEHAL WAJAHAT    US  | AVLIN IMAEDA    US,A61K031198 | A61K03939,US2010297271A1 | EP2211852A2 | WO2010121128A2 | WO2009051840A3 | WO2010121128A3 | US2009239831A1,6,3,Yes,Application,No
700,WO2009053828,A2,P3 HYDROXYAMINO MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS,US20070981613P,United States,2007-10-22T00:00:00Z,2007,2008-10-23T00:00:00Z,2009-04-30T00:00:00Z,2009,ENANTA PHARM INC,NIU DEQIANG    US  | LIU DONG    US  | GAI YONGHUA    US  | OR YAT SUN    US  | WANG ZHE    US,A61K03812,WO2009053828A3,1,1,Yes,Application,No
701,WO2009055006,A1,DEUTERATED DARUNAVIR,US20070000498P,United States,2007-10-26T00:00:00Z,2007,2008-10-24T00:00:00Z,2009-04-30T00:00:00Z,2009,CONCERT PHARMACEUTICALS INC,HARBESON SCOTT L    US,C07B05900,US2010113589A1 | AU2008317375A1 | EP2217548A1 | CA2703591A1 | US2009131363A1 | WO2009055006A8,6,5,Yes,Application,No
702,WO2009056818,A1,NOVEL ANTIRETROVIRAL COMBINATION,IN2007MU02141,India,2007-10-29T00:00:00Z,2007,2008-10-28T00:00:00Z,2009-05-07T00:00:00Z,2009,CIPLA LTD,LULLA AMAR    IN  | MALHOTRA GEENA    IN,A61K0314402 | A61P03118 | A61K031426,CN101909625A  | CA2703918A1 | AU2008320642A1 | PA8802001A1 | PE10152009A1 | MX2010004734A  | AP201005253D0 | EP2214668A1,9,9,Yes,Application,No
703,WO2009058919,A1,CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS,US20070984084P,United States,2007-10-31T00:00:00Z,2007,2008-10-30T00:00:00Z,2009-05-07T00:00:00Z,2009,GSK LLC,KAZMIERSKI WIESLAW MIECZYSLAW    US  | CHONG PEK YOKE    US  | DUAN MAOSHENG    US,A61K031454 | C07D40302 | C07D21132,None,1,1,Yes,Application,No
704,WO2009058921,A1,CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS,US20070984092P,United States,2007-10-31T00:00:00Z,2007,2008-10-30T00:00:00Z,2009-05-07T00:00:00Z,2009,GSK LLC,KAZMIERSKI WIESLAW MIECZYSLAW    US  | CHONG PEK YOKE    US  | DUAN MAOSHENG    US,A61K031454 | C07D40302 | C07D21132,None,1,1,Yes,Application,No
705,WO2009058923,A1,CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS,US20070984099P,United States,2007-10-31T00:00:00Z,2007,2008-10-30T00:00:00Z,2009-05-07T00:00:00Z,2009,GSK LLC,KAZMIERSKI WIELSAW MIECZYSLAW    US  | DUAN MAOSHENG    US,A61K031454 | C07D40302 | C07D21132,None,1,1,Yes,Application,No
706,WO2009058924,A1,CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS,US20070984076P,United States,2007-10-31T00:00:00Z,2007,2008-10-30T00:00:00Z,2009-05-07T00:00:00Z,2009,GSK LLC,KAZMIERSKI WIESLAW MIERCZYSLAW    US  | CHONG PEK YOKE    US,A61K031454 | C07D40302 | C07D21132,None,1,1,Yes,Application,No
707,WO2009059243,A1,TREATING AND PREVENTING VIRAL INFECTIONS,US20070984601P,United States,2007-11-01T00:00:00Z,2007,2008-10-31T00:00:00Z,2009-05-07T00:00:00Z,2009,THE UAB RESEARCH FOUNDATION,LUO MING    US  | YANG ZHEN    US,C07D23342 | C07D41706 | C07D40506,JP2011502998T  | EP2217573A1 | CN101990534A ,5,5,Yes,Application,No
708,WO2009061856,A1,NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS,US20070986990P,United States,2007-11-09T00:00:00Z,2007,2008-11-05T00:00:00Z,2009-05-14T00:00:00Z,2009,SALK INSTITUTE FOR BIOLOGICAL STUDIES,ELLEDER DANIEL    US  | YOUNG JOHN A T    US  | BAIGA THOMAS J    US  | NOEL JOSEPH P    US,A01N04378 | A61K031425,CA2704645A1 | US2010292232A1 | EP2217069A1,4,4,Yes,Application,No
709,WO2009064975,A1,QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS,US20070987958P,United States,2007-11-14T00:00:00Z,2007,2008-11-14T00:00:00Z,2009-05-22T00:00:00Z,2009,ENANTA PHARM INC,GAI YONGHUA    US  | OR YAT SUN    US  | WANG ZHE    US,A01N04360 | A61K031495,UY31470A1 | PE12122009A1 | KR20100098527A  | ECSP100254A  | AR069464A1 | CN101909446A  | CA2705807A1 | JP2011505339T  | EP2219453A4 | AU2008322537A1 | IL205611D0 | US2010003214A1 | MX2010005262A  | EP2219453A1,15,15,Yes,Application,No
710,WO2009073843,A1,INHALABLE COMPOSITIONS HAVING ENHANCED BIOAVAILABILITY,US20070992787P,United States,2007-12-06T00:00:00Z,2007,2008-12-05T00:00:00Z,2009-06-11T00:00:00Z,2009,"CYTOTECH LABS, LLC",PERSAUD INDUSHEKHAR    US  | MCCOOK JOHN PATRICK    US  | NARAIN NIVEN RAJIN    US,A01N04316 | A61K03135,JP2011506340T  | EP2227085A1,4,4,Yes,Application,No
711,WO2009075960,A1,CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS,US20070012984P,United States,2007-12-12T00:00:00Z,2007,2008-10-30T00:00:00Z,2009-06-18T00:00:00Z,2009,GSK LLC,KAZMIERSKI WIESLAW MIECZYSLAW    US  | CHONG PEK YOKE    US,A61K031454 | C07D40302 | C07D21132,None,1,1,Yes,Application,No
712,WO2009076173,A2,FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS,US20070992574P,United States,2007-12-05T00:00:00Z,2007,2008-12-04T00:00:00Z,2009-06-18T00:00:00Z,2009,ENANTA PHARM INC,GAI YONGHUA    US  | OR YAT SUN    US  | WANG ZHE    US,A61K031498 | A61K03147 | A61K03141 | C07D25704 | A61P03112 | C07D21520 | C07D24140,MX2010006210A  | CN101977621A  | WO2009076173A3 | CA2708150A1 | US2009197888A1 | EP2224942A2,7,7,Yes,Application,No
713,WO2009076195,A1,TREATMENT OF DRUG-INDUCED NAUSEA WITH OPIOID ANTAGONISTS,US20070992555P,United States,2007-12-05T00:00:00Z,2007,2008-12-05T00:00:00Z,2009-06-18T00:00:00Z,2009,THE UNIVERSITY OF CHICAGO,YUAN CHUN-SU    US,A61K031485 | A61P00112 | A61K031451 | A61K031427 | A61P00110 | A61K03855 | A61P03118 | A61K04506 | A61P00108,JP2011506339T ,2,2,Yes,Application,No
714,WO2009079412,A2,REVERSE TRANSCRIPTASE INHIBITORS,US20070013983P,United States,2007-12-14T00:00:00Z,2007,2008-12-12T00:00:00Z,2009-06-25T00:00:00Z,2009,ARDEA BIOSCIENCES INC,SHAGINIAN ALEKSANDR    US  | OUK SAMEDY    US  | VERNIER JEAN-MICHEL    US  | PINKERTON ANTHONY B    US,C07D48704 | A61P03118 | A61K03116 | A61K03114,US2009162319A1 | WO2009079412A3 | CA2709176A1 | EP2220091A2 | AR071739A1,5,5,Yes,Application,No
715,WO2009080534,A1,HETEROCYCLIC ANTIVIRAL COMPOUNDS,US20070016142P,United States,2007-12-21T00:00:00Z,2007,2008-12-11T00:00:00Z,2009-07-02T00:00:00Z,2009,F. HOFFMANN-LA ROCHE AG,BILLEDEAU ROLAND J    US  | SWEENEY ZACHARY KEVIN    US,C07D47104 | A61P03112 | A61K0315025 | A61K031437 | A61P03118 | C07D48704,CA2709348A1 | IL205863D0 | MX2010006397A  | AR069789A1 | CN101903382A  | PE11772009A1 | AU2008340422A1 | JP2011506535T  | KR20100095606A  | US2009170856A1 | EP2225239A1,11,11,Yes,Application,No
716,WO2009081174,A2,ANTI - RETROVIRAL COMBINATION,IN2007MU02538,India,2007-12-24T00:00:00Z,2007,2008-12-24T00:00:00Z,2009-07-02T00:00:00Z,2009,CIPLA LTD,LULLA AMAR    IN  | MALHOTRA GEENA    IN,A61K00920 | A61K031427 | A61K03134,AU2008339633A1 | US2011008429A1 | JP2011507940T  | PE15302009A1 | CN101925350A  | CA2710605A1 | MX2010007083A  | AP201005325D0 | WO2009081174A3 | EP2242482A2 | PA8809601A1,10,10,Yes,Application,No
717,WO2009082448,A2,MODIFIED OLIGONUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C INFECTION,US20070008046P,United States,2007-12-18T00:00:00Z,2007,2008-12-17T00:00:00Z,2009-07-02T00:00:00Z,2009,THE TEXAS A & M UNIVERSITY SYSTEM,KAO CHIA-CHENG    US  | THARACHAPARAMBA KUMAR RANJITH    US,A61K04800,US2010040576A1 | WO2009082448A3 | EP2231167A2,3,3,Yes,Application,No
718,WO2009082818,A1,NOVEL C-21-KETO LUPANE DERIVATIVES PREPARATION AND USE THEREOF,US20080018766P,United States,2008-01-03T00:00:00Z,2008,2008-12-23T00:00:00Z,2009-07-09T00:00:00Z,2009,VIROCHEM PHARMA INC,MOINET CHRISTOPHE    CA  | CHAN CHUN KONG LAVAL    CA  | COURCHESNE MARC    CA  | HALAB LILIANE    CA,C07J06300 | C07J05300 | A61K04500 | A61K03158 | A61K031575 | C07J04300 | A61P03112 | A61P03118 | C07J04100,CA2711420A1 | MX2010007374A  | CN101977924A  | WO2009082818A8 | EP2240504A1 | AU2008342536A1,7,7,Yes,Application,No
719,WO2009082819,A1,NOVEL LUPANE DERIVATIVES,US20080018759P,United States,2008-01-03T00:00:00Z,2008,2008-12-23T00:00:00Z,2009-07-09T00:00:00Z,2009,VIROCHEM PHARMA INC,MOINET CHRISTOPHE    CA  | CHAN CHUN KONG LAVAL    CA,C07J06300 | C07J05300 | A61K04500 | A61K03158 | A61K031575 | C07J04300 | A61P03112 | A61P03118 | C07J04100,US2011077227A1 | WO2009082819A8 | CN101981047A  | AU2008342537A1 | US2011077228A1 | CA2711424A1 | MX2010007375A ,9,8,Yes,Application,No
720,WO2009083042,A1,METHODS AND MEANS FOR THE TREATMENT OF CANCER,US20070017942P,United States,2007-12-31T00:00:00Z,2007,2008-06-17T00:00:00Z,2009-07-09T00:00:00Z,2009,VAN TELLINGEN OLAF,VAN TELLINGEN OLAF    NL,A61K0314188 | A61K031517 | A61K031473 | A61P03500,US2009170880A1,2,2,Yes,Application,No
721,WO2009084036,A2,COMPOSITION FOR TREATMENT OF VIRAL INFECTIONS,IN2007CH03070,India,2007-12-20T00:00:00Z,2007,2008-12-18T00:00:00Z,2009-07-09T00:00:00Z,2009,MATRIX LAB LTD,DIXIT AKHILESH ASHOK    IN  | BHUSHAN INDU    IN  | VERMA SANJAY DESHRAJ    IN  | DESHMUKH ABHIJIT MUKUND    IN,A61K00948,WO2009084036A3,1,1,Yes,Application,No
722,WO2009088719,A1,INHIBITORS OF CYTOCHROME P450,US20080019079P,United States,2008-01-04T00:00:00Z,2008,2008-12-19T00:00:00Z,2009-07-16T00:00:00Z,2009,GILEAD SCIENCES INC,DESAI MANOJ    US  | HUI HON CHUNG    US  | LIU HONGTAO    US  | XU LIANHONG    US,C07D27728 | C07D49304 | A61K031426 | A61K031341 | A61K03134 | C07D30720 | A61K0315375 | A61P03118,EP2231628A1 | CA2710679A1 | US2009175820A1 | AU2008346823A1,6,6,Yes,Application,No
723,WO2009089263,A2,NOVEL COMPOSITIONS AND METHODS OF USE,US20080019584P,United States,2008-01-07T00:00:00Z,2008,2009-01-07T00:00:00Z,2009-07-16T00:00:00Z,2009,ARDEA BIOSCIENCES INC,CHEN HUANMING    US  | SONG JIANLAN    US  | VERNIER JEAN-MICHEL    US  | PINKERTON ANTHONY B    US  | NAGASAWA JOHNNY Y    US,C07D47104,AR070518A1 | WO2009089263A3 | CA2711500A1 | EP2231665A2,5,5,Yes,Application,No
724,WO2009089295,A2,ANTI-HIV DOMAIN ANTIBODIES AND METHOD OF MAKING AND USING SAME,US20080019426P,United States,2008-01-07T00:00:00Z,2008,2009-01-07T00:00:00Z,2009-07-16T00:00:00Z,2009,"GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUM",DIMITROV DIMITER S    US,C07K01600 | C07K01610,EP2238165A2 | WO2009089295A3,3,3,Yes,Application,No
725,WO2009092897,A1,COMPOUNDS FOR PREVENTING OR TREATING A VIRAL INFECTION,FR20070007722,France,2007-11-02T00:00:00Z,2007,2008-10-31T00:00:00Z,2009-07-30T00:00:00Z,2009,INSTITUT PASTEUR | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE),ESTAQUIER JEROME    FR  | LAFORGE MIREILLE    FR  | SENIK ANNA    FR,A61K031404 | A61P03112 | A61K03147,FR2923160A1 | US2010298209A1 | EP2214665A1,4,4,Yes,Application,No
726,WO2009094190,A2,METHODS OF TREATING VIRAL INFECTIONS,US20080023633P,United States,2008-01-25T00:00:00Z,2008,2009-01-23T00:00:00Z,2009-07-30T00:00:00Z,2009,CHIMERIX INC,LANIER ERNEST RANDALL    US  | ALMOND MERRICK R    US  | PAINTER GEORGE R    US,A61K031675 | A61K00948 | A61K00920 | A61K00914 | A61P00116 | A61P03118,WO2009094190A3 | MX2010008148A  | AU2009206673A1 | WO2009094191A2 | US2011021464A1 | WO2009094191A3 | CN101977610A  | EP2254582A2 | CA2713105A1 | IL207170D0,9,8,Yes,Application,No
727,WO2009094205,A2,"3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-B][1,3,4]THIADIAZINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF",US20080006608P ,United States,2008-01-23T00:00:00Z,2008,2009-01-23T00:00:00Z,2009-07-30T00:00:00Z,2009,CYTOVIA INC,CAI SUI XIONG    US  | ZHANG HAN-ZHONG    US  | KEMNITZER WILLIAM E    US  | DREWE JOHN A    US  | SIRISOMA NILANTHA SUDATH    US,A61K031549,WO2009094205A3,1,1,Yes,Application,No
728,WO2009094443,A1,DIFLUORINATED TRIPEPTIDES AS HCV SERINE PROTEASE INHIBITORS,US20080023245P,United States,2008-01-24T00:00:00Z,2008,2009-01-22T00:00:00Z,2009-07-30T00:00:00Z,2009,ENANTA PHARM INC,GAI YONGHUA    US  | OR YAT SUN    US  | WANG ZHE    US,C07D22500 | C07D29500,US2009202486A1 | CA2713005A1 | MX2010008109A  | EP2245015A1,7,7,Yes,Application,No
729,WO2009097670,A1,COMBINATION OF IMMUNOMODULATOR AND ANTI-PATHOGENIC AGENT,BR2008PI01803,Brazil,2008-02-08T00:00:00Z,2008,2009-01-27T00:00:00Z,2009-08-13T00:00:00Z,2009,NUNES ISEU DA SILVA,NUNES ISEU DA SILVA    BR,A61K04500 | A61P03100 | A61K03100,BRPI0801803A2 | EP2259799A4 | EP2259799A1 | US2011028385A1,4,4,Yes,Application,No
730,WO2009098469,A1,NOVEL COMPOSITIONS AND USES THEREOF,GB20080002148 | GB20080002149 | GB20080002150,United Kingdom,2008-02-06T00:00:00Z,2008,2009-02-06T00:00:00Z,2009-08-13T00:00:00Z,2009,BIOSUSPENSIONS LTD,HAWKINS JOHN    GB,A61K04712 | A61K04726 | A61K04724,GB200802149D0 | CA2714002A1 | GB200802150D0 | AU2009211183A1 | WO2009098475A1 | GB200802148D0 | EP2254600A1,7,6,Yes,Application,No
731,WO2009102487,A2,GAS BASED WOUND AND TISSUE THERAPEUTICS,US20080028230P,United States,2008-02-13T00:00:00Z,2008,2009-02-13T00:00:00Z,2009-08-20T00:00:00Z,2009,OXYGEN BIOTHERAPEUTICS INC | VIRGINIA COMMONWEALTH UNIVERSITY,WARD KEVIN R    US  | DIEGELMANN ROBERT    US  | SPIESS BRUCE    US  | HUVARD GARY S    US  | SANDHU GURBHAGAT S    US  | BOWLIN GARY    US  | STERN CHRIS    US,A61L01516 | A61P01702 | A61K03304 | A61K03300 | A61K00920 | A61P01700 | A61K03340 | A61K03844,US2009202617A1 | EP2252333A2 | WO2009102487A3,3,3,Yes,Application,No
732,WO2009105430,A1,TREATING CANCER WITH DESTHIAZOLYL RITONAVIR,US20080029773P,United States,2008-02-19T00:00:00Z,2008,2009-02-17T00:00:00Z,2009-08-27T00:00:00Z,2009,THE REGENTS OF THE UNIVERSITY OF MINNESOTA,POTTER DAVID A    US  | MILANI MONICA    US  | SRIRANGAM ANJAIAH    US  | MITRA RANJANA    US  | REMMEL RORY P    US,A61K031164 | A61K031426 | A61K03117 | A61P03500,None,1,1,Yes,Application,No
733,WO2009105774,A2,AMINO ACID INHIBITORS OF CYTOCHROME P450,US20080030524P,United States,2008-02-21T00:00:00Z,2008,2009-02-23T00:00:00Z,2009-08-27T00:00:00Z,2009,SEQUOIA PHARMACEUTICALS,EISSENSTAT MICHAEL    US  | DUAN DEHUI    US,C07D40502,WO2009105774A3 | EP2280601A2 | CA2716347A1,4,4,Yes,Application,No
734,WO2009105776,A1,DIAMIDE INHIBITORS OF CYTOCHROME P450,US20080030541P,United States,2008-02-21T00:00:00Z,2008,2009-02-23T00:00:00Z,2009-08-27T00:00:00Z,2009,SEQUOIA PHARMACEUTICALS,EISSENSTAT MICHAEL    US  | DUAN DEHUI    US,A01N03734 | A61K031275,EP2257160A1 | CA2716348A1,4,4,Yes,Application,No
735,WO2009105781,A1,METHODS FOR INHIBITING DRUG DEGRADATION,US20080030536P,United States,2008-02-21T00:00:00Z,2008,2009-02-23T00:00:00Z,2009-08-27T00:00:00Z,2009,SEQUOIA PHARMACEUTICALS,EISSENSTAT MICHAEL    US  | DUAN DEHUI    US  | ERICKSON JOHN W    US  | GULNIK SERGEI    US,A01N03712 | A61K031195 | A61K03116,EP2254410A1 | CA2716349A1,4,4,Yes,Application,No
736,WO2009108865,A2,TABLETS AND PREPARATION THEREOF,US20080032145P,United States,2008-02-28T00:00:00Z,2008,2009-02-27T00:00:00Z,2009-09-03T00:00:00Z,2009,ABBOTT LAB,GOPINATHAN NISHANTH    US  | SCHROEDER RUDOLF    DE  | SANTIAGO ALBERT    US  | FAITSCH LYNN V    US  | WARDROP JACQUELINE    US  | MORRIS JOHN B    US  | BULTMANN MARTIN    DE  | SCHLAYER HEINZ    DE,A61K00920,US2010021540A1 | EP2257279A2 | CN101959506A  | WO2009108865A3 | CA2714190A1,6,6,Yes,Application,No
737,WO2009111040,A1,HAND SANITIZING PATCH,US20080034862P,United States,2008-03-07T00:00:00Z,2008,2009-03-05T00:00:00Z,2009-09-11T00:00:00Z,2009,LECTEC CORP,BERLIN JUDD US,A61K000970 | A61K000900,AU2009220147A1 | CA2717737A1 | CN102014886A | EP2268271A1 | KR10-2010-0122511A | US20110105976A1,7,7,Yes,Application,No
738,WO2009111638,A1,COMPOSITIONS AND METHODS FOR DRUG DELIVERY,US20080068151P,United States,2008-03-05T00:00:00Z,2008,2009-03-05T00:00:00Z,2009-09-11T00:00:00Z,2009,BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | BAXTER INTERNATIONAL INC.,BEDUNEAU ARNAUD    US  | GENDELMAN HOWARD    US  | RABINOW BARRETT    US  | WERLING JANE    US,A61K03944 | A61K031337 | A61K00951,US2009274765A1 | EP2259798A1 | IL207569D0 | CN101965195A ,4,4,Yes,Application,No
739,WO2009115652,A2,COMPOSITION AND METHODS USED DURING ANTI-HIV TREATMENT,US20080018688P,United States,2008-01-03T00:00:00Z,2008,2008-12-31T00:00:00Z,2009-09-24T00:00:00Z,2009,"UNIVERSITE DE LA MEDITERANNEE, AIX-MARSEILLE II",CAU PIERRE    FR  | BOURGEOIS PATRICE    FR  | BONNIOL VINCENT    FR  | LEVY NICOLAS    FR,A61K031675 | A61K04506 | A61K03122 | A61P03118,WO2009115652A3 | US2011046091A1 | AU2008353145A1 | CN101990432A  | CA2711569A1 | EP2234620A2,7,7,Yes,Application,No
740,WO2009117594,A1,FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS,US20080038096P,United States,2008-03-20T00:00:00Z,2008,2009-03-19T00:00:00Z,2009-09-24T00:00:00Z,2009,ENANTA PHARM INC,GAI YONGHUA    US  | OR YAT SUN    US  | WANG ZHE    US,C07D22500 | C07D29500,CN102015652A  | EP2268619A1 | CA2719008A1 | US2009238794A1,6,6,Yes,Application,No
741,WO2009117596,A1,ADAPTIVE BIOCHEMICAL SIGNATURES,US20050735529P,United States,2008-03-19T00:00:00Z,2008,2009-03-19T00:00:00Z,2009-09-24T00:00:00Z,2009,ONTHERIX INC,MASCARENHAS DESMOND    US,A61K031513 | A61K0314745,US2010152113A1 | US7611893B2 | CA2680708A1 | US2007134257A1 | US2008124346A1 | EP2125875A2 | EP2265272A1 | US2008039393A1 | EP1945263A2 | US7662624B2 | WO2008115525A9 | CA2629113A1 | WO2007056511A3 | WO2008115525A2 | CA2718969A1 | US7618816B2 | AU2006311538A1 | WO2008115525A8 | WO2007056511A2 | US2009053203A1,15,5,Yes,Grant,Yes
742,WO2009120240,A1,ANALYTE SENSOR,US19970811473,United States,1997-03-04T00:00:00Z,1997,2008-11-07T00:00:00Z,2009-10-01T00:00:00Z,2009,DEXCOM INC,KAMATH APURV U    US  | LEACH JACOB S    US  | ESTES MICHAEL J    US  | SHARIATI MOHAMMAD ALI    US  | NEALE PAUL V    US  | SIMPSON PETER C    US  | YANG RICHARD C    US  | BOOCK ROBERT    US  | LI YING    US,A61B0050245,US2007038044A1 | WO2005050277A3 | US2010228109A1 | US2010081908A1 | US2005232567A1 | US2008086273A1 | WO2005057173A3 | EP1624907A2 | US2010179408A1 | US2008013910A1 | US2007016381A1 | US2008195232A1 | US2010185073A1 | US2011028816A1 | US2008306444A1 | US2006036141A1 | MX2007012994A  | WO2006121661A2 | US2010030038A1 | US2006020191A1 | US7914450B2 | EP2228642A1 | WO2003100083A1 | CA2702799A1 | EP1914578A2 | US2009285540A1 | US2007163880A1 | US2005192557A1 | US2010179407A1 | US2007027385A1 | US2006249381A1 | US2008189051A1 | US2010198036A1 | US2008194935A1 | US2010174167A1 | US2006020187A1 | US2009036758A1 | US2008287764A1 | US7424318B2 | US2010185065A1 | US2006020189A1 | US6001067A  | US2010124392A1 | US2006020192A1 | EP1893084A4 | EP2264499A3 | US7899511B2 | US2006015024A1 | EP2223710A1 | US2008228054A1 | US7146089B2 | US2010234707A1 | US2010010332A1 | EP1718350A1 | CA2664426A1 | US2007173708A9 | US2010234796A1 | US2010081910A1 | EP2264500A2 | JP2008096448A  | WO2009055736A1 | US2010179401A1 | US7783333B2 | US7761130B2 | WO2006113817A2 | WO2008042625A3 | US2006020190A1 | WO2005057175A3 | US2006036139A1 | EP1991110A2 | US2006016700A1 | EP1711790B1 | US2010331648A1 | US7613491B2 | US2009287073A1 | US7591801B2 | US2010179409A1 | US2005027462A1 | JP2008506468T  | US2009192745A1 | US2008287765A1 | EP1804650A1 | WO2005057173A2 | US2010185074A1 | US2006040402A1 | AU2008262018A1 | DE602004029092D1 | WO2011003035A2 | EP2069772A2 | US2008208025A1 | US2006008233A1 | US2010198035A1 | AT474219T  | US7497827B2 | US2011024307A1 | AU2008266162A1 | EP1742568A4 | US2007027370A1 | JP2007501684T  | CN100589003C  | US2008033254A1 | EP1711802A2 | US2006155180A1 | EP1711791A4 | US2010036224A1 | US7171102B2 | US7778680B2 | US2010016687A1 | US2005187720A1 | US7917186B2 | US2005143635A1 | AU2003229330A1 | WO2005057175A2 | EP1875285A2 | JP2007511737T  | EP1624908A2 | US2008228051A1 | US2006198864A1 | CN101923195A  | US2009178459A1 | AU2004292229B2 | US2010168540A1 | US2006008231A1 | US2009297111A1 | US2009131776A1 | JP2007525276T  | US2009137887A1 | US2010235106A1 | US2010214104A1 | US7519408B2 | US2010185072A1 | EP1648298A4 | AT494018T  | AT480761T  | US2008195967A1 | WO2006073453A3 | US2008287766A1 | WO2006073453A2 | US7467003B2 | US2009124879A1 | CN1922525A  | WO2008154312A1 | US2008194936A1 | US6862465B2 | US2010185071A1 | US2006019327A1 | WO2007120381A3 | US2009043181A1 | US2006222566A1 | US2008086042A1 | CA2606770A1 | US2010240975A1 | US2009131769A1 | EP1711802A4 | US2007027384A1 | US2005027180A1 | US7713574B2 | EP1855588A2 | EP2256493A1 | US7081195B2 | US7088899B2 | US7200317B2 | US2008242961A1 | US2006068208A1 | US2010185069A1 | US2008200789A1 | US2007265515A1 | US2007197890A1 | US2007059196A1 | US7831287B2 | US2007208246A1 | WO2006127694A3 | US2010036216A1 | EP2226086A1 | US2005027181A1 | WO2005082436A1 | US2009043182A1 | US2009192380A1 | AU2008264211A1 | US2006036142A1 | KR20060132603A  | EP2129285A1 | WO2005057168A2 | US2008119703A1 | EP1711791A2 | US2008306434A1 | US2007208244A1 | US2008262469A1 | US2006257996A1 | US2010022855A1 | WO2008042918A3 | US2010030485A1 | US6983095B2 | WO2005011489A1 | US7775975B2 | US2008183399A1 | US2010174164A1 | US2010179400A1 | US2010030053A1 | US7599726B2 | US6435708B1 | US2009192724A1 | US2010161269A1 | US2010036225A1 | US2006086624A1 | WO2005082436A9 | JP2007514964T  | US2005161346A1 | WO2006017358A1 | US7471869B2 | US7835777B2 | US2006200020A1 | US2009287074A1 | EP2264499A2 | US2010223022A1 | US2008194937A1 | US2010305869A1 | US7715893B2 | WO9838906A1 | US2008108942A1 | US2010168544A1 | US2010174165A1 | US6741877B1 | EP1011425B1 | US2010240976A1 | US7920906B2 | EP1711802B1 | EP2155045A1 | US2007203966A1 | US2005112169A1 | WO2008042625A2 | US2008214915A1 | US7905833B2 | US2010174168A1 | WO2005050277A2 | US2011027453A1 | EP1648298A2 | US2010226615A1 | AU2008316630A1 | WO2007120442A3 | EP1893084A2 | US2010174157A1 | US2009299162A1 | JP2008538424T  | US7901354B2 | WO2005051170A2 | WO2007102842A2 | US2004045879A1 | US7792562B2 | US2009299276A1 | CA2681412A1 | US2005176136A1 | US2006200019A1 | WO2005057168A3 | US2010174166A1 | CN101547633A  | US2010099970A1 | WO2008118919A1 | WO2005079257A3 | US2009192722A1 | US2007235331A1 | US7460898B2 | WO2011003039A2 | US2009131768A1 | US2009062635A1 | US7809232B2 | US2010204559A1 | WO2007136390A1 | US2006020188A1 | WO2005025634A3 | EP2239566A3 | WO2006127694A2 | US2010185075A1 | US7310544B2 | US2009163790A1 | US7860545B2 | US2006204536A1 | US2011027127A1 | US2005245795A1 | US2009043541A1 | WO2007120381A2 | WO2006099151A3 | EP1742568A2 | WO2004105641A2 | US2010179399A1 | JP4124827B2 | WO2006110193A2 | US2010160760A1 | US2008083617A1 | US7276029B2 | US7771352B2 | WO2005052543A3 | US2009216103A1 | US7873255B2 | EP2301428A1 | EP1718350A4 | EP1855588A4 | US2004011671A1 | US2007213611A1 | US2006257995A1 | AU2008203181B2 | AU2007303239A1 | US2008183061A1 | CA2546072A1 | US2010298684A1 | US2007244379A1 | CA2664528A1 | US2011046467A1 | ES2286848T3 | US2006142651A1 | AU2004292229A1 | US2008086044A1 | US2009192366A1 | JP2008506469T  | AU2007305002A1 | US2006036140A1 | US2005203360A1 | US2008306435A1 | US2010185070A1 | EP2239567A2 | WO2005011520A2 | US7379765B2 | WO2009120239A1 | US7885697B2 | US7711402B2 | WO2005025634A2 | US7494465B2 | JP2007501028T  | US2005043598A1 | WO2006113618A1 | US7136689B2 | US2010045465A1 | US2011028815A1 | US2005177036A1 | WO2011003036A2 | US7640048B2 | US2006235285A1 | US2008119704A1 | US2010204555A1 | US2006195029A1 | EP1506307A1 | US2008306368A1 | US2010036223A1 | JP2007535991T  | EP1624908B1 | US2008008437A1 | US2009143660A1 | US2010217555A1 | EP2091409A2 | US7400816B2 | EP2152350A1 | US7896809B2 | US2006183985A1 | WO200213686A1 | WO2004105641A3 | US2010228497A1 | EP1648293A1 | US2005033132A1 | WO2005052543A2 | WO2007102842A3 | US2005251083A1 | JP4317519B2 | US7226978B2 | US2008071156A1 | US7366556B2 | EP1711790A2 | AU2008230832A1 | US7774145B2 | US2009204341A1 | DE602004030902D1 | US7110803B2 | US2010191082A1 | WO2006099151A2 | US2005054909A1 | US2010119693A1 | WO2008042918A2 | US7875293B2 | WO2005011520A3 | WO2006121661A3 | US2008200788A1 | US7844161B2 | US2006008234A1 | EP1776036A1 | US2010010324A1 | US2005105873A1 | US2009290843A1 | US2008188731A1 | US7364592B2 | EP2203741A1 | US2009012379A1 | US2009124964A1 | EP1711789A2 | AU200180886A  | US2007032706A1 | US2006020186A1 | US2008296155A1 | EP1011425A1 | US7192450B2 | WO2008157187A1 | US2011027458A1 | US2009043542A1 | US2010331655A1 | EP2264501A2 | AU2008203181A1 | US2009317045A1 | US2006270923A1 | US2010030484A1 | US7809235B2 | EP1711789A4 | US6931327B2 | US2007173710A1 | US2010168541A1 | US2010145172A1 | WO2007120442A2 | CN101163998A  | US2008008436A1 | US7828728B2 | US2009156919A1 | EP2264500A3 | US2010168546A1 | EP1648293A4 | DE69837709D1 | WO2005025634A9 | US2006253012A1 | US2006229512A1 | EP2239567A3 | US2010168657A1 | US2009124878A1 | US2007208245A1 | US2007066873A1 | US2005031689A1 | US2005027463A1 | US2009163791A1 | US2009043525A1 | US7797028B2 | CA2687980A1 | EP1011425A4 | US2010179402A1 | US2010217106A1 | US2008275313A1 | US2008197024A1 | WO2007084516A3 | US2010063373A1 | US2008021666A1 | WO2005079257A2 | US2009131777A1 | AT361024T  | US2009036763A1 | US2011024043A1 | US2009018424A1 | US2010179405A1 | US2007093704A1 | US2009076361A1 | US2006258929A1 | US2003217966A1 | AU6680098A  | US2006008232A1 | US2009124877A1 | US7369741B2 | US7583990B2 | US2011019966A1 | CA2688184A1 | US2010168545A1 | DK1011425T3 | US2010099971A1 | US2010168542A1 | US7657297B2 | US2008119706A1 | JP2005531755T  | US2010168543A1 | WO2006110193A3 | US2006183984A1 | WO2007002189A3 | US2006263763A1 | US7826981B2 | US2010174163A1 | US2009076356A1 | US2005154271A1 | US2006036144A1 | EP2239566A2 | EP2004796A2 | US2007032718A1 | US2010010331A1 | EP1711790A4 | US2006036143A1 | US7654956B2 | US2010174158A1 | EP2264501A3 | EP1914578A3 | US2008200791A1 | US2010331644A1 | US2010256779A1 | US2007232879A1 | KR20080005432A  | US2010036215A1 | US2009182217A1 | US2006200970A1 | US2006252027A1 | US2009143659A1 | US2006189856A1 | HK1100976A1 | US2009203981A1 | JP2001510382T  | US7646958B1 | US2005124873A1 | US2010041971A1 | US2008194938A1 | US2009156924A1 | US2010179406A1 | JP2006525853T  | US2005129379A1 | US7651596B2 | US2006258761A1 | US2007173709A1 | US2010036222A1 | US2010217557A1 | US7103255B2 | WO2007002189A2 | US2010212583A1 | US2010121169A1 | AU2006236319A1 | US6558321B1 | US7857760B2 | US2010286496A1 | US2009099436A1 | US2009192751A1 | US2006270922A1 | US7925321B2 | DE602004028164D1 | US2009137886A1 | US2010179404A1 | US2008214918A1 | US2010223023A1 | JP2010505534T  | US2010223013A1 | WO2007084516A2 | WO2005051170A3 | US2007045902A1 | US7615007B2 | US2006036145A1 | EP1692556A2 | DE69837709T2 | US2007032717A1 | US2010016698A1 | WO2006017359A1 | WO2006113817A3,392,10,Yes,Grant,Yes
743,WO2009121997,A2,PEGYLATED NANOPARTICLES CONTAINING A BIOLOGICALLY ACTIVE MOLECULE AND USE THEREOF,ES20080000958,Spain,2008-04-05T00:00:00Z,2008,2009-04-01T00:00:00Z,2009-10-08T00:00:00Z,2009,"INSTITUTO CIENTIFICO Y TECNOLOGICO DE NAVARRA, S.A",IRACHE GARRETA JUAN MANUEL    ES  | ZABALETA SANZ DE ACEDO VIRGINIA    ES,A61K00900,WO2009121997A3,2,2,Yes,Application,No
744,WO2009123768,A2,NANOCARRIER AND NANOGEL COMPOSITIONS,US20080042577P,United States,2008-04-04T00:00:00Z,2008,2009-04-06T00:00:00Z,2009-10-08T00:00:00Z,2009,"RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY",SINKO PATRICK J    US  | STEIN STANLEY    US  | KUTSCHER HILLIARD    US  | DESHMUKH MANJEET    US  | MENJOGE ANUPA    US  | SINGH YASHVEER    US,A61K00918,CA2720474A1 | WO2009123768A3,3,3,Yes,Application,No
745,WO2009126293,A2,POTENT CHIMERIC NRTI-NNRTI BIFUNCTIONAL INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE,US20080123768P,United States,2008-04-11T00:00:00Z,2008,2009-04-09T00:00:00Z,2009-10-15T00:00:00Z,2009,YALE UNIVERSITY | UNIVERSITY OF CAPE TOWN,ANDERSON KAREN S    US  | HUNTER ROGER    ZA,C07D48704 | C07D48702 | A61P03118,WO2009126293A3,1,1,Yes,Application,No
746,WO2009128947,A1,PIPERAZINE DERIVATIVES,US20080124665P,United States,2008-04-17T00:00:00Z,2008,2009-04-17T00:00:00Z,2009-10-22T00:00:00Z,2009,CONCERT PHARMACEUTICALS INC,LIU JULIE F    US  | PERSICHETTI ROSE A    US,C07D40114 | A61P03118 | A61K031506,US2009270336A1 | US2010120786A1,3,2,Yes,Application,No
747,WO2009129470,A2,METHODS FOR TREATING HERPES VIRUS INFECTIONS,US20080046262P,United States,2008-04-18T00:00:00Z,2008,2009-04-17T00:00:00Z,2009-10-22T00:00:00Z,2009,NANOBIO CORP,FLACK MARY R    US  | CIOTTI MARIE    US  | HAMOUDA TAREK    US  | SUTCLIFFE JOYCE A    US  | BAKER JAMES R    US,A61K009107,US2010075914A1,7,7,Yes,Application,No
748,WO2009134120,A1,MASS SPECTROMETRIC ANALYSIS OF SMALL MOLECULE ANALYTES,WO2008NL50267,WIPO,2008-04-29T00:00:00Z,2008,2008-04-29T00:00:00Z,2009-11-05T00:00:00Z,2009,ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM,LUIDER THEO MARTEN    NL  | VAN KAMPEN JEROEN J A    NL,G01N03368 | G01N03394,None,1,1,Yes,Application,No
749,WO2009134401,A2,METHODS OF INHIBITING INFECTION BY DIVERSE SUBTYPES OF DRUG-RESISTANT HIV-1,US20080125953P,United States,2008-04-29T00:00:00Z,2008,2009-04-29T00:00:00Z,2009-11-05T00:00:00Z,2009,PROGENICS PHARM INC,OLSON WILLIAM C    US  | KETAS THOMAS J    US  | MAROZSAN ANDRE    US,A61K03942,WO2009134401A9 | WO2009134401A3,1,1,Yes,Application,No
750,WO2009134616,A2,NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION,US20080045214P | US20080045219P ,United States,2008-04-15T00:00:00Z,2008,2009-04-14T00:00:00Z,2009-11-05T00:00:00Z,2009,INTERMUNE INC,BUCKMAN BRAD O    US  | WANG GUANGYI    US  | BEIGELMAN LEONID    US  | STOYCHEVA ANTITSA DIMITROVA    US,C07D28530 | A61P03114 | A61K0315415 | C07D41704 | C07D47104,WO2009134616A3 | KR20110004439A  | MX2010011307A  | CA2720846A1 | AU2009241514A1 | US2009257979A1 | EP2283002A2 | WO2009134616A8,9,9,Yes,Application,No
751,WO2009134987,A1,DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS,US20080049070P,United States,2008-04-30T00:00:00Z,2008,2009-04-30T00:00:00Z,2009-11-05T00:00:00Z,2009,ENANTA PHARM INC,GAI YONGHUA    US  | LIU DONG    US  | MOORE JOEL D    US  | OR YAT SUN    US  | WANG ZHE    US,C07D22500 | C07D29500,US2009274657A1,2,2,Yes,Application,No
752,WO2009142842,A2,NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION,US20080045220P,United States,2008-04-15T00:00:00Z,2008,2009-04-14T00:00:00Z,2009-11-26T00:00:00Z,2009,INTERMUNE INC,SEIWERT SCOTT    US  | BEIGELMAN LEONID    US  | BUCKMAN BRAD    US  | STOYCHEVA ANTITSA DIMITROVA    US  | PORTER STEVEN B    US  | BRADFORD WILLIAMSON ZIEGLER    US  | SEREBRYANY VLADIMIR    US,A61K03821 | C07D24504 | A61K0314725 | A61K0314709 | A61K031407 | A61K0314738 | C12N00999 | A61K031517 | A61K0317056,US2011059047A1 | AU2009249443A1 | KR20110005869A  | IL208529D0 | AP201005416D0 | WO2009142842A3 | US2009269305A1 | CA2720729A1 | EP2282762A2 | WO2009142842A9 | MX2010011306A  | AR072779A1,12,10,Yes,Application,No
753,WO2009145956,A2,USES OF CALPAIN INHIBITORS TO INHIBIT INFLAMMATION,US20080034265P,United States,2008-03-06T00:00:00Z,2008,2009-03-06T00:00:00Z,2009-12-03T00:00:00Z,2009,THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK,PRINCE ALICE    US,A61K04800,WO2009145956A3,2,2,Yes,Application,No
754,WO2009153654,A1,SOLID DOSAGE FORMS OF ANTIRETROVIRALS,IN2008CH01469,India,2008-06-17T00:00:00Z,2008,2009-06-15T00:00:00Z,2009-12-23T00:00:00Z,2009,AUROBINDO PHARMA LTD,GAMPA RAVINDRANATH    IN  | DUDE UDAYA KUMAR    IN  | ALLA KALIKA REDDY    IN  | VISHNUBHOTLA NAGAPRASAD    IN  | MEENAKSHISUNDERAM SIVAKUMARAN    IN,A61K00920 | A61K031513 | A61K031427,None,1,1,Yes,Application,No
755,WO2010000459,A1,CYCLOPROPYL POLYMERASE INHIBITORS,EP20080159396,European Patent Office,2008-07-01T00:00:00Z,2008,2009-07-01T00:00:00Z,2010-01-07T00:00:00Z,2010,CENTOCOR ORTHO BIOTECH INC.,JONCKERS TIM HUGO MARIA    BE  | RABOISSON PIERRE JEAN-MARIE BERNARD    BE  | VANDYCK KOEN    BE,C07H019073 | A61P03112 | A61K031513,AP201005505D0 | UY31950A  | EP2141172A1 | CA2729316A1 | AU2009266004A1 | AR072428A1,10,10,Yes,Application,No
756,WO2010009335,A1,DRUG DELIVERY MEDICAL DEVICE,US20080081691P,United States,2008-07-17T00:00:00Z,2008,2009-07-16T00:00:00Z,2010-01-21T00:00:00Z,2010,MICELL TECHNOLOGIES INC,MCCLAIN JAMES B    US  | TAYLOR DOUGLAS    US  | NEET JOHN    US,A61L03300,WO2010121187A2 | WO2011009096A1 | US2010015200A1 | US2010241220A1 | AU2009270849A1 | WO2010111196A2 | WO2010120552A2 | WO2010121187A3 | US2010272778A1 | CA2730995A1 | WO2010111196A3 | WO2010111232A9 | WO2010111232A2 | US2010239635A1 | WO2010120552A3 | US2010256748A1,14,5,Yes,Application,No
757,WO2010012466,A1,ANTITUMOR PROPERTIES OF NO MODIFIED PROTEASE INHIBITORS,US20080085555P,United States,2008-08-01T00:00:00Z,2008,2009-07-30T00:00:00Z,2010-02-04T00:00:00Z,2010,GANIAL IMMUNOTERAPEUTICS INC,NICOLETTI FERDINANDO    IT  | AL-ABED YOUSSEF    US  | GAROTTA GIANNI    FR,A61K03100 | A61P03118 | A61K0314725 | A61P03500 | C07D40112,WO2010005770A8 | WO2010005637A3 | US2009258946A1 | AU2009269074A1 | EP2306995A1 | WO2010005770A3 | WO2010005770A2 | WO2010012466A8 | WO2010134942A1 | CA2726314A1 | AU2009268884A1 | CA2726311A1 | US2010004337A1,4,3,Yes,Application,No
758,WO2010014130,A1,COMPOSITION AND METHOD TO PREVENT OR REDUCE DIARRHEA AND STEATORRHEA IN HIV PATIENTS,US20080152520,United States,2008-07-28T00:00:00Z,2008,2009-04-30T00:00:00Z,2010-02-04T00:00:00Z,2010,DIGESTIVE CARE INC,SIPOS TIBOR    US  | DAS SIMANTINI    US  | WIGNOT TERESE MARIE    US,A61K03854,US2010021505A1,2,2,Yes,Application,No
759,WO2010017432,A1,PHARMACEUTICAL FORMULATIONS OF AN HCV PROTEASE INHIBITOR IN A SOLID MOLECULAR DISPERSION,US20080086997P,United States,2008-08-07T00:00:00Z,2008,2009-08-07T00:00:00Z,2010-02-11T00:00:00Z,2010,SCHERING CORP,SHETH ASHLESH    US  | HU CHENGJIU    US  | YUE BAOHUA    US  | OMELCZUK MARCELO OSVALDO    US,A61K00920 | A61K03806 | A61K00948,CA2732777A1 | AR072991A1 | AU2009279520A1,5,5,Yes,Application,No
760,WO2010033614,A1,STABLE SOLID ORAL DOSAGE CO-FORMULATIONS,US20080097479P,United States,2008-09-16T00:00:00Z,2008,2009-09-16T00:00:00Z,2010-03-25T00:00:00Z,2010,SEQUOIA PHARMACEUTICALS,LUDTKE DOUGLAS    US  | DAGGER RAYMOND    US,A61K0314965,None,4,3,Yes,Application,No
761,WO2010033637,A1,DISSOLUTION OF ARTERIAL PLAQUE,US20050739143P,United States,2005-11-22T00:00:00Z,2005,2009-09-16T00:00:00Z,2010-03-25T00:00:00Z,2010,"Z & Z MEDICAL HOLDINGS, INC",ZADINI FILIBERTO    US  | ZADINI GIORGIO    US,A01N04500 | A61K03606 | A61K03156,WO2007084549A3 | US2007249543A1 | US2008187569A1 | WO2008144458A1 | US2007116755A1 | WO2007061820A3 | US2007129425A1 | US2008287429A1 | WO2007084549A2 | WO2007061820A2 | US2007116754A1 | US2009035348A1,11,2,Yes,Application,No
762,WO2010037402,A1,MOLECULAR VACCINES FOR INFECTIOUS DISEASE,DK20080001384 | US20080102126P,Denmark & United States,2008-10-02T00:00:00Z,2008,2009-10-02T00:00:00Z,2010-04-08T00:00:00Z,2010,DAKO DENMARK A/S,SCHOELLER JOERGEN    DK  | PEDERSEN HENRIK    DK  | BRIX LISELOTTE    DK,A61K03817 | A61K04748 | A61K03900 | A61P03104 | A61P03118 | C07K014705,None,1,1,Yes,Application,No
763,WO2010037566,A1,IMPROVED NANOPARTICULATE COMPOSITIONS OF POORLY SOLUBLE COMPOUNDS,EP20080165747,European Patent Office,2008-10-02T00:00:00Z,2008,2009-10-01T00:00:00Z,2010-04-08T00:00:00Z,2010,CAPSULUTION PHARMA AG,GONZALES FERREIRO MARIA    DE  | DUNMANN CHRISTOPH    DE  | KROEHNE LUTZ    DE  | VOIGT ANDREAS    DE,A61K00950 | A61K03100 | A61K00951,EP2172193A1,4,3,Yes,Application,No
764,WO2010038237,A2,COMPOSITIONS EXHIBITING DELAYED TRANSIT THROUGH THE GASTROINTESTINAL TRACT,IN2008MU02020,India,2008-09-22T00:00:00Z,2008,2009-09-22T00:00:00Z,2010-04-08T00:00:00Z,2010,RUBICON RESEARCH PRIVATE LIMITED,PILGAONKAR PRATIBHA SUDHIR    IN  | RUSTOMJEE MAHARUKH TEHMASP    IN  | GANDHI ANILKUMAR SURENDRAKUMAR    IN  | SUVARNAPATHAKI RUPALI KEDAR    IN,A23L00105 | A61K00920 | A23L001308 | A61K03500,WO2010038237A3,3,3,Yes,Application,No
765,WO2010041241,A2,HIV-1 INTEGRASE DERIVED PEPTIDES AND COMPOSITIONS,US20080103036P,United States,2008-10-06T00:00:00Z,2008,2009-10-01T00:00:00Z,2010-04-15T00:00:00Z,2010,YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD,LEVIN AVIAD    IL  | HAYOUKA ZVI    IL  | FRIEDLER ASSAF    IL  | LOYTER ABRAHAM    IL,A61K03816 | A61K03810 | A61K03808 | C07K00706 | C07K00716 | C07K01416,WO2010041241A3,2,2,Yes,Application,No
766,WO2010045266,A1,THERAPEUTIC ANTIVIRAL PEPTIDES,US20080105746P,United States,2008-10-15T00:00:00Z,2008,2009-10-13T00:00:00Z,2010-04-22T00:00:00Z,2010,INTERMUNE INC,SEIWERT SCOTT    US  | BEIGELMAN LEONID    US  | BUCKMAN BRAD    US  | SEREBRYANY VLADIMIR    US  | STOYCHEVA ANTITSA DIMITROVA    US,C07K00508 | C07D21522 | C07D20944 | A61P03114 | C07D23526 | C07D27766 | C07D27768,AR073880A1 | US2010119479A1,5,5,Yes,Application,No
767,WO2010047819,A1,HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES,US20080197190P,United States,2008-10-24T00:00:00Z,2008,2009-10-23T00:00:00Z,2010-04-29T00:00:00Z,2010,CONCERT PHARMACEUTICALS INC,HARBESON SCOTT L    US  | MASSE CRAIG E    US,A01N04106,WO2010047819A8,1,1,Yes,Application,No
768,WO2010057048,A1,THERAPIES FOR HEMATOLOGIC MALIGNANCIES,US20080114434P,United States,2008-11-13T00:00:00Z,2008,2009-11-13T00:00:00Z,2010-05-20T00:00:00Z,2010,"CALISTOGA PHARMACEUTICALS, INC.",GALLATIN MICHAEL W    US  | ULRICH ROGER G    US  | GIESE NEILL    US,A61K031519 | A61P03500 | A61K031517 | A61P03700,US2010202963A1,4,4,Yes,Application,No
769,WO2010059883,A1,DEGRADABLE HYDROGEL COMPOSITIONS AND METHODS,US20080115962P,United States,2008-11-19T00:00:00Z,2008,2009-11-20T00:00:00Z,2010-05-27T00:00:00Z,2010,"RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY",SINKO PATRICK JOHN    US  | DESHMUKH MANJEET    US  | SINGH YASHVEER    US  | GUNASEELAN SIMI    US,A61K00914 | A61K00916,None,1,1,Yes,Application,No
770,WO2010065079,A2,ANTIBODIES TO IL-6 AND USE THEREOF,US20060801412P,United States,2006-05-19T00:00:00Z,2006,2009-11-24T00:00:00Z,2010-06-10T00:00:00Z,2010,ALDER BIOPHARMACEUTICALS INC,GARCIA-MARTINEZ LEON    US  | JENSEN ANNE ELISABETH CARVALHO    US  | OLSON KATIE    US  | DUTZAR BEN    US  | LATHAM JOHN    US  | KOVACEVICH BRIAN    US  | SMITH JEFFREY T L    US  | LITTON MARK    US  | SCHATZMAN RANDALL    US,A61K05100 | C12N01563 | A61K04900 | A61K039395 | C12N00119 | A61P03500 | C07H02104 | C07K01624,AR074227A1 | US2009291089A1 | JP2010527615T  | CO6241159A2 | US2010290993A1 | US2010150829A1 | WO2008144753A3 | CA2688829A1 | CN101600793A  | EP2021463A1 | WO2008045140A1 | AU2008254578A1 | US2009104187A1 | US7906117B2 | US2009291082A1 | JP2009537176T  | CN101754772A  | WO2010065072A8 | CA2652392A1 | AU2007307324A1 | EP2162469A1 | WO2010065079A3 | WO2008144757A1 | NO20093387A  | CA2688146A1 | US2010158859A1 | CN101868477A  | MX2008014692A  | IL202232D0 | US2010129357A1 | WO2010065072A1 | JP2010528589T  | US2009238825A1 | KR20100028569A  | WO2010065077A3 | WO2010065077A2 | IL202238D0 | WO2008144763A2 | EP2021463A4 | US2009297436A1 | NO20084835A  | WO2010065078A1 | US2010143294A1 | KR20100028571A  | AU2008254584A1 | WO2008144763A3 | MX2009012492A  | MX2009012493A  | US2009028784A1 | US2009297513A1 | US2007269868A1 | EA200901533A1 | US2009022659A1 | US2009291077A1 | EP2164514A2 | WO2008144753A2,57,13,Yes,Grant,Yes
771,WO2010065118,A1,ANTI-INFLAMMATORY COMPOSITIONS AND METHODS,US20080315508 | US20080315504 | US20080315505 | US20080315506 | US20080315507 | US20080315509 | US20080315510 | US20080315511 | US20080315512 | US20080315513 | US20080315514 | US20080315515,United States,2008-12-02T00:00:00Z,2008,2009-12-02T00:00:00Z,2010-06-10T00:00:00Z,2010,SEARETE LLC,HYDE RODERICK A    US  | MALASKA STEPHEN L    US  | SWEENEY ELIZABETH A    US  | WOOD LOWELL L JR    US,G01N03353,US2010136094A1 | US2010137246A1 | US2010137844A1 | US2010135984A1 | US2010135908A1 | US2010137247A1 | US2010137843A1 | US2010136096A1 | US2010136095A1 | US2010136097A1 | US2010137787A1 | US2010135983A1,13,2,Yes,Application,No
772,WO2010068899,A1,NANOPARTICLES COMPRISING COMBINATIONS OF ANTIRETROVIRAL AGENTS AND USE THEREOF,US20080122139P,United States,2008-12-12T00:00:00Z,2008,2009-12-11T00:00:00Z,2010-06-17T00:00:00Z,2010,CREIGHTON UNIVERSITY,DESTACHE CHRISTOPHER J    US,A61K00951 | A61K031513 | A61K031427 | A61K031536,None,1,1,Yes,Application,No
773,WO2010075065,A2,METHODS FOR ENHANCING THE RELEASE AND ABSORPTION OF WATER INSOLUBLE ACTIVE AGENTS,US20080122497P,United States,2008-12-15T00:00:00Z,2008,2009-12-15T00:00:00Z,2010-07-01T00:00:00Z,2010,BANNER PHARMACAPS INC,FATMI AQEEL    US  | KIM TAE KYOUNG    US  | MADRIGAL KARLA E    US,A61K00950,US2011052682A1,3,2,Yes,Application,No
774,WO2010077061,A2,PHARMACEUTICAL FORMULATIONS CONTAINING ANTIVIRAL DRUGS,US20080141983P,United States,2008-12-31T00:00:00Z,2008,2009-12-29T00:00:00Z,2010-07-08T00:00:00Z,2010,"HANALL BIOPHARMA CO., LTD",KIM SUNG WUK    KR  | JUN SUNG SOO    KR  | LEE AH RAM    KR,A61K03170 | A61K031513 | A61K00922 | A61P03112 | A61K04730 | A61K04738 | A61K04742,WO2010077061A3,1,1,Yes,Application,No
775,WO2010077317,A2,PROTEASE INHIBITORS,US20080138428P,United States,2008-12-17T00:00:00Z,2008,2009-12-17T00:00:00Z,2010-07-08T00:00:00Z,2010,AMPLYX PHARMACEUTICALS INC,MUTZ MITCHELL    US  | BARR KENNETH J    US  | GESTWICKI JASON    US,C07D21134 | A61P03118 | A61K0314406,WO2010077317A3,1,1,Yes,Application,No
776,WO2010077734,A2,"NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE",US20080120939P,United States,2008-12-09T00:00:00Z,2008,2009-12-09T00:00:00Z,2010-07-08T00:00:00Z,2010,CYTOKINE PHARMASCIENCES INC,SIELECKI-DZURDZ THAIS M    US,C07C21568 | A61P03112 | A61K03144 | A61K031136 | C07D21371,WO2010077734A3,1,1,Yes,Application,No
777,WO2010077740,A2,"NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE",US20080120948P,United States,2008-12-09T00:00:00Z,2008,2009-12-09T00:00:00Z,2010-07-08T00:00:00Z,2010,CYTOKINE PHARMASCIENCES INC,SIELECKI-DZURDZ THAIS M    US,C07D23924 | A61P03112 | A61K031495,WO2010077740A3,1,1,Yes,Application,No
778,WO2010086844,A1,POLYMORPHS OF DARUNAVIR,US20090148055P,United States,2009-01-29T00:00:00Z,2009,2009-12-08T00:00:00Z,2010-08-05T00:00:00Z,2010,MAPI PHARMA HK LTD,MAROM EHUD    IL,A01N05700,None,1,1,Yes,Application,No
779,WO2010089763,A2,POLY(N-VINYL CAPROLACTAM-CO-ACRYLAMIDE) MICROPARTICLES FOR CONTROLLED RELEASE APPLICATIONS,IN2008MU01366,India,2008-06-30T00:00:00Z,2008,2009-06-29T00:00:00Z,2010-08-12T00:00:00Z,2010,RELIANCE LIFE SCIENCES PVT LTD,VADDE RAMESH BABU    IN  | RAGHAVENDRA CHALUVAYYA MUNDARGI    IN  | PRADIP PATEL    IN  | VIDHYA RANGASWAMY    IN  | TEJRAJ MALLESHAPPA AMINABHAVI    IN,A61K,WO2010089763A3,1,2,Yes,Application,No
780,WO2010089767,A1,DUAL RELEASE PHARMACEUTICAL SUSPENSION,IN2009DE00030,India,2009-01-09T00:00:00Z,2009,2010-01-08T00:00:00Z,2010-08-12T00:00:00Z,2010,PANACEA BIOTEC LTD,JAIN RAJESH    IN  | SINGH SUKHJEET    IN  | DHAWAN SANJU    IN,A61K00910 | A61K00916,None,1,2,Yes,Application,No
781,WO2010091413,A1,LINKED DIBENZIMIDAZOLE DERIVATIVES,US20090151079P,United States,2009-02-09T00:00:00Z,2009,2010-02-09T00:00:00Z,2010-08-12T00:00:00Z,2010,ENANTA PHARM INC,QIU YAO-LING    US  | WANG CE    US  | YING LU    US  | PENG XIAOWEN    US  | OR YAT SUN    US,A01N04350,US2010221215A1 | US2010266543A1 | US2010221214A1,4,2,Yes,Application,No
782,WO2010096462,A1,LINKED DIIMIDAZOLE DERIVATIVES,US20090153234P,United States,2009-02-17T00:00:00Z,2009,2010-02-17T00:00:00Z,2010-08-26T00:00:00Z,2010,ENANTA PHARM INC,OR YAT SUN    US  | PENG XIAOWEN    US  | YING LU    US  | CE WANG    US  | TANG DATONG    US  | QIU YAO-LING    US,A01N04350 | A61K031415,US2010226883A1 | US2010221216A1 | US2010226882A1,4,2,Yes,Application,No
783,WO2010099458,A1,"COMBINATION OF A NUCLEOSIDE POLYMERASE INHIBITOR WITH A MACROCYCLIC PROTEASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF HEPATITIS C, LIVER FIBROSIS AND IMPAIRED LIVER FUNCTION",US20090156414P,United States,2009-02-27T00:00:00Z,2009,2010-02-26T00:00:00Z,2010-09-02T00:00:00Z,2010,"INTERMUNE INC | F. HOFFMANN-LA ROCHE AG | PHARMASSET, INC",PORTER STEVEN B    US  | BRADFORD WILLIAMSON ZIEGLER    US  | SMITH PATRICK F    US  | YETZER ELLEN S    US  | DE LA ROSA ABEL    US  | ROGERS MICHAEL D    US  | SYMONDS WILLIAM T    US,A61K0314709 | A61P00116 | A61K0317068 | A61P03114,US2010221217A1,3,3,Yes,Application,No
784,WO2010099527,A1,HEPATITIS C VIRUS INHIBITORS,US20090156131P,United States,2009-02-27T00:00:00Z,2009,2010-03-01T00:00:00Z,2010-09-02T00:00:00Z,2010,ENANTA PHARM INC,QIU YAO-LING    US  | CE WANG    US  | PENG XIAOWEN    US  | YING LU    US  | OR YAT SUN    US,A01N04352,US2010260715A1 | US2010233122A1,3,2,Yes,Application,No
785,WO2010100381,A1,NOVEL ANTIVIRAL AGENT,FR20090051347,France,2009-03-04T00:00:00Z,2009,2010-03-04T00:00:00Z,2010-09-10T00:00:00Z,2010,CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE | UNIVERSITE DE STRASBOURG | UNIVERSITE DE LA MEDITERRANEE,CHABRIERE ERIC    FR  | ELIAS MIKAEL      | ROHR OLIVIER    FR  | SCHWARTZ CHRISTIAN    FR,A61K03817 | A61K03118 | A61K03100 | A61P02900 | G01N03350,FR2942717A1 | FR2942717B1,2,2,Yes,Grant,Yes
786,WO2010107831,A1,NANOCARRIER COMPOSITIONS AND METHODS,US20090160575P,United States,2009-03-16T00:00:00Z,2009,2010-03-16T00:00:00Z,2010-09-23T00:00:00Z,2010,"RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY",SINKO PATRICK J    US  | STEIN STANLEY    US  | GUNASEELAN SIMI    US  | POOYAN SHAHRIAR    US  | PALOMBO MATTHEW SEAN    US  | ZHANG XIAOPING    US,A61K04742,None,1,1,Yes,Application,No
787,WO2010111238,A2,IMPROVED BIODEGRADABLE POLYMERS,US20090162653P,United States,2009-03-23T00:00:00Z,2009,2010-03-23T00:00:00Z,2010-09-30T00:00:00Z,2010,MICELL TECHNOLOGIES INC,TAYLOR DOUGLAS    US  | MCCLAIN JAMES B    US  | SCHMITT EDWARD    US,C08G06308 | C08J00704 | C08G06390 | C08L06704 | C09D16704,WO2010111238A3 | US2010256746A1,2,2,Yes,Application,No
788,WO2010115981,A1,7-AZADISPIRO [3.0.4.1] DECANE-8-CARBOXAMIDES AS HEPATITIS C VIRUS INHIBITORS,US20090168415P,United States,2009-04-10T00:00:00Z,2009,2010-04-09T00:00:00Z,2010-10-14T00:00:00Z,2010,NOVARTIS AG,BRANDL TRIXI    CH  | RAMAN PRAKASH    US  | RIGOLLIER PASCAL    CH  | SEEPERSAUD MOHINDRA    US,C07D40112 | A61P03112 | A61K03144 | C07D40312 | C07D41312,UY32554A ,3,3,Yes,Application,No
789,WO2010116248,A1,ORGANIC COMPOUNDS AND THEIR USES,US20090168408P,United States,2009-04-10T00:00:00Z,2009,2010-04-09T00:00:00Z,2010-10-14T00:00:00Z,2010,NOVARTIS AG,BRANDL TRIXI    CH  | RAMAN PRAKASH    US  | RIGOLLIER PASCAL    CH  | SEEPERSAUD MOHINDRA    US  | SIMIC OLIVER    CH,C07D20996 | C07D40514 | A61P03122 | A61K031403 | C07D40314 | C07D40112 | C07K00508 | C07D41714 | C07D40114 | C07D40312,UY32551A  | US2010260709A1,3,3,Yes,Application,No
790,WO2010121351,A1,USE OF (HEXENOYL TRANS-3)HGRF(1-44)NH2 AND RITONAVIR IN COMBINATION THERAPY,US20090170862P,United States,2009-04-20T00:00:00Z,2009,2010-04-20T00:00:00Z,2010-10-28T00:00:00Z,2010,THERATECHNOLOGIES INC,MARSOLAIS CHRISTIAN    CA,A61K03816 | A61K03827 | A61K031427 | C07K01460 | C07K01702,US2010267635A1 | WO2010121351A8,2,2,Yes,Application,No
791,WO2010122087,A1,METHODS FOR IMPROVING PHARMACOKINETICS,US20090172722P,United States,2009-04-25T00:00:00Z,2009,2010-04-22T00:00:00Z,2010-10-28T00:00:00Z,2010,F. HOFFMANN-LA ROCHE AG,TRAN JONATHAN Q    US,A61K031404 | A61P03112 | A61K031426,US2010272682A1,2,2,Yes,Application,No
792,WO2010127099,A2,PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND A CARDIOVASCULAR AGENT AND METHODS OF USING THE SAME,US20090173759P,United States,2009-04-29T00:00:00Z,2009,2010-04-29T00:00:00Z,2010-11-04T00:00:00Z,2010,AMARIN CORP PLC,MANKU MEHAR    GB  | ROWE JONATHAN    US,A61K031202,None,1,1,Yes,Application,No
793,WO2010127272,A2,HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES,US20090214977P,United States,2009-04-30T00:00:00Z,2009,2010-04-30T00:00:00Z,2010-11-04T00:00:00Z,2010,CONCERT PHARMACEUTICALS INC,HARBESON SCOTT L    US  | TUNG ROGER D    US  | LIU JULIE F    US  | MASSE CRAIG E    US,C07D29304,US2010305173A1,2,2,Yes,Application,No
794,WO2010132163,A1,MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS,US20090177853P,United States,2009-05-13T00:00:00Z,2009,2010-04-13T00:00:00Z,2010-11-18T00:00:00Z,2010,ENANTA PHARM INC,GAI YONGHUA    US  | OR YAT SUN    US  | WANG GUOQIANG    US,A61K03821,US2011033420A1,2,2,Yes,Application,No
795,WO2010132494,A1,COMPOUNDS AND METHODS FOR TREATING AIDS AND HIV INFECTIONS,US20090177086P,United States,2009-05-11T00:00:00Z,2009,2010-05-11T00:00:00Z,2010-11-18T00:00:00Z,2010,GHOSH ARUN K,GHOSH ARUN K    US,A01N03744 | A61K031195 | A61K03116,None,1,1,Yes,Application,No
796,WO2010132511,A1,METHODS OF REDUCING THE RISK OF DRONEDARONE USE IN CERTAIN PATIENT POPULATIONS,US20090177409P,United States,2009-05-12T00:00:00Z,2009,2010-05-12T00:00:00Z,2010-11-18T00:00:00Z,2010,SANOFI,SCARAZZINI LINDA    US,A61K031343,US2010320099A1,2,2,Yes,Application,No
797,WO2010132663,A1,PEGYLATED AZAPEPTIDE DERIVATIVES AS HIV PROTEASE INHIBITORS,US20090216086P,United States,2009-05-13T00:00:00Z,2009,2010-05-13T00:00:00Z,2010-11-18T00:00:00Z,2010,CONCERT PHARMACEUTICALS INC,HARBESON SCOTT L    US  | TUNG ROGER D    US,C07D21342 | C07B05900 | A61P03100 | A61K0314402,None,1,1,Yes,Application,No
798,WO2010132664,A1,COMPOSITIONS AND METHODS FOR DRUG DELIVERY,US20090467230,United States,2009-05-15T00:00:00Z,2009,2010-05-13T00:00:00Z,2010-11-18T00:00:00Z,2010,BAXTER INTERNATIONAL INC.,RABINOW BARRETT    US  | BAIRSTOW SHAWN F    US  | CHAUBAL MAHESH V    US  | LEE SARAH    US  | WERLING JANE    US,A61K00914 | A61K04734 | A61K031337 | A61P03500,US2010290983A1,2,2,Yes,Application,No
799,WO2010143207,A1,TASTE-MASKED ORAL FORMULATIONS OF INFLUENZA ANTIVIRALS,IN2009MU01405,India,2009-06-11T00:00:00Z,2009,2010-06-10T00:00:00Z,2010-12-16T00:00:00Z,2010,RUBICON RESEARCH PRIVATE LIMITED,PILGAONKAR PRATIBHA SUDHIR    IN  | RUSTOMJEE MAHARUKH TEHMASP    IN  | GANDHI ANILKUMAR SURENDRAKUMAR    IN,A61K00900 | A61K00920,None,1,1,Yes,Application,No
800,WO2010144869,A2,PROTEASE INHIBITORS,US20090186768P,United States,2009-06-12T00:00:00Z,2009,2010-06-11T00:00:00Z,2010-12-16T00:00:00Z,2010,NEKTAR THERAPEUTICS,RIGGS-SAUTHIER JENNIFER    US,A61K04748,WO2010144869A3,1,1,Yes,Application,No
801,WO2010148006,A1,HEPATITIS C VIRUS INHIBITORS,US20090187374P,United States,2009-06-16T00:00:00Z,2009,2010-06-15T00:00:00Z,2010-12-23T00:00:00Z,2010,ENANTA PHARM INC,OR YAT SUN    US  | PENG XIAOWEN    US  | YING LU    CN  | TANG DATONG    US  | WANG CE    US  | QIU YAO-LING    US,A61K03155,US2011008288A1 | US2010316607A1,3,2,Yes,Application,No
802,WO2010148323,A2,DIAGNOSIS AND TREATMENT OF DISEASES OR DISORDERS ASSOCIATED WITH XENOTROPIC MURINE LEUKEMIA VIRUS,US20090268933P,United States,2009-06-18T00:00:00Z,2009,2010-06-18T00:00:00Z,2010-12-23T00:00:00Z,2010,WHITTEMORE PETERSON INSTITUTE FOR NEURO-IMMUNE DISEASE,MIKOVITS JUDY A    US  | LOMBARDI VINCENT C    US  | RUSCETTI SANDRA K    US  | RUSCETTI FRANCIS W    US,C12Q00170,WO2010148323A3 | US2010167268A1,4,2,Yes,Application,No
803,WO2010150100,A1,"THE USE OF SPINOSYNS AND SPINOSYN COMPOSITIONS AGAINST DISEASES CAUSED BY PROTOZOANS, VIRAL INFECTIONS AND CANCER",US20090220059P,United States,2009-06-24T00:00:00Z,2009,2010-06-23T00:00:00Z,2010-12-29T00:00:00Z,2010,ENTARCO SA,KRITIKOU CHRISTINE    GR  | SALIBA KEVIN J    AU,A61K0317048 | A61P03302 | A61P03112 | A61P03500,None,1,1,Yes,Application,No
804,WO2010151495,A2,MATERIALS AND METHODS FOR TREATING AND PREVENTING VIRAL INFECTIONS,US20090220920P,United States,2009-06-26T00:00:00Z,2009,2010-06-18T00:00:00Z,2010-12-29T00:00:00Z,2010,UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC,JOHNSON HOWARD M    US  | AHMED CHULBUL IQBAL M    US,A61K03810 | A61P03116 | A61P03112 | C07K00708,None,1,1,Yes,Application,No
